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The high levels of resistance elicited by both nucleoside (NRTI) and non-nucleoside (NNRTI) 
reverse transcriptase inhibitors have prompted the design of double-drugs combining these two 
entities with the aim of addressing the emergence of resistance as well as searching for 
synergism between the two drug target sites on HIV reverse transcriptase (RT). The strategy 
involves combining two different inhibitors into a single chemical entity via a linker, with the aim 
of developing a mixed-site inhibitor combining the inhibitory actions of each drug.  
 
This thesis describes the rational drug-design and synthesis of nine bifunctional drugs 
combining a nucleos(t)ide and a non-nucleoside reverse transcriptase inhibitor linked via 
different non-cleavable spacers. The C-5 position of the nucleos(t)ide portion of the bifunctional 
was used for attachment of the spacer throughout. However, the site of attachment on the non-
nucleoside drug varies according to the inhibitor type.  
 
Chapter Two describes the first series involving the synthesis of bifunctional HIV-drugs using 
d4U as the NRTI and UC-781 as the NNRTI. This resulted in two unthiated UC-781/d4U entities 
being synthesized in a convergent manner in 16 steps for the pentane-propyne target and 20 
steps for the target bearing PEG-propyne units using Sonogashira coupling methodology as a 
key step. 
 
Chapter Three describes the second series incorporating a new NNRTI in the form of 2- and 4-
pyrimidinylarylamine motifs. Key features in this chapter include the synthesis of tri-substituted 
anilines, the library generation of 2- and 4-pyrimidinylarylamine derivatives as model NNRTIs, as 
well as Sonogashira coupling reactions to obtain three bifunctional targets. 
 
The final part of this thesis describes the synthesis of a remarkable d4U/TMC120 bifunctional 
system, synthesized on the basis of molecular modeling. Biological results indicate that the d4U-
4-PEG-TMC120 bifunctional has the lowest EC50 anti-HIV activity of any NRTI-spacer-NNRTI 
bifunctional inhibitor synthesized to date. The NRTI was also triphosphorylated and the product 
evaluated in an in vitro RT inhibition assay, which culminated in a ‘proof of principle’ of synergy 
existing between the substrate site and the allosteric binding pocket. Also presented, is work 
carried out to change the rigid d4U to a more flexible acyclic nucleotide phosphonate in a 
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1.1 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 
The Human Immunodeficiency Virus (HIV) is an intracellular parasite, belonging to a class of 
viruses called retroviruses (viral family Retroviridae), and is the causative agent of Acquired 
Immunodeficiency Syndrome (AIDS). Retroviruses are ribonucleic acid (RNA) viruses, and in 
order to replicate they must make a deoxyribonucleic acid (DNA) copy of their RNA. It is the 
DNA genes that allow the virus to replicate. HIV exists as two distinct viruses: type-1 (HIV-1) and 
type-2 (HIV-2), which both have a similar molecular structure in that they contain a single-
stranded RNA genome but which differ in origin and gene sequence. The difference between 
them is that HIV-1 carries a vpu gene whereas HIV-2 carries the vpx gene, and HIV-2 is more 
geographically restricted to West Africa compared to HIV-1. HIV-2 also tends to have slower 
rates of disease progression to AIDS than HIV-1, although when this occurs the symptoms are 
almost indistinguishable between the two types.1,2 
 
1.2 THE STRUCTURE OF THE HIV-1 VIRION 
The structure of HIV-1 involves outer and inner cores. The outer core consists of a lipid bilayer 
acquired from the host cell, while the inner core contains two proteins, p24 and p17, as matrix 
proteins surrounding the nucleocapsid containing the genetic material. A single virion has an 
icosahedral shape with a knobby-looking envelope. The knobs are comprised of the envelope 
glycoproteins gp-120 and gp-41. Beneath the envelope are the viral matrix proteins p17 and 
p24, which, aside from structural maintenance, houses the nucleocapsid containing the viral 
genome for transmission to the host nucleus. The HIV genome transcribes nine genes: gag, pol, 
env, tat, rev, nef, vif, vpu and vpr, which carry all the information needed to make new viruses 
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Copies of reverse transcriptase (RT), integrase (IN), and protease (PR) necessary for replication 
purposes are also housed together with the HIV viral RNA. 
 
1.3 EPIDEMIOLOGY OF HIV/AIDS 
According to statistics released by UNAIDS and WHO for July 2008, every day, over 6800 
people become infected with HIV and over 5700 people die from AIDS. The estimated number of 
people having died from HIV/AIDS-related illnesses is around 2.1 million per annum for 2007. 
The annual number of new HIV infections (for 2008) stands at around 2.5 million, while the total 
number of people estimated to be living with HIV/AIDS is approximately 33.2 million [30.6-36.1 
million]. Sub-Saharan Africa presents itself as the region most heavily affected by HIV with 22.0 
million people living with HIV (Fig 1.2), accounting for 67% of all people living with HIV and 75% 























Figure 1.2 Estimated number of people living with HIV and adult HIV prevalence. Global HIV epidemic, 
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1.4 THE HIV LIFE-CYCLE 
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However, what differentiates HIV from other viruses and what makes it so lethal, is that HIV 
mostly infects cells of the immune system. HIV-1 will only infect a human cell that bears a CD4 
surface marker.8 Such cells include macrophages, some dendritic cells, and most importantly, 
CD4+ T-lymphocytes, also referred to as “T-helper cells”, which play an important role in the 
body’s immune-defence when foreign entities invade the body. HIV-1 entry into CD4+ cells 
involves several sequential steps (Fig. 1.4) that involve firstly the interaction of the HIV receptor 
gp-120 with the host CD4 receptor. This gp-120/CD4 complex leads to a loss of entropy (i.e. 
ordering) in gp-120, which is counteracted by a large enthalpy of formation (∆H  < 0). This 
interaction leads to conformational changes in gp-120, and to a lesser extent CD4, that enable 
the interaction of gp-120 with the CCR5 or CXCR4 co-receptor. Subsequently, the formation of a 
CD4-gp-120-CCR5/CXCR4 complex triggers conformational changes in the gp-41 that 
eventually allows fusion between the cellular and viral membranes leading to the viral core into 


















Figure 1.4 HIV-1 attachment and fusion to CD4+ cell.12 
 
Viral entry thus involves the following three distinct steps: CD4 binding, chemokine receptor 
engagement and the structural changes in the viral envelope required for fusion between viral 
and cellular membranes. HIV-1 entry inhibitors thus encompass three mechanistically distinct 
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such as Maraviroc™ (Met-RANTES, T-22, T-134), and the fusion inhibitor Fuzeon™ (Enfuvirtide, 
T-20).14 Once the HIV nucleocapsid enters the cell (Fig. 1.3), partial uncoating of the viral core 
occurs to release the genetic material of the virus into the host cell cytoplasm, where the viral 
enzyme reverse transcriptase (RT) transforms the ssRNA genome to a dsDNA form.14 RT 
promotes (catalyses) three types of reactions: RNA-directed DNA synthesis, DNA-directed DNA 
synthesis both of which are carried out by the polymerase moiety of RT, and RNA hydrolysis 
directed by ribonuclease (RNase H). The dsDNA is subsequently transported into the cell 
nucleus, where another virion-associated enzyme, HIV integrase, catalyses the integration of the 
viral DNA into the host-cell genome. Importantly though, the viral DNA lies dormant until called 
upon to transcribe, when, transcription of the integrated viral DNA leads to the production of 
genomic messenger RNA (mRNA) molecules that are transported back to the cell cytoplasm, 
where translation takes place leading to the production of Gag and Gag-Pol proteins. Immature 
Gag and fused Gag-Pol precursor are transported to the cell membrane, where viral progeny 
begin assembling and “budding” from the infected cells. Viral particles released following 
budding, however, do not contain the characteristic HIV condensed core and are not infectious. 
Virus infectivity is acquired after particle maturation, which is mediated by the virion-associated 
HIV aspartyl protease. This enzyme cleaves the immature Gag and Gag-Pol precursors into 
functional polypeptides.15  
  
1.5 HIV PATHOGENESIS 
AIDS results from selective depletion of CD4+ helper T-lymphocytes.16a,b Progressive CD4 cell 
depletion has been identified as the fundamental basis of AIDS, but the specific mechanism by 
which this cell death occurs is still not well understood. It is well accepted that in chronic disease 
less than 15% of all CD4 cells are infected. The proportional loss of CD4 cells in AIDS far 
exceeds this prevalence of cell infection, implying that a direct cytopathic effect of the virus 
cannot be the sole explanation of CD4 cell depletion. In recent years, it has been shown that 
during acute infection there is massive depletion of CD4 cells in the gastrointestinal associated 
lymphoid tissue (GALT) and other mucosal tissues. Importantly, CD4 cell depletion in these 
tissues appears to be significantly greater than that observed in peripheral blood.16b  
The function of CD4 cells is to help CD8+ cytotoxic T-lymphocytes to destroy other cells that 
express foreign antigens and also to enhance antibody production by B-lymphocytes. Thus, CD4 
cells represent a key component of the immune system. In a healthy individual, about 1200 CD4 
cells circulate per µL blood; when CD4 counts drop below 400/ µL, opportunistic infections start 
to occur.2  HIV eventually kills the helper T-cell that are vital for the immune system, and the 
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the functioning of the B-cells. Helper T-cell depletion inhibits the B-cells from differentiating into 
plasma cells and memory cells, thus impairing the immune system’s ability to fight against 
foreign antigens that have entered the body.17 A person with a CD4 level below 200/ µL defines 
a state of AIDS. 
 
1.6 THE REVERSE TRANSCRIPTASE ENZYME (RT) 
HIV reverse transcriptase (RT) is a multifunctional enzyme (Fig. 1.5) responsible for catalytic 
transformation of single-stranded viral RNA into double-stranded DNA (dsDNA) that in turn gets 
integrated into host cell chromosomes by integrase.18 In summary again, HIV-1 RT carries out 
reverse transcription by the following catalytic activities:  
(i) RNA-dependent DNA polymerization to form an RNA-DNA hybrid. 
(ii) RNase H degradation of the RNA strand from RNA-DNA hybrid. 
(iii) DNA-dependent DNA polymerization to form a dsDNA.     
 
Figure 1.5 (a) Structure of the HIV-1 reverse transcriptase enzyme adapted from Pata et al.19 (b) RNA-
directed followed by DNA-directed synthesis.18 
 
From a structural point of view, HIV-1 RT is a heterodimer consisting of two subunits: a 66 kDa 
one and a 51 kDa one (p66 and p51). The p66 subunit contains an N-terminal polymerase 
domain and a C-terminal RNase H domain. The p51 subunit is derived either from p66 or from a 
large gag-pol precursor by proteolytic cleavage with HIV-1 protease, and has the same amino 
acid sequence as the polymerase domain of p66. Crystal structures of RT have revealed the 
part of the p66 subunit responsible for transcription to resemble a right hand with fingers, palm, 
thumb, and connection subdomains. The p66 palm contains the polymerase active side that is 
defined by Asp110, Asp185, and Asp186 residues located in the β9-β10 sheet. These amino 
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The primary function of reverse transcriptase is to build a DNA strand from an RNA template, 
which is performed at the polymerase active site of the p66 subunit. This process is complex and 
requires the concerted function of two enzyme active sites in RT (Fig.1.6). Reverse transcription 
is initiated at the 3’-end of a cellular lysyl-tRNALys,3, hybridized to the primer binding site (PBS) of 
the HIV RNA genome, by the RNA-primed RNA-dependent DNA polymerase activity (RDDP) of 
RT. This elongates to produce viral DNA until the 5’-end of the HIV-1 RNA is reached (Fig. 1.6, 
Step 1). The product formed from this reaction is termed the minus strand strong-stop DNA. RT 
ribonuclease H (RNase H) activity then hydrolyzes the HIV genomic RNA (step 2), to allow the 
nascent DNA to hybridize with the repeat sequence (R) at the 3’-end of the HIV genomic RNA 
(step 3). After this strand transfer, the nascent DNA strand is further elongated by RT DNA-
primed RDDP activity. RNase H activity is again required to hydrolyze the rest of genome RNA 
except for a purine rich sequence, termed the polypurine tract (PPT), which serves as a primer 
for the initiation of second strand DNA synthesis (step 5). RNA-primed DNA-dependent DNA 
polymerase activity (DDDP) then elongates the PPT primer (step 6). Removal of the PPT and 
tRNA primers by RT RNase H activity (step 7) then allows second strand transfer to take place 









Figure 1.6 a) HIV reverse transcription mediated by the DNA polymerase, RNase H and the 
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HIV-1 RT DNA-primed DDDP activity including strand-displacement activity completes the 
synthesis of the double-strand proviral DNA precursor.                            
The final product of the complete reaction carries U3-R-U5 long terminal repeats (LTR) at both 
ends (step 9).22 As a result, the reverse transcriptase enzyme has played a key role in the HIV-1 
life-cycle, making it a primary target for development of new anti-HIV drugs used in the treatment 
of HIV/AIDS.14,23 
 
1.7 DEVELOPMENTS IN ANTI-HIV CHEMOTHERAPY 
With the onslaught of drug-resistant mutations, combination therapy comprising of at least three 
anti-HIV drugs, has become the standard treatment of HIV-infected patients.23 Drugs used in 
Highly Active Anti-retroviral Therapy (HAART) fall into one of three categories: (i) 
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), that following two 
phosphorylation steps (i.e. acyclic nucleotide phosphonates) or three phosphorylation steps (for 
nucleosides) act as chain terminators at the substrate binding site (Fig. 1.7) of RT; (ii) non-
nucleoside RT inhibitors (NNRTIs) that are able to interact with reverse transcriptase at an 
allosteric, non-substrate binding site; and (iii) protease inhibitors (PIs) that inhibit the virus-
associated protease.23 Other clinically approved drugs include the fusion inhibitor Fuzeon, the 
integrase inhibitor Raltegravir and the CCR5 antagonist Maraviroc. Generally, drug combinations 
involve two NRTI’s plus one NNRTI, or two NRTI’s and one PI. Protease inhibitors will not be 
dealt with in any further detail. 
 
Figure 1.7 Ribbon representation of HIV-1 RT in complex with efavirenz. The p66 and p51 domains of RT 
is highlighted in red in blue respectively. The DNA active site and the RNase H active site is higglighted 
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Recent studies have shown that the combination therapy of NRTIs, NNRTIs and PIs are able to 
significantly reduce the viral load, increase CD4 count, decrease mortality and delay disease 
progression.23 This type of therapy has been shown to work particularly well in AIDS patients 
with advanced immune suppression.24 In addition, there has been found to be a significant 
benefit in early aggressive anti-HIV chemotherapy, especially in patients showing no symptoms 
of the disease (asymptotic stage).25 HAART is able to partially restore the immune system in 
patients with advanced HIV infection, but also exacerbates cryptococcal meningitis.26 Thus, 
HAART has profound repercussions on various AIDS-associated diseases. 
Therefore, almost all current HIV-drug candidates, either in preclinical or advanced clinical 
development, target well-defined steps in the HIV replicative life cycle. These drugs fall into 
categories associated with the life cycle such as (i) viral adsorption (gp-120) inhibitors; (ii) viral 
co-receptor antagonists; (iii) viral fusion (gp-41) inhibitors; (iv) nucleocapsid protein (NCp7) Zn 
finger-targeted agents; (v) reverse transcriptase and integrase inhibitors; (vi) transcription 
(transactivation) inhibitors and (vii) HIV protease inhibitors.23 
The inhibitors that lie at the core of this project are the reverse transcriptase inhibitors. 
 
1.8 NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIs) 
The substrate (dNTP) binding site of HIV-1 reverse transcriptase is the obvious target for a large 
variety of NRTI analogues,23 and the HIV-1 binding site has been targeted for many years now 
as an efficient way of combatting HIV. In 1987, zidovudine (AZT), a nucleoside RT inhibitor 
(NRTI), was approved in the USA as the first chemotherapeutic agent against HIV/AIDS.23 
However, resistance to anti-HIV compounds develops rapidly, sometimes within a few days of 
initiating treatment. Errors made by the viral enzyme RT and cellular RNA polymerase II result in 
about one mutation per viral replication (1 base change in 10 000 RNA nucleotides), which, 
together with the rapid replication of the virus, is responsible for rapid emergence of drug 
resistant mutants.  This problem led many in pursuit of developing other NRTIs, and over 21 
years of research has culminated in seven US Food and Drug Administration (FDA) approved 
NRTIs. Examples of such NRTIs are zidovudine27 (AZT, 1987), didanosine28 (ddI, 1991), 
zalcitabine29 (ddC, 1992), stavudine30 (d4T, 1994), lamivudine31 (3TC, 1995), abacavir32 (ABC, 
1998) and emtricitabine33 (racemic FTC, 2000) all of which are FDA clinically approved drugs 
(Fig. 1.8).  
 
These NRTIs are pro-drugs and need to firstly be phosphorylated by cell-derived kinases to their 
5’-triphosphate forms, before they can halt the chain propagation step at the reverse 
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inhibitors (alternative substrates) with respect to the normal substrates (dATP, dGTP, dCTP or 




























































































Figure 1.8 Nucleoside reverse transcriptase inhibitors and Tenofovir (PMPA). 
 
D4T shows selective anti-HIV activity comparable to that of AZT in vitro. However, d4T is more 
toxic overall and less inhibitory to mitochondrial DNA replication than AZT.34a Together with the 
early PI’s, d4T is known to promote severe lipoatrophy and other body composition changes 
associated with antiretroviral therapy. However, there is some evidence that reducing or 
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the dose of d4T has also been shown to help to alleviate peripheral neuropathy, another side 
effect of the drug. The World Health Organization recommended in 2007 that d4T dosing should 
be reduced to 30mg twice a day in order to counter toxicity. 34b  
It has also been shown that under physiological conditions, RT can remove these chain-
terminators, thus unblocking the primer terminus with great efficiency and thus restoring DNA 
synthesis and viral replication.35 
 
In contrast to the nucleoside analogues, the nucleotide analogues (NtRTIs), e.g. PMPA, are 
mono-phosphorylated pro-drugs in the form of phosphonates (Fig. 1.8), and thus only require a 
further two phosphorylation steps by cellular kinases in order to be transformed into the active 
metabolite. NtRTIs can therefore by-pass the nucleoside-kinase reaction, the latter being well 
documented as generally the rate-determining step en route to the active triphosphate resulting 
in limitation of the activity of the dideoxynucleoside analogues.7 An included bonus is that the 
phosphonate, unlike the phosphate, cannot be cleaved by phosphatases that would normally 
convert nucleoside monophosphates back to their parent nucleoside. 
 
Figure 1.9 Mechanism of anti-HIV action of 2’, 3’-deoxynucleoside analogues- shown for 2,3’-               
                dideoxycytidine.7    
                   
 
Tenofovir36, which is FDA clinically approved, has proven to be antivirally active and has showed 
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chemotherapy. It is scarcely affected by HIV-1 RT mutations while at the same time retains its 
full potency as an antiretroviral. 
 
At present, the existing drugs still find it remarkably difficult to comply with the ever- increasing 
demands of higher activity (potency), lower toxicity (side-effects) and favorable resistance 
profiles required for anti-HIV drugs. As a result, several new NRTIs are in clinical development.37 
Racivir, also known as (±) FTC, is one such inhibitor. Its mechanism of action is precisely the 
same as that of zidovudine38, in that after successful phosphorylation to the active metabolite, 
the ddNTP competes with the normal substrates. Upon expulsion of the β, γ-diphosphate 
following nucleophilic substitution by the HIV DNA 3’-hydroxyl (attached to the primer terminus) 
with an incoming ddNTP, ddNMP is incorporated at the 3’-end of the DNA chain, leading to 
chain termination since the decoy inhibitor does not possess the necessary 3’-hydroxyl 
functionality for further elongation (Fig. 1.9). Racivir comprises a 50:50 racemic mixture of two 
enantiomers39a and is thus considered a form of combination therapy in which (-)-FTC is 
moderately more potent than (+)-FTC.39b Pharmacokinetic studies carried out by Anderson and 
co-workers39b revealed that compared to the (+)-isomer, (-)-FTC is more efficiently taken up into 
the cell and phosphorylated to its active triphosphate form. Also, by serving as a much poorer 
substrate of cytidine deaminase than the (+)-isomer, (-)-FTC is not degraded back to its parent 
nucleoside. FTC has also shown diminished resistance profiles. 
 
Further successes have come in the form of NtRTI prodrugs. 40,41, 42 Attempts have been made to 
synthesize 2’, 3’-dideoxynucleotide (ddNMP) prodrugs, as well as other forms of prodrugs that 
are taken up into the cell immediately in the nucleotide form. Successes have been achieved 
using this approach for a number of NRTIs such as d4T (more later). 
  
1.9 THE STRUCTURE OF HIV-1 RT IN COMPLEX WITH NUCLEOSIDE INHIBITORS 
Nucleotide analogues bind at the dNTP-binding site (Fig. 1.10), adjacent to the 3' terminus of the 
primer strand that is located in the palm subdomain of the p66 subunit.43 The catalytic triad of 
aspartic acids, (Asp110, Asp185 and Asp186), which are conserved in most polymerases are 
also located at this site. The nucleotide analogue binding site is composed of both protein and 
nucleic acid. The nucleic acid part of the binding site is made up of the 3'-primer terminus, which 
possesses the 3'-OH group that is the site for the covalent attachment of the incoming substrate. 
The base of the 3'-primer terminal nucleotide also helps to bind incoming substrate via base-
stacking interactions. The first base in the template overhang contributes base-specific H-bond 
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rules. Based on modelling experiments, residues Asp185 and Asp186 of the conserved Tyr-Met-
Asp-Asp motif and Asp110 are believed to bind the triphosphate moiety of the incoming dNTP 
via two chelated Mg2+ ions (Fig. 1.11).43 Once again, substitution with expulsion of the 
diphoshate (as described before) leads to incorporation of the resulting dNMP at the 3’-end of 
the DNA chain. 
 
Figure 1.10 Superposition of HIV-1 RT in complex with an inhibitor and in ternary complex with primer 
template DNA and incoming dNTP. Displacement of TRP-229 and concomitant displacement of the primer 
grip are indicated with arrows. Nonspecific contacts between the primer grip and the primer strand DNA 
are indicated with parallel lines.44 
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1.10 NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS (NtRTIs) 
In most cases the ultimate bottleneck in the metabolic pathway leading from 2’,3’-
dideoxynucleoside (ddN) analogues to their active 5’-triphosphate form is the first 
phosphorylation step.23 Unlike adefovir dipivoxil [9-(2-phosphonylmethoxyethyl)adenine (PMEA)] 
and tenofovir disoproxil [(R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA)] (Fig. 1.12) which 
are already equipped with a phosphonate group and therefore only require two more 
phosphorylations to be converted to their active metabolites (PMEApp and PMPApp, 









































































Figure 1.12 Acyclic nucleotides phosphonates: PMEA and PMPA in their prodrug forms. Prodrugs of  
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Figure 1.12 depicts various known versions of mono-phosphorylated nucleotide pro-drugs, which 
will be discussed. 
 
Many research groups have focused their attention on constructing 2’,3’-dideoxynucleotide 
(ddNMP) prodrugs as esters or amides, that once taken up by the cells, deliver the nucleotide 
(ddNMP) form. This so-called pronucleotide or prodrug approach (discussed in detail later) has 
proven successful for a number of NRTIs such as 2’,3’-dideoxyadenosine (ddA) and d4T (Fig. 
1.12). The bis(S-acetyl-2-thioethyl)phosphotriester of ddA [bis(SATE)ddAMP] was synthesized 
by Imbach  and co-workers46 and found to be 1000-fold more potent than the parent nucleoside. 
This increase in potency can be attributed to direct delivery of bis(SATE)ddAMP into the cells, 
which circumvents adenosine deaminase enzymes rapidly degrading ddA to ddI.46  
Similarly, McGuigan and co-workers47,48,49 have over a number of years synthesized and 
evaluated the highly potent arylphosphoramidate derivatives of d4T, AZT and ddU as prodrugs 
(Fig. 1.12). This prodrug comprises a phosphate derivative bearing aryloxy and alaninyl (methyl 
ester) O- and N-based groups respectively as a phosphoramidate derivative. Direct intake of 
aryloxyphosphoramidate derivatives of d4T, d4A and ddA intracellularly (via the alaninyl 
nucleoside-MP intermediate50) have provided anti-HIV activities that are 25- to 625-fold greater 
than the parent nucleosides.51 
Similarly, Meier and co-workers52,53 have introduced the cyclic saligenyl group (Fig. 1.12), which 
by-passes the rate-determining, thymidine kinase (in the case of d4T) and adenosine deaminase 
(in the case of ddA) enzymatic step. CycloSaligenyl pronucleotides deliver the monophosphate 
nucleotides of d4T and ddA exclusively under intracellular conditions of pH.54,55 To fully 
understand how this works, ‘the Prodrug Approach’ will now be discussed in detail. 
 
1.10.1 THE PRODRUG APPROACH (The Pronucleotide Approach) 
The first introduction of prodrugs to the field of medicinal chemistry is kindly attributed to Albert56 
in 1951 who wrote: “A prodrug is a molecule which does not have any intrinsic biological activity 
but which is capable during the different phases of its metabolism to generate a biologically 
active drug”. Furthermore, a potent suitable prodrug should overcome the crucial paradox: to be 
lipophilic enough to by-pass a membrane or metabolic barrier and to be hydrophilic enough to 
fulfill solubility, bioavailability or transport criteria.57 The systematic enzymatic cleavage of the 
chemical bond allowing efficient prodrug-to-drug conversion is of particular interest since it 
depends on the type of cleavable linkage: -carbonate, -ester, -amide, carbamate, -phosphate, -
phosphonate, -phosphoramidate, or –amidine.57 The enzymatic stability of the resulting prodrug 
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Figure 1.13 Metabolic transformation of d4T into active ddNTPP, after controlled selective delivery,   
                    i.e. the prodrug approach.58 
 
In contrast to d4T, the fate of the majority of nucleoside analogues has not yet been studied in 
detail. After being tested, many parent nucleosides are discarded after not displaying any 
biological activity. Thus, it is likely that such a lack of understanding of the metabolic blockade 
has prevented the successful development of certain nucleosides into active nucleotide 
prodrugs.58 
 
Nucleotides are very polar molecules that do not easily pass through cellular membranes and 
are dephosphorylated in the serum by non-specific phosphatases.58 However, this problem can 
be overcome by masking the phosphate or phosphonate moiety of the nucleotide with 
degradable lipophilic carrier groups as illustrated in Figure 1.13. This leads to neutral, 
membrane-permeable nucleotide delivery systems, which is known as the pronucleotide 
approach. 
Under physiological conditions, nucleotides are charged species (phosphate monoester pKa 
values are about 1.6 and ca. 6.6).  Therefore, as reported by Meier, one requires two masking 
groups to obtain a neutral lipophilic phosphate triester.58 
Several methods with corresponding mechanisms for achieving this have been employed. 
Strategies involving pure chemical hydrolysis of dialkyl, dibenzyl and diphenyl phosphate 
triesters have proven to be successful in in vitro and in vivo studies.59 However, recent 
pronucleotide approaches are based on enzymatic or chemical activation of the masking groups. 
These approaches use enzymatic activity and specific pH conditions.59,60 
 
An example of this is the neutral lipophilic phosphotriesters using pivaloyloxymethyl (POM) 
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Cleavage of one of the POM groups by non-specific cellular carboxyl esterases yields the 
hydroxymethyl analogue which is inherently chemically labile and spontaneously dissociates 




































Figure 1.14 Biotransformation of POM2 nucleoside 5’-monophosphate prodrugs.61 
 
 
Cleavage of the second POM group by cellular phoshodiesterases regenerates the desired 
parent nucleoside 5’-monophosphate.  These enzyme-triggered approaches on POC and POM 
phosphate-masking groups have proven very successful in in vitro intracellular delivery systems. 
61 
However, thus far, the only successful intracellular pH-driven nucleotide delivery strategy is the 
cycloSal approach.62,63 This designed chemically induced coupling, follows a cascade 
mechanism62-63, and goes as follows (Fig. 1.15): following nucleophilic attack of hydroxide at the 
phosphorus atom of cycloSal triester 1, the phenolate is displaced preferentially in an SNP 
reaction, since it is the best leaving group of the three OR groups. This leads to 2-
hydroxybenzylphosphate diester 2 via proton transfer. The resulting ortho substituent of the 
benzyl ether is changed from a very weak electron-donating group (phosphate) to a strong 
electron-donating group (hydroxy). This electronic change activates the remaining masking 
group and induces a spontaneous rupture of diester 2 to yield the nucleotide and salicyl alcohol 
8 (cascade reaction; steps b1 and b2). The bond cleavage proceeds after intramolecular proton 
transfer (intermediate 4) via zwitterion 5 or 2-quinone methide 6.58  
The disfavoured pathway involves cleavage of the benzyl ester bond (step c), in which cation 3 
is rapidly trapped by water to yield phenyl phosphate diester 7. However, no further chemical 
hydrolysis of the phosphate diester takes place at physiological pH and 7 comes to a dead end. 























































































Figure 1.15 Two possible cascade hydrolysis of cycloSal-d4TMP triester 1.58 
 
In summary, the cycloSal strategy requires one bifunctional masking group per equivalent 
nucleotide and is chemically triggered intracellularly at physiological pH to render the desired 
parent nucleotide-MP. 
 
1.10.2 THE ACYCLIC NUCLEOTIDE PHOSPHONATES (ANPs) 
The acyclic nucleotide phosphonates (ANPs) represent a new dimension for the treatment of 
DNA virus and retrovirus infections.64 These ANPs encompass three compounds that have been 
formally licensed for the treatment of (i) HCMV (human cytomegalovirus) infections (i.e. HCMV 
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infections (adefovir dipivoxil, Hepsera ®), and (iii) HIV (human immunodeficiency virus) 
infections (AIDS) [tenofovir disoproxil fumarate (TDF), Viread ®].40 
ANPs have therefore proved to be the cornerstone of anti-viral therapy. The question would 
therefore be: What is the significance of an acyclic nucleoside ‘phosphonate’? In regular 
nucleotides (or nucleoside phosphates), the phosphate group is attached to the 5’-oxygen as an 





































 Figure 1.16 a) Broad spectrum of acyclic nucleotide phosphonates (ANPs); b) Mechanism of action  
                     of cidofovir.40 
 
In the ANPs, the phosphate group, is attached to the nucleoside via a phosphonomethyl ether 
phosphonate grouping, which, unlike the phosphate ester linkage, should resist any attack from 
esterases, or any catabolic enzymes at large, by virtue of it having a more stable P-C bond over 
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The concept of ANPs  was born in 1986 with the discovery of the ANP prototype, (S)-9-(3-
hydroxyl-2-phosphonylmethoxypropyl)adenine (HPMPA) (Fig. 1.16), as a broad spectrum anti-
DNA virus agent.65 HPMPA itself could be envisaged as a kind of construct resulting from the 
replacement of the carboxylate group of phosphonoacetic acid [PAA, the predecessor of the 
antiviral agent phosphonoformic acid (foscarnet, Foscavir ®] by the acyclic nucleoside analogue 
DHPA [(S)-9-(2,3-dihydroxypropyl)adenine], which was described in 1978 an an acyclic 
nucleoside analogue with broad spectrum antiviral activity.66 
Cidofovir, adefovir, tenofovir and several others show high potential as therapeutic agents. 
According to their activity spectrum, the ANPs can be classified into two categories: (i) the 
‘HPMP’ derivatives, represented by HPMPC (cidofovir), which are active against a broad variety 
of DNA viruses (polyoma-, papilloma-, adeno-, herpes- and poxvirus, and (ii) the ‘PME’ and 
‘PMP’ derivatives, represented by PMEA (adefovir) and PMPA (tenofovir) (Fig. 1.12, pg. 14), 
which are primarily active against hepadna- and retroviruses. Their clinical usages, approved 
and potential are represented in Table 1.1. 
 
Table 1.1 Clinical applications of acyclic nucleotide phosphonates.40 
Compound 
Commercially available 
Dosage and route  
of administration 
Approved clinical  







(5 mg/kg weekly or 
two-weekly) 
CMV retinitis in AIDS 
patients         
- Severe polyoma-, 
papilloma-, adeno-, 








 - HPV-, HSV-1-, HSV-




(10 mg daily) 









(300 mg daily) 
AIDS (HIV infection) Chronic hepatitis B 
(HBV infection) 






(300 mg TDF daily) 
(200 mg emtricitabine 
daily) 
AIDS (HIV infection) Chronic hepatitis B 
(HBV infection) 







(300 mg TDF daily) 
(200 mg emtricitabine 
daily) 
(600 mg efavirenz 
daily) 
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1.11 NRTI RESISTANCE 
HIV-1 RT is very tolerant to non-standard base pairs and modified sugars which has advantages 
for chemotherapy. However, one drawback is the resultant mutations (no proof-reader), due to 
misincorporations ranging from 1/1700 to 1/4000 nucleotides. One estimate suggests about 10 
base changes in the HIV genome per replication cycle, and the resultant mutant strains can 
exhibit NRTI resistance. There are two currently known biochemical mechanisms of NRTI drug 
resistance. The first is mediated by mutations in the RT enzyme that allow it to discriminate 
against NRTIs during DNA synthesis, thereby preventing their addition to the growing DNA 
chain. The second mechanism (NEM) involves an increase in nucleotide excision rate in the 
mutant strain, resulting in continued DNA synthesis.67,68 In the second mechanism, the oxygen 
anion of a nucleoside diphosphate or triphosphate is used as a pyrophosphate nucleophile to 
attack and cleave the 3'/5'-phosphate bond of the primer, producing an unblocked primer and a 
dinucleoside tri- or tetraphosphate containing the dideoxynucleoside monophosphate from the 
primer terminus linked through its phosphate group to the distal phosphate of the free nucleoside 


























































Figure 1.17 Removal of NRTI from the primer terminus through dinucleoside polyphosphate synthesis 
  
Biochemical and modelling studies suggest that incorporation of AZT results in steric strain 
between the azido group and Asp185 of the mutant, resulting in an enhanced excision rate (Fig. 
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Figure 1.18 Steric hindrance when an AZT-terminated primer is bound to RT at the P site. The figure, 
based on the structure of the ternary RT-DNA-dNTP complex, shows that the distance between the azido 
of AZT and D185 (mutant) would cause steric conflict; the distance between D185 and the first and 
second azido nitrogens is less than the sum of the van der Waals radii.  
 
The M184V mutation causes the high-level of lamivudine resistance observed and emerges 
rapidly in patients receiving lamivudine monotherapy. This mutation (M184V) and other NRTI 
resistance mutations interfere with the effects of the NEMs. The mutational antagonism between 
the NEMs and several of the mutations that act by allowing RT to discriminate against NRTIs 
explains the clinical synergism observed with dual NRTI combinations such as 
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1.12 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIs) 
More than 30 structurally different classes of NNRTIs (Fig. 1.19) have been synthesized, 69,70 
since the well known TIBO derivatives71 were first discovered by the Janssen group in 1987. 
NNRTIs are a chemically diverse set of compounds, largely specific for HIV-1 RT and, unlike the 
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In general, NNRTIs are a group of small (< 600 Da) hydrophobic compounds with diverse 
structures, as can be seen in Figure 1.19. They specifically inhibit HIV-1, but not HIV-2 RT, 
which is unable to form the required pocket for binding. 
 
By far the chief pioneer for nearly 17 years in NNRTI development is the late Dr. Paul Janssen. 
Beginning in 1987, Janssen and his co-collaborators (Das, Clark, Arnold, De Corte, de Clercq, 
Pauwels, Lewi, Kukla and others) engineered the field of non-nucleoside reverse transcriptase 
inhibition of HIV-1 RT. Figure 1.20 provides crucial insight in the form of a historical synopsis of 
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TIBO (tetrahydroimadazobenzodiazepinone) analogues were discovered by screening a subset 
of a Janssen compound library in a cell-based anti-HIV test at the Rega Institute.71 Subsequent 
screening of the Janssen compounds led to the discovery (2nd lead series) of the α-APA (α-
anilinophenylacetamide) class of NNRTIs.73 Further chemical modification led to the class of 
potent ITU (iminothiourea) NNRTIs.74 In an attempt to synthesize the corresponding imino-N-
cyanoguanidine derivatives of ITU, an unexpected ring closure occurred, producing the first 
compound of the DATA (diaryltriazine) class of NNRTIs.75 
Molecular modeling studies suggested in 1996 that replacing the central aminotriazine ring of 
DATA with a pyrimidine ring would lead to greater activity. This was the birth of the DAPY 
(diarylpyrimidine) NNRTIs, of which TMC120 (R147681) is the prototype. TMC120 and TMC125 
have subsequently proved to be highly active in reducing viral loads.76  
Further collaborative work among medicinal chemists, crystallographers, and molecular 
modelers led in 2001 to the discovery of the cyanovinyl DAPY compounds, of which the E-
isomer TMC278 (R278474) is the prototype. The potency of TMC278 against wild-type and 
mutant HIV-1 RTs are compared in Table 1.2 below with those of two other DAPY compounds 
(TMC120 and TMC125), as well as with three approved NNRTI drugs.77 
 
Table 1.2 Potency data (EC50 μM) in of DAPY compounds and the three approved NNRTIs 
against HIV resistant strains.77 
 
Compound Wild-type K103N Y181C K103N/Y181C L100l L100l/K103N 
TMC278 
 
0.0004 0.0003 0.0001 0.0008 0.0005 0.008 
TMC125 
 
0.002 0.001 0.006 0.005 0.003 0.01 
TMC120 
 
0.001 0.004 0.008 0.044 0.016 >10 
Efavirenz 
 
0.001 0.039 0.002 0.04 0.038 >10 
Delavirdine 
 
0.016 >1 >1 >10 >1 N/A 
Nevirapine 0.085 >1 >1 >100 0.6 N/A 
** EC50 is defined as the concentration of compound required to inhibit syncytia formation in HIV-1 infected cells to 
50%. 
 
Table 1.2 reveals how first-generation NNRTIs (Nevirapine and Delavirdine) are effective in 
inhibiting wild-type HIV-1 RT, but are poor at overcoming single and double point mutations 
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NNRTI, is very good (1 nM range) at inhibiting wild-type HIV-1 RT, as well as being capable of 
inhibiting single point mutations. The flexible third-generation DAPY compounds, especially 
TMC125 and TMC278, display an outstanding anti-HIV profile for inhibition against all single 
point mutations as well as a remarkable 8 nM activity for TMC278 against the double point 
mutation of L100I/K103N. The mechanism by which this works will be discussed later.  
 
1.12.1 THE NNRTI-BINDING POCKET 
All NNRTIs bind to a single site on the p66 subunit of the HIV-1 RT p66/p51 heterodimer termed 
the NNRTI binding pocket (NNRTI-BP) (see Fig. 1.7 again), despite being a heterogeneous 
class of inhibitors with diverse chemical structures. The NNRTI-BP is situated between the β6-
β10-β9 and β12-β13-β14 sheets in the palm subdomain of the p66 subunit. This is also 
approximately 10Ǻ away from the RT DNA polymerase aspartic acid catalytic triad.20 The 
NNRTI-BP is predominantly hydrophobic in nature with substantial aromatic character (Y181, 
Y188, F227, W229 and Y232), but also contains hydrophilic residues (K101, K103, S105, D192, 
and E224 of the p66 subunit and E138 of the β7-β8 loop of the p51 subunit). A likely entrance to 
the NNRTI-BP is located at the p66/p51 interface, ringed by residues L100, K101, K103, V179, 
and Y181 (p66 subunit) and E138 (p51 subunit).78 In the absence of ligand, the side chains of 
Y181 and Y188 of p66 point into the hydrophobic core, and thus, the NNRTI-BP does not exist in 
the free ‘apo’-enzyme (Fig. 1.21).78,79 NNRTI-binding to HIV-1 RT causes the Y181 and Y188 to 
rotate away from their positions in the hydrophobic core thereby creating space for ligand 
accommodation.78 Effectively, this equates to an approx. 30o twisting of the β12-β13-β14 sheet, 
which leads to an expansion of the NNRTI-BP.70 
 
Figure 1.21 Close-up of the future binding pocket area in unliganded RT. Amino acid residue 100 (shown 
in blue) makes contact with residues Y181 and Y188 (shown in red) which undergo major structural 
rearrangement prior to non-nucleoside inhibitor binding. L100 also makes contact with K101 and K103 
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In NNRTI-bound RT, the p66 fingers and RNase H domain fluctuate in opposite directions (anti-
correlated motions), giving rise to open and close conformations (Fig. 1.22).70 The p66 palm and 
connection serve as a rigid support for the flexible regions. The p66 thumb, on the other hand, is 
subject to orthogonal, but cooperative motions, with respect to the p66 fingers and RNase H. 
Thus, the net effect of NNRTI-binding to RT is to change the direction of domain movements.81 
To understand this, the mechanism of NNRTI-RT inhibition will be discussed in detail. 
 
Figure 1.22 Residue fluctuations along the x-, y- and z-directions for unliganded (black line) and 
nevirapine-bound (blue line) RT. The X axis coincides with the out-of-plane direction; the Y and Z axis lie 
along the in-plane directions. The ribbon diagrams on the right represent the p66 fingers, thumb, RNase 
H, and the p51 thumb are coloured blue, red, pink and magenta, respectively.70 
 
 
1.12.2 THE NNRTI BINDING MODE AND MECHANISM OF RT INHIBITION 
A number of different mechanisms for NNRTI inhibition of RT have been proposed. In 1992, 
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arthritis’ whereby relative domain movements, similar to Figure 1.22 above, thought to be 
necessary for the catalytic cycle of the enzyme, are inhibited. Generally, crystal structures of RT 
with bound NNRTIs have the p66 thumb subdomain in an extended position. For unliganded RT, 
the thumb subdomain can either be folded down into the DNA-RNA cleft79a or can adopt a more 
extended position.79b Examination of various crystal forms of RT with different NNRTIs bound 
showed significant variations in relative domain positioning.79c Thus, there is no clear evidence 
that NNRTI binding induces a single positioning of the p66 thumb subdomain. Comparing the 
NNRTI bound and free forms of RT indicated a significant and consistent movement of strands 
β2-β3 containing the critical Asp110, Asp185 and Asp186 active site triad79b, which ultimately 
explains the inhibition of RT by NNRTIs (Figure 1.23). 
 
Figure 1.23 Diagram comparing the NNRTI site and polymerase active site in RT for the apo enzyme (in 
green) and for inhibitor-bound form (1051U91, shown in grey as ball and stick representation) in brown. 
The three key aspartic acid residues in the polymerase active site (110, 185 and 186) are shown as small 
spheres which mark their Cα atoms. The three-stranded β-sheet (strands β4, β7 and β8) moves as a rigid 
body on binding an NNRTI, thereby causing inhibition of the enzyme. The direction of movement is 
indicated by the arrow; Cα atom of Asp186 is displaced by 1.9 Ǻ.79b 
 
Parallel rapid reaction kinetic experiments showed that the rate limiting step inhibited was the 
chemical bond formation, in line with the proposed structural mechanism.79c An alternative to the 
active site displacement mechanism was proposed by Das and co-workers in 2007, in which the 
NNRTI distorts the catalytic triad position into a conformation incompatible with the binding of the 
divalent cations Mn2+/Mg2+.79d This idea was built on the back of an RT crystal structure 
determined in the absence of NNRTI and with ATP bound but in a mode significantly different to 
dNTP binding in the catalytic complex. The loss of Mn2+ or Mg2+ counter ion would be expected 
to significantly weaken the binding of dNTPs, since charge repulsion between the nucleotide 
phosphate groups and the catalytic aspartates would result. In fact, the opposite is the case as 
kinetic data shows that the presence of an NNRTI in fact significantly strengthens the binding of 










CHAPTER 1: _________________________________________________INTRODUCTION 
 29 
Additionally, there is a metal-ion dependency of dTTP binding in the complexes of 
nevirapine/delavirdine or efavirenz present, giving further evidence that the cations remain in 
place after an NNRTI is bound. These data hence argue against the proposal of the NNRTI-
shifted aspartates being unable to bind divalent cations.  
An alternative mechanism of NNRTI inhibition has been described which relates to movement of 
residues in the region of the primer grip.78 This region, containing residue Pro236, is however 
extremely flexible taking up very variable conformations which are unrelated to NNRTI potency. 
Interference of the catalytic step of the polymerase would thus be via an indirect route involving 
perturbations of the primer position. The effects of NNRTIs on the stability of RT heterodimer 
formation do not appear to significantly contribute to the mechanism of inhibition of the 
enzyme.79f,79g The status quo in 2009, on the NNRTI mechanism of RT inhibition, is that any of 
the above mechanisms are acceptable and that the precise mechanism is still not known. 
 
1.12.3 FIRST- AND SECOND-GENERATION NNRTIs: DIFFERENCES IN THE MODE 
OF BINDING TO HIV-1 RT 
NNRTIs can be broadly categorized into first- and third-generation compounds. Efavirenz 
appears to be the odd one out as a bridging second-generation type. First- generation NNRTIs 
such as nevirapine, delavirdine, TIBO and loviride were mainly discovered by random screening 
but are associated with rapid development of mutations due to their inherit rigidity. By 
comparison, third-generation NNRTIs, such as the DAPY compounds in view of their flexibility 
and hydrogen bonding ability to K101, were developed with ‘rational drug-design’ strategies in 
mind. These strategies include molecular modeling, rational-based drug synthesis and biological 
and pharmacokinetic evaluations. In general, third-generation NNRTIs tend to be more potent 
than first-generation counterparts and are more active against a broader spectrum of drug-
resistant strains of HIV-1.82 
The common pharmacophores83,84 that are crucial for tight and specific binding to the RT 
NNRTI-BP include an aromatic ring capable of π-stacking interactions at the back of the pocket, 
NH-C=O or NH-C=S groups able to participate in hydrogen-bonding, and a few more 
hydrocarbon-rich regions for hydrophobic contacts.70 The X-ray crystal structure analysis of HIV-
1 RT has demonstrated similarities in the geometry of the binding modes of both generation 
types.85 Generally, the binding of first-generation NNRTIs in the pocket resembles a ‘butterfly’ 
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Figure 1.24 Stereoview of a) nevirapine and b) delavirdine in a clear butterfly binding mode in the  
                    NNRTI-BP.70 
 
This butterfly-like mode is defined by Wing I, Wing II and the body/linker modular segments to 
which specific pharmacophores bind. The Wing II region is lined with aromatic amino acid 
residues Y181, Y188 and W229 at the back of the pocket that have favourable π-π interactions. 
Wing I has fewer hydrophobic interactions compared to Wing II and involves the side chains of 
K101, K103, V106, V179 and Y318. The body of the ‘butterfly’ has interactions with the main 
chain atoms of Y188, Y189 and G190, and with the side chains of V106 and V179. The back of 
the ‘butterfly’ is flanked with residues L100 and L234, which interact with both wings.70 
 
Recent studies, including crystallographic analysis and computational modeling, have made it 
possible to develop drugs based on a deeper understanding of the structural features required 
for anti-HIV activity as well as conformational changes that may help in minimizing the drug 
resistance. The thiocarboxanilide UC-781 is one of these prototype anti-HIV drugs and also a 
member of a series of carboxanilide derivatives (Figure 1.25).14 Although it failed at an advanced 
stage of clinical trials, it has been identified as a potent inhibitor of HIV-1 replication. Further 
studies have shown it to be a useful microbicide.86 
Table 1.3 shows the effectiveness of UC-781 in terms of treatment on HIV-1-infected cells. It has 
been shown to have a favourable combination of both high potency (EC50 = 9 nM) as well as 
resistance to single point mutations such as L100I, K103N, Y181C and V106A.14 These 



















































Figure 1.25 a) Series of carboxanilide derivatives14, b) Jorgensen’s 2-pyrimidinylarylamines with the 
incorporated UC-781 pendent ring at the C-2 position. 
 
Table 1.3 Potency of Carboxanilide compounds against HIV-1 RT Wild Type and Mutants14 
                                                                EC50 (µM) {fold resistance} 
HIV-1 strain UC-10 UC-38 UC-84 UC-781 
L100I 0.242 {2} 2.06 {71} >112 {>2700} 0.024 {3} 
K103N 1.140 {8} - - 0.069 {8} 
V106A 0.370 {3} 2.06 {71} >61 {>1500} 0.015 {2} 
Y181C 0.214 {2} 1.9 {66} 42 {1000} 0.033 {4} 
Wild type 0.142 {1} 0.029 {1} 0.042 {1} 0.009 {1} 
     
 
The results in Table 1.3 also show how UC-781 is far superior to all its counterparts. It has been 
reported that UC-781 is a rapid tight-binding inhibitor of RT (Figure 1.26). Crystallographic 
studies have attributed partial evidence for this. The UC-781 inhibitor is able to form a strong 
hydrogen bond between its thioamide sulfur (pharmacophore amide hydrogen) and the main-
chain carbonyl oxygen of Lys101 (Figure 1.27a). This hydrogen bond is believed to form an 
anchor around which the carboxanilide inhibitor can pivot itself.14 Thioamides orientate in the s-
trans-configuration, while amide bonds adopt an s-cis-configuration according to IUPAC 
prioritization. Using biochemistry nomenclature these designations are swopped (Fig. 1.27b) to 
just ‘cis’ for the thioamide and ‘trans’ for the amide as defined by the relative orientatation of the 
R groups. Using biochemistry nomenclature it can be seen that the UC-781 thioamide adopts 
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Very recently, Jorgensen87 has demonstrated the use of 2-pyrimidinylarylamines as potential 
NNRTI’s. His 2-pyrimidinylarylamines (Fig. 1.25) showed excellent biological activities (5 nM for 
X = CN; 6 nM for X = Cl) supporting the motif in Figure 1.29b with the aromatic ring firmly 
embedded into Wing 2. These inhibitors presented a very good structural activity study on what 
is essential for good binding in the NNRTI-BP without having to go through the more exotic 
synthesis of the DAPY compounds.  
 
 
Figure 1.26 Stereo view of UC-781 in the NNRTI-BP. The H-bond is shown as the yellow line.14 
 
 
Figure 1.27 a) Schematic representation of the NNRTI-residues interaction, exemplifying the Lys101-
thioamide H-bond.14 b) IUPAC and Biochemistry nomenclature for cis and trans assigments around 
thioamides. 
 
The crystal structures of third-generation NNRTIs (ITU, DATA and DAPY compounds) bound to 
HIV-1 RT show a different, unique ‘horseshoe’ or ‘U’ mode88 compared to the butterfly-like 
nevirapine above. DAPY derivatives can adapt to changes in the NNRTI-BP, which plays a 
crucial role in overcoming point mutations in the pocket. The torsional flexibility of the DAPY 
structure permits access to numerous conformational variants, and their compact structure 
permits repositioning and reorientation (Fig. 1.28) when mutations are present in the NNRTI-
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conformationally distinct mode explains the exceptional spectrum of activity observed for this 
compound (Table 1.2).89 
Depicted in Figure 1.29a, the proposed docking of TMC125 and X-ray structure of TMC120, 
sees the pyrimidine-unit firmly embedded into the Wing I compartment of RT, together with the 
less-substituted phenyl ring (attached to C-2 of the pyrimidine) into the hydrophobic Wing II 
(interacting with Lys101 and Tyr318). However, the more substituted phenyl ring (attached to C-
4 of the pyrimidine) clearly exits the ‘front’ entrance of the pocket through its ‘ortho-position’ and 
leads off towards Glu188 and the p66 subunit of RT. The ‘para’-position of the C-4 phenyl ring 
points towards W229 which will become important later as a crucial interaction. 
 





Figure 1.29 a) Proposed docking site for TMC125 at the entrance of NNRTI binding pocket of HIV-1 
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1.13 NNRTI RESISTANCE 
Resistance mutations associated with NNRTI treatment failure occur primarily in and around the 
NNRTI-BP. The most common NNRTI-resistance mutations include Leu100Ile, Lys103Asn, 
Tyr181Cys, Tyr 188Leu, and Gly190Ala.92,93 Structural and molecular modeling studies of drug-
resistant HIV-1 mutants94, both in the presence and in the absence of bound NNRTIs, have 
suggested possible mechanisms by which key mutations confer resistance to NNRTIs. 
The Gly190Ala mutation, which causes high-level resistance to loviride and HBY-097, has no 
significant effect on the ITU, DATA, and the DAPY inhibitors. The resistance was proposed to be 
caused by filling the area of the binding pocket that would otherwise be occupied by the 
linker/body portion of the butterfly-shaped NNRTIs like loviride or by the quinoxaline ring of HBY-
097.95 The ITU, DATA, and DAPY inhibitors are not affected by the mutation, since a Cβ atom 
introduced by the Gly190Ala mutation would point toward the central part of the inhibitors (a 
thiourea, triazine or pyrimidine group). A minimum distance of 6.0 Ǻ between the Cα atom of 
Gly190 and the central part of these inhibitors suggests that there would be no serious steric 
conflict between the alanine at position 190 and the bound NNRTI.90 
Leu100,96 Tyr181,97 and Tyr18898 amino acid residues form a portion of the hydrophobic core of 
the binding pocket that interacts with Wing I of the ITU, DATA, and DAPY NNRTIs. Mutations of 
one or more of these amino acids can affect inhibitor-protein interactions and the size, shape, 
and chemical environment of the binding pocket.90 Previous studies have shown that the 
Tyr181Cys98 and Tyr188Leu95 mutation affect the binding of an NNRTI by loss of favorable 
aromatic ring interactions. The Lys103Asn mutation possibly affects the kinetics of inhibitor-
binding by stabilizing the unbound state of RT via the generation of an additional hydrogen bond 
between the Tyr188 phenoxyl group and the Asn103 side chain.95 
 
As has been already discussed, the DAPY NNRTIs have improved potency when compared to 
other NNRTIs. Crystal structure analysis and molecular modeling studies have suggested a role 
for conformational flexibility in compensating for the effects of NNRTI-resistance mutations. To 
explain this, TMC128 complexed with RT will be discussed. 
 
 
1.13.1 HIGH RESOLUTION STRUCTURES OF HIV-1 RT/TMC278 COMPLEXES 
TMC278 (Fig. 1.30) is a diarylpyrimidine (DAPY) NNRTI that is highly effective in treating wild-
type and drug-resistant HIV-1 infections in clinical trials at doses of ~25-75 mg/day.77 In a recent 
PNAS77 communication, Arnold and co-workers determined the structure of wild-type HIV-1 RT 
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by systematic RT mutagenesis. This was a remarkable feat considering that the underlying 
difficulty associated with crystallization of DAPY compounds lies in its effectiveness (position 
wiggling and jiggling) as an anti-HIV drug. Thus, the flexibility of the drug, and its binding mode, 
introduces heterogeneity into the periodic arrangement of RT/drug complexes in the crystal 
lattice.88 Literally thousands of crystallization attempts failed and the ‘best’ crystals diffracted X-
rays to only ~6.0 Ǻ resolution  before crystal engineering strategies were employed. This high-
resolution crystal structure revealed that the cyanovinyl group of TMC278 is positioned in a 
hydrophobic tunnel (Fig. 1.30) connecting the NNRTI-binding pocket to the nucleic acid-binding 
cleft,77 this discovery being a vital component of this thesis.  
 
Figure 1.30 a) Chemical structure of TMC278. The τ angles define the torsional flexibility of TMC278, b) 
The position of TMC278 and conformation in complex with wild-type HIV-1 RT. The position and 
conformation were defined by the difference (IFoI – IFcI) electron density calculated at 1.8 Ǻ , c) The 
molecular surface (orange) defines the hydrophobic tunnel that accommodates the cyanovinyl moiety of 
TMC278.77 
 
The crystal structures of TMC278 in complexes with the double mutant K103N/Y181C (2.1 Ǻ)
and L100I/K103N HIV-1 RTs (2.9 Ǻ) demonstrated that TMC278 adapts to bind mutant RTs. In 
the K103N/Y181C RT/TMC278 structure, loss of the aromatic ring interaction caused by the 
Y181C mutation is counter-balanced by interactions between the cyanovinyl group of TMC278 
and the aromatic side chain of Y183.  
 
Figure 1.31 Superposition of K103N/Y181C mutant RT (cyan ribbon, yellow side chains)/TMC278 
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Furthermore, superposition of this structure onto the wild-type RT/TMC278 structure revealed 
moderate conformational changes for the bound TMC278, thus exemplifying its ability to adapt 
to mutations (Fig. 1.31).77 The number of distances < 4.5 Ǻ between pairs of atoms, one from 
RT and the other from TMC278, acts as an indicator of the extent of the hydrophobic interactions 
between RT and TMC278. In the K103N/Y181C mutant RT/TMC278 complex, the numbers of 
these distances tally 51, where as in the wild-type, it tallies 52. This clearly shows that the 
mutation has a negligible effect on tight and specific binding. A moderate tilting of the angle of τ3 
by 5o results in displacement of the dimethylphenyl-4-cyanovinyl group away from the mutated 
Y181C side chain. The once crucial aromatic interaction between the dimethylphenyl ring of 
TMC278 and the aromatic side chain of Y181 is lost, and a void is created by the mutation. 
Regardless of these mutations, TMC278 is still capable of inhibiting K103N, Y181C mutants, and 
the K103N/Y181C double mutant at an EC50 < 1 nM.77 
 
In the L100I/K103N RT/TMC278 structure, the binding mode is significantly altered so that the 
drug conforms to changes in the binding pocket primarily caused by the L100I mutation. 
TMC278 inhibits the double mutant at an EC50 of ~8 nM. L100 is near the centre of the pocket 
and by default interacts with the pyrimidine ring in wild-type RT/TMC278 complexes; K103 is 
located on the other side of the pyrimidine ring (Fig. 1.30). When TMC278 binds to the mutant 
L100I/K103N mutant RT (Fig. 1.32), the drug undergoes major structural rearrangements 
compared to its wild-type RT binding. To avoid steric conflict with the L100I mutation, TMC278 
shifts away from I100 and towards N103 and the entire molecule is displaced by 1.5 Ǻ in the 
pocket.  
 
Figure 1.32 Comparison of L100I/K103N mutant RT/TMC278 (cyan) structure with the wild-type RT 
(yellow side chains)/TMC278 (gray) structures reveals wiggling (A) and jiggling (B) of TMC278.77 
 
The number of distances < 4.5 Ǻ between TMC278 and I100 is 12 in the complex with 
L100I/K103N mutant RT, which is appreciably less than the 28 and 30 distances in wild-type and 
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Ǻ for the residue 103. This increases from 16 and 17 in the wild-type and K103N/Y181C mutant 
structures, respectively, to 27 in the L100I/K103N mutant RT/TMC278 structure.77 
 
Very importantly though, the recent discovery by Arnold of the opening to a tunnel connecting 
the NNRTI pocket and the NRTI substrate site has offered powerful support for the double-drug 
concept, a suggestion previously proposed by both Arnold99 et al and Anderson79e et al. The first 
suggestion came from Arnold99 et al in 1993 who wrote: “An interesting approach that would take 
optimal advantage of the currently available structural information would be to design and 
synthesize inhibitors that would incorporate structural features from both nucleoside analogue 
and non-nucleoside inhibitors…… Synthesis of these agents would be challenging, but there are 
a number of substituent positions that could be used for the linkage. Sites of attachment for the 
linkers to nucleoside analogues include sugar ring positions (e.g. 2’, 3’ and 5’-substitutions), 
extensions of mono-, di- and tri-phosphate esters, and positions on the nucleoside bases (e.g. 
the 5-position of pyrimidine rings). Selection of sites of attachment on the non-nucleoside 
moieties would vary according to the inhibitor type.” 
This was followed by a Science article in 1995 in which Anderson79e wrote: “We have 
established the mechanism of inhibition of RT by the three (clinically approved) NNRTIs. 
Athough the long-term inhibition of RT is limited by the high frequency of mutation of the 
enzyme, this detailed understanding of the action taken by RT when presented with these 
inhibitors (i.e. that binding of a NNRTI does not stop the binding process of a NRTI) should 
assist in the search for effective drugs to attenuate the AIDS virus. In particular, the interaction of 
the nucleotide binding site and the non-nucleoside inhibitor site may provide a means to 
increase the effectiveness of drugs used in combination therapy. A single drug combining the 
functionalities of a nucleotide analogue and a non-nucleoside inhibitor would bind much more 
tightly because of the cooperative interactions between the sites.” These two research 
contributions effectively gave birth to the field of HIV bifunctional double-drugs. 
 
1.14 THE DOUBLE-DRUG STRATEGY 
The double-drug strategy involves a chemotherapeutic approach which combines two different 
classes of inhibitor into a single molecular entity via a linker, with the aim of improving the 
physicochemical characteristics of the individual compounds.100 Apart from HIV, the double-drug 
strategy has been employed in the synthesis of cancer,101,102,103,104 malaria,105,106,107 anti-
inflammatory and cholinesterase108 inhibitors, as well as in Alzheimers’s109 disease, for catechol-
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1.14.1 DOUBLE-DRUGS IN CANCER AND MALARIA 
5-Fluoro-2’-deoxyuridine (FDU) either as its 5’-O-butanoate or as its 5’-O-butanoate-3’-O-
retinoate (from retinoic acid) diester (Fig. 1.33) have been synthesized to act as anti-cancer 
double prodrugs that would serve as a means of releasing at least two active drugs that act 
through different mechanisms. The FDU, once released and phosphorylated, could act as a 
competitive inhibitor for thymidylate synthase whereas retinoic acid and butyric acid once 
released were expected to induce cell differentiation. The ester derivatives exhibited comparable 
activity to FDU.101 
Retinoids have been reported to induce differentiation and arrest proliferation in a wide spectrum 
of cancer cells and are currently used for treatment of promyelocytic leukaemia. Butyric acid is 
an effective inhibitor of cell proliferation and inducer of cytodifferentiation. In the case of 5’-O-
butanoate-3’-O-retinoate, a mutual prodrug combining butyric acid and all-trans-retinoic acid into 
FDU was evaluated for anticancer activity and was found to be more potent than the parent 
drugs.102 Furthermore, the differentiation activity elicited by the double-drug was greater than 
that of the combined parent acids. The large increase in activity was attributed to two factors: 
(i) The all-trans-retinoic acid fragment imparted lipophilicity and facilitated the penetration 
of butyric acid to the cellular target site. 












Figure 1.33 Examples of 5-Fluoro-2’-deoxyuridine (FDU) either as its 5’-O-butanoate or as its 5’-O-
butanoate-3’-O-retinoate diester. 
 
Similarly, the statine-based inhibitor of Plasmepsin (II) (PLM II) was linked to the antimalarial 
drug Primaquine (PQ) using a dicarboxylic acid linker (Fig. 1.34).  PLM II is one of the aspartic 
proteases involved in the degradation of haemoglobin during the intraerythrocytic cycle of 
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humans. Its toxicity levels can be minimised and its activity increased by converting it into a 
peptide prodrug. The PQ-Statine double-drugs showed remarkable improvement in the inhibition 
of both PLM II and P. falciparum growth in vitro. The double drugs kill the parasites mainly by 




























Figure 1.34 [Primaquine]-4,4’-oxy-bis(benzoic acid)-[PLM II]. 
 
Biot et al.106,107 synthesized double-headed antimalarial prodrugs (Fig. 1.35) that target two 
essential functions of the malarial parasite, namely glutathione regeneration and heme 
detoxification, with the aim of exploring their synergistic or additive effects. The double drugs 
combined a glutathione reductase (GR) inhibitor to a 4-aminoquinoline moiety with a 


























Figure 1.35 Examples of double-headed antimalarial prodrugs. 
 
1.14.2 DOUBLE-DRUGS IN HIV 
Several strategies have been employed in the chemotherapy and chemoprophylaxis of HIV 
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cell receptor for viral entry into the cell; (ii) gp-120 as the viral glycoprotein involved in virus 
adsorption to the cells; (iii) CXCR4 and CCR5 as co-receptors for viral entry; (iv) gp-41 as viral 
glycoprotein required for virus-cell fusion; (v) NRTI binding site of the HIV reverse-transcriptase 
(RT) enzyme; (vi) NNRT binding site of RT; (vii) integration of the proviral DNA into the host 
genome by the HIV integrase; (viii) proviral DNA expression (ix) HIV protease as mentioned in 
Section 1.7.23 Based on a combination of inhibitors for these targets, double-drug inhibitors of 
HIV can be divided into the following classes: 
 
(A) Fused:  Two drugs fused together to create a single entity that is active on each drug-target 
corresponding to the individual drugs. 
(B) Cleavable: Two drugs joined by a cleavable (via hydrolysis) linker (spacer) that can target       
either the same or different drug-target. The cleavable linkers are stable outside the target cell, 
but are cleaved to individual drugs once in the cell cytoplasm. 
(C) Non-cleavable: Stable (to hydrolytic cleavage) bifunctional entity (“mixed-site inhibitors”) 
whose rationale is to bind the drug entities simultaneously at distinct binding sites that are in 
close proximity on the same drug target. 
 
(A) FUSED DOUBLE-DRUG INHIBITORS FOR RT AND INTEGRASE (IN)  
Vince and co-workers synthesized fused double-drug inhibitors, also referred to as 
“portamanteau inhibitors” based on the fusion of a non-nucleoside reverse transcriptase (RT) 
inhibitor (NNRTI) with a diketoacid (DKA) integrase (IN) inhibitor pharmacophore.112 The best 
double-drug (Fig. 1.36) had a low cytotoxicity (EC50: 24 nM against RT; 4.4 µM against IN; 10 








 Figure 1.36 Structure of a portamanteau inhibitor combining an RT inhibitor with an IN inhibitor. 
 
(B) CLEAVABLE DOUBLE-DRUG INHIBITORS  
These have been by far the most common type studied with the emphasis on the synergistic 
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(i) NRTI / Co-receptor antagonist as double-drugs 
A combination of an HIV protease inhibitor and AZT into a single molecule has also been 
successfully used to improve poor membrane permeation. The protease inhibitor, KNI-727, 
unable to penetrate the cell membrane, was linked to AZT by a cleavable linker (Fig. 1.37) 
resulting in a boost in potency according to a MTT-cell assay by virtue of the parent components 
being released intracellularly (EC50 = 5.3 nM for the double drug, compared to 92.0 nM for KNI-

























Figure 1.37 Structure of the [AZT]-succinic-[KNI-727] conjugate. 
 
Similarly, Tamamura et al.115 employed the double-drug strategy to synthesize a bifunctional 
drug that incorporated a CXCR4 inhibitor (T140) as a co-receptor antagonist with an NRTI (AZT) 
linked by succinate. T140 is a 14-amino acid peptide which inhibits infection of target cells by T 
cell-line-tropic strains of HIV through specific binding to its chemokine receptor, CXCR4. An 
equimolar mixture of AZT and T140 caused a significant increase in anti-HIV activity compared 
to the single compounds (Fig. 1.38). This result led to the synthesis of conjugated compounds 
which combined each entity into a single molecule. The conjugated drug exhibited a synergistic 
effect for anti-HIV in vitro (EC50 = 4.6 nM in MT-4 cells with HIV-1, SI = > 4300; AZT = 20 nM; 
T140-succinic acid = 310 nM). The mechanism of action is based on the hydrolysis of the 
























Figure 1.38 Structure of the [AZT]-succinate-[T140] conjugate. 
 
Daoudi et al.116 synthesized bifunctional compounds combining bicyclam AMD3100 and a 
galactosylceramide (GalCer) analogue in a single molecule with the aim of inhibiting several 
steps of the complex virus/cell cascade interactions (virus-cell adsorption/fusion processes). The 
double-drug [Gal]-[AMD3100] conjugate (Fig. 1.39) exhibited superior potency to that of 
AMD3100 (EC50 = 0.065 μM in MT-4 cells with HIV-1; AMD3100 = 2.9 μM; GalSer = > 100 μM). 
AMD3100 is a CXCR4 antagonist and interferes with viral binding to the cellular co-receptors, 
whereas GalCer provides an attachment platform (alternative receptor in CD4- cells) for the virus 
(through its gp-120 and/or gp-41) onto the cell. When compared to the activity of GalSer, the 





















Gal-AMD3100 Conjugates  
Figure 1.39 Structure of the Gal-AMD3100 conjugates. 
 
Similarly, AZT coupled onto k-carrangeenan using a succinate diester spacer (Fig. 1.40) was 
synthesized with the aim of enhancing AZT intracellular uptake as well as to test the synergism 
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from different species of red seaweed that have a common structural backbone of D-galactose 
residues. The k-form is characterised by a repeating unit of 4-sulfate-b-D-galactopyranose linked 
1Æ3 and 3,6-anhydro-a-D-galactopyranose linked 1Æ4. 

































Figure 1.40 Structure of [AZT]-succinate-[k-Carrangeenan Conjugates]. 
 
The k-carrangeenan was expected to act not only as a drug-delivery carrier for AZT, but also as 
an anti-HIV agent which would act synergistically with AZT. Carrangeenans possess anti-HIV 
activity and inhibit the binding of the virions to the cell as gp-120 adsorption inhibitors, as well as 
cell-to-cell fusion inhibition. The [k-carrangeenan]-succinate diester-[AZT] conjugate inhibited the 
binding of the virions to the MT-4 cells and concomitantly delivered AZT to these cells to further 
inhibit the RT (EC50 = 6.8 nM, SI = 3000; AZT = 25 nM). 
 
(ii) Reverse Transcriptase Double-Drugs 
- NRTI homo/heterodimers 
Several NRTI homo- and heterodimers targeting the HIV reverse transcriptase enzyme have 
been synthesized by attaching the linker at the 5', 5 or N-3 positions of the nucleosides. Ijichi et 
al.118 have reported the synthesis of nucleotide heterodimers of AZT, ddI and Ribavirin. The 
dimers were formulated as a mixed phosphate diester via the 5'-hydroxyl groups of the 
nucleoside, with the aim of releasing two nucleosides at the active site. Thus, 5'-O-
phosphorylation of AZT gave AZT cyanoethyl phosphate 1, which condensed with ddI 2 in the 
presence of p-toluenesulfonyl chloride to afford heterodimer [AZT]-cyanoethylphosphate-[ddI] 3. 
Deprotection of the cyanoethyl group with 1N NaOH led to the heterodimer 4 (Scheme 1.1). 
Similarly, [ddI-phospho-Ribavirin] 5 (EC50 > 17.5 mM) and [AZT-phospho-Ribavirin] 6 (EC50 = 
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heterodimers 4 and 6 showed enhanced anti-HIV activity relative to their monomers. 
Furthermore, AZT-P-ddI 4 (EC50 = 0.002 mM, CC50 = 18.2 mM) was ~2-fold more toxic than AZT 
to human granulocytes macrophage progenitor cells (EC50 = 0.002 mM, CC50 =10.7 mM) for AZT; 



































































































Figure 1.41 Structures of AZT, ddI, Ribavirin and HEPU heterodimers. 
 
In a similar fashion, homo- and heterodimers of ddI, AZT and d4T have been synthesized by 
Mohamed et al.119 with the aim of enhancing the antiviral activity of their components (Scheme 
1.2). An ester linkage was used to link to a glutaric acid spacer. The synthetic strategy involved 
converting d4T 7 into half ester 8 by treatment with glutaric anhydride in methylene chloride, 
followed by an EDC-promoted esterification of the glutarate with ddI to form the heterodimer 9 in 
good yield (Scheme 1.2). AZT-ddI and ddI-ddI heterodimers bearing an ester linkage were also 
synthesized using this methodology. Other spacers used in this class of compounds were 
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and carbamates 11, respectively (Fig. 1.42). Following intracellular hydrolysis of the carbonate 
or carbamate, the two nucleosides would be regenerated in the cytoplasm. The carbonates 
displayed anti-HIV activity comparable to AZT, while the carbamates displayed low anti-HIV 
activities. No synergistic effects on the inhibition of HIV replication was detected for either the 


































Scheme 1.2 Reagents and Conditions: (i) Glutaric anhydride, Et3N, CH2Cl2; 85%. (ii) ddI/DMAP/EDC, 
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Similarly, the Ladurée group has reported the synthesis of a NRTI/NNRTI heterodimer of the 
formula [NRTI]-Glycyl-Succinyl-[Trovirdine].120 Nucleosides d4U, d2U and d4T were varied as 
the NRTI and spacer linking was achieved via the C-5' hydroxyl group of NRTI with the N-
piperazine of trovirdine. A succinyl-glycine moiety was chosen as a spontaneously cleavable 
linker, and introduced via coupling of the NRTIs with Boc-gly-OH using DCC in the presence of 
DMAP in DMF to give the 5'-esters 12. Deprotection of Boc using 4M HCl/dioxane afforded the 
amine hydrochlorides 13 which were condensed with trovirdine analogue derivatives 14 using 
BOP/HOBt in the presence of triethylamine in DMF to afford the heterodimers 15 a-c in 35-45% 
yield. The heterodimers were unfortunately devoid of antiviral activity at non-toxic concentrations 
















































































Scheme 1.3 Reagents and Conditions: (i) HOOC–CH2–NHBoc, DCC, DMAP, DMF; 78%. (ii) 4M 
HCl/Dioxane; 87%. (iii) succinic anhydride, CH2Cl2; 64%. (iv) Et3N, HOBt, BOP, DMF; 35-45%. 
 
The synthesis of an analogous system using C-5/NRTI as the attachment point121,122 (Scheme 
1.4) was accomplished employing a Sonogashira reaction. Pd(0)-mediated Sonogashira 
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Deprotection of THP using CF3COOH in CH2Cl2 followed by condensation of the resultant 
alcohol with Boc-Gly-OH using DCC in the presence of DMAP and subsequent deprotection of 
the Boc group using 4M HCl in dioxane afforded the amine hydrochloride 18. Condensation of 
amine 18 with trovirdine derivative 14 followed by deprotection of the acetate group with cyanide 
ion gave the heterodimer 20 in 35-45% yield for the last step. The heterodimers displayed 
inferior anti-HIV activity (compound 20 displayed an IC50 > 20 mM) compared to the parent 
compounds. The lack of activity was attributed to the wrong positioning of the linker to either 






































































Scheme 1.4 Reagents and Conditions: (i) alkyne, (PPh3)4Pd, CuI, Et3N, DMF; 67%. (ii) CF3COOH, 
CH2Cl2, CH3OH (iii) HOOC–CH2–NHBoc, DCC, DMAP, DMF (iv) 4M HCl/Dioxane (v) 14, Et3N, HOBt, 
BOP, DMF; 48%. (vi) NaCN, MeOH; 38%. 
 
Pederson et al.123 has been recently reported the synthesis and antiviral activities of cleavable 
NRTI/ NNRTI double-prodrugs against HIV based on the mixed S-acyl-2-thioethyl (SATE) 
prodrug approach. The SATE prodrugs were first introduced in 1993 by Imbach. et al.124 as a 
carboxyesterase-labile protecting group for the ddU nucleotide. The double pro-drug in question 
incorporated d4T as a 5’-phosphate and as a SATE ester linking through the phosphate to N-3 
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(fig 1.4) had good activities against HIV-1 (EC50 = 0.03 µM) and the Y181C mutant strain (EC50 = 
















Figure 1.43 Structure of Pedersen’s SATE-prodrug.123 
 
 
(C) NON-CLEAVABLE DOUBLE-DRUG INHIBITORS (MIXED-SITE INHIBITORS) 
- NRTI/NNRTI heterodimers 
The combination of a nucleoside and a non-nucleoside RTI into a single molecular entity was 
advocated by Nanni et al in 1993.99 This was supported by structural99 and biochemical125 
studies which indicated that linking the compounds with an appropriate spacer might result in an 
improved inhibitory capacity. The first heterodimers incorporating an NRTI with an NNRTI were 
synthesized by the Camarasa group in 1995.126 They reported the synthesis of a family of anti-
HIV heterodimers based on combining AZT with either TSAO-T or HEPT via a polymethylene 
spacer between the N-3 of the thymine base of both compounds (Scheme 1.5). TSAO 
derivatives were first synthesized in 1992 and represent a unique structural class of NNRTI as 
they specifically interact at the interface between the p51 and p66 subunits of HIV-1 RT. The 
prototype compound of this family is the thymine derivative designated TSAO-T and the most 
selective compound is its 3-N-methyl substituted derivative TSAO-m3T.  The synthetic strategy 
for formation of 22 and 23 involved selective N-3 alkylation of AZT with a dibromoalkyl reagent 
followed by N-alkylation of the N-3-bromoalkyl AZT intermediate with TSAO-T or HEPT. The 
polymethylene spacer was varied in length from n = 3-6. Thus, treatment of AZT with 2 equiv of 
1,3-dibromopropane in dry acetone:DMF (1:1) in the presence of K2CO3 gave the N-3 
substituted derivative 21. Subsequent reaction of 21 with TSAO-T or HEPT under basic 























































































Scheme 1.5 Reagents and Conditions: (i) (CH2)nBr2 (n = 3-9), K2CO3, acetone, DMF (1:1). (ii) K2CO3, 
acetone, DMF (1:1). 
 
The most active compound in the series was [TSAO-T]-(CH2)3-[AZT] 22a (EC50 = 0.10 mM; 
TSAO-T = 0.06 mM; AZT = 0.006 mM) incorporating a short spacer. Heterodimers bearing 
polymethylene linkers [-(CH2)n-] with n = 4-6 showed good antiviral activity, while longer spacers 
with n > 7 showed diminished activity. The precursors to the dimers were also tested. 
Specifically, AZT derivatives such as 21 proved inactive irrespective of the chain length of the 
methylene spacer. The activity of the TSAO-T-spacer derivatives 22d decreased with increasing 
length of the spacer. Replacement of AZT with d4T resulted in improved anti-HIV activity. No 
marked differences in activity were observed when the spacer consisted of 1-butynyl, 1-butenyl 
or ethoxyethyl moieties. Similarly, heterodimers 22b,c were synthesized using the C-5 of the 
NRTI for attachment, and these showed comparable activities to that of 22a, whereas the 
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Spacer rigidity in the C-5 series did not markedly influence the antiviral potency since the 
heterodimer 22c bearing a flexible propyl group as spacer was endowed with anti-HIV-1 activity 
comparable to that of the corresponding propynyl analogue 22b (Fig. 1.44). Converting AZT, 
d4T and thymidine heterodimers to phenoxyphosphoramidate127 prodrug heterodimers had no 
improved activity over the corresponding non-phosphorylated analogues. Overall, the d4T 
heterodimers had better inhibitory efficacy than the AZT ones. 
 
By comparison, combinations of TSAO-m3T and foscarnet (PFA) (Fig. 1.45) also synthesized by 
the Camarasa group as individual entities at a variety of concentrations revealed that these 
compounds displayed additive antiviral activity.128 These results inspired the synthesis of a 
single molecule combining a TSAO derivative with foscarnet through a labile phosphate ester 
bond. PFA is an effective antiviral agent approved for intravenous treatment of Human 
Cytomegalovirus (HCMV) Retinitis in patients with AIDS.129 It is also effective against HIV 




















Figure 1.45 Structure of TSAO-m3T and Foscarnet. 
 
Thus, treatment of TSAO derivative 24 with the foscarnet-based phosphorylating reagent 25 in 
the presence of triethylamine led to the formation of the PFA diester 17 in moderate yield. 
Catalytic hydrogenolysis of 26 yielded the [TSAO-T]-[PFA] conjugate 27 in 60% yield (Scheme 
1.6). Unfortunately, conjugate 27 was less active than the parent compound 24, displaying no 
additive or synergistic anti-HIV activity and thus indicating the activity to be due to the TSAO part 










































































Scheme 1.6 Reagents and Conditions: (i) (a) 25, Et3N, CH2Cl2, -20 °C (b) H2O; 54%. (ii) H2, Pd/C, MeOH; 
60%. 
 
The design, synthesis and anti-HIV-1 evaluation of several non-cleavable heterodimers of the 
general formula [d4T]-NH(CH2)n–NH-[imidazo[1,5-b]pyridazine] (n = 6-12) involving a C-5 
linkage to d4T was reported by Ladurée et al.131 in 1998. Imidazo[1,5-b]pyridazine was chosen 
as the NNRTI due to its exceptional potency. The synthetic strategy involved synthesis of the 
NNRTI linked to a 1,n-diaminoalkyl spacer followed by substitution onto d4T via a C-5 
chloromethyl group. The synthesis of the d4T coupling derivative (Scheme 1.7) involved C-5 
hydroxymethylation of protected uridine 29 to give 30 in good yield followed by C-2'/3' double-
bond introduction to afford 31 and selective chlorination of the hydroxymethyl group in the 
















































Scheme 1.7 Reagents and Conditions: (i) 2,2-DMP, APTS, MeCOMe. (ii) CH2O, Et3N, 60 °C; 93%. (iii) 
TMSCl, 1,4-dioxane, 60 °C. 
 
Imidazo[1,5-b]pyridazine 33 was synthesized in seven steps from alanine, and was heated with 
a 1,n-diaminoalkane at 120 °C to give monomers 34a-d via aromatic nucleophilic substitution. 
Condensation of 34a-d with 32 in DMF gave heterodimers 35a-d in 72-85% yield (Scheme 1.8). 
The anti-HIV activity of the NNRTI linked to its spacer 34a-d was evaluated independently and 
the results revealed a decrease in activity compared to the unsubstituted NNRTI. The activity of 
the heterodimers 35a-d was comparable to that of d4T and thus mainly due to the nucleoside 






































Scheme 1.8 Reagents and Conditions: (i) H2N–(CH2)n–NH2; a: n=6, b: n=8, c: n=10, d: n=12. (ii) 
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Similarly in 2000, Monneret and co-workers132 synthesized a variety of (N-3 and C-5)AZT -HEPT 
bifunctional conjugates displaying anti-HIV activity ranging between 2-5 μM. In the same report, 
a non-cleavable ddC-HEPT conjugate was found to exhibit an anti-HIV potency of 0.45 μM 
against HIV-1 (wild-type and the Y181C nevirapine-resistant strain) and HIV-2 in cell culture. 
The ddC component in the mixed inhibitor 38 (Scheme 1.9) was prepared in a one-pot 
procedure (33% yield), involving reaction of 5’-O-acetyl-2’,3’-dideoxyuridine 36 with 
triisopropylbenzenesulfonyl (TPS) chloride, followed by treatment with 1,12-diaminododecane. 
Coupling of amino derivative 37 with 37a using N-methylmorpholine (NMM) and 2-chloro-4,6-































Scheme 1.9 Reagents and Conditions: (i) TPSCl, Et3N, DMAP, DCM, then NH2(CH2)12NH2 (33%); (ii) 
CDMT, NMM, DMF, then 37a (69%). 
 
No synergistic effects were observed, and 38 appeared to inhibit RT through interaction of only 
one component (NNRTI) in its bis-substrate structure. A plausible reason offered by the authors 
is that the tethering arm is poorly adapted to permit the nucleoside and the NNRTI motifs to 
communicate simultaneously with their respective sites.  
 
In 2006, Hunter and co-workers100 reported the synthesis of [d4U]-butyne-[HI-236] as a non-
cleavable, bifunctional NRTI/NNRTI HIV-1 reverse transcriptase inhibitor. The Sonogashira 
coupling partner 40 was synthesized by iodinating 5'-O-benzoyl d4U 39, which was prepared in 
four steps from uridine according to the Bristol-Myers Squibb procedure for producing d4T from 
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nitrate (CAN) in acetonitrile at 60°C in 80% yield (Scheme 1.10) to afford 40, which underwent 
Sonogashira coupling with alkyne 41 to yield the desired coupled product 42 in 69% yield. With 
42 in hand, benzoyl deprotection, Boc removal and thiourea installation remained for completion 
of the synthesis, and a number of permutations were tried out. Eventually, it was established that 
debenzoylation as the final step worked best, as the protected alkylated d4U moiety appeared to 
be less prone to acid-catalysed anomeric cleavage with the trifluoroacetic acid used to deprotect 
the Boc group. Thus deprotection of the Boc group of 42 using trifluoroacetic acid in methylene 
chloride at 0 °C furnished the crude amine as a trifluoroacetate salt. Processing involved adding 
Hünig’s base to liberate the amine, and condensing directly with thiocarbonyl derivative 43 at rt 
overnight in THF.  This contrasted with the much harsher conditions used by Bell and co-
workers of heating in DMF at 100 °C. In this fashion, bifunctional benzoate 44 was produced in 






























































Scheme 1.10 Reagents and Conditions: (i) I2, CAN, CH3CN, 60 °C, 1 h (80%); (ii) alkyne 38, (PPh3)4Pd 
(10%), CuI (50%), Et3N (2 eq.), DMF:THF (1:2), rt, 4 h (69%); (iii) CF3COOH, CH2Cl2, 0 °C; (iv) EtN(i-Pr)2 
followed by 40, THF, rt / overnight (60% for 2 steps); (v) NaOMe (cat), MeOH, 0 °C, 20 min (51%). 
 
Final deprotection with catalytic methoxide in methanol furnished the target 45 in 51% yield and 
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infected cells of the prototype bifunctional compound 45 was found to be 0.25 μM. The biological 
results (EC50 = 0.0048 μM for HI-236; d4T = 1 μM) led to the conclusion that the prototype 
compound 45, as with the Monneret compound 38 in Scheme 1.9, behaves as an extended 
NNRTI with no synergistic effects. 
 
In conclusion, most approaches have pursued the easier synthetic option of connecting the 
tether via the C-5' OH or N-3 of the nucleoside base. For the C-5 heterodimers, linker 
attachment has been achieved via a Pd(0) Sonogashira coupling (compound 20) or 
hydroxymethylation of uridine (compound 35a-d). Most of the heterodimers were designed as 
prodrugs linked with a cleavable tether, with the aim of regenerating the parent drugs once in the 
cell cytoplasm. Non-cleavable systems have as yet not demonstrated the mixed-site synergistic 
principle, probably as a result of inappropriate choice of the positioning of the spacer 
attachment.  
Crucial to this thesis, was the use of either d4T or d4U as the NRTI Sonogashira coupling 
partner used in most of the syntheses covered above, thus strategies towards this important 
coupling partner will be discussed in next.  
 
1.15 STRATEGIES USED IN THE SYNTHESIS OF D4T 
Horwitz et al.133 reported the first synthesis of d4T 7 in 1964 as a potentially novel anti-cancer 
drug. The strategy involved conversion of 3',5'-anhydrothymidine 47 to d4T by a base-mediated 
elimination reaction. Thus, 2'-deoxythymidine 46 was readily converted into 1-(3',5'-anhydro-2-
deoxy-b-D-threo-pentofuranosyl)-thymine 47 by converting it first into its 3',5'-di-O-mesyl 
derivative, and then by heating the crude product under reflux with an excess of aq. sodium 
hydroxide. Formation of oxetane 47 from the dimesylate of 46 proceeded via intermediacy of the 
pyrimidine base with the ring closing step as shown. Eliminative opening of oxetane 47 was 
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Prolonged exposure of d4T to strong base at high temperature led to decomposition to give 
thymine as an undesired product thereby decreasing the overall yield. 
 
In an attempt to overcome the decomposition of d4T just mentioned, Mansuri et al. 134 
precipitated the 5'-alkoxide potassium salt of d4T by adding solvents such as toluene and 
acetone during work-up. Skonezny et al,135 in a US patent, disclosed an improved process for 
producing d4T from the oxetane intermediate 47 by eliminating with potassium hydroxide in 
isopropanol. 
 
In a modified procedure of Horwitz, Reese et al. (Scheme 1.12) converted 2'-deoxythymidine 46 
directly in one step into anhydro derivative 48 in 68% yield via a 3'-sulfite ester leaving group. 
The key elimination reaction to form d4T in 76% yield was achieved by reacting anhydro 

























Scheme 1.12 Reagents and Conditions: (i) (PhO)2SO, 1-methylimidazole, DMA; 65%. (ii) NaH, DMA, 100 
°C; 81%. 
 
Chen et al. (Scheme 1.13) from the Bristol-Myers Squibb group synthesized d4T from 5-
methyluridine. This was achieved by base-mediated conversion of the trimesylate of 49 into 
epoxide 51 via intermediate 50, which opened with acetyl bromide to afford a regioisomeric 
mixture of trans bromoacetates 52a-b. b-Elimination with a Zn/Cu couple afforded 5'-mesyl d4T 
53 under mild reductive elimination conditions, without significant nucleoside bond cleavage137 































































Scheme 1.13 Reagents and Conditions: (i) (1) MsCl, NMM, acetone (2) 1N NaOH/H2O; 82%. (ii) (1) AcBr, 
MeOH (2) AcBr, CH2Cl2; 92%. (iii) Zn/Cu, MeOH; 88%. (iv) PhCO2Na, DMF; 91%. (v) BuNH2; 90%. 
 
 
Alternatively, the use of a sulfonyl group at the 3'-position of 5-methyluridine instead of an acetyl 
group in the syn-bromomesylate 56 completely avoided the undesired cleavage of the thymine 
base (Scheme 1.14). D4T was prepared employing this methodology in 75% overall yield 
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Scheme 1.14 Reagents and Conditions: (i) MsCl, NMM, acetone; 97%. (ii) PhCO2Na, CH3CONH2; 90%. 
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The key step in the synthesis was the zinc-induced reductive elimination of bromomesylate 56, 
which afforded d4T without nucleoside bond cleavage. Sodium benzoate acted as a base to 
form anhydro ring 55 as well as a nucleophile to displace the 5'-mesyl group, preparing the way 
for the final facile deprotection with butylamine.  
 
1.16 OBJECTIVE OF THE STUDY 
The use of combinations of different drugs is designed to prevent resistant HIV strains by 
effectively suppressing viral replication overall, thus denying HIV the opportunity to produce new 
mutations. This principle holds provided there is minimised cross-resistance between the drugs. 
NNRTIs act by slowing down the chemical step catalyzed by RT, and this retardation allows the 
two-step binding of NRTI to come to equilibrium leading to tighter binding of the nucleotide. The 
research in this thesis aimed to:  
(i) Synthesize and evaluate the anti-HIV activity of heterodimers of the general   
                        formula [NRTI]-spacer-[NNRTI] involving a biologically non-cleavable spacer, in  
                        the search for evidence of synergism between the two drugs and hence sites.   
                        The NRTI chosen initially was d4U, but was later evaluated as a acyclic  
                         nucleoside in an attempt to accommodate phosphorylation problems. The  
                         NNRTI employed moved from the second-generation UC-781139 to the third- 
                         generation TMC120.140 
(ii) Evaluate a structure-activity relationship by synthesizing different length linkers, 
as well as to probe the exact/minimum components of the NNRTI required to 
achieve good biological activity. In this study the possibility existed for finding new 
exciting lead compounds/derivatives for further exploration. 
(iii) Synthesize and evaluate the anti-HIV activity of all compounds synthesized. 
  
UC-781 and TMC120 were selected due to their potency against wild-type and NNRTI resistant 
HIV-1 strains (carrying the NNRTI resistant mutations K103N, V106A and Y181C). D4T is 
currently used to treat HIV, and was chosen owing to its higher inhibitory effect compared to 
AZT.  
As proposed by Arnold, the attachment for the linkers to nucleoside analogues include sugar 
ring positions (e.g. 2’, 3’ and 5’-substitutions), extensions of mono-, di- and tri-phosphate esters, 
and positions on the nucleoside bases (e.g. the 5-position of pyrimidine rings). Selection of sites 
of attachment on the non-nucleoside moieties would vary according to the inhibitor type. These 
attachment points and the rational behind it will be discussed in detail in the results and 
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SYNTHESIS OF d4U-SPACER-UC-781 DOUBLE-DRUGS 
 
2.1 Strategy for the synthesis of [d4U]-spacer-[UC-781] 
The bifunctional molecules 58 and 59 targeted in this chapter are shown in Fig. 2.1 below. The 
C-5 position on the pyrimidine moiety (base) of d4U was chosen as the appropriate attachment 
point for the tether following a report by Ruth and Cheng in the early 1980’s, which 
demonstrated that a chain extension at the C-5 position caused minimum steric hindrance with 
DNA base-pairing.141 Furthermore, it has been reported142 that tethering at the C-5 position with 
a flexible chain of about 10 Ǻ still allows 5’-triphosphate generation leading to incorporation into 
nucleic acids. In our study, two variations were explored in the physiochemical composition of 
the spacer. Target 58 was chosen containing a simple aliphatic tether joined to an alkynyl 





























C-5 of the base
C-2 of the furan
 
Figure 2.1 Structures of the target molecules. 
 
Very recently, the Jorgenson group has provided excellent insight into the attachment point of 
the tether to d4U through their modeling studies.143 At the time of project inception, no computer 
modeling studies had been reported, though, in the bifunctional setting. Over the years, many 
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of understanding the mechanism through which these inhibitors operate, including key residue 
binding interactions in their respective sites and their ability or lack thereof to combat drug 
resistant mutations. Crystal structure information was available, but none dealing with issues 
relating to synergy between the substrate binding site and the NNRTI-BP. Therefore, our C-5 
connection to d4U was based on a rudimentary molecular modeling interpretation of the growing 
DNA chain at the substrate active site. Work done by Uckun and co-workers143 in 2000 depicted 
in Figure 2.2 clearly shows how a C-5 connection to the base (in this instance a 5-methyluracil 
moiety of a 5’-phosphorylated thymidine unit in the DNA chain) with an appropriately long spacer 
might ‘exit’ the substrate site with low interference to DNA base-pairing, leading to the NNRTI-
BP. The NNRTI-BP is referred to as the ‘NNI’ in the Uckun paper, and so also in Figure 2.2.  
 
Figure 2.2 Modeling studies of the C-5 extension point of d4U.143 
 
Structural studies carried out by Stammers and co-workers14 on UC-781 in complex with HIV-1 
RT, have revealed that elongation at the C-2 or C-5 positions of UC-781 could lead past Trp229 
towards Glu138 and the p66 subunit, which in theory might access the NRTI binding site (Fig. 
2.3). The C-2 position was chosen as the attachment point to the spacer (tether) based on the 
synthetic promise for C-2-alkylation of the furan moiety of UC-781. Again, it is well worth 
mentioning that at the time of our study we were not aware of the hydrophobic tunnel that could 
plausibly exist (connecting the NNRTI-BP to the nucleic acid-binding cleft) upon binding of an 
NNRTI as described by Arnold77 in his recent TMC-278 work (Fig. 2.3), and all our attachment 










CHAPTER 2:_________________________________R & D - Synthesis of d4U-spacer-UC-781 
 61 
rational in-depth considerations were made regarding both the attachment points of the NRTI 
and the NNRTI in view of the difficulty previous groups had in understanding these issues. 
 
Figure 2.3 a) Schematic drawing of UC-781 in the NNRTI-BP. b) Hydrophobic exit tunnel as illustrated by 
Arnold and co-workers for TMC278. 
 
Attachment of the linker to the C-5 position of the nucleoside was thought to be accessible via a 
Sonogashira144 palladium cross-coupling reaction of a terminal alkyne with a 5-iodo nucleoside. 
This particular method has been used extensively by the Ladurée129,130 group in preparation of 
C-5 tethered heterodimers. Furthermore, C-5 substituted pyrimidine nucleosides constitute a 
class of biologically significant molecule and the C-5 alkenyl and alkynyl-substituted ones have 
shown various antiviral activities. For example, (E)-5-(2-bromovinyl)-2’-deoxyuridine (BVDU) 
(Fig.2.4) is a highly potent and selective anti-Herpes agent currently in limited clinical use for 
Herpes Simplex virus type 1 (HSV-1).145 Also, 5-iodo-2’-deoxyuridine (IDU) and 5’-
trifluoromethyl-2’-deoxyuridine (TFT) are both administered as eye drops or ophthalmic cream in 
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2.1.1 Retrosynthetic analysis of [d4U]-spacer-[UC-781] 
The total synthesis of targets 58 and 59 was conceived as achievable via a convergent strategy 
involving the coupling of 5’-iodo d4U 60 to an alkyne of type A followed by deprotection of the 
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where PG = Bz 
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It was anticipated that sodium methoxide would be used to deprotect the benzoyl group without 
promoting nucleoside base cleavage. However, there was some concern regarding the reactivity 
and potential interference of the thioamide group in A under Sonogashira coupling conditions. 
Alkyne A would be obtained from amide coupling of furanoic acid B with substituted arylamine 
61, whose synthesis is discussed in Chapter 3. The development of new Wittig carbon-carbon 
bond-forming methodology for the 2-alkylation of phosphonate salt 63 with aldehyde D to furnish 
C was planned as new methodology for the 2-alkylation of 3-furoates.147 
 
The key 5-iodo d4U 60 would be synthesized according to the Bristol-Myers-Squibb138 
methodology for d4T (Stavudine) production as outlined in Scheme 1.14. 
 
2.1.2 Literature overview on Sonogashira Coupling 
The Sonogashira coupling of 5-iodouridine with terminal alkynes has been extensively 
studied,148 and the mechanism of this reaction involves oxidative insertion of Pd (0) into the 
aryl/alkenyl-halide bond. CuI activates the alkyne by forming a copper acetylide, which 
undergoes transmetallation with the palladium complex to form the alkynyl-Pd-R intermediate. 
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Figure 2.6 Sonogashira reaction mechanism. 
 
Regarding literature precedent for our approach, Crisp and Flynn149 have demonstrated that the 
C-5 alkynyl derivatives 66 could be obtained in high yield (70-90%) by cross-coupling of 
acetylated uridine triflate 64 with a range of terminal alkynes 65 (Scheme 2.1) using 
tetrakis(triphenylphosphine)palladium(0) as a catalyst. A slight elevation of reaction 
temperatures from ambient to 45 oC increased the rate of coupling. In this case, 
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Similarly, Robins et al150 applied the Sonogashira reaction to couple protected 2’-deoxythymidine 
derivatives 68 with several alkynes 69 in triethylamine at 50 oC in the presence of 
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In this case, the extent of cyclization to form 71 was dependent on the reactants. Thus, coupling 
of 68a with (trimethylsilyl)acetylene gave the target product 70 in 80% yield, whereas the use of 
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same conditions gave the cyclized furanopyrimidin-2-one compound 71 as the major product. 
Conversely, coupling reactions with the same range of alkynes but using the nucleoside 
protected as its p-toluyl ester proceeded smoothly with minimal formation of deiodinated and 
furanopyrimidin-2-one by-products.150 
 
Hobbs151 (Scheme 2.3) attempted to use conditions optimized by Robins et al to couple 
propargylamine derivative 73 with unprotected 5-iodouridine 72 but failed owing to the 
nucleoside’s insolubility in triethylamine. Successful coupling was achieved to form the coupled 
products 74 in good yields (70-90%) by using DMF as a solvent and 
tetrakis(triphenylphosphine)palladium as a catalyst instead of the Pd(II) used by Robins. He 
concluded that the successful coupling by Robins revealed that the use of DMF significantly 

































Sonogashira coupling of protected propargylamine 73a with 2’-deoxynucleoside 75 by the 
Robins group in the presence of triethylamine as a base furnished the target nucleoside 76 
together with triethylammonium salts that were difficult to separate. To improve the purification of 
these nucleosides, Garg et al.153 developed a heterogeneous protocol that employed a 
palladium-on-carbon catalyst and a resin-bound tertiary amine (Amberlite IRA-67) as a base. 
These conditions furnished the coupled product 76 in good yield (Scheme 2.4). The study 
involved a cross-coupling reaction of nucleoside 75 in the presence of Amberlite IRA-67 and 
Pd(0) (10 mol%), which resulted in the coupled compound 76 in 79% yield after filtration of the 
reaction media and purification by column chromatography. The authors then substituted Pd(0) 











































C-5 alkynylated d4U analogues 79 and 81 have been synthesized via the smooth and efficient 
coupling of alkynes 78 and 80 with 5’-O-acetyl-5-iodo d4U 77 in DMF under co-catalysis of Pd 
and CuI (Scheme 2.5). Reaction with unprotected alkynes 80 gave the coupled compounds 81 
after 22-24 hrs in low yields (35-45%), whereas the protected alkynes 78 gave the target 
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In summary, the use of CuI as a co-catalyst has been shown to give better results. A mole ratio 
of 2:1 copper to palladium has been shown to offer the best coupling conditions for alkynes, 
leading to the minimization of side products (cyclic furanopyrimidine). It is noteworthy that 
performing the reaction in the presence of CuI has also been reported to increase the 
conversion rate to by-products. The choice of solvent has been reported to be an important 
determinant for the successful coupling of terminal alkynes with iodonucleosides,152 and the use 
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percentage of cyclized by-product was isolated when longer reaction times were employed or 
when an electron-withdrawing group on the nucleoside was present. In general, optimal 
conditions have been found to be 2.0-2.5 eq of terminal alkyne, 10% Pd(PPh3)4, 20% CuI and 
1.2 eq Et3N in DMF. Pd(0) has been reported to give better results than Pd (II).148 
 
2.2 Synthesis of Target double-drug compounds 
 
2.2.1 Synthesis of [d4U]-pentane-propyne-[UC-781] 
2.2.1.1 Synthesis of 5'-iodo d4U 
The 5’-O-benzoyl d4U derivative 86 was synthesized in four steps according to the Bristol-Myers 
Squibb procedure outlined in Scheme 2.6.138 Thus, reaction of uridine with methanesulfonyl 
chloride (3.0 eq.) in pyridine yielded trimesylate 83 in good yield. Isolation of the product was 
achieved by adding the reaction mixture to ice-cold water and allowing for the product to 
precipitate out. Filtration of the precipitate followed by extensive washing (H2O) and drying on 
the pump gave the desired 83 as evidenced by its 1H NMR spectrum, which revealed the 
presence of three mesylate singlets resonating at δH 3.22, δH 3.33 and δH 3.35. Its 13C NMR 
spectrum displayed resonances at δC 37.9, 37.9 and 36.9 for the three methyl groups together 
with the other (uridine) signals. 
 
The next step involved a chemoselective substitution reaction at the C-5’ centre as well as a C-
2,2’-anhydro ring-closure required for subsequent bromination. To this end, trimesylate 83 was 
reacted with sodium benzoate in molten acetamide at 140 oC. After 1 hr, the reaction mixture 
was poured into ice-cold water, the precipitate stirred at 0 oC for 15 min and the desired 
(Baldwin’s rules favours 5-exo-tet) solid product 84 was filtered off in 75% yield. Its 1H NMR 
spectrum displayed the absence of an NH singlet at δH 11.51 present in 83 as well as the 
appearance of additional resonances in the downfield region for the aromatic protons of the 
benzoyl group. Its 13C NMR spectrum displayed the appearance of a second carbonyl carbon at 
δC 170.6 as well as aromatic carbons, further confirming the presence of the benzoyl group, 
which could be assigned as being on the C-5’ oxygen in view of the relative deshielding of the 
diastereotopic H-5’ protons. There was also a significant downfield shift in the C-2’ carbon from 
δC 76.0 in 83 to δC 86.0 in 84, thus confirming that displacement of the mesylate and formation of 
the anhydro ring had taken place at this carbon. C-2’ over C-3’ attack by the pyrimidine base is 
favoured in agreement with Baldwin’s rules that state that a 5-exo-tet cyclization should be 
kinetically faster than a 6-exo-tet process. A further factor, possibly even more dominant, is the 




























































Scheme 2.6 Reagents and Conditions: (i) (1) MsCl, pyr, 0 oC, 5 hrs (71 %); (ii) NaOBz, CH3CONH2, 140 
oC, 1 hr (75%); (iii) AcBr, EtOAc/MeOH (10:1), reflux, 1 hr (97%); (iv) Zn, EtOAc/MeOH; rt (89%); (v) I2, 
CAN, CH3CN, 35 oC, 3 hrs (80%). 
 
 
Acid-catalyzed anhydro-ring opening of 84 by bromide ion generated as HBr in situ from the 
reaction between acetyl bromide with MeOH in EtOAc (1:10) gave the C-2’ substituted cis-
bromomesylate 85 in an excellent yield of 97%. The presence of the bromine atom in product 85 
was evident in the 1H NMR spectrum which displayed an upfield shift in the H-2’ protons from δH 
5.69 in 84 to δH 4.67 in 85. The 13C displayed a similar trend for the C-2’ resonance moving 
upfield from δC 86.0 in 84 to δC 47.5 in 85, consistent with a bromide substitution. The 
mechanism of the reaction involves an SN2 displacement by bromide at the C-2’ position via a 
protonated pyrimidine moiety acting the role of the leaving group. The resultant effect is 
inversion of configuration at C-2’ to afford the syn stereochemistry shown in 85. 
 
Reductive elimination of bromomesylate 85 using zinc metal in ethyl acetate and methanol 
containing acetic acid afforded the 5’-O-benzoate ester of d4U 86 in 89% yield. A downfield shift 
was observed for the C-2’ and C-3’ carbons in the 13C spectrum of 86 from δC 75.6 and δC 47.5 
in 85 to δC 133.6 and δC 127.2 respectively, confirming the introduction of the double bond via 
elimination of the bromine and mesylate groups. The disappearance of the mesylate carbon at 
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trans-elimination of bromine and the uracil base at C-1’ was not observed, in spite of the 
preference of anti over syn on stereoelectronic grounds. This was undoubtedly due to the 
superior leaving ability of mesylate, an issue well thought out by the Bristol-Myers-Squibb group. 
 
As mentioned before, halogen-substituted nucleosides exhibit interesting antiviral 
properties.145,155 Prusoff et al described the first 5-iodination of uridine using an iodine/nitric acid 
combination.156 Dale et al subsequently reported the iodination of 5-mercuriuridine derivatives 
using elemental iodine in aqueous alcohol.157 The CAN-mediated C-5 halogenation of uracil 
derivatives was first reported by Asakura, et al in 1990, in which either molecular iodine, NaI or 
LiI were used as the source of iodine.155 In this project the CAN-mediated strategy for 
conversion of 86 to its 5-iodo d4U 60 derivative using elemental iodine and CAN at 35 oC was 
chosen. The reaction was very much time and temperature sensitive. Excessive heating over 35 
oC or long reaction times (over 4 hrs) resulted in the migration of the benzoyl group from the C-
5’-hydroxyl to the pyrimidine nitrogen. However, one could obtain a high yield (80%) running the 
reaction at 35 oC for 3 hrs. The 1H NMR spectrum supported iodination by virtue of the 
disappearance of the two uracil doublets for H-5 and H-6, and the appearance of a singlet for H-
6 at δH 7.86. 
 
2.2.1.2 Synthesis of tethered UC-781, Sonogashira coupling and Deprotection 
2,3-Disubstituted furans constitute a widely encountered sub-unit in a range of natural and 
synthetic products.  The 2-alkylation of 3-furoic acids has been a commonly employed strategy 
for entry158 into this sub-unit with two carbanionic methodologies standing out as versatile 
options.  Knight was the first person to demonstrate159 that treatment of 3-furoic acid with two 
equivalents of LDA (THF / -78°C) regioselectively furnishes the dianion 87 (Figure 2.7), which 
can be C-2 alkylated with a range of reactive electrophiles. However, with less reactive 
electrophiles, e.g. ethyl iodide, yields were low.  Keay and co-workers subsequently 
demonstrated160 that 2-methyl-3-furoic acid reacts with two equivalents of n-BuLi at -20°C to 
furnish the 2-lithiomethyl dianion 88 which is more stable than 87, giving higher yields with less 
reactive electrophiles.  Development of 88 followed pioneering work by Tada et al161 on use of 


























Figure 2.7 Well known strategies for 2-alkylation of 3-furanoic acids. 
 
In view of both the need for access to reasonable quantities of 2-alkylated-3-furoates in 
conjunction with incorporation of the non-nucleoside inhibitor UC-781 into the bifunctional 
inhibitor, and the unattractive prospect of using large quantities of n-BuLi, we embarked on a 
study to identify a large-scale alternative. It occurred to us that Wittig methodology based on the 
3-methoxycarbonyl-2-furanylmethylphosphonium salt (see 90 in Scheme 2.7) might provide the 
answer in view of the option of using a mild base to generate the stabilized ylide. Although 2-
furanylmethylphosphonium salts162 have been known and used in synthesis for some time, the 
corresponding 3-furoates were hitherto unknown before our study.   
 
To this end, radical bromination of commercially available methyl 2-methyl-3-furoate using 
conditions reported by Khatuya163 furnished methyl 2-bromomethyl-3-furoate in high yield, which, 
following evaporation of solvent and addition of triphenylphosphine in toluene furnished (rt, 
overnight) the desired and novel triphenylphosphonium salt 90 by filtration.  Isolation of product 
involved no chromatography, with a single crystallization from methanol returning analytically 
pure material in 80% overall yield. 
Pleasingly, reaction of 90 in methanol with sodium methoxide as base at room temperature 
followed by addition of hexanal (1.2 eq) as a model aldehyde resulted in rapid transformation to 
the Wittig product 91a in high yield (92%) as a mixture (~1:1) of E/Z stereoisomers.  Carrying the 
reaction out in THF using sodium hydride as base gave a significantly lower yield (~50%) of the 
Wittig product in a higher E/Z ratio to that obtained using sodium methoxide. Subsequent 
hydrogenation (H2 / Pd-C) gave the anticipated 2-alkylated product 91b in high yield (80%).  A 
small percentage (~10%) of the 4,5-dihydro-2-alkylated product164 was also obtained, which 































(iii) =  Wittig product 91a
 
Scheme 2.7 Reagents and conditions: (i) NBS, (BzO)2  (cat), CCl4, ∆; (ii) PPh3, toluene rt, (80% over two 
steps); (iii) NaOMe (1.1 eq), MeOH, C5H11CHO (92%); (iv) H2, Pd-C, EtOH (80%). 
 
A range of aldehydes appropriate to producing alkylated side chains were subjected to the 
olefination/hydrogenation sequence and the results are presented in Table 2.1. Reactions 
involving formaldehyde, ethanal and 5-benzyloxypentanal all underwent smooth Wittig reactions 
in high yield as with the model reaction and, where appropriate, similarly gave products with 
about an equal E/Z isomer ratio. Subsequent hydrogenation of each one gave a small 
percentage of the 4,5-dihydro derivative as in the hexanal case, which could be separated from 
the desired alkylated product by careful silica-gel column chromatography. This new 
methodology culminated in a Tetrahedron Letters communication147 being published in 2005. 
The Wittig product of interest for the synthesis of the tethered UC-781 was 92d which was 
obtained in a 91% yield. The 1H NMR spectrum of 92d displayed a characteristic E:Z ratio of 1:1 
best evaluated using the allylic H-3’ quartet of doublets signals resonating at δH 2.62 and δH 2.28 
for the E- and Z-isomers respectively (Fig. 2.8). This ratio (1:1) was further supported by the 
appearance of the vinyl H-2’ doublet of triplets resonating at δH 6.51 (J = 16.0, 7.1 Hz, E-2’) and 
δH 5.84 (J = 12.0, 7.6 Hz, Z-2’). Finally, a correct HRMS evaluation (m/z HRMS (EI) 314.1511, 


















92 93  















CHAPTER 2:_________________________________R & D - Synthesis of d4U-spacer-UC-781 
 72 
Table 2.1 Wittig olefination and hydrogenation of 90 with various aldehydes 
R of RCHO % Yield of 92 % Yield of 93 
a) H 92 80 
b) CH3 90 61 
c) C5H11 92 80 
d) C4H9OBn (90a) 91 94 
 
 
Figure 2.8 1H NMR spectrum of 92d displaying the E:Z ratio of 1:1. 
 
Hydrogenation of alkene 92d resulted in concomitant hydrogenolysis of the benzyl ether 
(Scheme 2.8), which will be the only derivative further discussed because the others (i.e. 92a-
92c) were all model reactions. To this end, hydrogenolysis of 93d in situ rendered the desired 
alcohol 94 in 94% yield. Key spectroscopic assignments in its 1H NMR spectrum were the 
disappearance of the benzyl ether aromatic signals at δH 7.20 - δH 7.40 in 92d as well as the 
benzyl ether methylene signal at δH 4.52. This was further supported by the absence of the 
double bond signals at δH 6.53 and δH 5.82. Subsequent tosylation of 94 using p-toluenesulfonyl 
chloride and triethylamine in dichloromethane with a catalytic amount of N,N-
dimethylaminopyridine furnished 95 in 94% yield after silica-gel chromatography. Diagnostic 
peaks in the 1H NMR spectrum of 95 were the methyl singlet at δH 2.42 integrating for the three 
hydrogens of the aromatic methyl, together with the appearance of the typical aromatic AB 
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NMR spectrum of 95 clearly displayed new aromatic signals at δC 129.7 and δC 127.8 for the 
aromatic carbons bearing hydrogens. Substitution of tosylate 95 with propargyloxy anion, formed 
in situ from the reaction of sodium hydride and propargyl alcohol in tetrahydofuran at room 
temperature furnished the propargyl ether 96. Interestingly, the substitution proceeded more 
efficiently this way round, i.e. was superior than propargylation of the alkoxide of 94 with 
propargyl bromide. The propargyl ether 3-furoate 96 was never isolated because TLC always 
revealed a considerable amount of hydrolysis to the furoic acid 97. Thus, a one-pot base-
mediated ester hydrolysis with potassium hydroxide dissolved in ethanol was developed to yield 
furoic acid 97 in 98% yield over two steps. Conversion to the acid chloride 98 with an excess of 
thionyl chloride was achieved in 1 hr at 40 oC, after which the excess thionyl chloride was 
removed under reduced pressure. The crude product was redissolved in dichloromethane and 
subsequent addition of dry pyridine at 0 oC followed by the substituted aniline 61 (Figure 2.5) 
furnished amide 99 in a high overall yield (78%; 2 steps) from the acid. The 1H NMR spectrum of 
99 confirmed that a successful amide coupling had taken place with the appearance of a broad 
amide NH signal at δH 7.36 (Fig. 2.9). The dimethylallyl (DMA) substituent peaks at δH 5.50 
(olefin H-9’), δH 4.58 (methylene H-8’), δH 1.74 and δH 1.78 (two methyl groups H-10’, 11’), as 
well as an increase in aromatic peaks (see details in Fig. 2.9) also supported the formation of 99. 
13C NMR analysis supported amide formation further with the presence of a carbonyl signal 
resonating at δC 161.9. HRMS evaluation (m/z HRMS (EI) 443.1786, C25H30O4NCl requires m/z 
443.1791) returned the correct molecular ion for 99.  
Scheme 2.9 Reagents and conditions: (i) p-TsCl, NEt3, CH2Cl2, DMAP (cat) (94%); (ii) propargyl alcohol 
(10 eq), NaH (10 eq), THF, ∆; (iii) KOH, EtOH, (98%, 2 steps); (iv) SOCl2, ∆; (v) RNH2 61, pyr, (78%, 2 
steps to give amide 99); (vi) Lawesson’s reagent, NaHCO3, toluene, ∆, (70%).  
 
Finally, thiation of amide 99 with Lawesson’s reagent165 in toluene at 90 oC with an equivalent of 
sodium hydrogen carbonate produced the C-2 elongated UC-781 derivative 100 for biological 
probing of substituent effects in the HIV reverse-transcriptase pocket, (Scheme 2.9). This 
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taken with the amount of Lawesson’s reagent added to the reaction mixture, keeping in mind a 
possible conversion of the furan ring into its corresponding thiophene.  
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The partial double-bond character of an amide renders the oxygen atom of the amide 
nucleophilic character, and the latter is thus more nucleophilic than the furan oxygen. Hence, no 
thiophene formation was observed and the C-2 tethered UC-781 derivative was isolated in 70% 
yield after purification. Chromatographic success was only secured after the numerous failures 
on silica-gel columns were replaced by using flash-purification over neutral alumina. The 
thioamide 100 seemed to be very sensitive to the acidity of silica-gel columns, although the 
product could be obtained in lower yields (between 50-70%) on silica-gel after spiking the 
column with 5% triethylamine before loading commenced. Very importantly though, the reaction 
was only stopped after TLC confirmed the complete consumption of starting material, as the 
thioamide 100 had a very similar Rf to that of amide 99 on the plates. Evaluation of the products’ 
1H and 13C NMR spectra provided sufficient evidence for establishing the formation of thioamide 
100. The 1H NMR spectrum of thioamide 100 revealed a similar pattern to that of amide 99 (Fig. 
2.9) but with some significant shifts. However, confirmatory evidence was to come from infrared 
and mass spectrometry analysis. A distinguishing feature was the lack of a shift for the C-5 
hydrogen (normally < 7 ppm for thiophenes) in the 1H NMR spectrum indicating that thiophene 
conversion had not taken place as the H-5 signal resonated at δH 7.15 in 100, relative to δH 7.32 
in 99. This was further confirmed in the 13C NMR spectrum with the C-2 signal resonating 
steadily at δC 141.1 in 100, compared to δC 140.9 in 99. One surprise was that there was no 
visible shift in the 13C NMR spectrum for the carbonyl signal of the thioamide, with the most 
deshielded signal resonating at δC 160.0. Literature precedence suggested that the thioamide 
signal should be very deshielded at around δC 200.0. Infrared spectroscopy (Fig. 2.10) finally 
provided positive results with the disappearance of the amide carbonyl stretching band at 1674 
cm-1 in 99 (insert b, Fig. 2.10), and the appearance of thioamide stretching bands at 1162 and 
1389 cm-1 in 100. Finally, a correct HRMS evaluation (m/z HRMS (EI) 459.1634, C25H30O3NSCl 
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Figure 2.10 Infrared spectroscopy of a) thioamide 100, and insert b) of amide 99.  
 
The next and penultimate step in the total synthesis of bifunctional target 58 was the 
Sonogashira coupling reaction of thioamide 100 to 5’-O-benzoyl-5-iodo-d4T 60. Careful 
degassing of the tetrahydrofuran and dimethylformamide solvent mixture was carried out by 
bubbling pure crystal argon (~99.9% pure) through the solvents for ~1 hr in the presence of 
triethylamine to ensure complete de-oxygenation. This was vitally important in preventing 
oxidation of the Pd(0) and Cu(I) salts to be added.  Thereafter, the dual-catalyst system was 
introduced after an hour and the mixture allowed to stir at room temperature. Unfortunately, 
every single attempt at this reaction failed to work. Reaction conditions were modified by 
increasing reaction temperatures, or changing the molar equivalents of catalysts added, yet no 
reaction occurred. It was assumed that the lack of reactivity was very likely due to the thioamide 
interfering in the Sonogashira reaction. The sulphur atom of the thioamide is a strong donor 
ligand capable of preventing oxidative insertion of R-X with Pd(0), ultimately terminating the 
mechanistic cycle of the Sonogashira reaction. To support this theory, we embarked on coupling 
amide 99 lacking the sulphur atom to see if a successful coupling could be obtained. 
To this end, alkyne 99 was also subjected to a Sonogashira reaction with the nucleoside reverse 
transcriptase inhibitor derivative, 5’-O-benzoyl-5-iodo-d4T 60, to afford benzoyl protected 
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for thioamide 99, the reaction progressed smoothly and 101 was isolated in 61% yield after 
column chromatography. The 1H NMR spectral data for 101 revealed signals for both 99 and 
d4U moieties in the ratio of 1:1 (Fig. 2.11). A successful coupling was further confirmed by the 
absence of a terminal alkyne proton at around δH 2.02 ppm. The 13C NMR spectrum of 101 
displayed diagnostic resonances at δC 144.0 (C-9), 90.6 (C-5), 58.8 (C-12) thus further 
confirming the presence of both the nucleoside and the alkyne. The structure was further 
confirmed by 2D NMR correlation.  
Subsequent benzoyl group deprotection using 1M sodium methoxide in methanol yielded the 
unthiated bifunctional conjugate 102 in 51% yield. Debenzoylation was confirmed by an upfield 
shift in the diastereotopic protons at C-1 from δH 4.58 (multiplet) in 101 to δH 3.88 (dd, J 2.7, 12.4 























99 where R = Bz (101),






Scheme 2.10 Reagents and conditions: (i) 5’-Benzoyl-5-iodo-d4T, Pd(PPh3)4 (10%), CuI (50%), NEt3 (2 
eq), DMF/THF (1:2), rt, (61%); (ii) NaOMe, MeOH, rt, (51%).  
 
 
The presence of a broad hydroxyl singlet at δH 2.80, as well as the absence of aromatic protons 
for the benzoyl group also confirmed the loss of the benzoyl group. The absence of the carbonyl 
carbon resonating at δC 166.3 as well as carbons for the aromatic group further confirmed that 
debenzoylation had taken place. Importantly, the olefinic protons of the ribose ring integrated 
correctly in the 1H NMR spectrum. Other signals were intact indicating that no other 
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Figure 2.11 1H NMR spectra of a) 101 and b) 102. 
 
Unfortunately, all attempts at thiation of 101 or 102 using Lawesson’s reagent failed. Compound 
102 is the first example of a UC-781-derived conjugate (unthiated) as a result of developing this 
methodology.  
The inhibition of viral replication in HIV-infected cells of the prototype tethered UC-781 
compounds 99 and 100, as well as unthiated bifunctional entity 102 were measured against HIV-
1 (IIIB) replication in MT-2 cell culture using an MTT assay (Appendix I). Compound 100 had an 
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An examination of the inhibitory properties for these compounds offers insight into the design of 
a prototypical bifunctional compound, as well as offering valuable information regarding 
structure-activity relationships. Firstly, the fact that thioamide 100 is active and amide 99 not, 
suggests that the configuration around the thioamide is crucial for biological activity. Thioamides 
orientate in the s-trans-configuration (S larger than R), while amide bonds adopt an s-cis-
configuration (R larger than O) according to IUPAC prioritization. Using biochemistry 
nomenclature, these designations are swopped (Fig. 2.12) to just ‘cis’ for the thioamide and 
‘trans’ for the amide as defined by the relative orientation of the R groups. Here we will use the 





















= Z or "s-cis" = trans
 
Figure 2.12 IUPAC and Biochemistry preferred configurations and nomenclature. 
 
This configurational preference is easily understood by evaluating the size difference of a 
sulphur vs oxygen atom. In the cis-configuration, thioamide 100 is able to bind tightly and 
specifically to key residues in the NNRTI-BP such as Lys101 through two important hydrogen 
bonds as depicted in Figure 2.3. An important Wing II hydrophobic interaction between the DMA 
group and Tyr188 further cements the docking into the pocket. Thus, the incorrect trans-
configuration of the amide 99 renders the molecule ineffective at binding to important 
pharmacophores residing in the NNRTI-BP. This may explain why bifunctional 102 showed no 
anti-HIV activity. In summary, the 100 fold reduction in potency, which casted doubt regarding 
the choice of tether attachment to the drug, together with the difficulties encountered in carbonyl 
group thiation, led us to ultimately change the NNRTI. 
 
2.2.2 Synthesis of [d4U]-pentane-diPEG-propyne-[UC781] 
 
2.2.2.1 Synthesis of the elongated spacer 
The first priority in the synthesis of the elongated bifunctional target 59, was to develop efficient 
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concurrently with the synthesis of target 58 and we were thus unaware of the end-game 
problems as described above in the synthesis of target 58. Key to the spacer of 59 are two 
fragments A and B that are simplified in Figure 2.13. 
OHOO O O O (CH2)4CH2OO+
   SN2 
alkylation
A B C  
     
 where:  = primary alcohol protecting group stable against strong bases 
   = a leaving group 
Figure 2.13 Illustration of two key fragments (A and B) required for the development of the spacer. Also  
                    included are the relevant functional groups which are essential in the synthetic route.  
 
Therefore, the starting point in the synthesis of the spacer was to develop two key building 
blocks as: (i) a mono-protected diethylene glycol unit A, and (ii) a linear 5-carbon chain unit B, 
bearing both the functionalities of a leaving group and a protected alcohol, respectively, at the 
termini. The diethylene glycol unit A was introduced to overcome expected solubility issues in 
cell-culture testing. 
   
Thus, the synthesis began with mono-protection of diethylene glycol via alkylation with benzyl 
bromide in tetrahydrofuran at room temperature (Scheme 2.11) using sodium hydride as base. 
An excess of diethylene glycol was used to avoid dialkylation, which could be separated in the 
extraction because of its water-solubility. The reaction was complete after 6 hours, and following 
work-up, the crude product was distilled to produce 103 in 70% yield.  
OHOOH OHOBnO





Scheme 2.11 Reagents and conditions: (i) BnBr, NaH, THF, rt (70%). 
 
Much more challenging and time consuming, was the synthesis of the 5-carbon chain 
intermediate. The project explored two different hydroxyl protecting groups as tetrahydropyranyl 
(THP) and p-methoxyphenyl (PMP), as well as changing the leaving group from a bromide to a 
mesylate.   
To this end, the transformation of commercially available 1,5-pentanediol 104 into intermediates 
104b, c and e was carried out via either a two or three-step conversion (Scheme 2.12). The first 
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using hydrogen bromide (1.2 equivalents) and toluene at refluxing temperatures. A 55% yield 
was obtained after 10 hours without the azeotropic removal of water as reported in the literature 
procedure.166 A small amount of the dibromide product was observed on TLC but was not 
isolated. The dibromide is a consistent by-product associated with this reaction,166 but the 
bromopentanol 104a could easily be purified by column chromatography. 
Of the three routes undertaken to synthesize the 5-carbon chain intermediate (Scheme 2.12), 
two (104b and 104c) required only one further step and so this was attempted first. The bromide 
leaving group was in place and all that remained was to protect the alcohol with a base-stable 
protecting group. 
The first protecting group selected was the THP ether which was prepared using 3,4-dihydro-2H-
pyran and Amberlite® in dichloromethane (Scheme 2.12, 104a to 104b) to afford compound 
104b in 82% yield. Although the yield was excellent, alternative protecting groups were explored 
because of difficulties experienced in the subsequent SN2 alkylation described later.  
 
OH OH Br OH Br OTHP




















                (ii)
                (iii) (iv)
(v)
  
Scheme 2.12 Reagents and conditions: (i) HBr, H2O, toluene, ∆ (55%); (ii) DHP, Amberlite®, CH2Cl2 
(82%); (iii) p-methoxyphenol, PPh3, DIAD, THF (56%); (iv) p-methoxyphenol, NaH, solvent, ∆ (T HF-46%, 
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The second protecting group studied was the p-methoxyphenyl group. This was introduced via 
two methods. In the first approach, a Mitsunobu reaction (Scheme 2.12, 104a to 104c) was 
used, in which the hydroxyl group is activated to an oxyphosphonium salt via the Mitsunobu 
reagents (triphenylphosphine and diisopropyl azodicarboxylate).167 Subsequent substitution 
occurs via the phenoxide ion of p-methoxyphenol (or 4-hydroxyanisole) accompanied by an 
inversion of configuration, which has no stereochemical significance in this case. The procedure 
was carried out by adding p-methoxyphenol, triphenylphosphine and diisopropyl 
azodicarboxylate (DIAD) together in tetrahydrofuran (THF) to 104a. Even though the reaction 
proceeded to completion in 2 hours at room temperature, enormous difficulty was experienced in 
trying to separate the desired product 104c from the hydrogenated DIAD. Silica-gel TLC showed 
a small separation of the two components using pure hexane as solvent. However, column 
chromatography using the same solvent gave poor separation and the hydrogenated DIAD 
consistently co-eluted with 104c. A 56% yield of product mixed with DIAD was finally obtained. 
The resulting 1H NMR spectrum displayed diagnostic signals for the methoxy peak at δH 3.77, as 
well as an aromatic singlet at δH 6.83.  
 
The second method used (Scheme 2.12, 104a to 104d to 104e) for p-methoxyphenyl 
introduction involved a longer but less problematic sequence involving nucleophilic substitution 
of the bromide end of 104a.168 Thus, p-methoxyphenol was added to a suspension of sodium 
hydride in THF or dimethoxyethane (DME) as solvent, at 0oC. To the resulting alkoxide anion, in 
situ, was added 104a and the reaction mixture refluxed. After 24 hours, following work-up and 
column chromatography, a crystalline compound 104d was obtained in variable yields (Table 
2.2) depending on the solvent. A significantly improved yield for 104d was obtained when the 
reaction was performed in DME (70%), rather than THF (46%). This effect can be attributed to 
the sodium ion’s ability to chelate to the higher boiling solvent. Elemental analysis returned good 
combustion data for 104d. Diagnostic signals in the 1H NMR spectrum were the methoxy peak at 
δH 3.77 and the aromatic singlet at δH 6.82, integrating correctly against the polymethylene 
groups of the chain. Further confirmation was gained using infrared spectroscopy with a broad 
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Table 2.2 Percentage yield of protection of 104a in different solvents 







104b 82% - - 
104c - 56% - 
104d - 46% 70% 
 
The last step involved conversion of the hydroxyl group of the alcohol 104d into a better leaving 
group. The mesylate was chosen for this purpose using methanesulfonyl chloride and pyridine 
as base in dichloromethane, with catalytic amounts of 4-dimethylaminopyridine (DMAP) added. 
The desired mesylate 104e was obtained in 93% yield after column chromatography. The 
appearance in the 1H NMR spectrum of a methyl singlet at δH 3.00, as well as the strong sulfonyl 
stretches at 1356 and 1175 cm-1 in the infrared spectrum supported the formation of 104e.    
This concluded the synthesis of the 5-carbon intermediate chain. 
 
The next step in the synthesis of the spacer was the alkylation of 103 via an SN2 reaction (as 
illustrated in Figure 2.12), with each of the three 5-carbon chain intermediates 104b, c and e 

























Scheme 2.13 Reagents and conditions: (i) NaH, solvent, ∆ (a = THF = 41%); (b = THF = 37%); (c = THF 
= 72%, DME = 74%). 
 
Each reaction of 103 was carried out with sodium hydride suspended in THF or DME at 0oC in 
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separate reactions. Furthermore, each reaction was performed in different solvents, as above, 
and at different temperatures. The reaction between 103 and 104b gave low yields (41%) of 
compound 105 in THF at 0oC, in which the starting material decomposed at elevated 
temperatures. From the observed results it was concluded that the tetrahydropyranyl group was 
unstable and this was therefore eliminated as a synthetic option.  
The reaction between 103 and 104c also gave low isolated yields (37%) of 105a, following 
refluxing in THF, even though the reaction proceeded to completion after just 2 hours. When 
taking into account the difficulties encountered in purifying 104c, it was eliminated as the 
synthetic route to follow. 
Most impressive was the reaction between 103 and 104e. The alkylation produced good yields 
of 105a following refluxing the reaction. Also discovered, very importantly, was that the reaction 
was solvent dependent. A summary of all the results is given in Table 2.3.  
 
Table 2.3 Percentage yields for formation of 105a from the alkylation reaction using three   
                different 5-carbon chain intermediates in different solvents 











104b 41% - 69 24 
104c 37% - 69 2 
104e 72% 74% 69 and 102 20 (THF), 5 (DME) 
 
Table 2.3 shows how much more effective the alkylation proceeded using the mesylate 104e 
compared to the bromide 104c as the leaving group. Also, importantly, the reaction using a 
higher boiling solvent, such as DME, went to completion much faster than with THF. This 
significant reduction in time may also be attributed to the sodium ions chelating to DME, lowering 
the activation energy barrier of the reaction and thereby going to product formation faster.  
Evidence that coupling to compound 105a had taken place was provided by its 1H NMR 
spectrum, in which two aromatic peaks at δH 6.82 and δH 7.35, together with the methoxy singlet 
at δH 3.76 and the benzyl methylene at δH 4.57, in the correct relative integration, could be 
observed. The 13C spectrum returned the correct number of signals (19 as 8:8:3).  Preparation of 
mesylate 104e was subsequently scaled-up as this was chosen as the synthetic intermediate of 
choice.  
In the next step, deprotection of the p-methoxyphenyl protecting group of 105a was achieved 
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originally reported169,170 (Scheme 2.14). The mechanism of the reaction is thought to proceed170 
via a single-electron radical oxidation and occurs very rapidly. Careful monitoring of the reaction 









Scheme 2.14 Reagents and conditions: (i) CAN, CH3CN:H2O (4:1), 0 oC (86%); (ii) DMSO, (COCl)2, NEt3, 
CH2Cl2, -78 oC (98%). 
 
The reaction was found to go to completion after only 10 minutes. Observing colour changes of 
the reaction mixture from start to finish was also a very reliable way to monitor the reaction 
progress. CAN was always added last to the reaction mixture, and after its addition the solution 
turned an immediate dark purple colour. The dark colour then slowly faded until completion 
when the solution became a clear orange colour.  
CAN is a very harsh oxidising agent and it was found that leaving the reaction to go for any 
longer than 10 min resulted in the formation of undesirable by-products. It was suspected that 
the low pH of the reaction was also not favourable. Column chromatography purification 
following extractive work-up yielded the alcohol 106 in 86% yield. The key spectroscopic 
indicators in the 1H NMR spectrum of 106 were the broad -OH singlet at δH 1.96, together with 
the disappearance of the aromatic peak around δH 6.82, as well as the methoxy peak around δH 
3.76, confirming that deprotection had taken place. The 13C NMR spectrum returned the correct 
number of resonances, i.e. 14. 
 
The final reaction carried out, before coupling of the inhibitor building blocks commenced, was to 
transform alcohol 106 into aldehyde 107 via a Swern oxidation (Scheme 2.14). Dimethyl 
sulfoxide was thus added to dichloromethane and to the suspension was added oxalyl chloride 
at -78oC. Addition of the alcohol 106 was followed by stirring for 15 min and the reaction mixture 
finally treated with triethylamine and allowed to warm to room temperature. The desired 
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diagnostic signal in the 1H NMR spectrum of 107 was the singlet at δH 9.73 for the aldehyde 
proton. Infrared spectroscopy supported this with a strong stretching frequency at 1710 cm-1 
characteristic of an aldehyde. 
 
2.2.2.2 Synthesis of the tethered UC-781 
In line with the retrosynthetic analysis proposed, a Wittig and subsequent hydrogenation 
reaction was employed to be a versatile method for C-2 chain elongation. Thus, it was decided 
to directly apply the methodology to aldehyde 107. 
 
To this end, phosphonium salt 90 was first reacted in dry methanol with 1.1 equivalents of a 
concentrated sodium methoxide/methanol mixture (4.63 M). The resultant concentration was 
about 0.10 M in methanol, at 0oC (Scheme 2.15). The resulting ylide is stabilized because of the 
conjugation of the ylid carbanion into the ester, and therefore the reaction was expected to be E-
selective and under thermodynamic control. Once again, colour was a very effective manner of 
monitoring the reaction progress. After addition of aldehyde 107 to the reaction mixture, the 
solution turned an immediate dark-red colour, which changed to light-orange at around 50% 
completion by TLC. Completion of the reaction was indicated by an almost clear solution within 3 
hours. The same colour-changing pattern was observed in the model study carried out using 
hexanal and formaldehyde with the same phosphonium salt 90 above.  
   
Surprisingly though, the experimentally observed ratio of E:Z isomers was found to be 3:2 after 
repeated attempts at the reaction, with yields for 108 consistently fluctuating at around 80%. A 
3:2 ratio suggests a more kinetically controlled reaction preventing equilibration to the more 
stable product. Key spectroscopic indicators in the 1H NMR spectrum of 108 were the two allylic 
methylene peaks at δH 2.27 and δH 2.60, which could be seen in a 3:2, E:Z ratio. The 3:2 ratio, 




































Scheme 2.15 Reagents and conditions: (i) phosphonium salt 90, NaOMe, MeOH, rt (81%); (ii) H2, Pd/C, 
EtOH, rt. 
 
The hydrogenation reaction (Scheme 2.15) was intended to hydrogenate the double bond with 
concomitant hydrogenolysis of the benzyl group. The reaction was carried out by dissolving the 
tethered furan ester 108 in absolute ethanol with catalytic amounts of palladium-on-carbon 
added. The reaction vessel was then exposed to a constant atmosphere of hydrogen gas at 
room temperature and then carefully monitored at 10 min intervals by TLC. After ½ hr, TLC 
showed that the starting material had disappeared to form two spots running very close to each 
other. One spot ran slightly higher (i.e. less polar) than the starting material and sprayed red on 
TLC, while the other spot ran slightly lower (i.e. more polar) than the starting material and 
sprayed a bright-yellow colour on TLC. It was tentatively concluded that the less polar spot 
involved over-reduction of the furan ring to form the tethered dihydrofuran product 109a, which 
formed simultaneously (see next paragraph) with the desired product 109.  
After a further ½ hr the deprotection of the benzyl group was complete, marked by a significantly 
more polar product on TLC. Unfortunately, no solvent system was able to separate the 
undesired dihydro-product 109a from the desired product 109. No yields were thus reported for 
this step. As before in the model study, TLC suggested after 10 min that the external olefinic 
bond is reduced first, after which over-reduction of the furan ring (according to 1H NMR the 4,5-
bond is reduced, not the 2,3-bond on the furan ring) starts. Debenzylation was slower and there 
seemed to be no difference in deprotection of the benzyl group between the two intermediates, 
with simultaneous debenzylation being observed after numerous attempts. The events can be 
reasoned as follows: the external olefin is reduced first because of its lower activation energy 
compared to stability associated with the heteroaromatic ring, although furan is notorious for 
having a much lower resonance energy (furan = 65 kJ/mol compared to benzene = 150 kJ/mol). 
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probably because of the steric difficulty associated with reduction of a tetra-substituted double 
bond compared to a di-substituted double bond.  
 
For chain extension, the tethered furan alcohol 109 was then converted into a tosylate as a 
leaving group for the propargylation step (Scheme 2.16), which involved p-toluenesulfonyl 
chloride together with triethylamine in dichloromethane. A catalytic amount of DMAP was added 
to speed up the reaction. The desired tosylated tether 110 was thus obtained in 76% yield after 
column chromatography. It was also possible to separate the over-reduced tosylated compound 
in 12% yield, which revealed the reduction of the 4,5-double bond as expected. Diagnostic 
signals in the 1H NMR spectra of 110 were the tosyl group methyl peak at δH 2.41 and the 
aromatic peaks at δH 7.31 and δH 7.79. Infrared spectroscopy also showed two strong peaks at 
1177 and 1369 cm-1 characteristic of a sulfonyl (S=O) stretch and this supported the formation of 

































Scheme 2.16 Reagents and conditions: (i) p-TsCl, NEt3, CH2Cl2, DMAP (cat) (76%); (ii) propargyl alcohol 
(10 eq), NaH (10 eq), THF, ∆; (iii) KOH, EtOH, (95%, 2 steps); (iv) SOCl2, ∆; (v) RNH2, 61, pyr, (78%, 2 
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A significant feature of the 1H NMR spectrum of 110 (Figure 2.14) were the protons between δH 
3.49 - δH 3.68 (3 peaks), as well as the peak at δH 4.15 assigned to the methylene protons 
connected to the glycol. Unlike previous spectra, these resonances were separated owing to the 
strong deshielding effect of the tosylate. The 13C NMR was completely assigned using HSQC 
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The subsequent propargylation reaction (Scheme 2.16), was achieved by firstly forming an 
alkoxide 110a (in large excess) from the reaction between propargyl alcohol and sodium hydride 
in THF at 0oC. The tosylated tether 110 was subsequently added at refluxing temperature, and 
after an hour, all starting material had disappeared on TLC. The mechanism is presumably SN2. 
A few drops of 1M NaOH were added to the reaction mixture to hydrolyse the ester to the 
corresponding carboxylic acid and the mixture refluxed for a further hour. Carboxylic acid 111 
was thus obtained in 95% yield after column chromatography.  The appearance in the 1H NMR 
spectrum of an alkyne proton at δH 2.41 and an alkyne methylene doublet at δH 4.20 supported 
the formation of 111 (Figure 2.15). Infrared spectroscopy also confirmed the presence of a 




Figure 2.15 1H NMR spectrum of the alkyne tether 111. 
 
It is important to note from Figure 2.15 that the cluster of peaks between δH 3.58 - δH 3.70 
designated to the methylenes of the glycol had now coalesced. Interestingly, previous studies on 
analogous systems had shown that the propargylation reaction worked best this way round, i.e. 
better than using the alkoxide of 109 with propargyl bromide. This may have something to do 
with the softness of the propargyloxy anion.  
 
The first compound to be synthesized for anti-HIV testing was the amide 112 (Scheme 2.16). To 
this end, alkyne tether 111 was dissolved in excess thionyl chloride and heated to 40oC for 1 
hour, whereafter the excess reagent was removed in vacuo. Pyridine was then added to the 
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left at room temperature. The reaction went to completion within 30 min (TLC) and amide 112 
was obtained in 78% yield after column chromatography. Definitive spectroscopic signals in the 
1H NMR spectra of 112 were the amide NH signal at δH 7.58, together with the two methyl peaks 
at δH 1.74 and δH 1.78. A strong peak at 3304 cm-1 in the infrared spectrum further confirmed the 
formation of the amide. 
 
2.2.2.3 Sonogashira coupling and final deprotection 
The final reaction carried out in this part of the project was a Sonogashira coupling of a 5’-iodo-
d4U derivative 60 to the amide 112 (Scheme 2.17).  
   
Scheme 2.17 Reagents and conditions: (i) 5’-Benzoyl-5-iodo-d4T, Pd(PPh3)4 (10%), CuI (50%), NEt3 (2 
eq), DMF/THF (1:2), rt, (61%). 
 
The Sonogashira coupling reaction conditions involved adding triethylamine and reactants to a 
mixture of dimethylformamide and tetrahydrofuran (1:2, v/v), which was thoroughly degassed 
before the onset of the reaction to avoid unwanted oxidation of the palladium(0) catalyst. 
Introduction of the catalyst combination of Pd(0) / CuI in the form of solids resulted in product 
113 formation after 2 hrs in 61% yield after column chromatography. Inherant to Sonogashira 
reactions are the undesirable Glaser-Edlington coupling of two molecules of alkyne leading to a 
homodimer. Fortunately, none of this undesired by-product was observed though. Key 
spectroscopic indicators in the 1H NMR spectra (Fig. 2.16) of 113 were the d4U anomeric proton 
at δH 6.93, the imide proton at δH 8.63 as well as the UC-781 amide proton at δH 8.03. The 
appearance of a benzoyl aromatic multiplet between δH 7.45-7.55 was also diagnostic and the 
resonances from each fragment integrated correctly. The 13C NMR returned the correct number 
of resonances of 44. 
 
Again, every effort was put into conversion of 113 to the thioamide using Lawesson’s reagent 
varying all of the reaction parameters, but without success. All of the material was consumed 
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benzoyl group of 113 was thus attempted. As expected, amide 112 had no anti-HIV activity, 
presumably for the same reasons as outlined before. Compound 113 was not tested for anti-HIV 
activity. 
 
Figure 2.16 1H NMR spectrum of the alkyne tether 113. 
 
In summary, new methodology applicable to large-scale work has been developed for C-2 
alkylation of 3-furoates of interest to both natural product synthesis and medicinal chemistry. 
Thiation of 102 and 113 was crucial in trying to probe the RT enzyme, and failure to do so led us 
to replace the NNRTI, thus creating a new bifunctional target for studying possible synergy 
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SYNTHESIS OF d4U-SPACER-PYRIMIDINYLARYLAMINE DOUBLE-DRUGS 
 
3.1 Strategy for the synthesis of [d4U]-spacer-[pyrimidinylarylamine] 
A replacement NNRTI for UC-781 (Chapter 2) was identified as TMC120 based on the clinically 
approved TMC125 (Fig. 3.1) belonging to the family of diarylpyrimidines (DAPY’s). These so-
called third-generation NNRTI’s were chosen for their remarkable anti-HIV potency against wild-
type (2 nM for TMC125 and 1 nM for TMC120), as well as against single- and double-point 















Figure 3.1 Structures of TMC120, TMC125 and TMC278 belonging to the family of DAPY’s. 
 
Thus, the initial objective of this part of the project became the synthesis of bifunctional 
compounds of the general formula [d4U]-spacer-[DAPY] in search of synergism between the two 
inhibitors. Molecular modeling studies published independently by Balzarini91 (Fig. 3.2 a) and 
Pauwels73 (Fig. 3.2 b) on the binding of the DAPY derivative, TMC125, were used to ascertain 
the optimal connecting point for spacer elongation from the NNRTI. According to the Pauwels 
modeling interpretation depicted in Figure 3.2 (b), the proposed docking of TMC125 sees the 
pyrimidine unit firmly embedded into WING I of the RT NNRTI pocket, together with the less-
substituted phenyl ring (attached to C-2 of the pyrimidine) bound in the hydrophobic WING II 
(interacting with Lys101 and Tyr318). The more substituted phenyl ring (attached to C-4 of the 
pyrimidine) snuggles in towards the back of WING II near to Tyr188 and Tyr181 but its ortho-
methyl group offers the possibility of exiting the ‘front’ of the pocket towards Glu138 and the p66 
subunit of RT. By comparison, the para-methyl group of the C-4 phenyl ring points towards 
Trp229, newly described by Arnold as the ‘back exit tunnel’ which in theory might access the 
NRTI binding site.171 It should be noted though, that at the start of this part of the project, this so-
called ‘back exit tunnel’ was unknown to all and thus the para-methyl group was not considered 
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Figure 3.2 a) Proposed docking91 site for TMC125 at the entrance of NNRTI-BP of HIV-1 RT, b) Proposed 
docking of 2-pyrimidinylarylamines at the entrance of the NNRTI-BP of HIV-1 RT.73 
 
Recently, Jorgensen87,172,173 has demonstrated the use of both 2-pyrimidinylarylamines and 2-
thiazolylarylamines as potential NNRTI’s (Fig. 3.3). Of interest to us were his 2-
pyrimidinylarylamines of general formula (Het-NH-ArX), where Het is a pyrimidine heterocycle 
and X a substituent of the phenyl (Ar) ring, which showed excellent biological activities (5 nM for 
X = CN; 6 nM for X = Cl) supporting the motif in Figure 3.3 (b) with the C-2 aromatic ring firmly 
embedded into WING II. Jorgensen’s simplified motif thus strips off the C-4 aromatic ring, in 















        Jorgensen's
2-pyrimidinylarylamines
C-2 C-2





Figure 3.3 a) Jorgensen’s potent NNRTIs, (b) Proposed docking of 2-pyrimidinylarylamines at the 
entrance of the NNRTI-BP of HIV-1 RT.87 
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Therefore, in view of the synthetic challenges of constructing a TMC120 bifunctional, initially a 
prototype [d4U]-spacer-[pyrimidinylarylamine] heterodimer system was chosen, with one 
aromatic ring of TMC120 removed and the other arylamine, at either the C-2 or C-4 position of 
the pyrimidine intended by us for linking the NNRTI binding pocket with the NRTI substrate 
binding site. Both the C-2 and C-4-substituted pyrimidines needed to be explored regarding 
tethering from the aromatic ring, in view of the multiple conformations of TMC compounds, 
although a spacer elongation from the C-4 aromatic ring was considered to be the more likely 
bifunctional prototype system to return biological activity. 
  
Therefore, the bifunctional molecules 114, 115 and 116 shown in Figure 3.4 were selected as 
targets. As in Chapter 2, the C-5 position on the pyrimidine moiety (base) of d4U was chosen as 
the appropriate attachment point for the tether. Also, ethylene glycol units in the spacer were 
chosen in view of their anticipated water solubility. The meta-position on the C-2 or C-4 aromatic 
ring of the pyrimidinylarylamine was chosen as the spacer extension point in view of us being in 
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3.1.1 Retrosynthetic analysis of [d4U]-spacer-[2- or 4-Pyrimidinylarylamines] 
The total synthesis of targets 114-116 was conceived as achievable via a convergent strategy, 
involving the coupling of protected 5’-iodo d4U 60 to a 2- or 4-pyrimidinylamine of type A or B 
followed by deprotection of the benzoyl group to render the target compounds directly (Fig. 3.5). 
Synthesis of 2- or 4-pyrimidinylarylamines of type A and B was envisaged possible from the 
coupling of commercially available pyrimidines 117 and 118 with a common arylamine 
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It was also well understood that 2- and 4-pyrimidinylarylamine derivatives of type A and B would 
have to be undertaken and synthesized, in which the substitution pattern of the aniline was 
varied to accommodate an ortho-extended arylamine component of type E, in order to achieve a 
successful SAR study. Since the molecular modeling studies by Pauwels (reviewed earlier) 
suggested that it was plausible to consider a spacer extension from both the ortho- and meta-
positions on the key substituted aniline, it was also planned to couple various ortho- and meta-
extended substituted arylamines to commercially available pyrimidines 117 and 118, and the 
respective 2- and -4-pyrimidinylarylamine derivatives obtained tested for their anti-HIV activity.  
 
2-Chloro-4-methoxy-1,3-pyrimidine 118 was chosen as the pyrimidine partner on the grounds 
that Jorgenson had identified activity with this template for his 2-pyrimidinylarylamines.87 4-
Amino-6-chloro-2-methylthio-1,3-pyrimidine 117 was chosen because of its close resemblance 
to TMC125 in the substitution pattern on its pyrimidine ring. 
 
3.2 Synthesis of the substituted anilines 
3.2.1 Synthesis of the meta-extended substituted anilines 
Synthesis of the arylamine subunit of the bifunctional targets 115 and 116 started from 
commercially available 2-amino-5-nitrophenol and involved a two-step procedure.175 The first 
step was a Sandmeyer diazonium-promoted amino substitution to the chloride 119a (Scheme 
3.1). This was achieved by charging a reaction flask with concentrated hydrochloric acid at 0 oC 
and adding to this a mixture of 2-amino-5-nitrophenol and sodium nitrite in water. After 
maintaining this temperature for 3 hrs, sulfamic acid (H2NSO3H) was added slowly and the 
mixture poured carefully into a solution of 20% aqueous hydrochloric acid containing copper (I) 
chloride over 1hr. TLC confirmed reaction completion after stirring at room temperature for a 

























Scheme 3.1 Reagents and conditions: (i) HCl (conc), NaNO2, CuCl (73%); (ii) Fe mesh, HCl, ∆ (73%); (iii) 
propargyl bromide, K2CO3, n-Bu4NI, acetone, r.t (79%). 
 
The mechanism of the reaction involves an SN1 nucleophilic aromatic substitution as depicted in 
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from the reaction between sodium nitrite and a strong acid, for example hydrochloric acid. It 
should be noted, though, that in dilute acid the actual species is N2O3, which acts as a carrier of 























































Formation of reactive NO+ species:
Formation of the diazonium salt:
Cl-
SN1 nucleophilic aromatic substitution:
+
Cl-
- (N2 + CuCl2)
+ CuCl . Cl-CuCl
 
Figure 3.6 Mechanism for diazonium SN1 nucleophilic aromatic substitution. 
 
The NO+ cation is then attacked by the lone pair of the amine and dehydration follows after a 
succession of proton transfers to yield the diazonium salt. The penultimate step involves a 
reduction of the diazonium ion by the cuprous ion, which results in the formation of an aryl 
radical. Finally, the aryl radical abstracts a halogen radical from cupric chloride, reducing it. CuCl 
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and H2NO2+. Nucleophiles (e.g. Cl-, SCN-, thiourea) catalyze the reaction by converting HONO to 
a better electrophile (e.g. HNO2  +  Cl-  +  H+  →  NOCl  +  H2O). A key diagnostic feature in the 
1H NMR spectrum of 119a was the absence of the amino group hydrogens from the starting 
material integrating for two protons. The 13C NMR spectrum of 119a displayed a new downfield 
signal at δC 130.9 for the halogen bearing C-2. Infrared spectroscopy provided further evidence 
for conversion with the appearance of a strong carbon-halogen stretching band at 738 cm-1 for 
119a. Subsequent nitro-group reduction using iron mesh in refluxing ethanol with hydrochloric 
acid yielded key intermediate 119b in a good yield of 73% after column chromatography. Its 1H 
NMR spectrum revealed signals at δH 4.62 (integrating for two protons) and 8.06 (integrating for 
one proton) for the amine and hydroxyl groups respectively. 
 
In anticipation of using a Sonogashira coupling strategy for linking the two drugs, 119b was 
propargylated using propargyl bromide, potassium carbonate and a catalytic amount of tetra-
butylammonium iodide in acetone at room temperature to afford 120 in a good yield of 79% after 
column chromatography (Scheme 3.1). The 1H NMR spectrum of 120 displayed a signal for the 
alkyne proton (H-3’) at δH 2.54 which appeared as a triplet of J 2.4 Hz, due to allylic coupling with 
the H-1’ methylene protons (Fig. 3.7). Additional signals in the spectrum at δH 4.71 for H-1’ and 
δH 3.75 for the amino group confirmed the formation of 120. The 13C NMR spectrum displayed 
diagnostic signals at δC 76.0 and δC 78.2 for C-3’ and C-2’ respectively.  
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Similarly, the UC-781 arylamine subunit 61 was prepared in two steps (Scheme 3.2) from the 
common intermediate 119a. Alkylation of 119a was carried out using 4-bromo-2-methyl-2-
butene, potassium carbonate and tetra-butylammonium iodide in methylethylketone to afford 
119c in 94% yield after column chromatography. The 1H NMR spectrum of 119c confirmed the 
formation of the ether with the absence of the OH singlet at δH 9.73 in 119a, and the appearance 
of two methyl signals at δH 1.80 and δH 1.81. The allylic methylene doublet at δH 4.70, and the 


















Scheme 3.2 Reagents and conditions: (i) 4-bromo-2-methyl-2-butene, K2CO3, n-Bu4NI, MEK, r.t (94%); (ii) 
Fe mesh, HCl, ∆ (88%). 
 
Iron-mesh reduction of 119c using the same conditions as described above for 119b, rendered 
the desired arylamine 61 in 88% yield after chromatographic purification over silica-gel. The 1H 
NMR spectrum of 61 displayed the appearance of an NH2 singlet at δH 3.62. The 13C NMR 
spectrum of 61 displayed a slight upfield shift in the C-1 carbon from δC 148.2 in 119c to δC 
146.2 in 61, in agreement with the formation of 61. The integrity of all the other signals remained 
the same with signals at δC 65.9 (C-1’), δC 101.5 (C-2), δC 107.9 (C-6), δC 112.1 (C-4), 119.5 (C-
2’), 130.4 (C-5) and 154.9 (C-3). Finally, a correct HRMS evaluation (m/z HRMS (EI) 211.07668, 
C11H14NOCl requires m/z 211.07652), confirmed the structure of 61. 
 
3.2.2 Synthesis of the ortho-extended substituted anilines 
In keeping with our objective of preparing pyrimidinylarylamine derivatives, the next challenge 
was to generate methodology for ortho-extended anilines to be used as the aryl component in 
the Het-NH-ArX motif of the pyrimidinylarylamine derivatives. Literature methodologies for 
accessing ortho-extended anilines are quite scarce, with directed-ortho-metallation (DOM) and 
photo-Fries rearrangement methodologies as the principal options.  However, with the success 
of the Wittig C-2 extension in the UC-781 series (Chapter 2), our minds once again shifted 
towards this reliable carbon-carbon bond-forming methodology. To this end, radical bromination 
(Scheme 3.3) of commercially available 2-nitro-m-xylene was performed using N-
bromosuccinimide and azobisisobutyronitrile in dry carbon tetrachloride to obtain benzylic 
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phosphonium salt 122 was subsequently prepared in 89% yield after reaction of 121 with 
triphenylphosphine in toluene (Scheme 3.3). Recrystallization from methanol/ethyl acetate (1:1) 
secured analytically pure material (99% recovery). The 1H NMR spectrum of 122 displayed the 
enantiotopic methylene protons α to the phosphorus centre as a doublet at δH 5.21 due to 
phosphorus coupling (2H, d, JP-H = 15.0 Hz, CH2P), as well as multiplets for the three new 
phenyl moieties at δH 7.65 and δH 7.90.  Microanalysis returned good combustion data as: Found 
C, 63.17; H, 4.70; N, 2.74%; C26H23O2NPBr requires C, 63.17; H, 4,75; N, 2.85%. 
Gratifyingly, reaction of 122 in methanol with sodium methoxide as base (2M in MeOH, 1.1 eq.) 
at room temperature followed by addition of acetaldehyde (2 eq.) resulted in rapid transformation 
to the Wittig product 122a after 30 min. The crude alkene was put through an aqueous work-up 
and after removing the solvent was used in the next step without purification, in which nitro 
group reduction of crude 122a in refluxing ethanol with iron mesh and hydrochloric acid, 
rendered the desired ortho-alkenylated aniline 122b.  Filtration of excess iron followed by 
evaporation of solvent and direct hydrogenation of 122b using palladium-on-carbon in alcoholic 
hydrogenated solvent gave the anticipated ortho-alkylated product 123 in an excellent yield of 















ortho-alkylation of anilines accessable
                via  Wittig reactions
R = CHCH3 (122a)
R = H (commercially available)
R = CH2CH3 (123)
122
(vi)
R = H (124),







R = CHCH3 (122b)
(iv)
(i) = cmpd 121
 
Scheme 3.3 Reagents and conditions: (i) NBS, AIBN, CCl4, ∆ (70%); (ii) PPh 3, Toluene, ∆ (89%); (iii) 
NaOMe, acetaldehyde, MeOH, r.t; (iv) Fe mesh, HCl, ∆; (v) H 2, Pd-C, MeOH,THF (1:1) (77% over 3 
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Diagnostic signals in the 1H NMR spectrum of 123 were the appearance of the NH2 (2H) singlet 
at δH 3.61 confirming the reduction of the nitro moiety, and an increase in aliphatic proton 
signals. 
 
The last transformation in the synthesis of the ortho-extended arylamine subunit was the 
incorporation of a halogen at the para-position relative to the amino group of 123 (Scheme 3.3). 
It was decided to include a cyano-functionality in this position because of the excellent biological 
data for TMC125. To this end, para-cyanation of the arylamine was accomplished via a two-step 
procedure. The first step involved regioselective and environmentally friendly bromination178 of 
substituted aniline 123. The study also included 2,6-dimethylaniline as a model arylamine. This 
was carried out using ammonium bromide as a bromine source and hydrogen peroxide (as 
oxidant) in acetic acid at room temperature. In this reaction, it is assumed that hydrogen 
peroxide oxidizes the Br - (ammonium bromide) to Br + (HOBr), which reacts in the presence of 
acetic acid (Bronsted acid) with anilines to give the desired electrophilic substitution product (Fig. 
3.8).178 TLC confirmed completion of the electrophilic substitution after 2 hrs furnishing 124 














NH4Br + H2O2 NH4OH HOBr+
HOBr CH3COOH H2O CH3COO- Br++
R = H (124),






Figure 3.8 Mechanism of bromination of anilines. 
 
The 1H NMR spectrum of 124 revealed the absence of a singlet at δH 7.14 for the H-4 proton 
(Scheme 3.3) as well as the appearance of H-3/5 as a singlet at δH 7.15, implying that 
substitution had taken place. The 13C NMR spectrum of 124 recorded the correct number of 
resonances as 5. The C-4 quaternary carbon bearing the halogen resonated at δC 113.7 
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and 1H NMR spectra. For example, in 125, the C-4 carbon bearing the halogen resonated at δC 
112.9. 
Palladium-catalyzed cyanations of aryl halides dominate the literature.179-181 A major 
disadvantage of such procedures is the relatively expensive palladium-catalyst combinations 
employed, although the use of non-toxic sources of cyanide such as potassium 
hexacyanoferrate (II), K4[Fe(CN)6], and ligand-free reaction conditions provide significant 










R = H (124),
R = CH2CH3 (125)
R = H (126),







resonance view of 
    126 and 127
 
Scheme 3.4 Reagents and conditions: (i) CuCN, DMF, ∆ (126-47%, 127-84%). 
 
The Pd(0) methodology was first attempted on aryl bromides 124 and 125 using K4[Fe(CN)6] in 
dimethylacetamide without any success. Harsher cyanation conditions were then tried out as 
described by Mayr and co-workers182 by subjecting aryl bromides 124 and 125 to cuprous 
cyanide (CuCN) in refluxing dimethylformamide for 6 hrs to produce para-cyanated products 126 
and 127 after column purification (Scheme 3.4). The respective 1H NMR spectra of 126 and 127 
looked identical to that of their aryl bromide counterparts. However, the 13C NMR spectrum 
supported the formation of 126 with the appearance of a C-4 upfield shift (due to resonance - 
see boxed Figure) from δC 113.7 in 124 to δC 99.1 in 126. Also, a new signal indicative of a 
quaternary cyanide carbon (relaxed) resonated at δC 120.4. Once again, the same trends were 
observed in the 13C NMR spectrum of 127. 
 
3.3 Synthesis of [d4U]-propyne-[4-pyrimidinylarylamines] 
3.3.1 Synthesis of the 4-pyrimidinylarylamine derivatives 
With the substituted anilines now in hand, attention focused on synthesizing the 4-
pyrimidinylarylamine derivatives. Commercially available 4-amino-6-chloro-2-methylthio-
pyrimidine 117 was thus coupled to the different meta- and ortho-extended arylamines under a 
variety of reaction conditions to furnish a range of new model 4-pyrimidinylarylamine derivatives 
to probe for anti-HIV activity. 
For the aromatic meta-substituted 4-pyrimidinylarylmine derivatives, pyrimidine 117 was first 
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molar equivalent of anhydrous p-toluenesulfonic acid to be added to the pyrimidine starting 
material in 1,4-dioxane first, suggesting the condensation to occur via a protonated pyrimidine 
ring, after which an addition-elimination reaction results in formation of the desired compound 
128 in 47% yield after silica-gel purification. As expected, the amine functionality won the 

















































Scheme 3.5 Reagents and conditions: (i) 4-amino-6-chloro-2-(methylthio)pyrimidine, arylamine, p-TsOH, 
1,4-dioxane, 100oC (128-47%, 130-49%); (ii) allyl bromide, K2CO3, n-Bu4NI, acetone, r.t (46%). 
 
 
The 1H NMR spectrum of 128 revealed a thiomethyl singlet at δH 2.43, a singlet for the 
pyrimidine H-5 proton at δH 5.65 and a broad singlet NH2 at δH 5.76. The bridging NH signal 
resonated at δH 8.08 in close proximity to the free OH signal at δH 8.58. The 13C NMR spectrum 
displayed the vital C-4 and C-1’ signals resonating at δC 164.3 and δC 141.1 respectively, 
assigned with the aid of 2-D NMR. 
Compound 128 was then O-allylated by treatment with allyl bromide in acetone with potassium 
carbonate as a mild base to yield the model NNRTI derivative 129 in a moderate yield of 46% 
after column purification. Key diagnostic signals in the 1H NMR spectrum of 129 were the allylic 
methylene protons signal at δH 4.65 and the disappearance of the OH signal at δH 8.58 in 128. 
Finally, a correct HRMS evaluation (m/z HRMS (ES) 323.0732 [M+H]+, C14H16N4OSCl requires 
m/z 323.0735 [M+H]+), confirmed the structure of 129. 4-Pyrimidinylarylamine 129 was 
synthesized in order to do a comparative study with that of Jorgensen’s on the activity of 2-vs 4-
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The Sonogashira coupling partner, 4-pyrimidinylarylamine 130 was next synthesized employing 
identical reaction conditions to that used in making 128, except using the propargylated 
intermediate 120. A 49% yield was obtained after column chromatography. The 1H NMR 
spectrum of 130 (Fig. 3.9) displayed the typical alkyne triplet at δH 2.46 for H-3’’. The 13C NMR 
spectrum complemented this well (Fig. 3.9) with three distinct propargyloxy signals at δC 56.9 (C-




Figure 3.9 1H and 13C NMR spectra of 4-pyrimidinylarylamine 130. 
 
Finally, condensation of the ortho-extended arylamines to 4-amino-6-chloro-2-
methylthiopyrimidine 117 was undertaken in order to evaluate the affect of extended ortho-
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simply to synthesize these aromatic ortho-extended model 4-pyrimidinylarylamine derivatives for 
anti-HIV probing, and not to generate bifunctional entities. To this end, different arylamines were 
all reacted in each case as a melt with 4-amino-6-chloro-2-methylthiopyrimidine 117 without the 
need for solvent, and the desired 4-pyrimidinylarylamine products (131-134) were isolated in low 






























































Scheme 3.6 Reagents and conditions: (i) melt neat with arylamine at 160 oC (131-28%, 132-35%); (ii) 
melt neat with arylamine at 220 oC (133-35%, 134-35%). 
 
 
The low yields were never optimized as the primary objective was to get the derivatives tested 
and to evaluate the feasibility of an ortho-extended aromatic ring attached to the C-4 position on 
the pyrimidine. The 1H NMR spectra of 131-134 displayed the characteristic pyrimidine and 
arylamine signals in a 1:1 ratio (see Table 3.1). A fair degree of consistency for the 13C signals in 
the 13C NMR spectra for 132-134 was observed as revealed in Table 3.2 for selected 
resonances.  
 
Table 3.1 Some 1H chemical shifts for 4-pyrimidinylarylamine derivatives 131-134 
Position 131 132 133 134 
SCH3 2.39 2.41 2.39 2.38 
H-5 5.50 5.60 6.16 6.14 
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NH 9.01 9.46 7.22 7.25 
H-3' 7.49 7.75 7.18 7.15 
 
 
Table 3.2 Some 13C chemical shifts for 4-pyrimidinylarylamine derivatives 131-134 
Position 131 132 133 134 
2 170.1 170.5 172.1 172.1 
4 164.3 164.7 165.2 166.8 
5 82.1 83.2 98.5 99.6 
6 160.8 160.2 158.4 160.5 
1' 140.9 146.1 149.8 151.7 
2' 131.9 133.7 131.4 130.9 
3' 121.9 119.2 120.9 125.4 
4' 113.2 102.5 95.9 99.1 
C≡N - 120.2 120.2 120.6 
 
 
3.3.2 Sonogashira coupling and final deprotection 
For bifunctional generation (Scheme 3.7), the 4-pyrimidinylarylamine derivative 130 was 
subjected to a Sonogashira reaction with 5’-O-benzoyl-5-iodo-d4U 60, which was prepared in 4 
steps from uridine according to the Bristol-Myers Squibb procedure. The coupling used 
conditions described previously for UC-781 and was complete in 2 hrs to afford 135 in 83% yield 
following chromatography. Its 1H NMR spectrum revealed signals for both the arylpyrimidinyl and 
d4U moieties in the ratio of 1:1. A successful coupling was further supported by the absence of a 
terminal alkyne proton at around δH 2.46. The 13C NMR spectrum of 135 displayed diagnostic 
resonances at δC 144.1 (C-12), 90.9 (C-5), 57.3 (C-15), thus confirming the presence of both the 
nucleoside and the alkyne. The structure was further confirmed by 2D NMR.  
Finally, 135 was deprotected with sodium methoxide in methanol to furnish 114 in 76% yield 
(Scheme 3.7). The 1H NMR spectrum of 114 (Fig. 3.10) revealed resonances for both inhibitors, 
notably the d4U double bond signals and the H-12 uracil singlet at δH 8.28, as well as a 
characteristic set of aromatic and heteroaromatic signals for the APY unit together with the 
thiomethyl singlet at δH 2.45. Signals from both drug fragments integrated correctly. Its 13C 
spectrum returned the correct number of singlets (23) and 2D-NMR techniques (HSQC, HMBC) 
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HRMS (ES) 529.1073, C23H22N6O5SCl requires m/z 529.1061), confirmed the structure of 114 as 
shown in Scheme 3.6. Compound 114 illustrates the first example of a prototype d4U / 4-
pyrimidinylarylamine bifunctional heterodimer that culminated in an Afinidad communication 






























































Scheme 3.7 Reagents and conditions: (i) 5’-Benzoyl-5-iodo-d4U, Pd(PPh3)4 (10%), CuI (50%), NEt3 (2 
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3.4 Synthesis of [d4U]-spacer-[2-pyrimidinylarylamines] 
 
3.4.1 Synthesis of the [d4U]-propyne-[2-pyrimidinylarylamines] 
3.4.1.1 Synthesis of the 2-pyrimidinylarylamine derivatives 
For the 2-pyrimidine substituted bifunctionals tethered at the meta-position of the aromatic ring, 
commercially available 2-chloro-4-methoxy-1,3-pyrimidine 118 was coupled to different meta-
extended arylamines under a variety of reaction conditions to furnish a range of new model 2-
pyrimidinylarylamine derivatives to either probe for anti-HIV activity as model NNRTIs (also 
extending the library of Jorgensen’s derivatives), or to be used to generate double-drug entities. 
Thus, condensation of 118 with arylamine 119b in the presence of p-toluenesulfonic acid in 1,4-
dioxane yielded 2-pyrimidinylarylamine 136 in 95% yield after column purification (Scheme 3.8). 
The 1H NMR spectrum of 136 displayed two aromatic signals at δH 6.23 (d, J = 5.7 Hz) and δH 
8.16 (d, J = 5.7 Hz) corresponding to H-5 and H-6 respectively (Scheme 3.7). The pyrimidine 
methoxy singlet at δH 3.93, the bridging NH at δH 8.46 and the OH signal at δH 2.85 further 
confirmed formation of 136. The 13C NMR spectrum of 136 revealed corresponding resonances 
at δC 99.2 (C-5), δC 158.3 (C-6), δC 53.3 (OCH3). The crucially important resonances for C-2 and 














































Scheme 3.8 Reagents and conditions: (i) p-TsOH, 1,4-dioxane, 100oC (136-95%, 137-73%). 
 
 
Similarly, the Sonogashira coupling partner 137 was prepared in an identical manner to that for 
136 and obtained in a 73% yield after column purification. The key diagnostic signals in its 1H 
NMR spectrum were the alkyne proton at δH 3.10 and the propargylic methylene protons at δH 
4.87 integrating correctly against the pyrimidine AB doublet pair for H-5/H-6. The 13C NMR 
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(C-1''), δC 76.8 (C-3'') and δC 78.7 (C-2''). Combustion microanalysis returned good data: Found 
C, 58.00; H, 4.40; N, 14.64%; C14H12N3O2Cl requires C, 58.04; H, 4.17; N, 14.50%. 
 
3.4.1.2 Sonogashira coupling and final deprotection 
The Sonogashira coupling of 137 with 5’-O-benzoyl-5-iodo-d4U 60 using identical conditions to 
those for forming bifunctional 114 was carried out and after silica-gel purification bifunctional 138 
was isolated in a moderate 55% yield (Scheme 3.9). Its 1H NMR spectrum revealed resonances 
for both inhibitor moieties in a 1:1 ratio, key being the disappearance of a terminal alkyne proton 
at δH 3.10.  Its 13C NMR spectrum returned the correct number of resonances as 28 for 30 
carbons (revealing the characteristic appearance of only 4 singlets for the 6 carbons of the 
benzoyl phenyl) and was assigned using 2-D techniques such as HSQC and HMBC. The final 
benzoyl group deprotection (Scheme 3.9) was achieved under basic conditions with sodium 
methoxide in methanol at room temperature, with TLC confirming reaction completion after 2 
hrs. Direct flash chromatography afforded bifunctional 115 in an excellent yield of 88% of 












































Scheme 3.9 Reagents and conditions: (i) 5’-Benzoyl-5-iodo-d4U, Pd(PPh3)4 (10%), CuI (50%), NEt3 (2 
eq), DMF/THF (1:2), rt, (55%); (ii) NaOMe, MeOH, rt, (88%).  
 
Thus, the 1H NMR spectrum of 115 (see Figure 3.11) revealed the disappearance of the 
aromatic signals integrating for the benzoyl group. Once again, the 13C NMR spectrum of 115 
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evaluation (m/z HRMS (ES) 498.1184 [M+H]+, C23H21N5O6Cl requires m/z 498.1180 [M+H]+), 
confirmed the structure of 115. 
 
Figure 3.11 1H NMR spectrum of 115. 
 
3.4.2 Synthesis of the [d4U]-monoPEG-propyne-[2-pyrimidinylarylamines] 
3.4.2.1 Synthesis of the 2-pyrimidinylarylamine derivatives 
With a plausible route developed for the prototype propyne heterodimers, attention was turned 
towards synthesizing heterodimers with longer spacers for structure-activity purposes. A 
polyethylene (PEG) unit was chosen as the repeating unit in view of its synthetic accessibility as 
well as its promotion of water solubility. It was envisaged that a counterpart 2-
pyrimidinylarylamine derivative of 137 would be prepared with a modified spacer for 
Sonogashira coupling as described previously. The overall synthetic scheme for the initial phase 
of the synthesis is shown in Scheme 3.10. Following the method described by Marshall et al.,183 
1,2-ethanediol 139 was mono-protected as its monobenzyl ether 140 in 53% yield with benzyl 
bromide and sodium hydride in THF. The product was easily isolated by distillation, and although 
obtained only in moderate yield, the mono-benzylation could be carried out on a large scale. The 
presence of a benzyl group in the product was confirmed by the 1H NMR spectrum, which 
revealed aromatic protons integrating for 5 protons resonating at δH 7.34 as well as methylene 





















































































Scheme 3.10 Reagents and conditions: (i) BnBr, NaH, THF, reflux, 20 hrs (53%); (ii) PPh3, CBr4, CH2Cl2, 
0 oC, 30 min (95%); (iii) 136, K2CO3, n-Bu4NI, acetone, r.t (100%); (iv) H2, Pd/C, EtOH, rt (70%); (v) p-
TsCl, NEt3, CH2Cl2, DMAP (cat) (70%); (vi) propargyl alcohol, NaH, THF, ∆ (98%). 
 
Treatment of alcohol 140 with carbon tetrabromide and triphenylphosphine in dichloromethane 
(Scheme 3.10) smoothly yielded the bromide 141 in 95% yield. Work-up involved evaporating 
the solvent and purifying the crude product directly by column chromatography. Mechanistically, 
the reaction of triphenylphosphine with carbon tetrabromide generates a bromophosphonium ion 
in situ which then reacts with the alcohol to give an alkoxyphosphonium ion (Fig. 3.12). The 
phosphonium ion intermediate then undergoes nucleophilic attack by the bromide ion, with the 
expulsion of triphenylphosphine oxide. The driving force for the cleavage of the C-O bond is the 
formation of the strong phosphine oxide bond (P=O), and the process is overall neutral as the 
other by-product formed is bromoform (CHBr3). 
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The 1H NMR spectrum of bromide 141 revealed the absence of a hydroxyl proton at δH 2.52, 
while its 13C NMR spectrum revealed an upfield shift of the carbon at C-1 from δC 61.8 in alcohol 
140 to δC 30.4, thus confirming that substitution by bromine had taken place. 
 
The next step in the reaction sequence was the nucleophilic substitution of 141 by 2-
pyrimidinylarylamine intermediate 136 to give 142. The alkylation proceeded smoothly using 
potassium carbonate as a base in acetone to afford the desired compound 142 in 100% isolated 
yield. The 1H NMR spectrum of 142 revealed a downfield shift of the protons α to bromine at δH 
3.50 for the bromide 141 to δH 4.29 in 142, as well as the presence of signals for the phenolic 
moiety, thus confirming that the alkylation had occurred.   
Catalytic hydrogenation of 142 using palladium-on-carbon catalyst in ethanol furnished 143 in 
70% yield (Scheme 3.10). The appearance of a hydroxyl proton as a broad singlet resonating at 
δH 2.25 and the absence of the characteristic benzylic methylene singlet at δH 4.67 for 142 
provided sufficient evidence that debenzylation had taken place. 
Subsequently, for O-propargylation, the same two-step sequence was used as with the UC-781 
bifunctionals. Thus, the hydroxyl group of 143 was converted to its tosylate 144 in 70% yield by 
reacting it with p-toluenesulfonyl chloride in the presence of triethylamine and a catalytic amount 
of DMAP in dichloromethane. The 1H NMR spectrum of 144 displayed pyrimidine aromatic 
protons with AB coupling (JAB = 8.6 Hz) resonating at δH 7.45 and δH 7.84 as well as a methyl 
singlet at δH 2.43. The presence of additional aromatic signals in the 13C NMR spectrum further 
confirmed the presence of a tosylate group. 
Alkylation (Scheme 3.10) of tosylate 144 was accomplished in the presence of sodium hydride 
and a large excess of propargyl alcohol in THF at reflux. Aqueous work-up followed by 
purification by column chromatography furnished the alkyne 145 in 98% yield. An upfield shift of 
the H-2’’ signal in the 1H NMR spectrum from δH 4.34 in tosylate 144 to δH 3.96 in 145 supported 
the displacement of the tosylate, while the 13C NMR spectrum of compound 145 displayed 
signals for the alkyne carbons at δC 78.3 for C-2’’’ and δC 76.8 for C-3’’’. As before, this sequence 
was preferred to direct propargylation of 143 with propargyl bromide. 
 
3.4.1.2 Sonogashira coupling and final deprotection 
Sonogashira coupling of 5’-O-benzoyl-5-iodo-d4U 60 with alkyne 145 using conditions 



























































Scheme 3.11 Reagents and conditions: (i) 5’-Benzoyl-5-iodo-d4U, Pd(PPh3)4 (10%), CuI (50%), NEt3 (2 
eq), DMF/THF (1:2), rt, (70%); (ii) NaOMe, MeOH, rt, (51%).  
 
The 1H NMR spectrum of 146 showed the disappearance of the alkyne proton of 145 at δH 2.45. 
Some of the resonances for 146 derived from both 60 and 145 included a broad singlet at δH 
7.66 (1H, H-12), a multiplet with allylic coupling at δH 6.76 (1H, H-5), a singlet at δH 3.91 (3H, 
OMe) and a doublet at δH 8.21 (1H, H-29). The 13C NMR spectrum displayed diagnostic signals 
for the alkyne carbons at δC 84.3 (C-13) and δC 98.1 (C-14), as well as the anomeric carbon of 
the sugar (C-5) at δC 90.1. 
Deprotection of the benzoyl group (Scheme 3.11) was achieved using sodium methoxide in 
methanol to give the deprotected target compound 116 in a moderate 51% yield. The reaction 
proceeds spot-to-spot on TLC and the low yield can only be attributed to compound loss during 
extractive work-up. The 1H NMR spectrum of 116 (Fig. 3.13) exhibited an expected upfield shift 
for the diastereotopic H-1 protons to δH 3.61 in 116 from δH 4.49 in 146 as a result of the loss of 
the deshielding effect of the carbonyl group. Similarly, the 13C NMR spectrum showed the 
disappearance of a carbonyl carbon at δC 165.6 and an upfield shift of C-1 from δC 65.2 in 146 to 
δC 64.8 in 116. The deprotection was further confirmed by a broad band in the infrared spectrum 
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Figure 3.13 1H NMR spectrum of target 116. 
 
3.5 Biological evaluation and SAR interpretation 
The inhibition of viral replication in HIV-infected cells of the 4-pyrimidinylarylamine derivatives 
(128-134), 2-pyrimidinylarylamine derivatives (136-137 and 143,145),  as well as bifunctional 
targets 114-116 was measured against HIV-1 (IIIB) replication in MT-2 cell culture using an MTT 
assay (see Appendix I). None of the 2- or 4-pyrimidinylarylamine derivatives or the bifunctional 
targets synthesized (Table 3.3) showed any anti-HIV activity, i.e. they all had an EC50 = not 
active (N/A). CC50 values measuring cytotoxicity of normal cells had generally high micromolar 
values. 
 
Table 3.3 Anti-HIV results of compounds tested in cell-culture. 



























































































































































































































a Effective concentration that inhibits viral-mediated T-cell death by 50% and as an average of three results. 
bCytotoxicity = concentration that kills 50% of the T-cells and as an average of three results. 
 
Once again, examination of the activity (or lack thereof) of these compounds offered important 
insight into the design of future bifunctional compounds, as well as offering valuable information 
regarding structure-activity relationships. Firstly, the meta-tethered 2-pyrimidinylarylamine 
derivatives (137, 143 and 145) surprisingly were biologically inactive. In particular, a lack of 
activity for derivatives 136 and 137 was considered significant in view of Jorgensen’s success 
with 2-pyrimidinylarylamines. A plausible explanation is that any meta-extension on the aryl 
component in the Het-NH-ArX motif other than the Jorgensen dimethylallyl (DMA) one, has 
weakened hydrophobic interactions with the Wing II residues. The mono-PEG-propyne 
derivatives 143 and 145, as well as bifunctional targets 115 and 116 revealed that a spacer 
extension from the meta-position of the 2-substituted aromatic component attached to the 
pyrimidine was definitely not the correct connection point for a bifunctional synthesis. 
Secondly, the fact that 4-pyrimidinylarylamine derivatives 128-134 were inactive also, including 
the prototype [d4U]-propyne-[4-pyrimidinylarylamines] bifunctional 114 does not necessarily 
mean that the spacer extention point on the aryl component in the Het-NH-ArX motif (whether 
meta or ortho) was incorrect, but could imply that the C-2 position of the pyrimidine (Het) moiety 
needs to be also substituted with an aryl component as in the potent DAPY derivatives such as 
TMC120 or TMC125. The lack of this vital C-2 pyrimidine linkage (which gives rise to important 
Wing II hydrophobic interactions with Lys101 and Tyr318) could have caused the NNRTI portion 
of the heterodimer not to bind tightly and specifically to the NNRTI-BP (or in our case not bind at 
all) with resulting lack of biological activity. Therefore, this structural study proved to be of great 
value in depicting how important every component of the potent DAPY compounds were in 
trying to achieve maximum biological activity. 
 
Thus, these results allowed the following conclusions regarding rational drug design changes to 
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(i) A full DAPY would have to be synthesized; 
(ii) The best attachment point for the tether onto the NNRTI would be the para-
position (2nd best meta-position) of the aromatic substituent attached to C-4 of the 
pyrimidine; 
(iii) Variable spacer sizes needed to be evaluated for optimal activity and their 
influence on the entropy of activation addressed; 
(iv) The need for molecular modeling and its part in understanding and probing for 
synergy between the NRTI active site and the NNRTI-BP had become evident in 
trying to develop a predictive model to work with, and finally; 
(v) To gain insight into the requirements at the NRTI, d4U would have to be 
substituted by and then compared with a more flexible and mono-phosphorylated 
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SYNTHESIS OF NRTI-SPACER-TMC120 DOUBLE-DRUGS 
 
4.1 Strategy for the synthesis of [NRTI]-spacer-[TMC120] bifunctionals 
Following the synthesis of the d4U-spacer-pyrimidinylarylamines in Chapter 3, many conclusions 
were made with regards to a more rational drug design approach. It became apparent that a full 
diarylpyrimidine (DAPY) would have to be synthesized, incorporating a flexible spacer linked to 
not only the rigid d4U, but also an acyclic nucleotide phosphonate (ANP). The activation entropy 
(∆S#) was likely to be greater for an ANP compared to the pre-organized form of d4U, however 
in theory, the ANP moiety might be able to adopt conformations where its enthalpy of activation 
(∆H#) would be lower (due to cooperativity), resulting in an overall lower Gibbs activation free 
energy (∆G#) leading to a greater negative ∆G overall (faster and tighter binding). However, it was 
decided not to completely abandon d4U, but rather retain it for a comparative study with the 
ANP. 
 
At the onset of this new strategy in 2007, collaborative work between Professors Roger Hunter 
(University of Cape Town), Karen Anderson and William Jorgenson (both Yale University) led 
the groups in search of a new target structure, this time an anti-HIV double-drug of the general 
formula [NRTI]-spacer-[TMC120]. Variation on the NRTI would cover both d4U and an ANP. 
Unlike in Chapter 3, a TMC120 (dapivirine) NNRTI template was chosen in which the Br and 
NH2 groups in the pyrimidine ring are absent (Fig. 4.1). TMC120 is based on the clinically 
approved TMC125 (etravirine) belonging to the family of highly potent diarylpyrimidines 
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Before the start of any synthesis this time around, molecular modeling was used to extrapolate 
vital drug-design considerations. Thus, the Yale modeling group under supervision of Professor 
William Jorgenson came up with the following results. 
 
4.2 Molecular modeling studies 
4.2.1 Parameters for Molecular Modeling of d4U-n-PEG-TMC bound to HIV-1 
RT:template:primer.   
Since there was no crystal structure of RT complexed with both a NRTI and a NNRTI, a model 
was created starting from the crystal structures of the RT:template:primer complex from Huang 
et al.184 (PDB entry 1rtd) and the Das et al. complex of the TMC120-R147681 NNRTI90 (PDB 
entry 1s6q). First, both of these files were read into the UCSF Chimera program185 and 
superimposed using the matchmaker utility. A composite protein was then created by combining 
residues 1a-92a, 108a-178a, 241a-554a, 3b-249b, the template, primer and the 4 Mg2+ ions 
from 1rtd and 93a-107a, 179a-240a, and the ligand from 1s6q. 
 
The initial 3D structure of the bifunctional ligand (bf4) was created by drawing it in ChemDraw186 
and energy minimization using the MM2 force field in Chem3D187 and writing as a PDB file. After 
reading this structure in Chimera, the nucleotide end of this molecule was superimposed to the 
dNTP of the composite protein created above, and a few of the dihedrals on the polyethylene 
glycol (PEG) spacer were manually changed to g+ or g- to superimpose as best as possible the 
NNRTI end to the TMC120 crystallographic ligand. The sidechain torsions χ1 and χ2 of Y188a 
were adjusted by -30 and +30° respectively to avoid a severe steric clash. Finally, the 
crystallographic dNTP and TMC120 were then removed and the resulting complex exported as a 
PDB file. 
 
The creation of the model was completed by reading the PDB files created by Chimera in 
Schrödinger’s Maestro 7.5188 and adding the hydrogen atoms needed at protonation states 
appropriate to pH = 7. The following set of energy minimizations were sequentially run with the 
Impact program189 using the OPLS 2001 force field with a distance-dependent dielectric ε = 4r, a 
12 Å cutoff for non-bonded interactions, and the steepest descent algorithm. First, the newly 
created ligand and the segments of the protein chains originally from the 1s6q structure (93a-
107a, 179a-240a) as well as all the residues within 4 Å of those were allowed to moved while 
the rest were kept fixed at their original positions during a 100-step optimization during which the 
total energy of the system decreased from 6.1 x 1014 to 927.0 kcal/mol. The resulting structure 
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the same degrees of freedom during which the energy decreased further to -187.2 kcal/mol. The 
entire system was then allowed to relax for successive optimizations of 100 and 300 steps 
reduced the total energy from 8,490.5 to -3,398.0 kcal/mol. The Cα rms deviation of the final 
structure to the initial 1rtd is only 0.27 Å which shows that there was relative little distortion 
created by the process. 
 
4.2.2 Results from the molecular modeling  
Molecular modeling suggested a 4-PEG spacer would be long enough to span the NNRTI 
binding pocket and the active site (Fig. 4.2 -A). This is the first ever modeling interpretation of a 
bifunctional entity complexed to HIV-1 RT as there are none in the literature.  The 4-PEG spacer 
was identified as the minimum distance between the two sites, but the incorporation of longer 
PEG units would be very interesting from a SAR point of view. Very importantly, the modeling 
finally confirmed our earlier prediction, following a suggestion by Ruth and Cheng, that a C-5 
connection to the base clearly ‘exits’ the substrate binding site with low interference to DNA 
base-pairing (Fig. 4.2 -B).141  
 
Figure 4.2 A) d4U-4PEG-TMC120 double drug bound to HIV-1 RT; B) NRTI position zoomed in, depicting 
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Most interestingly, the PEG spacer was predicted to protrude from the NNRTI binding pocket 
toward (Fig. 4.3 -D and E) the active site through a hydrophobic tunnel, similar to the tunnel 




Figure 4.3 C) TMC278 bound to HIV-1 RT; D) The PEG spacer protruding from the NNRTI binding pocket 




As depicted in Figure 4.3 -E, the C-2 aromatic ring of the DAPY (see Figure 4.1 for numbering) 
is firmly embedded in the Wing II hydrophobic compartment of the RT NNRTI-BP, but the C-4 
aryl ring is closer to residues near the ‘exit tunnel’ of interest, whilst the central pyrimidine unit 
binds strongly in the Wing I region. The para-position on the C-4 aromatic ring of the DAPY was 
identified as the optimal connection point for the spacer elongation (Fig. 4.3 -C/D). From the 
pictures generated, it was now evident that an ortho-extension on the C-4 aromatic ring would 
not work (as in Chapter 3), and that a meta-extension would probably not return any biological 
activity, but should definitely be synthesized and evaluated. These conclusions are in line with 
that made by Arnold and co-workers in his recent PNAS communication,77 although his study did 
not include extensions to bifunctional entities.  
 
Thus, it was decided to synthesize double-drugs of the general formula [NRTI]-spacer-[TMC120] 
using a para-connection to the spacer. The first such double-drugs would incorporate d4U as the 
NRTI. The bifunctional structures identified as possible targets are shown in Figure 4.4. 
Triphosphate 148 was identified for carrying out in vitro inhibition studies on RT directly in order 
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4.3 Retrosynthetic analysis of [d4U-TP]-propyne-tetraPEG-propyne-[TMC120] 
The total synthesis of target 147 was conceived using chemistry previously described via a 
convergent strategy involving the coupling of 5'-iodo d4U 60 to alkyne 149 followed by 
deprotection of the benzoyl group to render the target compound directly (Figure 4.5). This 
would be followed by a triphosphate salt incorporation to give the second target compound 148. 
Alkyne 149 would in turn be formed from the propargylation of alcohol 150, following tosylation 
and in situ generation of the propargyloxy anion from the reaction between propargyl alcohol 
and sodium hydride. Compound 150 would be tested for substituent effects in the HIV reverse 
transcriptase pocket, and could be obtained from the Sonogashira coupling of mono-
propargylated tetraethylene glycol 151 and TMC120 derivative 152. 
TMC120 derivative 152 was anticipated to come from aryl coupling of appropriately substituted 
phenol 153 and key intermediate 154. Key intermediate 154 could be obtained over three steps 
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4.4 Synthesis of [d4U-TP]-propyne-tetraPEG-propyne-[TMC120] 
4.4.1 Synthesis of the tethered (propyne-tetraPEG-propyne)-TMC120 derivative 
Our first challenge towards the synthesis of 147 and 148 was to access the very important 
Sonogashira coupling partner 152. Intermediate 152 would be required in large quantities and 
thus a viable synthetic route needed to be explored. Isomura and co-workers published a 
report190 in 1997 in which they synthesized 152 in a 72% overall yield over four steps (Scheme 
4.1). To this end, commercially available 2-amino-4-chloro-1,3-pyrimidine 157 was di-protected 
at the C-2 amine using di-tert-butyldicarbonate and N,N-4-dimethylaminopyridine in THF at room 






























Scheme 4.1 Reagents and conditions: (i) (Boc)2O (2 eq), THF, DMAP (85%); (ii) 153, Cs2CO3, DMF, 90 
oC; (iii) CF3CO2H (10 eq), CH2Cl2, r.t (86% over two steps); (iv) 160, t-BuOK, DMSO, 50 oC (45%). 
 
This was followed by an addition-elimination type nucleophilic aromatic substitution reaction at 
the C-4 position of the pyrimidine using the iodophenol 153 and cesium carbonate in DMF at 90 
oC. Subsequent filtration of excess cesium carbonate and removal of solvent under reduced 
pressure, followed by deprotection of the Boc-groups employing trifluoroacetic acid in 
dichloromethane at room temperature gave 159 in 86% yield over two steps. Finally, 152 was 
prepared by reacting 159 together with potassium tert-butoxide in DMSO at 50 oC, which after 
addition of arylamine 160 returned key TMC-intermediate 152 in a low 45% yield after column 
chromatography.  
 
Not satisfied with the efficacy of this route, it was decided to develop an alternative based on a 
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arylisocytosines. This approach required less column chromatography and made use of 
relatively cheap starting materials compared to the Isomura strategy. Thus, 2-thiouracil (Scheme 
4.2) was subjected to sodium hydroxide dissolved in water and methyl iodide for 24 hrs at room 
temperature, which following acidification using acetic acid, rendered 2-(methylthio)pyrimidin-
4(3H)-one 161 in 73% yield after crystallization from boiling ethanol. The 1H NMR spectrum of 
161 revealed only one NH signal present at δH 6.65, as well as the diagnostic thiomethyl singlet 
resonating at δH 2.43. The 13C NMR spectrum confirmed formation of 161 with a singlet at δC 
12.3 for the thiomethyl and a carbonyl peak at δC 164.1. The melting point of 188-189 oC was in 
full agreement with that reported in the literature (185-188 oC).  
 
The next step (Scheme 4.2) involved treatment of 161 with a small excess of arylamine 156 in 
refluxing bis(2-methoxyethyl) ether (diglyme) resulting in precipitation of N2-arylisocytosine 162 
in a low yield of 36%. The yield was obtained after repeated crystallization of 162 from boiling 
methanol. Key diagnostic signals in the 1H NMR spectrum of 162 were the new AB aromatic 
protons at δH 7.71 (d, J = 8.7 Hz, H-3') and δH 7.81 (d, J = 8.7 Hz, H-2'). The 13C NMR spectrum 
of 162 validated this further with new aromatic signals at δC 101.7 (C-4’), δC 118.7 (C-3’), δC 
132.7 (C-2’) and δC 145.9 (C-1’), as well as the indicative CN singlet at δC 118.9. Once again, the 







































Scheme 4.2 Reagents and conditions: (i) CH3I, NaOH, H2O, CH3CO2H, r.t (73%); (ii) 156, diglyme, ∆ 
(36%); (iii) neat P2O5 (xs), 100 oC (90%). 
 
Subsequent, chlorination of 162 using neat POCl3 for 5 hrs at 100 oC gave compound 154 in 
90% yield after column purification. The 1H NMR spectrum of 154 displayed two AB doublet 
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and δH 8.06 for H-2’ of the C-2 aromatic ring. The 13C NMR spectrum of 154 revealed the 
disappearance of the carbonyl signal at δC 162.0 in 162 and the appearance of a singlet at δC 
129.7 for the halogen-bearing carbon (C-4). Combustion microanalysis returned favorable data: 
Found C, 57.12; H, 3.09; N, 24.29; C11H7N4Cl requires C, 57.28; H, 3.06; N, 24.29. 
 
Phenol 153 needed to be synthesized first for key intermediate 152 to be completed (Scheme 
4.3). This was accomplished192 using commercially available 2,6-dimethylphenol 163, iodine and 
morpholine dissolved in diethyl ether, in which TLC confirmed reaction completion after 1½  hrs. 
Subsequent column purification returned the para-substituted phenol 153 in an excellent yield of 
90%. The 1H NMR spectrum of 153 displayed a free OH singlet at δH 4.62, as well as an 
aromatic proton singlet resonating at δH 7.31 integrating for two hydrogens. The 13C NMR 






















Scheme 4.3 Reagents and conditions: (i) I2, morpholine, diethyl ether (90%); (ii) 154, Cs2CO3, DMF, 90 oC 
(99%). 
 
Successful coupling of phenol 153 to pyrimidine 154 was attained using identical conditions to 
that of Isomura, making use of cesium carbonate as base in hot DMF.193 TMC-derivative 152 
was obtained after 1 hr in 99% yield following silica-gel purification. The 1H NMR spectrum of 
152 revealed the absence of the free OH at δH 4.62 in 153. The 13C NMR spectrum of 152 
displayed vital resonances at δC 159.0 (C-2), δC 168.0 (C-4), δC 144.4 (C-1’) and δC 149.5 (C-1’’). 
Finally, a correct HRMS evaluation (m/z HRMS (ES) 443.0348 [M+H]+, C19H16N4OI requires m/z 
443.0369 [M+H]+), confirmed the structure of 152 as shown in Figure 4.3. 
 
With the TMC-derivative 152 now in hand, our attention shifted to the synthesis of the spacer. 
The overall synthetic scheme for the initial phase of the spacer incorporation is shown in 
Scheme 4.4. Thus, propargylation of commercially available tetraethylene glycol194 164 (1.0 eq.) 
was achieved using sodium hydride (1.0 eq.) and propargyl bromide (1.1 eq.) in THF at room 
temperature in 42% yield after column purification. The 1H NMR spectrum of 151 displayed the 
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(d, J = 2.4 Hz). The 13C NMR spectrum of 151 displayed characteristic alkyne resonances at δC 






































Scheme 4.4 Reagents and conditions: (i) propargyl bromide, NaH, THF, r.t (42%); (ii) 152, Pd(PPh3)4 
(10%), CuI (50%), NEt3 (2 eq), DMF/THF (1:2), r.t (75%). 
 
The Sonogashira coupling of TMC-derivative 152 with the 4-PEG alkyne 151, using identical 
conditions to those described in Chapters 2 and 3, was carried out and the 4-PEG-elongated 
TMC120 derivative 150 isolated after silica-gel purification in a good yield of 75% (Scheme 4.4). 
Compound 150 was the first derivative in this series synthesized for anti-HIV probing. Of note, 
was that hydroxyl group protection was unnecessary, which greatly reduced the number of 
steps. 
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The 1H NMR spectrum of 150 (Fig. 4.6) revealed resonances for both moieties in a 1:1 ratio, key 
being the disappearance of an alkyne proton at δH 2.42.  The 13C NMR spectrum of 150 returned 
the correct number of resonances, i.e. 30 and was assigned using 2-D techniques such as 
HSQC and HMBC. 
 
In anticipation of a second Sonogashira coupling of the end of the spacer (in 150) to 5'-O-
benzoyl-5-iodo-d4U 60, the two-step conversion developed previously was necessary as 
depicted in Scheme 4.5. Thus, the hydroxyl group of 150 was converted to its tosylate 165 in 
93% yield by reacting it with p-toluenesulfonyl chloride in the presence of triethylamine and a 
catalytic amount of DMAP in dichloromethane. The 1H NMR spectrum of 165 displayed aromatic 
protons with AB coupling (JAB = 8.6 Hz) resonating at δH 7.45 and δH 7.62 as well as a methyl 
singlet at δH 2.08. The presence of additional aromatic signals in the 13C NMR spectrum further 
confirmed the presence of a tosylate group. 
Substitution of tosylate 165 was accomplished in the presence of sodium hydride and a large 
excess of propargyl alcohol in THF at reflux as described for the UC-781 work. Aqueous work-up 
followed by purification by column chromatography furnished the alkyne 149 in 86% yield. The 
1H NMR spectrum of 149 displayed the characteristic alkyne signal at δH 2.42, while its 13C NMR 
















where: R = H (150),







Scheme 4.5 Reagents and conditions: (i) p-TsCl, NEt3, CH2Cl2, DMAP (cat) (93%); (ii) propargyl alcohol, 
NaH, THF, ∆ (86%). 
 
From a SAR point of view, the C-4 aromatic ring attached to the pyrimidine still needed to be 
extended from the meta-position. It was expected that such a derivative would have little to no 
biological activity, but this exploration would definitely validate the molecular modeling studies 
carried out at the onset of this part of the project. To this end, commercially available 
tetraethylene glycol 164 was mono-protected as its monobenzyl ether 166 in 39% yield with 
benzyl bromide and sodium hydride in THF after column chromatography (Scheme 4.6). The 
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revealed aromatic protons integrating for 5 protons resonating at δH 7.34 as well as methylene 
protons resonating at δH 4.56. The 13C NMR spectrum displayed a methylene carbon at δC 73.1.  
Treatment of alcohol 166 with carbon tetrabromide in dichloromethane (Scheme 4.6) rendered 
the bromide 167 in 95% yield. Work-up involved evaporating the solvent and purifying the crude 
product directly by column chromatography. The 1H NMR spectrum of bromide 167 revealed the 
absence of a hydroxyl proton at δH 2.80, while its 13C NMR spectrum revealed an upfield shift of 
the carbon at C-1 from δC 61.6 in alcohol 166 to δC 30.2, thus confirming that substitution by 

























Scheme 4.6 Reagents and conditions: (i) BnBr, NaH, THF, reflux, 20 hrs (39%); (ii) PPh3, CBr4, CH2Cl2, 0 
oC, 30 min (88%).  
 
The next step (Scheme 4.7) involved coupling of pyrimidine 154 to arylamine 119b (prepared 
previously - see Chapter 3) using p-toluenesulfonic acid in 1,4-dioxane at 100oC to yield DAPY 
168 quantitatively. The 1H NMR spectrum of 168 displayed the appearance of two independent 
NH signals at δH 9.43 and δH 10.02, as well as an OH singlet at δH 9.66. Finally, a correct HRMS 
evaluation (m/z HRMS (ES) 337.0738 [M+], C17H12N5OCl requires m/z 337.0738 [M+]), confirmed 
the structure of 168. 
Subsequent nucleophilic substitution of the bromide 167 by DAPY intermediate 168 was 
achieved using potassium carbonate as a base in acetonitrile at 50 oC to afford the desired 
compound 169 in 100% isolated yield. The 1H NMR spectrum of 169 revealed a downfield shift 
of the protons α to bromine at δH 3.45 for the bromide 167 to δH 4.10 in 169 as a result of the 
deshielding effect of the phenoxy group, as well as the presence of signals for the phenolic 
moiety, thus confirming that the alkylation had occurred.   
Catalytic hydrogenation of 169 (Scheme 4.7) using palladium-on-carbon catalyst in ethanol and 
THF furnished 170 in 70% yield as a more polar spot on TLC. The appearance of a hydroxyl 
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6where: R = Bn (169),
            R = H (170)
 
Scheme 4.7 Reagents and conditions: (i) 119b, p-TsOH, 1,4-dioxane, 100 oC (100%); (ii) 167, K2CO3, 
CH3CN, 50 oC (100%); (iii) H2, Pd/C, EtOH/THF (1:1), r.t (30%). 
 
4.4.2 Sonogashira coupling and final deprotection 
For bifunctional generation, the elongated TMC120-derivative 149 (see Figure 4.5) was 
subjected to a Sonogashira reaction with 5'-O-benzoyl-5-iodo-d4U 60, under similar conditions 
as described before (Scheme 4.8). The coupling afforded 171 in 59% yield. The 1H NMR 
spectrum data for 171 revealed signals for both the alkynyl 149 and d4U moieties in the ratio of 
1:1. A successful coupling was further confirmed by the absence of a terminal alkyne proton at 
around δH 2.42. The 13C NMR spectrum of 171 displayed diagnostic resonances at δC 143.6 (C-
12), 90.6 (C-5), 59.0 (C-15) thus confirming the presence of both the nucleoside and the alkyne. 
The structure was further analyzed by 2D NMR in a satisfactory manner (see experimental for 
assignments). 
Finally, 171 was deprotected with sodium methoxide in methanol to furnish 147 in 94% yield 
following neutralization with a few drops of acetic acid, evaporation of methanol and direct flash 
chromatography using DCM/MeOH (95:5). The 1H NMR spectrum of 147 (Fig. 4.7) revealed 
resonances for both inhibitors, notably the d4U double bond signals and the H-12 uracil singlet 
at δH 8.34, as well as a characteristic set of aromatic and heteroaromatic signals for the DAPY 
unit. Its 13C spectrum returned the correct number of singlets (42) and 2D-NMR techniques 
(HSQC, HMBC) were utilized to make a full structural assignment. Finally, a correct HRMS 
evaluation (m/z HRMS (EI) 793.3204 [M+H]+, C23H22N6O5SCl requires m/z 793.3191 [M+H]+), 

































































Scheme 4.8 Reagents and conditions: (i) 5'-Benzoyl-5-iodo-d4U, Pd(PPh3)4 (20%), CuI (50%), NEt3 (3 
eq), DMF/THF (1:2), rt, (59%); (ii) NaOMe, MeOH, rt, (94%). 
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4.4.3 Biological evaluation and SAR interpretation 
The inhibition of viral replication in HIV-infected cells of the TMC-derivatives 150 and 170, as 
well as bifunctional target 147 was measured against HIV-1 (IIIB) replication in MT-2 cell 
cultures using an MTT assay (see Appendix I). The results are summarized in Table 4.1 below. 
 
Table 4.1 Anti-HIV results of compounds tested in MT-2 cell cultures using MTT assay. 
































































The results above were fascinating. By probing the effect of the spacer elongation onto the 
NNRTI (150), a 20 nM activity for 150 (as a 10-fold reduction from TMC120) was obtained 
suggesting that the correct attachment point was chosen. As predicted, no anti-HIV activity was 
displayed by derivative 170. This validated the molecular modeling studies and also depicts how 
extremely sensitive drug-design strategies are to error, i.e. moving from a para-elongated 
system to a meta-derivative defines the border between activity and no-activity in this case. The 
bifunctional 147 gave an impressive 100 nM activity, as a 50-fold reduction from TMC120 in the 
cell culture assay. Although this was a hugely encouraging result, the activity was still not 
comparable to that of the individual NNRTI (i.e. TMC120), thus indicating that a truly mixed-site 
inhibitor was not being realized. At this point, the question of whether the nucleoside was being 
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bifunctional was being ‘switched on’ for incorporation into the growing DNA chain, it was decided 
to perform RT enzyme studies on the compounds tested above, as well as synthesize and test a 
triphosphorylated nucleotide form of 147. 
 
4.4.4 Triphosphate generation 
In 1989, Eckstein195 reported a four-step protocol for effective triphosphorylation of the 5'-
hydroxyl group of a nucleoside. His procedure involved formation of a triethylammonium 
triphosphate salt which was useful as a water soluble metabolite required for cell-culture testing. 
Thus, subsequent treatment of nucleoside 147 (Scheme 4.9) with 2-chloro-1,3,2-
benzodioxaphosphorin-4-one, pyridine and DMF at 0 oC DMF, followed by 
bis(tributylammonium) pyrophosphate, iodine and TEAB yielded triphosphate 148 in 37% yield 
after chromatography on a Sephadex ion-exchange (DEAE) column using aq. TEAB 
(triethylammonium bicarbonate) as the mobile phase.  The bifunctional triphosphate eluted at 
around 0.6 M.  TLC’s were evaluated on amine-impregnated silica-gel plates using TEAB/MeOH 
= 3.5/6.5). The reaction proceeds via formation of a mixed phosphite, which is substituted by 


































Scheme 4.9 Reagents and conditions: (i) 2-Chloro-1,3,2-benzodioxaphosphorin-4-one, pyr, DMF, 0 oC-r.t; 
(ii) bis(tributylammonium) pyrophosphate, NEt3, DMF; (iii) I2, pyr/H2O; (iv) TEAB, DMF/THF, r.t (37% over 
4 steps). 
 
The bifunctional [d4U-TP]-propyne-4-PEG-propyne-[TMC120] 148 was further analyzed by high-
pressure liquid chromatography (HPLC) on a DNA Pac PA-100 analytical column (Dionex, 
Sunnyvale, CA) using the following conditions: mobile phase A, 0.05 M triethylammonium 
bicarbonate (TEAB), pH 8.0; mobile phase B, 0.5 M TEAB, pH 8.0. Mobile phase flow rate was 1 
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five minutes.  The mobile phase flow rate was 1 mL / min using a gradient of 100% A to 50% A / 
50% B for ten minutes and then to 100% B for five minutes.  Absorbance was measured at 260 
nm. The HPLC trace is presented in Figure 4.8, displaying purity in the appearance of a single 
peak with a retention time of 22 min under these conditions. 
 
Figure 4.8 HPLC trace of [d4U-TP]-4PEG-[TMC120] 148. 
 
The 1H NMR spectrum of 148 revealed the absence of an OH signal at δH 3.48 and the 
appearance of 27 protons resonating at δH 1.25 for the three triethylammonium moieties. The 
fourth cation for the triphosphate is presumably provided by a protonated pyrimidinium ion. Its 
13C NMR spectrum further supported TP incorporation in 148 with peaks at δC 9.1 and δC 47.2 for 
the triethylammonium moieties. However, clear-cut evidence was provided in the 31P NMR 
spectrum of 148 (Fig. 4.9), displaying the necessary two-doublet / triplet set of signals resonating 
at δP -8.9 (d, J = 20.2 Hz), δP -9.8 (d, J = 20.2 Hz) and δP -22.1 (t, J = 20.2 Hz) for the two 
terminal phosphates and central one respectively. Finally, a correct HRMS evaluation (m/z 
HRMS (EI) 1031.2035 [M+H]+, C42H48N6O19P3 requires m/z 1031.2036 [M+H]+), confirmed the 
structure of 148 as a triphosphoric acid. 
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4.4.5 Biological evaluation and SAR interpretation 
For the in vitro RT inhibition assays, dTTP and dGTP were purchased from GE Biosciences.  
Oligonucleotide primers and template were synthesized at the Keck Facility at Yale University 
and were purified using 20% denaturing gel-electrophoresis. The DNA primer template used in 
this study was as follows: D23 (5’-TCA GGT CCC TGT TCG GGC GCC AC -3’), D24 (5’-TCA 
GGT CCC TGT TCG GGC GCC ACT-3’) for the primer, and D36 (5’-TCT CTA GCA GTG GCG 
CCC GAA CAG GGA CCT GAA AGC-3’) for the template.  Labeling and annealing of 
primer/templates were performed as described by Anderson.196 
  
Expression and Purification of HIV-1 RT.  C-terminal histidine tagged heterodimeric p66/p51 
wild-type HIV-1 RT was expressed and purified as described previously197 using a clone 
generously provided by Stephen Hughes, Paul Boyer, and Andrea Ferris (Fredrick Cancer 
Research and Development Center, Fredrick, MD).   
IC50 determination. 8 nM RT (active sites based on pre-steady state active site determination) 
was pre-incubated for at least 15 minutes with 1 μM 5'-labeled primer/template prior to mixing 
with appropriate concentrations of inhibitor and allowed to incubate for a minimum of 15 
additional minutes on ice.  DMSO concentrations were kept constant at less than 2%. DMSO 
alone was added as a no inhibitor control for each set of experiments.  Reactions were initiated 
with the addition of 5 μM dNTP and 10 mM MgCl2 and were quenched after 15 minutes at 37° C 
with 0.3 M EDTA.  All concentrations represent final concentrations after mixing.  Reaction 
products were subjected to 20% denaturing polyacrylamide gel-electrophoresis and quantitated 
on a Bio-Rad Molecular Imager FX.  Product formation was plotted as a function of inhibitor 
concentration and fitted to a hyperbola to generate IC50 curves.  IC50 values are defined as the 
concentration of inhibitor that inhibits steady-state single nucleotide incorporation by 50%. 
Incorporation Assays.  Incorporation experiments were performed under single turnover 
conditions; 50 μM d4U-TP-4PEG-TMC and 10 mM MgCl2 were mixed with 250 nM RT (active 
sites) and 50 nM 5’-labeled primer/template to initiate the reaction.  Negative controls were 
performed under identical conditions without MgCl2.  The reaction was allowed to proceed for 30 
minutes at 37° C, after which the reaction was quenched with 0.3 M EDTA.  Reaction products 
were subjected to 20% denaturing polyacrylamide gel- electrophoresis and analyzed on a Bio-
Rad Molecular Imager FX.  
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Table 4.2 Anti-HIV results of compounds tested in the RT enzyme assay vs cell-culture results. 





NC TMC120  
 





















































14 ± 2 




























The RT inhibition assay involved measuring the interference of dTTP uptake into the DNA primer 
of the primer/template (both short DNA strands) as catalysed by RT, by competing uptake of the 
inhibitor, i.e. the nucleoside portion of the bifunctional entity. DNA products were quantified 
using gel-electrophoresis. Quite interestingly, the results revealed a drop in activity for TMC120 
and compound 150 compared to the cell-culture assay. As suspected, no anti-HIV activity was 
displayed by derivative 170. Impressively, though, a 14 nM activity was obtained for bifunctional 
147 in the enzyme assay, compared to the 100 nM activity in the cell-culture assay (Table 4.1). 
The higher activity of the free bifunctional nucleoside 147 in vitro over cell-culture, was credited 
to the instability of 147 in cell-culture as well as permeability issues. The low IC50 (close to that of 
the NNRTI) in vitro suggests some level of mixed-site interaction, possibly involving H-bonding 
at the substrate site. Most significant, however, was that triphosphate 148 returned an 
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TMC120. This finally offered us a proof of principle of the existing synergy between the active 
site and the NNRTI-BP. However, proof beyond doubt would require an X-ray crystal structure, 
which has been elusive up till now.  
 
It was now important to validate the incorporation of 148 into the primer. To this end, the 
incorporation of triphosphate 148 into the primer strand of a D23/D36 (correct base-pairing) 
primer/template was studied, as well as the incorporation into a D24/D36 (mismatch base-
pairing) primer/template as schematically represented in Figure 4.10. In theory, triphosphate 148 
was expected to be better recognized in the D23/D36 case than the mismatch case. This is 
because the nucleotide portion of the bifunctional 148, resembling a C-5 elongated thymidine-
triphosphate, was expected to compete better against dTTP uptake (with an A coding in the 
template strand) than against dGTP uptake in the mismatch experiment where a C in the 
template demands a G uptake in the primer. 
 
 
Figure 4.10 Schematic representation of correct vs mismatch base-pairing experiments for 148. 
 
Pleasingly a polyacrylamide gel-electrophoresis revealed excellent incorporation of triphosphate 
148 into the D23 primer of the D23/D36 BP experiment (Figure 4.11).  
.  
 0m                  60m 
Figure 4.11 Bifunctional TP 148 incorporation as shown in a gel-electrophoresis experiment. 
    5’-TCTCTAGCAGTGGCGCCCGAACAGGGACCTGAAAGC-3’ Template 
*  3’-  CACCGCGGGCTTGTCCCTGGACT-5’     Primer 
Th-TP / Bif-TP 
  D23/D36 
‘correct BP’ 
 3 -  TCACCGCGGGCTTGTCCCTGGACT-5’      Primer 
dGTP / Bif-TP 
 *    D24/D36 ‘mismatch BP’ 
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The huge increment by which the D23-TP148 monophosphate (MP) band shifts relative to the 
D23 primer can be attributed to the increase in size of the DNA fragment now coupled to a large 
bifunctional entity. 
The in-vitro RT results for the correct and mismatch BP assay are summarized in Table 4.3. The 
results revealed that all the compounds listed in Table 4.3 showed better activity for the ‘correct 
BP’ compared to the ‘mismatch BP’ assay. Most importantly, the activity of triphosphate 148 
(38.1 nM) was effectively the same for the mismatch experiment as the free bifunctional 
nucleoside 147 (35.0 nM), providing compelling evidence that the nucleotide of bifunctional 148 
in the matched experiment is getting incorporated, with a remarkable 1.7 nM activity. The fact 
that nucleotides only inhibit at low μM concentration and that the bifunctional nucleotide-TP 148 
returned a lower nM activity IC50 than the NNRTI alone (5.2 nM), provides convincing evidence 
for in vitro synergy in a mixed-site fashion. 
 
Table 4.3 Correct vs mismatch BP results for in vitro RT assay 
Compound IC50 (nM) 
Correct BP (D23/D36) 
IC50 (nM) 





NC TMC120  
 
5.2 ± 3.3 
 

















15.4 ± 3.6 
 
 


















1.7 ± 1.0 
 
38.1 ± 6.8 
 
Although the inhibition results of the bifunctionals 147 and 148 were hugely encouraging, the 
overall conclusion was that the lower activity of the bifunctional 147 compared to TMC120 in 
cell-culture (50-times less active) implied a lack of in vitro phosphorylation. Therefore, it was 
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4.5 Synthesis of [ANP]-propyne-n-PEG-propyne-[TMC120]: where n = 4 and 6 
A major feature of design of the bifunctional inhibitors described up to date was the incorporation 
of the rigid, non-flexible d4U as the NRTI portion of the heterodimer. The overall free energy 
demand on binding such a large non-cleavable entity could be somewhat attenuated with the aid 
of a more flexible inhibitor. For this reason, it was decided to change d4U to an acyclic 
nucleotide phosphonate (ANP). The prodrug would incorporate a phosphonate entity and this 
would circumvent the first intracellular kinase phosphorylation step increasing the likelihood of 
activation to the active 5’-triphosphate metabolite.  
The ANP model chosen had uracil as its Watson-Crick base pair as opposed to cytosine used in 
the clinically approved cidofovir ANP. This choice of ANP was mainly influenced by having 
available the uracil chemistry required for the synthesis as well as the fact that 5’-fluorouracil 
acyclic nucleotide was known to be active with an EC50 of 34 μM (Fig. 4.12).198-200 The uracil 
acyclic nucleotide was chosen as a prototype phosphonate that was considered relatively simple 
to synthesize under the time constraints. Its main objective was to study how such an entity 













Figure 4.12 Known 5’-fluoro uracil acyclic nucleotide. 
 
4.5.1 Retrosynthetic analysis of [ANP]-propyne-n-PEG-propyne-[TMC120] 
Synthesis of the ANP incorporated bifunctionals 172 and 173 were envisaged as being 
achievable via a convergent Sonogashira coupling of elongated TMC-derivatives 149 (or 174) 
and pyrimidine-tethered phosphonate 175b (Fig. 4.13). Phosphonate 175b would be generated 
from CAN iodination of 175a, which in turn would be prepared from 1N-alkylation of unprotected 
uracil to a modified two carbon tethered phosphonate of type A. The latter was envisaged as 
available via alkylation of protected alcohol 140 by phosphonate 176. Known chemistry in the 
form of the Pudovik reaction would be employed for the synthesis of 176. This new strategy was 













































































where: n = 4 (172),










where: n = 4 (149),
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4.5.2 Synthesis of the ANP moiety 
The synthesis towards 5-iodo-ANP 175b began with large-scale (10 g) esterification of 
phosphorus trichloride with three equivalents of isopropanol (IPA) using two equivalents of 
sodium hydride in THF as outlined in a publication in 2004 by Fakhraian and co-workers201 
(Scheme 4.10). Diisopropyl hydrogen phosphonate 177 (DAHP) was isolated in 98% yield after 
an aqueous work-up using ammonium chloride and evaporation of solvent, without the need of 
any column chromatography. It was judged by 1H NMR spectroscopy to be pure enough for 
taking to the next step without purification. The mechanism of the reaction (Fig. 4.14) reveals the 
importance of only adding two equivalents of base. Three equivalents of HCl are produced 
during the course of the reaction (step 1), of which only two equivalents can be mopped up by 
the base. The remaining equivalent of HCl is used in the protonation of the phosphorus of the 
trialkylphosphite, which rearranges to the more stable pentavalent phosphorus in the form of the 
desired dialkyl hydrogen phosphonate (DAHP) via an Arbuzov-type dealkylation. In the case of 
adding three equivalents of base, no DAHP is produced, but only the phosphite. The reaction 
can also be performed under base-free conditions, but this means having to neutralize large 
quantities of HCl in the work-up. The 1H NMR spectrum of 177 revealed the characteristically 
large P-H coupling for the hydrogen attached to phosphorus at δH 6.77 (1H, d, JHP = 687.0 Hz) 














177 178  
Scheme 4.10 Reagents and conditions: (i) IPA (3eq), NaH (2eq), THF, r.t (98%); (ii) (H2CO)n, K2CO3, IPA, 

































CHAPTER 4:_____________________                     R & D - Synthesis of NRTI-spacer-TMC120 
 143 
The diisopropyl α-hydroxymethylphosphonate 178 was synthesized by reacting 177 with 
paraformaldehyde and anhydrous potassium carbonate as a catalyst in IPA at 60 oC, in a 
reaction better known as the Pudovik reaction (Fig. 4.15).202 Carbonates are commonly used in 
heterogeneous phase as a non-nucleophilic solid ‘soft’ base because they are easy to handle 
and to eliminate by filtration at the end of the reaction. Therefore, the α-
hydroxymethylphosphonate 178 was isolated in 98% yield without the need for silica-gel 
chromatography. 
 
Figure 4.15 Proposed mechanism of the Pudovik reaction in heterogeneous conditions.202 
 
The 1H NMR spectrum of 178 revealed a diagnostic OH singlet at δH 2.15, as well as a 
methylene signal at δH 3.82 (2H, d, JHP  = 6.6 Hz, CH2P). Its 31P NMR spectrum displayed a 
characteristic signal at δP 22.9, exactly as reported in the literature.202 
 
Subsequent tosylation of alcohol 178 (Scheme 4.10) using p-toluenesulfonyl chloride in the 
presence of triethylamine and a catalytic amount of DMAP in dichloromethane, returned the 
desired tosylate 176 uneventfully in 92% yield after column chromatography. The 1H NMR 
spectrum of 176 displayed aromatic protons with AB coupling (JAB = 8.0 Hz) resonating at δH 
7.36 and δH 7.80 as well as a methyl singlet at δH 2.46. The presence of additional aromatic 
signals in the 13C NMR spectrum further confirmed the presence of a tosylate group. 
 
With 176 now in hand, our next challenge was to incorporate a two carbon tether (Scheme 
4.11). This was accomplished through the use of mono-benzyl ether 140 and sodium hydride in 
THF at reflux, to obtain tethered phosphonate 179 in 72% yield after column purification. The 1H 
NMR spectrum of 179 revealed an upfield shift of methylene protons α to phosporus at δH 4.12 
(d, JHP  = 10.0 Hz, CH2P) for the tosylate 176 to δH 3.82 in 179, as well as the presence of the 
benzylic methylene protons at δH 4.54.  Its 31P NMR spectrum returned a single peak at δH 19.7. 
Finally, a correct HRMS evaluation (m/z HRMS (ES) 331.16681 [M+H]+, C16H28O5P requires m/z 







































Scheme 4.11 Reagents and conditions: (i) 140, NaH, THF, ∆ (72%); (ii) H2, Pd/C, MeOH:THF (1:1), r.t 
(77%); (iii) p-TsCl, NEt3, CH2Cl2, DMAP (cat), r.t (90%). 
 
Catalytic hydrogenation of 179 using palladium-on-carbon catalyst in methanol/THF (1:1) 
furnished 180 in 77% yield (Scheme 4.11). The appearance of a hydroxyl proton as a broad 
singlet resonating at δH 2.52 and the absence of the characteristic benzylic methylene singlet at 
δH 4.54 for 180 provided further evidence that debenzylation had taken place. 
 
The hydroxyl group of 180 was subsequently converted to tosylate 181 in 90% yield by reacting 
it with p-toluenesulfonyl chloride in the presence of triethylamine and a catalytic amount of 
DMAP in dichloromethane (Scheme 4.11). The 1H NMR spectrum of 181 displayed aromatic 
protons with AB coupling (JAB = 8.3 Hz) resonating at δH 7.33 and δH 7.78 as well as a methyl 
singlet at δH 2.43. The presence of additional aromatic signals in the 13C NMR spectrum further 
confirmed the presence of a tosylate group. The 31P NMR spectrum returned a singlet peak at δP 
18.6 for the phosphonate. 
 
The final part in the synthesis of the ANP involved coupling of the modified tethered 
phosphonate 181 (Scheme 4.12) via 1N-alkylation of uracil and was carried out using cesium 
carbonate in DMF at 100 oC. ANP 175a was isolated following aqueous work-up and purification 
by column chromatography in a moderate 56% yield. The 1H NMR spectrum of 175a displayed 
two doublets at δH 5.62 (d, J = 7.9 Hz) and δH 7.34 (d, J = 7.9 Hz) for the H-5 and H-6 protons 
respectively. An upfield shift of the H-1’ signal in the 1H NMR spectrum from δH 4.14 in tosylate 
181 to δH 3.93 in 175a supported the displacement of the tosylate. The 13C NMR spectrum of 
compound 175a displayed signals for the ANP at δC 66.1 (d, JC-P = 168.4 Hz, C-3'), δC 48.3 (C-
1'), δC 101.5 (C-5) and δC 145.8 (C-6). Its 31P NMR spectrum displayed the diagnostic 























































Scheme 4.12 Reagents and conditions: (i) Cs2CO3, DMF, 100 oC (56%); (ii) I2, CAN, CH3CN, 35 oC, 2 hrs 
(63%). 
 
Finally, compound 175a was iodinated (Scheme 4.12) using elemental iodine and cerium 
ammonium nitrate (IV) at 35 oC. TLC confirmed reaction completion after 2 hrs and 175b was 
obtained in 63% yield after column chromatography. The 1H NMR spectrum of 175b (Fig. 4.16) 
supported iodination revealing the absence of a doublet at δH 5.62 for H-5 and a downfield shift 
in H-6 from δH 7.34 (a doublet) in 175a to δH 8.04 (now a singlet) in 175b. Its 13C NMR spectrum 
also displayed a large upfield shift for C-5 from δC 101.5 in 175a to δC 67.3 in 175b. The 31P 
NMR spectrum of 175b revealed a singlet at δP 20.1. Combustion microanalysis returned 
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4.5.3 Synthesis of [ANP]-propyne-tetraPEG-propyne-[TMC120] 
The final reaction carried out in this part of the project was a Sonogashira coupling of a 5-iodo-
ANP derivative 175b to the 4-PEG alkyne 149 (Scheme 4.13).  
The standard Sonogashira coupling reaction conditions were used involving adding triethylamine 
and reactants to a mixture of dimethylformamide and tetrahydrofuran (1:2, v/v), which was 
thoroughly degassed before addition of catalysts in order to avoid unwanted oxidation of the 
palladium(0) catalyst. Introduction of the catalyst combination of Pd(0) / CuI in the form of solids 
resulted in product 172 formation after 3 hrs in 60% yield after column chromatography. Key 
spectroscopic indicators in the 1H NMR spectra (Fig. 4.17) of 172 were the ANP uracil proton (H-
6) at δH 7.87, the absence of an alkyne signal at δH 2.42 as well as the characteristic aromatic 
signals for the TMC120 moiety. The 13C NMR spectrum of 172 returned the correct number of 
resonances of 46. Its 31P NMR spectrum displayed the definitive phosphonate resonance at δP 
23.2. All carbon resonances could be identified and assigned using 2D-NMR techniques. Finally, 
a correct HRMS evaluation (m/z HRMS (ES) 917.3848 [M+H]+, C46H58N6O12P requires m/z 





































Scheme 4.13 Reagents and conditions: (i) 5-iodo-ANP, Pd(PPh3)4 (10%), CuI (50%), NEt3 (2 eq), 
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Figure 4.17 1H NMR spectrum of bifunctional 172. 
 
4.5.4 Synthesis of [ANP]-propyne-hexaPEG-propyne-[TMC120] 
The next target chosen was one with a longer spacer (6-PEG) in order to explore SAR. Time 
constraints precluded making all members of the set so it was decided to go ‘longer’ than 
‘shorter’, especially in view of the parameters set by the modeling. The overall synthetic scheme 
for the 6-PEG spacer incorporation is shown in Scheme 4.14, and is identical to that used for the 
4-PEG. Thus, propargylation of commercially available hexaethylene glycol 182 was achieved 
using sodium hydride and propargyl bromide in THF at room temperature in 53% yield after 
column purification. The 1H NMR spectrum of 183 displayed the key alkyne proton at δH 2.43 (t, 
J = 2.4 Hz). The propargyl methylene signal resonated at δH 4.15 (d, J = 2.4 Hz). The 13C NMR 
spectrum of 183 displayed characteristic alkyne resonances at δC 58.2 (C-13), δC 74.4 (C-15) 
and δC 79.5 (C-14). 
 
The Sonogashira coupling of TMC-derivative 152 with the 6-PEG alkyne 183, using identical 
conditions to that described above, was carried out and the 6-PEG-elongated TMC120 
derivative 184 isolated after silica-gel purification in a moderate 46% yield (Scheme 4.14). The 
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disappearance of an alkyne proton at δH 2.43.  The 13C NMR spectrum of 184 returned the 






































Scheme 4.14 Reagents and conditions: (i) propargyl bromide, NaH, THF, r.t (53%); (ii) 152, Pd(PPh3)4 
(10%), CuI (50%), NEt3 (2 eq), DMF/THF (1:2), r.t (46%). 
 
In anticipation of a second Sonogashira coupling to the free hydroxyl end of the spacer (in 184) 
to 5-iodo-ANP, a two step conversion was necessary depicted in Scheme 4.15. Thus, the 
hydroxyl group of 184 was converted to the tosylate 185 in 57% yield by reacting it with p-
toluenesulfonyl chloride in the presence of triethylamine and a catalytic amount of DMAP in 
dichloromethane. The 1H NMR spectrum of 185 displayed aromatic protons with AB coupling 
(JAB = 8.4 Hz) resonating at δH 7.46 and δH 7.81 as well as a methyl singlet at δH 2.45. The 
presence of additional aromatic signals in the 13C NMR spectrum of 185 further confirmed the 
















where: R = H (184),





Scheme 4.15 Reagents and conditions: (i) p-TsCl, NEt3, CH2Cl2, DMAP (cat) (57%); (ii) propargyl alcohol, 
NaH, THF, ∆ (89%). 
 
Alkylation of tosylate 185 was accomplished using sodium hydride and a large excess of 
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chromatography furnished the alkyne 174 in 89% yield. The 1H NMR spectrum of 174 displayed 
the characteristic alkyne signal at δH 2.89. The 13C NMR spectrum of 174 displayed signals for 






































Scheme 4.16 Reagents and conditions: (i) 5-iodo-ANP, Pd(PPh3)4 (10%), CuI (50%), NEt3 (2 eq), 
DMF/THF (1:2), rt, (70%). 
 
Once again, a Sonogashira reaction was carried out to secure the synthesis of the double-drug. 
To this end, alkyne 174 was subjected to a Sonogashira reaction with the nucleotide reverse 
transcriptase inhibitor derivative, 5-iodo-ANP 175b, to afford bifunctional 173 (Scheme 4.16).  As 
expected, under the identical conditions as mentioned above, the reaction progressed smoothly 
and 173 was isolated in 70% yield after column chromatography. The 1H NMR spectral data for 
173 revealed signals for both the alkynyl 174 and 5-iodo-ANP moieties in the ratio of 1:1 (Fig. 
4.18). A successful coupling was further confirmed by the absence of a terminal alkyne proton at 
around δH 2.89 ppm. The 13C NMR spectrum of 173 displayed diagnostic resonances at δC 64.7 
(d, JC-P = 150.1 Hz, C-3), δC 66.9 (C-4), δC 119.2 (C≡N) and δC 149.6 (C-11) thus confirming the 





















Figure 4.18 1H NMR spectrum of bifunctional 173. 
 
4.5.5 Biological evaluation and SAR interpretation 
The inhibition of viral replication in HIV-infected cells of the bifunctional targets 172 and 173 was 
measured against HIV-1 (IIIB) replication in MT-2 cell culture using an MTT assay (see Appendix 
I). The results are summarized in Table 4.4 below. 
 
Table 4.4 Anti-HIV results of bifunctionals 172 and 173 in cell-culture. 




















































































a Effective concentration that inhibits viral-mediated T-cell death by 50% and as an average of three results. 
bCytotoxicity = concentration that kills 50% of the T-cells and as an average of three results. 
c In vitro therapeutic index (CC50 /EC50) 
 
The results revealed that the membrane-permeable, stable ANP phosphonate bifunctionals 172 
and 173, although more flexible than d4U, were still not able to give comparable activity to 
TMC120 in cell-culture testing. The best one, ANP 4-PEG derivative 172 showed a 60-fold 
decrease in activity compared to TMC120 and, more importantly was slightly less active than its 
4-PEG d4U counterpart (100 nM). The results once again revealed a lack of in vitro 
phosphorylation, even with the incorporation of a membrane-permeable phosphonate. A 
possible reason for this could be the stability of the isopropyl ester protecting groups towards 
hydrolysis needed for conversion first to the acid as precursor for further phosphorylation. In 
addition, even assuming hydrolysis to the acid, the EC50 result (120 nM) suggests that further 
phosphorylation is not occurring as a result of poor substrate recognition. The fact that the d4U 
4-PEG counterpart 147 gave a 100 nM activity, compared to the 120 nM activity for the ANP, 
also rendered compelling evidence in support of the notion that some degree of in vitro 
phosphorylation for the d4U bifunctional does take place in order to achieve this level of activity. 
Moreover, the results for 172 and 173 certainly suggest that the debate over the correct 
attachment point for spacer elongation has finally been resolved. The 120 nM activity of the 6-
PEG derivative 173 is extremely interesting as normally one sees a significant reduction of 
activity for longer PEGS. This result not only suggests significant binding of both drugs (NRTI 
and NNRTI) to compensate a large entropy penalty, but also suggests, as hoped, that the longer 
PEG still allows NtRTI binding because of greater flexibility in the ANP NtRTI. This suggests that 
ANP-type structures are worthwhile pursuing in the future as the NtRTI component. CC50 values 
showed modest TI (SI) values, revealing high toxicity. 
 
From all this, it can be concluded that the synthetic and biological work in this thesis has shown 
the way forward towards realizing synergy between the substrate binding site and NNRTI-BP. 
This promise certainly stands out in the enzyme assay work as reflected in outstanding results in 
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in contrast to earlier studies involving: (i) linkage of a spacer to Trovirdine by Ladurée and co-
workers120 which led to dimer formation with no anti-HIV activity; (ii) the linkage of AZT and 
TSAO-T inhibitors via a polymethylene spacer between the N-3 of the thymine base of both 
compounds by Camarasa and co-workers126-129 which yielded moderate anti-HIV activity and; (iii) 
work by Monneret and co-workers132 in synthesizing a variety of (N-3 and C-5) AZT-HEPT 
bifunctional conjugates displaying anti-HIV activity ranging between 2-5 μM. None of these 
cases reported any formal evidence of employing a rational drug-design strategy involving the 
use of extensive crystal structure analysis of the site of interest, or molecular modelling for 
assisting with choices in the attachment points to both the NRTI and the NNRTI moieties of the 
bifunctional entity. Hence, no proof of synergy was obtained.  
The results of this thesis have thus developed and established a new level of rational drug-
design for bifunctional HIV-drugs. 
 
Final Conclusions 
The following points may be concluded for future work in this field: 
i) The correct attachment point for spacer elongation to TMC120 has been settled, 
and a four PEG spacer seems to be the optimal length for connecting the active 
site and the NNRTI-BP when using d4U as the NRTI. The data on the NRTI-PEG-
TMC bifunctionals in conjunction with molecular modeling strongly supports the 
idea that the two sites link through a tunnel exiting the ‘back’ of the pocket close 
to W229. Such a linking would imply that the NNRTI “slides in” through the back 
from the substrate DNA side, rather than the NRTI exiting through the back of the 
pocket. This discovery is a new innovation contrasting with the alternative of 
linking the two sites via exiting the ‘front’ of the NNRTI pocket. ANP-PEG-TMC 
bifunctionals hold promise for accommodating more flexibility in the spacer. The 
correct choice of NtRTI might provide even better results. 
ii) Bifunctional NRTI phosphorylation to an active triphosphorylated substrate 
appears to be a limitation for the concept of bifunctional NRTI/NNRTI HIV double-
drugs. Future work could involve changing the relatively robust isopropyl ester 
groups of the ANP derivatives (172 and 173) described into inherently labile 
pivaloyloxymethyl (POM) or pivaloyloxymethylcarbonyl (POC) phosphonate-
masking groups, which can also penetrate into cells via passive diffusion. D4U 
could also be converted to a cycloSal prodrug, which is well known to give the 
desired parent-nucleotide-MP intracellularly at physiological pH. This 
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d4U. A full change-over to a clinically known ANP such as Tenofovir or Cidofovir 
would be worthwhile pursuing for hopefully overcoming the phosphorylation 
limitations. 
iii) Finally, computational modeling has shown how rational drug-design strategies 
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CONCLUSION 
The results of this thesis have developed and established a new level of rational drug-design for 
the synthesis of bifunctional HIV-drugs. It displays an evolution in ideas for development of 
double-drug entities starting from extensive crystal structure analysis of individual inhibitors to 
innovative molecular modeling to extrapolate vital drug-design considerations. This work is in 
contrast to earlier studies involving for example: (i) linkage of a spacer to Trovirdine by Ladurée 
and co-workers120 which led to dimer formation with no anti-HIV activity; (ii) the linkage of AZT 
and TSAO-T inhibitors via a polymethylene spacer between the N-3 of the thymine base of both 
compounds by Camarasa and co-workers126-129 which yielded moderate anti-HIV activity and; (iii) 
work by Monneret and co-workers132 in synthesizing a variety of (N-3 and C-5) AZT-HEPT 
bifunctional conjugates displaying anti-HIV activity ranging between 2-5 μM. None of these 
cases reported any formal evidence of employing a rational drug-design strategy involving the 
use of extensive crystal structure analysis of the site of interest, or molecular modelling for 
assisting with choices in the attachment points to both the NRTI and the NNRTI moieties of the 
bifunctional entity.  
 
This thesis describes its origin with a UC-781/d4U bifunctional synthesis in which a second-
generation NNRTI was employed. A drawback in this synthesis was the inability to thiate the UC-
781 amide which led us to progress our ideas to a more sophisticated second-generation NNRTI 
in the form of a pyrimidinylarylamine motif.  
Further development of this system, steered by biological activity in conjunction with a structural-
activity relationship study, ultimately culminated in a highly potent TMC120/d4U bifunctional 
synthesis. Biological results indicated the d4U-4-PEG-TMC120 bifunctional to have the lowest 
EC50 (100 nM) anti-HIV activity of any NRTI-spacer-NNRTI bifunctional inhibitor synthesized to 
date. The NRTI was also triphosphorylated and the product evaluated in an in vitro RT inhibition 
assay, to establish whether the bifunctional was being ‘switched on’ for incorporation into the 
growing DNA chain, which culminated in a ‘proof of principle’ of synergy existing between the 
substrate site and the allosteric binding pocket.  
Exchanging d4U for a more flexible uracil-base ANP was attempted to address in vitro 
phosphorylation issues. The results suggested significant binding of both drugs (NRTI and 
NNRTI) to compensate a large entropy penalty, but also suggests, as hoped, that the longer 6-
PEG still allows NtRTI binding because of greater flexibility in the ANP NtRTI. This suggests that 
ANP-type structures are worthwhile pursuing in the future as the NtRTI component. Future work 














6.1 General procedures 
All solvents were freshly distilled. Diethyl ether and tetrahydrofuran were dried over sodium wire 
with benzophenone and distilled under nitrogen. Dichloromethane was distilled from phosphorus 
pentoxide under nitrogen. Other reagents were purified according to standard procedures. All 
commercial chemicals were purchased from Aldrich, Merck or Saarchem and were used as 
such.  
 
Unless otherwise stated, reactions were run under an atmosphere of argon and monitored by 
thin-layer chromatography (TLC) using pre-coated silica gel 60 F254 sheets (0.2 mm layer) 
purchased from Merck. A 50:50 mixture (v/v) of 10% H2SO4 and 5% p-anisaldehyde were used 
to spray TLC plates and compounds were detected by UV absorption at 254 nm.  
Column chromatography was effected by using Merck Kieselgel 60 silica-gel (0.040-0.063 mm). 
All products were dried on a nitrogen pump before yields were determined.  
 
Nuclear Magnetic Resonance spectra were recorded on a Varian Unity 400 MHz (100 MHz for 
13C) or Varian Mercury 300 MHz (75 MHz for 13C) and were carried out in chloroform-d unless 
otherwise stated. Chemical shifts (δ) were recorded using residual chloroform (δ 7.26 in 1H NMR 
and δ 77.00 in 13C NMR). All chemical shifts are reported in ppm, 1H resonances to two decimal 
places and 13C ones to one. 
 
Optical rotations were obtained using a Perkin Elmer 141 polarimeter at 20°C. The concentration 
c refers to g/100ml. Melting points were obtained using a Reichert Jung Thermovar hot-stage 
microscope and are uncorrected. Elemental analyses were performed using a Fisons EA 1108 
CHN elemental analyser. Infrared spectra were recorded on a Perkin-Elmer Paragon 1000 FT-IR 
spectrometer in either dichloromethane or chloroform. These spectra were recorded from 4000 
to 600 cm-1 on sodium chloride plates. High-resolution mass-spectrometry was performed at the 
mass-spectrometry unit of the University of Witwatersrand using a VG70-SEQ micromass 
spectrometer or at The School of Chemistry, University of Stellenbosch on an API Q-TOF Ultima 
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Sodium hydride (60%, 3.04 g, 76 mmol) was suspended in dry THF (250 mL) at 0oC (ice slurry), 
and to the solution was added 1,5-pentanediol (8.0 g, 76 mmol) portionwise. Once gas evolution 
had subsided, benzyl bromide (9.03 mL, 76 mmol) was added slowly. The ice bath was then 
removed and the mixture refluxed. TLC confirmed completion of the reaction after 20 hrs. The 
reaction mixture was cooled to room temperature, diluted with H2O (150 mL) and extracted with 
diethyl ether (3 × 100 mL). The combined organic fractions were washed with brine (150 mL) 
before being dried over MgSO4 and the solvent removed under reduced pressure. Purification by 
chromatography using a silica-gel column (70 g; EtOAc/hexane, 5:5) afforded product 90b as a 
colourless oil, (7.90 g, 53%). νmax /cm-1 (CHCl3): 3617b (O-H, free), 2871s + 2941s (C-H, 
aliphatic), 1508s (C=C, aromatics); ¹H NMR (CDCl3, 400 MHz) δH 1.42 (2H, m, H-3), 1.57 (2H, 
m, H-4), 1.65 (2H, m, H-2), 3.49 (2H, t, J = 6.5 Hz, H-5), 3.62 (2H, t, J = 6.5 Hz, H-1), 4.50 (2H, 
s, H-6), 7.33 (5H, m, Ar-H); ¹³C NMR (CDCl3, 100 MHz) δC 22.4 (C-3), 29.4 (C-2), 32.4 (C-4), 
62.7 (C-1), 70.3 (C-5), 72.9 (C-6), 127.5 (Ar-p), 127.6 (Ar-o), 128.3 (Ar-m), 138.5 (Ar-i); HRMS 
(EI): m/z 194.13228 [M+]. Calculated for C12H18O2, 194.13068 [M+]. 
 










To a mixture of dimethyl sulfoxide (6.60 mL, 92 mmol) in dichloromethane (200 mL) at -78oC 
(dry-ice in acetone), was added oxalyl chloride (4.05 mL, 46.4 mmol) and the reaction mixture 
stirred for 15 min under a constant argon purge. Subsequent dropwise addition of alcohol 90b 
(6.0 g, 31 mmol) was followed by stirring for a further 20 min. Triethylamine (22 mL, 155 mmol) 
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completion after 15 min.  The reaction mixture was then diluted with aqueous NaHCO3 (150 mL) 
and extracted with dichloromethane (3 × 150 mL). The organic extract was dried over MgSO4 
and removed under reduced pressure to give a viscous yellow oil. Purification by 
chromatography on a silica-gel column (70 g; EtOAc/hexane, 2:8) afforded aldehyde 90a as a 
light yellow oil, (5.90 g, 99%). νmax /cm-1 (CHCl3): 2940s + 2872s (C-H, aliphatic), 1710s (C=O, 
aldehyde), 1495w (C=C, aromatic); ¹H NMR (CDCl3, 400 MHz) δH 1.61 (2H, m, H-3), 1.70 (2H, 
m, H-4), 2.43 (2H, t, J = 6.5 Hz, H-2), 3.47 (2H, t, J = 6.5 Hz, H-5), 4.50 (2H, s, H-6), 7.33 (5H, 
m, Ar-H), 9.85 (1H, s, CHO); ¹³C NMR (CDCl3, 100 MHz) δC 19.2 (C-4), 29.4 (C-3), 43.8 (C-2), 
69.9 (C-5), 73.2 (C-6), 127.8 (Ar-p), 127.8 (Ar-o), 128.6 (Ar-m), 139.0 (Ar-i), 202.1 (CHO); HRMS 
(EI): m/z 192.25812 [M+]. Calculated for C12H16O3, 192.25820 [M+]. 
 





















The methyl furanylphosphonium salt 90 (4.56 g, 9.50 mmol) was dissolved in a mixture of dry 
methanol (30 mL) and sodium methoxide (4.63 M, 2.27 mL, 10.5 mmol) added via syringe under 
nitrogen at 0oC (ice-water slurry). Aldehyde 90a (1.82 g, 9.50 mmol) was slowly added and the 
reaction mixture stirred at room temperature. The reaction mixture turned an immediate dark-red 
colour that progressively faded to a light-orange colour as it went to completion within 3 hrs. The 
reaction mixture was then diluted with brine (200 mL) and extracted with EtOAc (3 × 200 mL). 
The organic extract was dried over MgSO4 and removed under reduced pressure. A yellow 
powder was obtained which was subjected to column chromatography using a silica-gel column 
(120 g; EtOAc/hexane, 0.3:9.7) to afford product 92d (both E-and Z-stereoisomers in a 1:1 ratio) 
as a colourless oil, (2.70 g, 91%). νmax /cm-1 (CHCl3): 2928m + 2867s (C-H, aliphatic), 1715s 
(C=O, ester), 1649m (C=C, alkene), 1567m (C=C, aromatic); ¹H NMR of E-isomer (CDCl3, 400 
MHz) δH 1.60 (2H, m, H-4’), 1.69 (2H, m, H-5’), 2.29 (2H, qd, J = 7.5, 1.7 Hz, H-3’), 3.50 (2H, t, J 
= 6.4 Hz, H-6’), 3.83 (3H, s, CO2Me), 4.50 (2H, s, H-7’), 6.51 (1H, dt, J = 16.0, 7.1 Hz, H-2’), 
6.71 (1H, d, J = 2.0 Hz, H-4), 6.96 (1H, dt, J = 16.0, 1.6 Hz, H-1’), 7.29 (1H, d, J = 2.0 Hz, H-5), 
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H-5’), 2.62 (2H, qd, J = 7.2, 1.3 Hz, H-3’), 3.50 (2H, t, J = 6.4 Hz, H-6’), 3.83 (3H, s, CO2Me), 
4.50 (2H, s, H-7’), 5.84 (1H, dt, J = 12.0, 7.6 Hz, H-2’), 6.67 (1H, d, J = 2.0 Hz, H-4), 6.90 (1H, 
dt, J = 12.0, 1.7 Hz, H-1’), 7.23 (1H, d, J = 2.0 Hz, H-5), 7.33 (5H, m, Ar-H); 13C NMR of E/Z 
isomers (75 MHz, CDCl3) δC 25.6/26.1 (C-4’), 29.8/29.4 (C-5’), 29.4/32.8 (C-3’), 51.3/51.4 (CO-
2Me), 70.1/70.2 (C-6’), 72.8/72.9 (C-7’), 111.3/111.4 (C-4), 112.2 (C-3), 116.0/118.0 (C-1’), 127.4 
(C-11’), 127.5/127.6 (C-9’/C-13’), 128.3 (C-10’/C-12’), 135.8/136.8 (C-2’), 138.6/138.7 (C-8’), 
140.6/140.8 (C-5), 157.0/157.6 (C-2), 163.9/164.0 (CO2Me); HRMS (EI): m/z 314.15111 [M+]. 
Calculated for C19H22O4, 314.15181 [M+]. 
 
















The furan ester 92d (1.46 g, 4.64 mmol) was dissolved in absolute ethanol (10 mL) and stirred at 
room temperature. Subsequent addition of palladium-on-carbon (10%, 494 mg, 0.46 mmol) was 
followed by careful placement of a hydrogen gas balloon over the reaction flask. TLC confirmed 
reaction completion after 1 hr. The reaction mixture was filtered through a Celite-packed sintered 
funnel and washed with EtOAc (50 mL). Purification of the residue following solvent evaporation 
by chromatography using a silica-gel column (70 g; EtOAc/hexane, 1:9) afforded product 94 as a 
colourless oil, (983 mg, 94%). νmax /cm-1 (CHCl3): 3472b (O-H, free), 2940s + 2839s (C-H, 
aliphatic), 1720s (C=O, ester), 1612s (C=C, aromatic); ¹H NMR (CDCl3, 400 MHz) δH 1.38 (4H, 
m, H-3’, H-4’), 1.48 (1H, bs, OH), 1.63 (4H, m, H-2’, H-5’), 3.00 (t, J = 7.6 Hz, H-1'), 3.61 (2H, t, J 
= 6.5 Hz, H-6'), 3.81 (3H, s, CO2Me), 6.61 (1H, d, J = 2.0 Hz, H-4), 7.21 (1H, d, J = 2.0 Hz, H-5); 
¹³C NMR (CDCl3, 75.5 MHz) δC 24.1 (C-3'), 27.9 (C-1'), 28.0 (C-4'), 28.1 (C-2'), 29.1 (C-5'), 51.2 
(CO2Me), 70.5 (C-6'), 110.6 (C-4), 112.8 (C-3), 140.5 (C-5), 162.9 (C-2), 164.7 (CO2Me); HRMS 
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Compound 94 (622 mg, 2.75 mmol) was dissolved in dichloromethane (15 mL). Triethylamine 
(0.77 mL, 5.50 mmol) was added at 0oC followed by a catalytic amount of DMAP (17 mg, 0.12 
mmol) to the reaction mixture. p-Toluenesulfonyl chloride (787 mg, 4.10 mmol) was then added 
dropwise and the solution left to stir at room temperature. TLC confirmed completion of the 
reaction after 2½ hrs. The reaction mixture was diluted with brine (50 mL) and extracted with 
dichloromethane (3 × 50 mL). The organic fractions were dried with MgSO4 and removed under 
reduced pressure. Purification by chromatography using a silica-gel column (50 g; 
EtOAc/hexane, 1:9) afforded product 95 as a colourless oil, (974 mg, 94%). νmax /cm-1 (CHCl3): 
2937s + 2864s (C-H, aliphatic), 1715s (C=O, ester), 1599s (C=C, aromatic), 1369s + 1177s (-
SO2-O-); ¹H NMR (CDCl3, 300 MHz) δH 1.32 (4H, m, H-3', H-4'), 1.61 (4H, m, H-2', H-5'), 2.42 
(3H, s, H-7''), 2.93 (2H, t, J = 7.6 Hz, H-1'), 3.79 (3H, s, CO2Me), 3.99 (3H, t, J = 6.5 Hz, H-6'), 
6.62 (1H, d, J = 2.0 Hz, H-4), 7.21 (1H, d, J = 2.0 Hz, H-5), 7.34 (2H, d, J = 7.9 Hz, H-3'', H-5''), 
7.76 (2H, d, J = 7.9 Hz, H-2'', H-6''); ¹³C NMR (CDCl3, 75.5 MHz) δC 21.6 (C-7''), 24.9 (C-3'), 27.3 
(C-1'), 27.6 (C-4'), 28.4 (C-2'), 28.7 (C-5'), 51.2 (CO2Me), 70.5 (C-6'), 110.6 (C-4), 112.9 (C-3), 
127.8 (C-2'', C-6''), 129.7 (C-3'', C-5''), 133.3 (C-4''), 140.4 (C-5), 144.6 (C-1''), 162.9 (C-2), 
164.3 (CO2Me); HRMS (EI): m/z 380.42675 [M+]. Calculated for C19H24O6, 380.42679 [M+]. 
 


















To a sodium hydride (60%, 464 mg, 11.6 mmol) suspension in THF (30 mL) at 0oC, was added 
propargyl alcohol (0.9 mL, 14.5 mmol) slowly whilst stirring. To this was added tosylate 95 (1.1 g, 
2.9 mmol) and the reaction mixture refluxed. After 1 hr, 1M NaOH (10 drops) was added and the 
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reaction mixture was diluted with 1M HCl (100 mL) and extracted with EtOAc (2 × 100 mL). The 
organic fractions were dried with MgSO4 and removed under reduced pressure. Purification by 
chromatography using a silica-gel column (100 g; EtOAc/hexane, 1:9) afforded product 97 as a 
colourless oil, (822 mg, 98%). νmax /cm-1 (CHCl3): 3157b (O-H, H-bonded), 2935s + 2865s (C-H, 
aliphatic), 2254s (C≡C, alkyne), 1683s (C=O, carboxylic acid), 1596s (C=C, aromatic) ; ¹H NMR 
(CDCl3, 300 MHz) δH 1.38 (4H, m, H-3', H-4'), 1.60 (2H, m, H-2'), 1.69 (2H, m, H-5'), 2.41 (1H, t, 
J = 2.4 Hz, H-9'), 3.02 (2H, t, J = 7.4 Hz, H-1'), 3.51 (2H, t, J = 6.6 Hz, H-6'), 4.13 (2H, d, J = 2.4 
Hz, H-7'), 6.68 (1H, d, J = 2.0 Hz, H-4), 7.26 (1H, d, J = 2.0 Hz, H-5); ¹³C NMR (CDCl3, 75.5 
MHz) δC 25.7 (C-3'), 27.5 (C-1'), 27.7 (C-4'), 28.9 (C-2'), 29.3 (C-5'), 57.9 (C-7'), 70.1 (C-6'), 74.0 
(C-9'), 80.0 (C-8'), 110.8 (C-4), 112.6 (C-3), 140.6 (C-5), 164.7 (C-2), 169.6 (CO2H); HRMS (EI): 
m/z 250.12053 [M+]. Calculated for C14H18O4, 250.12051 [M+]. 
 
2-(6-Propargyloxyhexyl)furan-3-carboxylic acid [4-chloro-3-(3-methyl-but-2-enyl-1-oxy)-




































The acid 97 (108 mg, 0.32 mmol) was dissolved in thionyl chloride (1 mL) and the mixture 
heated to 40oC under nitrogen for 1 hr with constant stirring. The excess thionyl chloride was 
then reduced on a vacuum pump and the resulting oil dissolved in dichloromethane (3 mL). 
Subsequent addition of pyridine (0.08 mL, 0.96 mmol) at 0oC was followed by the arylamine 61 
(68 mg, 0.32 mmol) and the reaction mixture stirred at room temperature. TLC (EtOAc/hexane, 
3:7; Rf = 0.35) confirmed completion of the reaction after 30 min. The reaction mixture was 
diluted with EtOAc (50 mL) and extracted with 1M HCl (4 × 15 mL). The organic fractions were 
dried with MgSO4 and removed under reduced pressure. Purification by chromatography using a 
silica-gel column (10 g; EtOAc/hexane, 1.5:8.5) afforded product 99 as a yellow oil, (133 mg, 
78%). νmax /cm-1 (CHCl3): 3304s + 3440 m (N-H, amide), 2935s + 2864s (C-H, aliphatic), 2253s 
(C≡C, alkyne), 1674s (C=O, amide), 1595s (N-H and C-N stretching), 1513s + 1492s (C=C, 
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s, H-10’,11’), 2.39 (1H, t, J = 2.4 Hz, H-9’’), 3.04 (2H, t, J = 7.6 Hz, H-1’’), 3.48 (2H, t, J = 6.6 Hz, 
H-6’’), 4.10 (2H, d, J = 2.4 Hz, H-7’’), 4.58 (2H, d, J = 7.3 Hz, H-8’), 5.50 (1H, tq, J = 6.6, 1.5 Hz, 
H-9’), 6.53 (1H, d, J = 2.2 Hz, H-4), 6.88 (1H, dd, J = 8.8, 2.2 Hz, H-7’), 7.26 (1H, d, J = 8.8 Hz, 
H-6’), 7.30 (1H, d, J = 2.2 Hz, H-5), 7.46 (1H, s, H-1’), 7.58 (1H, d, J = 2.2 Hz, H-3’); 13C NMR 
(75 MHz, CDCl3) δC 18.2 (CH3), 25.7 (CH2), 25.8 (CH3), 27.4 (C-1’’), 27.8 (CH2), 28.9 (CH2), 29.3 
(CH2), 57.9 (C-7’’), 66.1 (C-8’), 70.0 (C-6’’), 74.0 (C-9’’), 80.0 (C-8’’), 106.1 (C-3’), 107.9 (C-4), 
112.4 (C-7’), 115.5 (C-3), 118.0 (C-5’), 119.0 (C-9’), 129.9 (C-6’), 137.6 (C-2’), 138.6 (C-12’), 
140.6 (C-5), 154.6 (C-4’), 161.8 (C-2), 161.9 (CONH); HRMS (EI): m/z 443.17863 [M+]. 







































The amide 99 (40 mg, 0.10 mmol) was dissolved in toluene (2 mL) and to this was added 
Lawesson’s reagent (73 mg, 0.18 mmol) and sodium hydrogen carbonate (84 mg, 1 mmol) with 
constant stirring. The reaction mixture was then slowly heated to 90oC. TLC on neutral alumina 
(EtOAc/hexane, 3:7; Rf = 0.66) confirmed completion of the reaction after 4 hrs. The reaction 
mixture was filtered, washed with EtOAc (20 mL) and the solvent removed under reduced 
pressure. Purification by chromatography using a neutral alumina column (7 g; EtOAc/hexane, 
0.8:9.2) afforded product 100 as a yellow oil, (27 mg, 59%). νmax /cm-1 (CHCl3): 3234m (N-H, 
thioamide), 2858s (C-H, aliphatic), 2270s (C≡C, alkyne), 1618s (C=C, aromatic), 1162s + 1389s 
(C=S stretches), 1550s + 1453s (C=C, aromatic); 1H NMR (400 MHz, C6D6) δH 1.24 - 1.46 (8H, 
m, H-2’’,3’’,4’’,5’’), 1.45 + 1.51 (6H, 2 × s, H-10’,11’), 2.02 (1H, t, J = 2.4 Hz, H-9’’), 3.00 (2H, t, J 
= 7.6 Hz, H-1’’), 3.28 (2H, t, J = 6.4 Hz, H-6’’), 3.83 (2H, d, J = 2.4 Hz, H-7’’), 4.41 (2H, d, J = 6.1 
Hz, H-8’), 5.47 (1H, tq, J = 6.2, 1.4 Hz, H-9’), 6.13 (1H, d, J = 1.9 Hz, H-4), 6.38 (1H, d, J = 7.5 
Hz, H-7’), 6.82 (1H, d, J = 7.5 Hz, H-6’), 7.15 (1H, d, J = 1.9 Hz, H-5), 7.98 (1H, s, H-1’), 8.17 
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29.1 (CH2), 29.5 (CH2), 57.8 (C-7’’), 66.1 (C-8’), 69.8 (C-6’’), 73.9 (C-9’’), 80.5 (C-8’’), 106.1 (C-
3’), 108.1 (C-4), 109.4 (C-7’), 115.7 (C-3), 119.7 (C-5’), 120.6 (C-9’), 130.1 (C-6’), 138.2 (C-2’), 
138.7 (C-12’), 141.1 (C-5), 154.8 (C-4’), 157.3 (C-2), 160.0 (CSNH); HRMS (EI): m/z 459.16343 
























































Amide 99 (50 mg, 0.09 mmol) was added together with the 5-iodo-d4U benzoate 60 (41 mg, 
0.094 mmol) and the mixture dried carefully on a vacuum pump. A mixture of degassed 
DMF:THF  (1:2 (v/v), 1 mL) was then added to the reaction vessel whilst the mixture stirred at 
room temperature under nitrogen. Subsequent addition of triethylamine (0.03 mL, 0.20 mmol) 
was followed by addition of copper(I) iodide (8.95 mg, 0.05 mmol) and 
tetrakistriphenylphosphinepalladium (10.9 mg, 0.01 mmol) respectively. The reaction was stirred 
continuously at room temperature and TLC (EtOAc/hexane, 3:7; Rf = 0.24) confirmed completion 
of the reaction after 2 hrs. The reaction mixture was diluted with a 5% EDTA solution (30 mL) 
and extracted with chloroform (3 × 20 mL). The organic fractions were dried with MgSO4 and 
removed under reduced pressure. Purification by chromatography using a silica-gel column (10 
g; EtOAc/hexane, 3:7) afforded product 101 as a clear oil, (48 mg, 61%). [α]D -16.1° (c = 1.13, 
CHCl3); νmax /cm-1 (CHCl3): 2932s (C-H, aliphatic), 2254s (C≡C, alkyne), 1720s (C=O, ester), 
1693s (C=O, amide), 1599s (N-H and C-N stretching), 1514s + 1492s (C=C, aromatic); 1H NMR 
(400 MHz, CDCl3) δH 1.30 - 1.35 (8H, m, H-14,15,16,17), 1.73 - 1.77 (6H, 2 × s, H-33,34), 3.03 
(2H, t, J = 7.7 Hz, H-18), 3.40 (2H, t, J = 6.7 Hz, H-13), 4.07 (2H, s, H-12), 4.58 (4H, m, H-1, H-
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6.38 (1H, dt, J = 5.7, 1.6 Hz, H-4), 6.56 (1H, d, JAB = 2.2 Hz, H-21), 6.93 (2H, m, H-5, H-29), 7.26 
(1H, m, H-28), 7.30 (1H, d, JAB = 2.2 Hz, H-22), 7.41 - 7.57 (5H, m, H-2’,3’,4’), 7.67 (1H, s, H-9), 
7.73 (1H, s, NH), 8.00 (1H, s, H-25), 8.73 (1H, bs, NH); 13C NMR (75 MHz, CDCl3) δC 18.3 (C-
33/C-34), 25.7 (C-33/C-34), 25.8 (CH2), 27.4 (C-18), 27.8 (CH2), 28.9 (CH2), 29.4 (CH2), 58.8 (C-
12), 64.9 (C-1), 66.1 (C-30), 70.0 (C-13), 75.3 (C-8), 75.9 (C-10), 85.0 (C-2), 90.6 (C-5), 102.2 
(C-11), 105.9 (C-25), 108.0 (C-21), 112.4 (C-29), 115.4 (C-20), 117.9 (C-27), 119.1 (C-31), 
127.0 (C-4), 128.7 (C-3’, C-5’), 129.3 (C-1’), 129.8 (C-2’, C-6’), 129.9 (C-28), 133.5 (C-3), 133.6 
(C-4’), 137.6 (C-24), 138.5 (C-32), 140.6 (C-22), 144.0 (C-9), 150.0 (C-6), 154.6 (OCOC6H5), 
















































Sodium methoxide (4.63 M, 0.02 mL, 0.09 mmol) was added together with methanol (1.5 mL) at 
0oC. This was followed by addition of 101 (56 mg, 0.08 mmol) at 0oC and the reaction mixture 
left to stir at room temperature. TLC (EtOAc/hexane, 6:4; Rf = 0.12) confirmed completion of the 
reaction after 1 hr. The reaction mixture was diluted with saturated NH4Cl (20 mL) and extracted 
with EtOAc (3 × 20 mL). The organic fractions were dried with MgSO4 and removed under 
reduced pressure. Purification by chromatography using a silica-gel column (5 g; EtOAc/hexane, 
8:2) afforded product 102 as a clear oil, (26 mg, 51%). [α]D -15.7° (c = 1.03, CHCl3); νmax /cm-1 
(CHCl3): 3592b (O-H, free), 2932s (C-H, aliphatic), 2254s (C≡C, alkyne), 1720s (C=O, ester), 
1693s (C=O, amide), 1599s (N-H and C-N stretching), 1514s + 1492s (C=C, aromatic); 1H NMR 
(400 MHz, CDCl3) δH 1.24 - 1.33 (8H, m, H-14,15,16,17), 1.73 - 1.79 (6H, 2 × s, H-33, H-34), 
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12.4, 3.0 Hz, H-1), 3.88 (1H, dd, J = 12.4, 3.0 Hz, H-1), 4.21 (2H, s, H-12), 4.59 (2H, d, J = 6.5 
Hz, H-30), 4.91 (1H, m, H-2), 5.51 (1H, tq, J = 6.8, 1.4 Hz, H-31), 5.83 (1H, m, H-3), 6.32 (1H, m, 
H-4), 6.56 (1H, d, JAB = 2.2 Hz, H-21), 6.96 (2H, m, H-5, H-29), 7.26 (1H, m, H-28), 7.30 (1H, d, 
JAB = 2.2 Hz, H-22), 7.53 (1H, s, H-9), 7.74 (1H, s, NH), 8.05 (1H, s, H-25), 9.0 (1H, s, NH); 13C 
NMR (75 MHz, CDCl3) δC 18.3 (C-33/34), 25.6 (C-33/34), 25.8 (CH2), 27.2 (C-18), 27.7 (CH2), 
28.7 (CH2), 29.2 (CH2), 58.7 (C-12), 63.0 (C-1), 66.2 (C-30), 70.2 (C-13), 76.8 (C-8), 76.8 (C-10), 
87.6 (C-2), 90.3 (C-5), 99.5 (C-11), 106.4 (C-25), 108.2 (C-21), 112.7 (C-29), 115.6 (C-20), 
118.0 (C-27), 119.1 (C-31), 125.9 (C-4), 129.9 (C-28), 135.0 (C-3), 137.7 (C-24), 138.6 (C-32), 










To a solution of 1,5-pentanediol (5.40 g, 50 mmol) in toluene (150 mL) was added HBr in ether 
(6.75 mL, 60 mmol), under a constant argon purge whilst stirring. The mixture was then refluxed 
at 110oC for 10 hrs by which time TLC confirmed reaction completion (EtOAc/hexane, 3:7; Rf = 
0.45). The reaction mixture was cooled to room temperature and then carefully diluted with 
aqueous NaHCO3 (2 × 50 mL), until fizzing subsided. The mixture was shaken in a separating 
funnel (care), the toluene layer collected, which was washed with brine (40 mL). The organic 
extract was then dried over MgSO4 and the solvent removed under reduced pressure. 
Purification by chromatography using a silica-gel column (70 g; EtOAc/hexane, 1:1) afforded 
product 104a as a clear yellow oil, (4.30 g, 52%). 1H NMR (400 MHz, CDCl3) δH 1.48-1.67 (4H, 














To a solution of 104a (334 mg, 2.0 mmol) dissolved in dry THF (10 mL) was added p-
methoxyphenol (261 mg, 2.1 mmol) and triphenylphosphine (577 mg, 2.2 mmol) under a 
constant argon gas flow, whilst stirring. DIAD (0.453 mL, 2.3 mmol) was added last and the 
solution turned an immediate yellow colour and was left to stir at room temperature for 3 hrs. 
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performed and the reaction mixture was simply reduced in volume under pressure. Purification 
by chromatography using a silica-gel column (12 g; EtOAc/hexane, 2:8) afforded product 104c 
as a viscous yellow oil, (304 mg, 56%). νmax /cm-1 (CHCl3): 3004s (C-H, aromatic), 2837m + 
2870m + 2945s (C-H, aliphatic), 1508s + 1591s (C=C, aromatic); 1H NMR (300 MHz, CDCl3) δH 
1.62 (2H, m, H-3’), 1.79 (2H, q, J = 6.9 Hz, H-4’), 1.94 (2H, q, J = 7.3 Hz, H-2’), 3.44 (2H, t, J = 
6.9 Hz, H-5’), 3.77 (3H, s, OMe), 3.92 (2H, t, J = 7.3 Hz, H-1’), 6.83 (4H, s, Ar-H); HRMS (EI): 















The methods (i) and (ii) below, relate to studying different solvents for the reaction. 
 
(i) Sodium hydride (60%, 322 mg, 8.05 mmol) was suspended in dry THF (10 mL) at 0oC (ice 
slurry), and to the solution was added p-methoxyphenol (1.0 g, 8.05 mmol) portionwise. Once 
gas evolution had subsided, 5-bromo-1-pentanol 104a (1.34 g, 8.05 mmol) was added slowly. 
The ice bath was then removed and the mixture refluxed. TLC confirmed completion of the 
reaction (EtOAc/hexane 3:7; Rf = 0.24) after 20 hrs. The reaction mixture was cooled to room 
temperature, diluted with H2O (30 mL) and extracted with EtOAc (2 × 30 mL). The organic 
fractions were washed with brine (30 mL) before being dried over MgSO4 and the solvent 
removed under reduced pressure. Purification by chromatography using a silica-gel column (50 
g; EtOAc/hexane, 6:4) afforded product 104d as a colourless solid, (765 mg, 46%). The product 
was recrystallized from diethyl ether and petroleum ether before being submitted for spectral 
analysis. 
 
(ii) Sodium hydride (60%, 988 mg, 24.7 mmol) was suspended in dry DME (10 mL) at 0oC (ice 
slurry), and to the solution was added p-methoxyphenol (3.80 g; 30.6 mmol) portionwise. Once 
gas evolution had subsided, 5-bromo-1-pentanol 104a (3.93 g, 23.5 mmol) was added slowly. 
The ice bath was then removed and the mixture refluxed. TLC confirmed completion of the 
reaction (EtOAc/hexane 3:7; Rf = 0.24) after 24 hrs. The reaction mixture was cooled to room 
temperature and diluted with H2O (30 mL) and extracted with EtOAc (2 × 30 mL). The organic 
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removed under reduced pressure. Purification by chromatography using a silica-gel column (70 
g; EtOAc/hexane, 1:1) afforded product 104d as a colourless solid, (3.19 g, 69%). The product 
was recrystallized from diethyl ether and petroleum ether before being submitted for spectral 
analysis. M.p. 53 - 56oC; νmax /cm-1 (CHCl3): 3617b (O-H, free), 2871s + 2941s (C-H, aliphatic), 
1508s (C=C, aromatics); 1H NMR (400 MHz, CDCl3) δH 1.53 (2H, m, H-3), 1.64 (2H, q, J = 7.0 
Hz, H-2), 1.79 (2H, q, J = 6.8 Hz , H-4), 3.67 (2H, m, H-1), 3.76 (3H, s, OMe), 3.92 (2H, t, J = 6.8 
Hz, H-5), 6.82 (4H, s, Ar-H); 13C NMR (100 MHz, CDCl3) δC 22.4 (C-3), 29.1 (C-4), 32.4 (C-2), 
55.7 (OMe), 62.8 (C-1), 68.5 (C-5), 114.7 + 115.4 (C-2’,3’), 153.2 (C-1’), 154.0 (C-4’); HRMS 
(EI): m/z 210.12436 [M+]. Calculated for C12H18O3, 210.12559 [M+]; C, H, N Microanalysis found: 
C, 68.54; H, 8.64%; C12H18O3 requires C, 68.54; H, 8.63%. 
 
















Alcohol 104d (3.15 g, 15.0 mmol) was added to pyridine (2.42 mL, 30.0 mmol) at 0oC (ice slurry) 
and under a constant argon purge while stirring. Dichloromethane (20 mL) was added to the 
mixture, followed by the dropwise addition of methanesulfonyl chloride (1.74 mL, 22.5 mmol) and 
the reaction left to stir. TLC confirmed completion of the reaction (EtOAc/hexane, 3:7; Rf = 0.20) 
after 1½ hrs. To the reaction mixture was then added EtOAc (50 mL) and the organic fraction 
extracted with 1M HCl (2 × 30 mL). The organic fraction was finally washed with brine (30 mL), 
dried over MgSO4 and removed under reduced pressure. Purification by chromatography using a 
silica-gel column (70 g; EtOAc/hexane, 3:7) afforded mesylate 104e as a colourless oil, (4.02 g, 
93%). νmax /cm-1 (CHCl3): 2950s + 2871m (C-H, aliphatic), 1508s (C=C, aromatic), 1356s + 
1175s (-SO2-O-); 1H NMR (400 MHz, CDCl3) δH 1.60 (2H, m, H-2), 1.81 (4H, m, H-3, H-4), 3.00 
(3H, s, CH3SO2), 3.76 (3H, s, OMe), 3.92 (2H, t, J = 6.1 Hz, H-5), 4.26 (2H, t, J = 6.6 Hz, H-1), 




































Three reactions were carried out varying the electrophilic alkylating agent as bromide or 
mesylate, as well as solvent (THFor DME): 
 
(i) Sodium hydride (60%, 30 mg, 0.75 mmol) was dissolved in dry THF (3 mL) at 0oC (ice slurry) 
while stirring. This was followed by the dropwise addition of 103 (99 mg, 0.5 mmol) and 104c 
(137 mg, 0.5 mmol) respectively. The ice slurry was then removed and the mixture refluxed. The 
reaction was stopped after 2 hrs and TLC suggested product formation (EtOAc/hexane, 1:9; Rf = 
0.13). After cooling to room temperature, the reaction mixture was then diluted with H2O (30 mL) 
and extracted with EtOAc (3 × 30 mL). The organic fractions were then washed with brine (20 
mL), dried over MgSO4 and the solvent removed under reduced pressure. Purification by 
chromatography using a silica-gel column (5 g; EtOAc/hexane, 1:9) afforded product 105a as a 
colourless oil, (71 mg, 37%). 
 
(ii) Sodium hydride (60%, 48 mg, 1.20 mmol) was dissolved in dry THF (5 mL) at 0oC (ice slurry) 
while stirring. This was followed by dropwise addition of 103 (157 mg, 0.80 mmol), and the 
mesylate 104e (230 mg, 0.80 mmol) added after gas evolution had subdued. The ice slurry was 
then removed and the mixture refluxed. The reaction was complete after 20 hrs and TLC 
suggested product formation (EtOAc/hexane, 1:9; Rf = 0.13). After cooling to room temperature, 
the reaction mixture was then diluted with H2O (30 mL) and extracted with EtOAc (3 × 30 mL). 
The organic fractions were then washed with brine (20 mL), dried over MgSO4 and the solvent 
removed under reduced pressure. Purification by chromatography using a silica-gel column (10 
g; EtOAc/hexane, 1:9) afforded product 105a as a colourless oil, (222 mg, 72%). 
 
(iii) Sodium hydride (60%, 624 mg, 15.6 mmol) was dissolved in dry DME (20 mL) at 0oC (ice 
slurry) while stirring. This was followed by dropwise addition of 103 (2.04 g, 10.4 mmol), and the 
mesylate 104e (3.0 g, 10.4 mmol) added after gas evolution had subdued. The ice slurry was 
then removed and the mixture refluxed. The reaction was complete after 5 hrs and TLC 
suggested product formation (EtOAc/hexane, 1:9; Rf = 0.13). After cooling to room temperature, 
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The organic fractions were then washed with brine (20 mL), dried over MgSO4 and the solvent 
removed under reduced pressure. Purification by chromatography using a silica-gel column (70 
g; EtOAc/hexane, 1:9) afforded product 105a as a colourless oil, (2.96 g, 74%). νmax /cm-1 
(CHCl3): 2940s + 2869s (C-H, aliphatic), 1591m + 1591s (C=C, aromatic); 1H NMR (400 MHz, 
CDCl3) δH 1.52 (2H, m, H-2’), 1.66 (2H, quin, J = 7.0 Hz, H-3’), 1.78 (2H, quin, J = 7.0 Hz, H-4’), 
3.50 (2H, t, J = 6.6 Hz, H-5’), 3.66 (8H, m, H-6’,7’,8’,9’), 3.76 (3H, s, OMe), 3.90 (2H, t, J = 6.4 
Hz, H-1’), 4.57 (2H, s, H-10’), 6.82 (4H, s, H-2,3), 7.35 (5H, m, H-12’,13’,14’) 13C NMR (75 MHz, 
CDCl3): δC 22.6 (C-4’), 29.1 (C-3’), 29.3 (C-2’), 55.6 (OMe), 68.4 (C-9’, C-1’), 69.4 (C-6’), 70.1 + 
70.6 (C-7’, C-8’), 71.2 (C-5’), 73.1 (C-10’), 114.5 (C-2/C-3), 115.3 (C-2/C-3), 127.4 + 127.6 + 
128.2 (C-12’,13’,14’), 138.2 (C-11’), 153.2 (C-1), 153.6 (C-4); HRMS (EI): m/z 388.22540 [M+]. 
















The p-methoxyphenyl ether 105a (2.29 g, 5.88 mmol) was added to a mixture of acetonitrile (16 
mL) and water (4 mL). The mixture was brought to 0oC and cerium(IV) ammonium nitrate (16.1 
g, 29.4 mmol) added portionwise. The solution turned an immediate dark-red colour and the 
reaction was complete after 10 min, as indicated by TLC (EtOAc/Hex, 1:1; Rf = 0.12). The 
reaction mixture was diluted with H2O (30 mL) and extracted with dichloromethane (2 × 30 mL).  
The organic fractions were then washed with brine (30 mL), dried with MgSO4 and the solvent 
removed under reduced pressure. Purification by chromatography using a silica-gel column (70 
g; EtOAc/hexane, 6:4) afforded product 106 as an orange oil, (1.75 g, 86%). νmax /cm-1 (CHCl3): 
3472b (O-H, free), 2938s + 2867s (C-H, aliphatic), 1496w + 1454s (C=C, aromatics); 1H NMR 
(400 MHz, CDCl3) δH 1.40 (2H, m, H-3), 1.58 (4H, m, H-2, H-4), 1.96 (1H, s, OH), 3.46 (2H, t, J = 
6.6 Hz, H-5), 3.62 (10H, m, H-1,1’,2’,3’,4’), 4.55 (2H, s, H-5’), 7.32 (5H, m, Ar-H); 13C NMR (75 
MHz, CDCl3) δC 22.2 (C-3), 29.2 + 32.4 (C-2, C-4), 62.5 (C-1), 69.4 (C-4’), 70.0 + 70.6 + 71.2 (C-
1’,2’,3’), 70.5 (C-5), 73.2 (C-5’), 127.5 (C-9’), 127.6 (C-7’), 128.3 (C-8’), 138.2 (C-6’); HRMS (EI): 

































To a mixture of dimethyl sulfoxide (1.24 mL, 17.5 mmol) in dichloromethane (30 mL) at -78oC 
(dry-ice in acetone), was added oxalyl chloride (0.76 mL, 8.75 mmol) and the reaction mixture 
stirred for 15 min under a constant argon purge. Subsequent dropwise addition of alcohol 106 
(1.65 g, 5.83 mmol) was followed by stirring for a further 20 min. Triethylamine (4.06 mL, 29.2 
mmol) was then added and the reaction allowed to warm to room temperature. TLC suggested 
completion after 15 min (EtOAc/hexane, 4:6; Rf = 0.54).  The reaction mixture was then diluted 
with aqueous NaHCO3 (50 mL) and extracted with dichloromethane (3 × 30 mL). The organic 
extract was dried over MgSO4 and the solvent removed under reduced pressure, to give a 
viscous yellow oil. Purification by chromatography on a silica-gel column (70 g; EtOAc/hexane, 
3:7) afforded aldehyde 107 as a yellow oil, (1.60 g, 98%). νmax /cm-1 (CHCl3): 2940s + 2872s (C-
H, aliphatic), 1710s (C=O, aldehyde), 1495w (C=C, aromatic); 1H NMR (300 MHz, CDCl3) δH = 
1.64 (4H, m, H-3,4), 2.43 (2H, td, J = 7.0, 1.4 Hz, H-2), 3.47 (2H, t, J = 6.2 Hz, H-5), 3.64 (8H, m, 
H-1’,2’,3’,4’), 4.56 (2H, s, H-5’), 7.32 (5H, m, Ar-H), 9.73 (1H, d, J = 1.4 Hz, H-1). 
 























The methyl furanylphosphonium salt 90 (2.68 g, 5.57 mmol) was dissolved in a mixture of dry 
methanol (30 mL) and sodium methoxide (4.63 M, 1.32 mL, 6.12 mmol) was added via syringe 
under nitrogen at 0oC (ice-water slurry). Aldehyde 107 (1.56 g, 5.57 mmol) was slowly added 
and the reaction mixture stirred at room temperature. The reaction mixture turned an immediate 
dark-red colour that progressively faded to a light-orange colour as it went to completion within 3 
hrs. The reaction mixture was then diluted with brine (50 mL) and extracted with EtOAc (3 × 30 
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pressure. A yellow powder was obtained which was subjected to column chromatography using 
a silica-gel column (70 g; EtOAc/hexane, 1.5:8.5) to afford product 108 as a mixture of E- and Z-
stereoisomers in a 3:2 ratio and as a colourless oil, (1.73 g, 81%). νmax /cm-1 (CHCl3): 2928m + 
2867s (C-H, aliphatic), 1715s (C=O, ester), 1649m (C=C, alkene), 1567m (C=C, aromatic); ¹H 
NMR of E-isomer (CDCl3, 400 MHz) δH 1.54 (2H, m, H-4’), 1.64 (2H, m, H-5’), 2.28 (2H, qd, J = 
7.2, 1.3 Hz, H-3’), 3.48 (2H, t, J = 6.4 Hz, H-6’), 3.58-3.67 (8H, m, H-7’-H-10’), 3.82 (3H, s, 
CO2Me), 4.56 (2H, s, H-11’), 6.49 (1H, dt, J = 16.0, 7.1 Hz, H-2’), 6.69 (1H, d, J = 2.0 Hz, H-4), 
6.94 (1H, dt, J = 16.0, 1.4 Hz, H-1’), 7.30 (1H, d, J = 2.0 Hz, H-5), 7.33 (5H, m, Ar-H); ¹H NMR of 
Z-isomer (CDCl3, 400 MHz) δH 1.54 (2H, m, H-4’), 1.64 (2H, m, H-5’), 2.61 (2H, qd, J = 7.2, 1.3 
Hz, H-3’), 3.48 (2H, t, J = 6.4 Hz, H-6’), 3.58-3.67 (8H, m, H-7’-H-10’), 3.82 (3H, s, CO2Me), 4.56 
(2H, s, H-11’), 5.82 (1H, dt, J = 12.0, 7.6 Hz, H-2’), 6.66 (1H, d, J = 2.0 Hz, H-4), 6.88 (1H, dt, J 
= 12.0, 1.7 Hz, H-1’), 7.21 (1H, d, J = 2.0 Hz, H-5), 7.33 (5H, m, Ar-H); 13C NMR of E/Z isomers 
(75 MHz, CDCl3) δC 25.5/26.0 (C-4’), 29.1/29.2 (C-5’), 29.4/32.8 (C-3’), 51.3/51.4 (CO2Me), 69.5 
(OCH2), 70.1/70.2 (C-6’), 70.6 (OCH2), 71.1 (OCH2), 71.2 (OCH2), 73.1 (C-11’), 111.2/111.3 (C-
4), 112.2 (C-3), 115.9/117.9 (C-1’), 127.5 (C-15’), 127.6 (C-13’/C-17’), 128.3 (C-14’/C-16’), 
136.0/136.9 (C-2’), 138.3 (C-12’), 140.7/140.8 (C-5), 157.0/157.6 (C-2), 163.9/164.0 (CO2Me); 
HRMS (EI): m/z 402.20186 [M+]. Calculated for C23H30O6, 402.20424 [M+]. 
 

















The furan ester 108 (660 mg, 1.64 mmol) was dissolved in absolute ethanol (5 mL) and stirred at 
room temperature. Subsequent addition of palladium on carbon 10% (175 mg, 0.164 mmol) was 
followed by careful placement of a hydrogen gas balloon over the reaction flask. TLC 
(EtOAc/hexane, 3:7; Rf = 0.10) confirmed completion of the reaction after 1 hr. The reaction 
mixture was filtered through a Celite packed sintered funnel with EtOAc. The organic solvent 
was then removed under reduced pressure. No purification was performed and the crude 
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Compound 109 (478 mg, 1.52 mmol) was dissolved in dichloromethane (10 mL). Triethylamine 
(0.43 mL, 3.04 mmol) was added at 0oC followed by a catalytic amount of DMAP (10 mg, 0.076 
mmol) to the reaction mixture. p-Toluenesulfonyl chloride (437 mg, 2.29 mmol) dissolved in 
dichloromethane (2 mL) was then added dropwise and the solution left to stir at room 
temperature. TLC (EtOAc/hexane, 3:7; Rf = 0.36) confirmed completion of the reaction after 1½ 
hrs. The reaction mixture was diluted with brine (30 mL) and extracted with dichloromethane (3 × 
30 mL). The organic fractions were dried with MgSO4 and the solvent removed under reduced 
pressure. Purification by chromatography using a silica-gel column (60 g; EtOAc/hexane, 
1.5:8.5) afforded product 110 as a colourless oil, (540 mg, 76%). νmax /cm-1 (CHCl3): 2937s + 
2864s (C-H, aliphatic), 1715s (C=O, ester), 1599s (C=C, aromatic), 1369s + 1177s (-SO2-O-); 1H 
NMR (400 MHz, CDCl3) δH 1.33 (4H, m, H-3’, H-4’), 1.53 (2H, m, H-2’), 1.67 (2H, m, H-5’), 2.41 
(3H, s, H-7’’), 2.97 (2H, t, J = 7.3 Hz, H-1’), 3.39 (2H, t, J = 6.6 Hz, H-6’), 3.49 (2H, m, H-7’), 3.55 
(2H, m, H-8’), 3.68 (2H, m, H-9’), 3.80 (3H, s, CO2CH3), 4.15 (2H, m, H-10’), 6.62 (1H, s, H-4), 
7.22 (1H, s, H-5), 7.31 + 7.79 (4H, 2 × d, JAB = 8.4 Hz, H-2’’, 3’’, 5’’, 6’’); 13C NMR (75 MHz, 
CDCl3) δC 21.5 (C-7’’), 25.7 + 27.8 + 28.9 + 29.4 (C-2’,3’,4’,5’), 27.4 (C-1’), 51.2 (CO2CH3), 68.7 
(C-9’), 69.2 (C-10’), 70.0 (C-7’), 70.7 (C-8’), 71.4 (C-6’), 110.5 (C-4), 112.8 (C-3), 127.9 (C-2’’, C-
6’’), 129.7 (C-3’’, C-5’’), 133.1 (C-4’’), 140.3 (C-5), 144.7 (C-1’’), 163.2 (C-2), 164.4 (CO2CH3); 
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To a sodium hydride (60%, 69 mg, 1.72 mmol) suspension in THF (2 mL) at 0oC, was added 
propargyl alcohol (0.13 mL, 2.14 mmol) slowly whilst stirring. To this was added 110 (200 mg, 
0.43 mmol) and the reaction mixture refluxed. After 1 hr 1M NaOH (4 drops) was added and the 
reaction mixture refluxed for a further hour. TLC (EtOAc/hexane, 3:7; Rf = 0.10) confirmed 
completion after a total of 2 hrs. The reaction mixture was diluted with 1M HCl (20 mL) and 
extracted with EtOAc (2 × 30 mL). The organic fractions were dried with MgSO4 and the solvent 
removed under reduced pressure. Purification by chromatography using a silica-gel column (12 
g; EtOAc/hexane, 3:7) afforded product 111 as a colourless oil, (138 mg, 95%). νmax /cm-1 
(CHCl3): 3157b (O-H, H-bonded), 2935s + 2865s (C-H, aliphatic), 2254s (C≡C, alkyne), 1683s 
(C=O, carboxylic acid), 1596s (C=C, aromatic); 1H NMR (400 MHz, CDCl3) δH 1.36 (4H, m, H-
3’,4’), 1.57 (2H, quin, J = 6.9 Hz, H-2’), 1.70 (2H, quin, J = 7.3 Hz, H-5’), 2.41 (1H, t, J = 2.4 Hz, 
H-13’), 3.01 (2H, t, J = 7.4 Hz, H-1’), 3.45 (2H, t, J = 6.4 Hz, H-6’), 3.58 - 3.70 (8H, m, H-
7’,8’,9’,10’), 4.20 (2H, d, J = 2.4 Hz, H-11’), 6.67 (1H, d, J = 2.1 Hz, H-4), 7.26 (1H, d, J = 2.1 Hz, 
H-5); 13C NMR (75 MHz, CDCl3) δC 25.6 (CH2), 27.4 (CH2), 27.7 (CH2), 28.7 (CH2), 29.4 (CH2), 
58.4 (C-11’), 69.1 (OCH2), 70.0 (OCH2), 70.4 (OCH2), 70.7 (C-6’), 71.3 (OCH2), 74.4 (C-13’), 
79.6 (C-12’), 110.9 (C-4), 112.6 (C-3), 140.6 (C-5), 164.4 (C-2), 168.5 (CO2H); HRMS (EI): m/z 
338.17678 [M+]. Calculated for C18H26O6, 338.17294 [M+]. 
 
2-{6-[2-Propargyloxyethoxy)-2-ethoxy]-1-hexyl}furan-3-carboxylic acid [4-chloro-3-(3-
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The acid 111 (108 mg, 0.32 mmol) was dissolved in thionyl chloride (1 mL) and the mixture 
heated to 40oC under nitrogen for 1 hr with constant stirring. The excess thionyl chloride was 
then reduced on a vacuum pump and the resulting oil dissolved in dichloromethane (3 mL). 
Subsequent addition of pyridine (0.08 mL, 0.96 mmol) at 0oC was followed by the arylamine 61 
(68 mg, 0.32 mmol) and the reaction mixture stirred at room temperature. TLC (EtOAc/hexane, 
3:7; Rf = 0.35) confirmed completion of the reaction after 30 min. The reaction mixture was 
diluted with EtOAc (50 mL) and extracted with 1M HCl (4 × 15 mL). The organic fractions were 
dried with MgSO4 and the solvent removed under reduced pressure. Purification by 
chromatography using a silica-gel column (10 g; EtOAc/hexane, 1.5:8.5) afforded product 112 as 
a yellow oil, (133 mg, 78%). νmax /cm-1 (CHCl3): 3304s + 3440 m (N-H, amide), 2935s + 2864s 
(C-H, aliphatic), 2253s (C≡C, alkyne), 1674s (C=O, amide), 1595s (N -H and C-N stretching), 
1513s + 1492s (C=C, aromatic); 1H NMR (400 MHz, CDCl3) δH 1.34 - 1.69 (8H, m, H-
2’’,3’’,4’’,5’’), 1.74 + 1.78 (6H, 2 × s, H-10’,11’), 2.39 (1H, t, J = 2.4 Hz, H-13’’), 3.02 (2H, t, J = 
7.5 Hz, H-1’’), 3.41 (2H, t, J = 6.8 Hz, H-6’’), 3.55 - 3.67 (8H, m, H-7’’,8’’,9’’,10’’), 4.17 (2H, d, J = 
2.4 Hz, H-11’’), 4.58 (2H, d, J = 6.6 Hz, H-8’), 5.51 (1H, tq, J = 6.6, 1.4 Hz, H-9’), 6.55 (1H, d, J = 
2.1 Hz, H-4), 6.91 (1H, dd, J = 8.7, 2.4 Hz, H-7’), 7.25 (1H, d, J = 8.7 Hz, H-6’), 7.29 (1H, d, J = 
2.1 Hz, H-5), 7.54 (1H, d, J = 2.4 Hz, H-3’), 7.58 (1H, s, NH); 13C NMR (75 MHz, CDCl3) δC 18.1 
× 2 (CH3), 25.8 (CH2), 27.2 (C-1’’), 27.4 (CH2), 29.0 (CH2), 29.5 (CH2), 58.3 (C-11’’), 66.1 (C-8’), 
66.2 (OCH2), 69.2 (OCH2), 70.2 (C-6’’), 70.7 (OCH2), 71.5 (OCH2), 74.5 (C-13’’), 79.6 (C-12’’), 
106.2 (C-3’), 107.9 (C-4), 112.5 (C-7’), 115.5 (C-3), 117.9 (C-5’), 119.2 (C-9’), 129.9 (C-6’), 
137.6 (C-2’), 138.3 (C-12’), 140.5 (C-5), 154.6 (C-4’), 161.9 (C-2), 161.9 (CONH); HRMS (EI): 


















































































Amide 112 (50 mg, 0.09 mmol) was added together with the 5-iodo-d4U benzoate 60 (41 mg, 
0.094 mmol) and the mixture dried carefully on a vacuum pump. A mixture of degassed 
DMF:THF  (1:2 (v/v), 1 mL) was then added to the reaction vessel whilst the mixture stirred at 
room temperature under nitrogen. Subsequent addition of triethylamine (0.03 mL, 0.20 mmol) 
was followed by addition of copper(I) iodide (8.95 mg, 0.05 mmol) and 
tetrakistriphenylphosphinepalladium (10.9 mg, 0.01 mmol) respectively. The reaction was stirred 
continuously at room temperature and TLC (EtOAc/hexane, 3:7; Rf = 0.24) confirmed completion 
of the reaction after 2 hrs. The reaction mixture was diluted with a 5% EDTA solution (30 mL) 
and extracted with chloroform (3 × 20 mL). The organic fractions were dried with MgSO4 and the 
solvent removed under reduced pressure. Purification by chromatography using a silica-gel 
column (10 g; EtOAc/hexane, 3:7) afforded product 113 as a clear oil, (48 mg, 61%). νmax /cm-1 
(CHCl3): 2932s (C-H, aliphatic), 2254s (C≡C, alkyne), 1720s (C=O, ester), 1693s (C=O, amide), 
1599s (N-H and C-N stretching), 1514s + 1492s (C=C, aromatic); 1H NMR (400 MHz, CDCl3) δH 
1.35 - 1.69 (8H, m, H-18,19,20,21), 1.74 (3H, s, H-37/H-38), 1.79 (3H, s, H-37/H-38), 3.04 (2H, t, 
J = 7.7 Hz, H-22), 3.42 (2H, t, J = 6.6 Hz, H-17), 3.65 (8H, m, H-13,14,15,16), 4.24 (2H, s, H-12), 
4.60 (4H, m, H-1, H-34), 5.20 (1H, s, H-2), 5.51 (1H, tq, J = 6.6, 1.4 Hz, H-35), 5.99 (1H, d, JAB = 
5.8 Hz, H-3), 6.41 (1H, d, JAB = 5.8 Hz, H-4), 6.55 (1H, d, JAB = 1.4 Hz, H-25), 6.89 (1H, m, H-
33), 6.93 (1H, s, H-5), 7.26 (1H, m, H-32), 7.30 (1H, d, JAB = 1.4 Hz, H-26), 7.45 - 7.55 (5H, m, 
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(75 MHz, CDCl3) δC 18.3 (C-37/C-38), 25.7 (C-37/C-38), 25.8 (CH2), 27.4 (C-22), 27.8 (CH2), 
28.9 (CH2), 29.4 (CH2), 58.8 (C-12), 64.9 (C-1), 66.1 (C-34), 68.1 (OCH2), 69.3 (OCH2), 70.3 (C-
17), 70.6 (OCH2), 71.3 (OCH2), 71.3 (C-8), 75.3 (C-10), 85.0 (C-2), 90.6 (C-5), 101.0 (C-11), 
106.2 (C-29), 108.0 (C-25), 112.4 (C-33), 115.4 (C-24), 117.9 (C-31), 119.1 (C-35), 127.0 (C-4), 
128.7 (C-3’, C-5’), 129.3 (C-1’), 129.8 (C-2’, C-6’), 129.9 (C-32), 133.5 (C-3), 133.6 (C-4’), 137.6 
(C-28), 138.5 (C-36), 140.6 (C-26), 144.0 (C-9), 150.0 (C-6), 154.6 (C-30), 159.6 (C-23), 161.9 

















Methanesulfonyl chloride (8.7 mL, 113 mmol) was added to a cold and stirring solution of uridine 
(6.1 g, 25 mmol) in pyridine (35 mL) at 0oC. The reaction mixture was stirred at 0oC for 5 hrs and 
then poured into an ice-water slurry (250 mL) with stirring. The resulting mixture was then stirred 
for a further 10 min. The precipitate formed was collected by filtration and washed with water (3 
× 100 mL) and dried to give 83 as a white solid (12.1 g, 100%). Mp: 170-171 oC (lit. 184-186oC); 
1H NMR (400 MHz, DMSO-d6) δH 3.22 (3H, s, O3SCH3), 3.33 (3H, s, O3SCH3), 3.35 (3H, s, 
O3SCH3), 4.46 (2H, m, H-5’), 4.53 (1H, m, H-4’), 5.35 (1H, t, J = 5.3 Hz, H-3’), 5.60 (1H, t, J = 5.3 
Hz, H-2’), 5.69 (1H, m, J = 1.5, 8.0 Hz, H-5), 5.97 (1H, d, J = 4.4 Hz, H-1’), 7.69 (1H, d, =  8.0 
Hz, H-6); 13C NMR (75 MHz, DMSO-d6) δC 36.9 (O3SCH3), 37.9 (O3SCH3), 37.9 (O3SCH3), 67.3 







































Trimesylate 83 (3.0 g, 6.3 mmol) was added to a stirred slurry of sodium benzoate (3.16 g, 21.9 
mmol) in acetamide (25 g) at 115 oC. The reaction mixture was stirred at 115 oC for 65 min and 
then poured into an ice-water slurry (600 mL). The mixture was stirred at 0 oC for 15 min. The 
white solid was filtered, washed with water and dried to afford 84 (1.93, 75%) as colourless 
needles. Mp: 243-244 oC (lit. 226-227 oC); 1H NMR (400 MHz, DMSO-d6) δH 3.43 (3H, s, 
O3SCH3), 4.22 (1H, dd, J = 7.4, 12.1 Hz, H-5’), 4.33 (1H, dd, J = 4.8, 12.1 Hz, H-5’), 4.77 (1H, m, 
H-4’), 5.62 (1H, d, J = 2.4 Hz, H-3’), 5.69 (1H, d, J = 5.6 Hz, H-2’), 5.87 (1H, d, J = 7.6 Hz, H-5), 
6.45 (1H, d, J = 5.6 Hz, H-1’), 7.49 (2H, t, J = 7.8 Hz, H-3’’, H-5’’), 7.65 (1H, m, H-4’’), 7.89 (3H, 
m, H-6, H-2’’, H-6’’); 13C NMR (75 MHz, DMSO-d6) δC 37.5 (O3SCH3), 62.5 (C-5’), 80.9 (C-3’), 
82.1 (C-4’), 86.0 (C-2’), 89.7 (C-1’), 109.0 (C-5), 128.7 (C-3’’, C-5’’), 128.9 (C-1’’), 129.2 (C-2’’, 






















Acetyl bromide (2.5 mL, 33.9 mmol) was added dropwise to a stirring mixture of 5’-O-Benzoyl-3’-
O-methanesulfonyl-2’-anhydrouridine 84 (1.90 g, 4.8 mmol) in EtOAc (50 mL) and MeOH (5 mL). 
The mixture was refluxed for 1 hr and then cooled. To the reaction mixture was added EtOAc (3  
× 50 mL) and the organic layer washed with aq. NaHCO3 (50 mL) followed by brine (50 mL). The 
organic layer was dried over MgSO4 and the solvent removed under reduced pressure. The 
crude product was recrystallized from EtOAc/pet. ether to afford 85 as a white solid (2.23 g, 
97%). 1H NMR (400 MHz, CDCl3) δH 3.18 (3H, s, O3SCH3), 4.65 (3H, m, H-4’, H-5’), 4.74 (1H, m, 
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d, J = 8.1 Hz, H-6), 7.46 (2H, m, H-3’’, H-5’’), 7.60 (1H, m, H-4’’), 8.01 (2H, m, H-2’’, H-6’’), 9.49 
(1H, brs, NH); 13C NMR (75 MHz, CDCl3) δC 38.8 (O3SCH3), 47.2 (C-2’), 62.2 (C-5’), 75.6 (C-3’), 
80.7 (C-4’), 91.9 (C-1’), 103.4 (C-5), 128.7 (C-3’’, C-5’’), 129.0 (C-1’’), 129.6 (C-2’’, C-6’’), 133.8 




















Acetic acid (0.25 mL) and zinc dust (0.50 g, 7.69 mmol) were added to a suspension of 85 (2.19 
g, 4.61 mmol) in a mixture of EtOAc (40 mL) and MeOH (13 mL) at 18 oC. After 3.5 hrs, the 
excess zinc was removed by filtration and the cake was washed with a 3:1 mixture of 
EtOAc/MeOH (2 × 20 mL). The solvent was removed under reduced pressure and more 3:1 
mixture of EtOAc/MeOH (6 mL) added. To this solution was then added water (75 mL) and the 
solution stirred for 30 min. The resulting precipitate was filtered and the product washed with 
water and dried (over P2O5) to afford 86 as colourless crystals (1.14 g, 83%). Mp: 141-142 oC (lit. 
138.5-139 oC); 1H NMR (400 MHz, CDCl3) δH 4.53 (1H, dd, J = 2.9, 12.7 Hz, H-5’), 4.70 (1H, dd, 
J = 3.6, 12.7 Hz, H-5’), 5.16 (1H, m, H-4’), 5.33 (1H, d, J = 8.3 Hz, H-5), 5.89 (1H, dq, J = 1.4, 
5.9 Hz, H-2’), 6.39 (1H, dt, J = 1.7, 5.9 Hz, H-3’), 7.00 (1H, m, H-1’), 7.34 (1H, d, J = 8.3 Hz, H-
6), 7.46 (2H, m, H-3’’, H-5’’), 7.60 (1H, m, H-4’’), 7.99 (2H, m, H-2’’, H-6’’), 9.10 (1H, brs, NH); 
13C NMR (75 MHz, CDCl3) δC 64.5 (C-5’), 84.8 (C-4’), 89.8 (C-1’), 102.7 (C-5), 127.2 (C-2’), 
128.6 (C-3’’, C-5’’), 129.6 (C-2’’, C-6’’), 135.6 (C-3’), 133.6 (C-4’’), 133.8 (C-1’’),139.8 (C-6), 
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Cerium ammonium nitrate (IV) (0.77 g, 1.4 mmol) and iodine (0.43 g, 1.68 mmol) were added to 
a solution of 5’-O-Benzoyl-2’-3’-didehydro-2’3’-dideoxyuridine 86 (0.88 g, 2.8 mmol) in CH3CN 
(40 mL). The mixture was stirred at 35 oC for 4 hrs. EtOAc (170 mL) was added to the residue 
and the solid product formed was removed by filtration. The filtrate was washed with a solution of 
NaHSO3 (2 × 100 mL), water (2 × 100 mL), the organic layer dried over MgSO4 and the solvent 
removed under reduced pressure. Recrystallization using CH2Cl2/pet. ether gave 60 as white 
needles (1.05 g, 85%). Mp: 141-142 oC (lit. 138.5-139 oC); 1H NMR (400 MHz, Acetone-d6) δH 
4.57 (1H, dd, J = 3.2, 12.3 Hz, H-5’), 4.63 (1H, dd, J = 4.4, 12.3 Hz, H-5’), 5.25 (1H, m, H-4’), 
6.16 (1H, dq, J = 1.1, 6.1 Hz, H-2’), 6.60 (1H, dt, J = 1.7, 6.1 Hz, H-3’), 6.88 (1H, m, H-1’), 7.53 
(2H, m, H-3’’, H-5’’), 7.64 (1H, m, H-4’’), 7.86 (1H, s, H-6), 8.04 (2H, m, H-2’’, H-6’’), 10.37 (1H, 
brs, NH); 13C NMR (75 MHz, Acetone-d6) δC 65.0 (C-5’), 68.9 (C-5), 85.1 (C-4’), 90.6 (C-1’), 
127.1 (C-2’), 128.8 (C-3’’, C-5’’), 129.3 (C-1’’), 129.8 (C-2’’, C-6’’), 133.5 (C-3’), 133.5 (C-4’’), 












A reaction flask was charged with conc. HCl (20 mL) at 0 oC. To this was slowly added a mixture 
of 2-amino-5-nitrophenol (6.56 g, 42.6 mmol) and sodium nitrite (3.32 g, 48.2 mmol) in H2O (7.5 
mL). The reaction mixture was stirred for 3 hrs at 0oC, after which sulfamic acid (0.15 g) was 
added slowly. The resulting mixture was then carefully added to a vigorously stirring 20% HCl 
solution (5 mL) containing copper(I)chloride (0.85 g, 85.8 mmol) over 1hr. TLC confirmed 
reaction completion after stirring at r.t. for a further 1 hr. The reaction mixture was diluted with 
1M HCl (60 mL) and extracted EtOAc (3 × 100 mL), the organic layer dried over MgSO4 and the 
solvent removed under reduced pressure. Purification by chromatography using a silica-gel 
column (100 g; EtOAc/hexane, 2:8) afforded product 119a as a yellow precipitate, (4.61 g, 70%). 
Mp. 102-103 oC; νmax /cm-1 (CHCl3): 1629s (C=C, aromatic), 1523s + 1346s (N-O, aromatic 
nitro), 738s (C-Cl, halogen); ¹H NMR (Acetone-D6, 400 MHz) δH 7.63 (1H, d, J = 8.8 Hz, H-3), 
7.74 (1H, dd, J = 8.8, 2.6 Hz, H-4), 7.84 (1H, d, J = 2.6 Hz, H-6), 9.73 (1H, bs, OH); ¹³C NMR 
(Acetone-D6, 100 MHz) δC 111.3 (C-6), 115.5 (C-4), 127.9 (C-3), 130.9 (C-2), 148.1 (C-5), 153.8 
(C-1); HRMS (EI): m/z 172.98877 [M+]. Calculated for C6H4O3NCl, 172.98846 [M+]; C, H, N 






















Iron mesh (1.20 g, 20 mmol) was added to a mixture of ethanol (5 mL), H2O (1 mL) and HCl (0.2 
mL), and the reaction heated. The reaction flask was fitted with a dropping funnel containing 2-
chloro-5-nitrophenol 119a dissolved in ethanol (1 mL), and upon refluxing of the reaction mixture 
the contents of the funnel was dropped in slowly. TLC confirmed reaction completion after 2 hrs. 
The solution was cooled, filtered through a Celite pad and washed with hot ethanol (10 mL). The 
solvent was removed under reduced pressure.  Purification by chromatography using a silica-gel 
column (80 g; EtOAc/hexane, 6:4) afforded product 119b as a white precipitate, (0.60 g, 73%). 
Mp. 97-99 oC; νmax /cm-1 (CHCl3): 3387s + 3321s (NH, primary amine), 1632s (C=C, aromatic), 
815m (C-Cl, halogen); ¹H NMR (Acetone-D6, 400 MHz) δH 4.62 (2H, bs, NH2), 6.19 (1H, dd, J = 
8.8, 2.6 Hz, H-4), 6.34 (1H, d, J = 2.6 Hz, H-6), 6.94 (1H, d, J = 8.8 Hz, H-3), 8.06 (1H, bs, OH); 
¹³C NMR (Acetone-D6, 100 MHz) δC 102.7 (C-6), 107.6 (C-4), 107.8 (C-2), 129.9 (C-3), 149.0 (C-
5), 153.4 (C-1); HRMS (EI): m/z 143.01377 [M+]. Calculated for C6H6N3ClO, 143.01379 [M+]; C, 

















To a solution of 2-chloro-5-nitrophenol 119a (5.09 g, 29 mmol) dissolved in methyl ethyl ketone 
(25 mL) was added both K2CO3 (4.50 g, 32.5 mmol) and tetra-butylammonium iodide (500 mg). 
Finally, 4-bromo-2-methyl-2-butene (4 mL, 35 mmol) was added and the reaction mixture stirred 
at r.t overnight. The solution was diluted with H2O (100 mL) and extracted with EtOAc (3×100 
mL). The combined organic extracts were then washed with brine (100 mL), dried over MgSO4 
and the solvent removed under reduced pressure. Purification by chromatography using a silica-
gel column (70 g; EtOAc/hexane, 0.1:99.9) afforded product 119c as a white precipitate, (6.7 g, 
94%). Mp. 90-93 oC; νmax /cm-1 (CHCl3): 2978m + 2930m (CH, aliphatic), 1638s (C=C, aromatic), 
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(3H, d, J = 1.5 Hz, H-5’), 1.81 (3H, d, J = 1.5 Hz, H-4'), 4.70 (2H, d, J = 7.0 Hz, H-1’), 5.49 (1H, 
tsep, J = 7.0, 1.5 Hz, H-2’), 7.50 (1H, d, J = 8.8 Hz, H-5), 7.78 (1H, dd, J = 8.8, 2.6 Hz, H-6), 
7.79 (1H, d, J = 2.6 Hz, H-2); ¹³C NMR (CDCl3, 100 MHz) δC 18.3 (C-4'), 25.9 (C-5’), 66.6 (C-1’), 
108.2 (C-2), 116.0 (C-6), 118.8 (C-2’), 130.4 (C-5), 130.5 (C-4), 140.7 (C-3’), 148.2 (C-1), 155.8 
(C-3); HRMS (EI): m/z 241.05048 [M+]. Calculated for C11H12NO3Cl, 241.05057 [M+]; C, H, N 

















Iron mesh (3.27 g, 58.5 mmol) was added to a mixture of ethanol (10 mL), H2O (2 mL) and HCl 
(0.23 mL), and the reaction heated. The reaction flask was fitted with a dropping funnel 
containing 4-chloro-3-(3-methyl-but-2-enyl-1-oxy)nitrobenzene 119c (4.03 g, 16.7 mmol) 
dissolved in ethanol (5 mL), and upon refluxing of the reaction mixture the contents of the funnel 
were slowly dropped in. TLC confirmed reaction completion after 3½ hrs. The solution was 
cooled, filtered through a Celite pad and washed with hot ethanol (200 mL). The solvent was 
removed under reduced pressure.  Purification by chromatography using a silica-gel column 
(100 g; EtOAc/hexane, 0.5:9.5) afforded product 61 as a white precipitate, (3.10 g, 88%). Mp. 
82-85 oC; νmax /cm-1 (CHCl3): 3387s + 3321s (NH, primary amine), 2978m + 2930m (CH, 
aliphatic), 1638s (C=C, aromatic), 738s (C-Cl, halogen); ¹H NMR (CDCl3, 300 MHz) δH 1.73 (3H, 
d, J = 1.5 Hz, H-5’), 1.78 (3H, d, J = 1.5 Hz, H-4'), 3.63 (2H, bs, NH2), 4.53 (2H, d, J = 7.0 Hz, H-
1’), 5.50 (1H, tsep, J = 7.0, 1.5 Hz, H-2’), 6.21 (1H, dd, J = 8.8, 2.6 Hz, H-6), 6.27 (1H, d, J = 2.6 
Hz, H-2), 7.09 (1H, d, J = 8.8 Hz, H-5); ¹³C NMR (CDCl3, 75.5 MHz) δC 18.2 (C-4'), 25.7 (C-5’), 
65.9 (C-1’), 101.5 (C-2), 107.9 (C-6), 112.1 (C-4), 119.5 (C-2’), 130.4 (C-5), 137.8 (C-3’), 146.2 
(C-1), 154.9 (C-3); HRMS (EI): m/z 211.07668 [M+]. Calculated for C11H14NOCl, 211.07652 [M+]; 
C, H, N Microanalysis found: C, 62.44; H, 6.77; N, 6.64%; C11H14NOCl requires C, 62.41; H, 
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To a solution of 119b (200 mg, 1.40 mmol) dissolved in acetone (7 mL) was added anhydrous 
K2CO3 (207 mg, 1.50 mmol) at room temperature. Propargyl bromide (0.15 mL, 1.7 mmol) was 
slowly added to this mixture followed by tetra-butylammonium iodide (30 mg, cat.). The reaction 
mixture was left to react at room temperature. After 5 hrs, the mixture was diluted with H2O (50 
mL) and extracted with EtOAc (3 × 50 mL), the organic layer dried over MgSO4 and the solvent 
removed under reduced pressure. Purification by chromatography afforded product 120 as a red 
viscous oil, (200 mg, 79%). νmax /cm-1 (CHCl3): 3387s + 3321s (NH), 2253s (C≡C), 1632s (C=C, 
Ar), 815m (C-Cl); ¹H NMR (CDCl3, 300 MHz) δH 2.54 (1H, t, J = 2.4 Hz, H-3’), 3.75 (2H, bs, NH2), 
4.71 (2H, d, J = 2.4 Hz, H-1’), 6.25 (1H, dd, J = 8.8, 2.6 Hz, H-6), 6.42 (1H, d, J = 2.6 Hz, H-2), 
7.11 (1H, d, J = 8.8 Hz, H-5); ¹³C NMR (CDCl3, 75 MHz) δC 56.8 (C-1’), 76.0 (C-3’), 78.2 (C-2’), 
101.9 (C-2), 109.0 (C-6), 112.3 (C-4), 130.6 (C-5), 146.3 (C-1), 153.7 (C-3). HRMS (EI): m/z 
182.0376 [M+H]+. Calculated for C9H9NOCl, 182.0373 [M+H]+.  
 












Triphenylphosphine (3.8 g, 14.4 mmol) and 2-(bromomethyl)-6-methylnitrobenzene 121 (3.3 g, 
14.4 mmol) were dissolved in toluene (100 mL) and the solution refluxed for 12 hrs. The salt was 
filtered-off and washed with EtOAc (100 mL), affording product 122 as a white precipitate, (2.5 g, 
78%). Mp. = 165 – 168oC; νmax /cm-1 (CHCl3): 2986s (CH, aliphatic), 1639s (C=C, aromatic); 
1528s + 1375s (N-O, nitro aromatic); ¹H NMR (CDCl3, 300 MHz) δH 2.15 (3H, s, ArCH3), 5.21 
(2H, d, JHP = 15.0 Hz, CH2P), 7.06 (1H, d, J = 7.8 Hz, H-3), 7.35 (1H, t, J = 7.8 Hz, H-4), 7.47 
(1H, d, J = 7.8 Hz, H-5), 7.65-7.74 (12H, m, Ph), 7.90 (3H, m, Ph); ¹³C NMR (CDCl3, 75.5 MHz) 
δC 17.4 (ArCH3), 25.7 (d, JCP = 38 Hz, CH2P), 116.7 (C-2), 117.5 (Phq), 120.9 (C-6), 130.1 (Phm), 
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m/z 491.06439 [M+]. Calculated for C26H23O2NPBr, 491.06491 [M+]; C, H, N Microanalysis found: 





2,6-Dimethylaniline (2.0 g, 16.5 mmol) was dissolved in AcOH (20 mL). The temperature of the 
solution was lowered to 0oC and ammonium bromide (1.9 g, 20 mmol) added. After stirring for 5 
min, H2O2 (1.14 mL, 20 mmol) was carefully dropped into the mixture and the reaction allowed to 
warm to room temperature. The solution was diluted with aq. NaHCO3 (200 mL) and extracted 
with EtOAc (3 × 200 mL), dried over MgSO4 and the solvent removed under reduced pressure. 
Purification by chromatography using a silica-gel column (100 g; EtOAc/hexane, 1:9) afforded 
product 124 as a dark-red oil, (1.6 g, 49%). νmax /cm-1 (CHCl3): 3491s + 3379s (NH, primary 
amine), 2965m + 2939m (CH, aliphatic), 1639s (C=C, aromatic); 794m (C-Br, halogen); ¹H NMR 
(CDCl3, 300 MHz) δH 2.14 (6H, s, ArCH3), 4.11 (2H, bs, NH2), 7.17 (2H, s, H-3); ¹³C NMR 
(CDCl3, 75.5 MHz) δC 17.1 (ArCH3), 113.7 (C-4), 121.3 (C-2), 131.9 (C-3), 147.2 (C-1); HRMS 





4-Bromo-2,6-dimethylaniline 124 (1.2 g, 5.8 mmol) was dissolved in DMF (10 mL) and CuCN 
(0.63 g, 7.0 mmol) added. The mixture was refluxed for 6 hrs after which TLC confirmed reaction 
completion. The reaction mixture was then poured into a freshly prepared aqueous ferric 
chloride solution (2.4 g) in conc. HCl (6 mL), H2O (40 mL). The resulting mixture was heated to 
70oC and stirred vigorously for 20 min. After cooling, the mixture was extracted with diethyl ether 
(3 × 100 mL). The combined organic fractions were washed again with HCl (100 mL), H2O (100 
mL) and 10% NaOH (100 mL), dried over MgSO4 and the solvent removed under reduced 
pressure. Purification by chromatography using a silica-gel column (75 g; EtOAc/hexane, 3:7) 
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(CHCl3): 3495s + 3389s (NH, primary amine), 2961m + 2931m (CH, aliphatic), 2209s (C-N, 
nitrile), 1633s (C=C, aromatic); ¹H NMR (CDCl3, 300 MHz) δH 2.14 (6H, s, ArCH3), 4.11 (2H, bs, 
NH2), 7.17 (2H, s, H-3); ¹³C NMR (CDCl3, 75.5 MHz) δC 17.1 (ArCH3), 99.1 (C-4), 120.4 (CN), 
121.3 (C-2), 131.9 (C-3), 147.2 (C-1); HRMS (EI): m/z 146.08409 [M+]. Calculated for C9H10N2, 
146.08440 [M+]; C, H, N Microanalysis found: C, 73.90; H, 7.06; N, 19.16%; C9H10N2 requires C, 














The alkene 122b (1.30 g, 9.1 mmol) was dissolved in absolute ethanol (10 mL) and THF (10 mL) 
and stirred at room temperature. Subsequent addition of palladium-on-carbon (10%, 0.97 g, 0.90 
mmol) was followed by careful placement of a hydrogen gas balloon over the reaction flask. TLC 
confirmed completion of the reaction after 1 hr. The reaction mixture was filtered through a 
Celite-packed sintered funnel with EtOAc (50 mL). The organic solvent was then removed under 
reduced pressure. Purification by chromatography using a silica-gel column (60 g; 
EtOAc/hexane, 0.5:9.5) afforded product 123 as a clear oil, (1.01 g, 74%). νmax /cm-1 (CHCl3): 
3407s + 3391s (NH, primary amine), 2978m + 2930m (CH, aliphatic), 1661s (C=C, aromatic); ¹H 
NMR (CDCl3, 400 MHz) δH 1.05 (3H, t, J = 7.3 Hz, H-10), 1.71 (2H, sext, J = 7.7 Hz, H-9), 2.22 
(3H, s, H-7), 2.53 (2H, t, J = 7.3 Hz, H-8), 3.61 (2H, s, NH2), 6.71 (1H, t, J = 7.3 Hz, H-4), 6.98 
(2H, d, J = 7.3 Hz, H-3, H-5); ¹³C NMR (CDCl3, 100 MHz) δC 14.3 (C-10), 17.8 (C-7), 21.9 (C-9), 
33.7 (C-8), 118.0 (C-4), 122.4 (C-2/C-6), 126.8 (C-2/C-6), 127.4 (C-3/C-5), 128.2 (C-3/C-5), 
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2-Methyl-6-propylaniline 123 (1.0 g, 6.7 mmol) was dissolved in AcOH (20 mL). The temperature 
of the solution was lowered to 0oC and ammonium bromide (0.80 g, 8.0 mmol) added. After 
stirring for 5 min, H2O2 (0.5 mL, 8.0 mmol) was carefully dropped into the mixture and the 
reaction gradually allowed to warm to ambient temperature. The solution was diluted with 
NaHCO3 (100 mL) and extracted with EtOAc (3×100 mL), dried over MgSO4 and the solvent 
removed under reduced pressure. Purification by chromatography using a silica-gel column (100 
g; EtOAc/hexane, 1:9) afforded product 125 as a dark red oil, (0.83 g, 53%). νmax /cm-1 (CHCl3): 
3491s + 3379s (NH, primary amine), 2965m + 2939m (CH, aliphatic), 1639s (C=C, aromatic); 
794m (C-Br, halogen); ¹H NMR (CDCl3, 300 MHz) δH 0.98 (3H, t, J = 7.8 Hz, H-10), 1.62 (2H, 
sext, J = 7.8 Hz, H-9), 2.13 (3H, s, H-7), 2.42 (2H, t, J = 7.8 Hz, H-8), 4.19 (2H, bs, NH2), 7.15 
(2H, s, H-3, H-5); ¹³C NMR (CDCl3, 75.5 MHz) δC 13.7 (C-10), 17.2 (C-7), 20.9 (C-9), 32.7 (C-8), 
112.9 (C-4), 121.6 (C-2/C-6), 125.4 (C-2/C-6), 130.9 (C-3/C-5), 131.6 (C-5/C-5), 146.8 (C-1); 





4-Bromo-2-methyl-6-propylaniline 125 (0.60 g, 2.6 mmol) was dissolved in DMF (7 mL) and 
CuCN (0.28 g, 3.2 mmol) added. The mixture was refluxed for 6 hrs after which TLC confirmed 
reaction completion. The reaction mixture was then poured into a freshly prepared aqueous 
ferric chloride solution (1.04 g) in conc. HCl (3 mL), H2O (20 mL). The resulting mixture was 
heated to 70oC and stirred vigorously for 20 min. After cooling, the mixture was extracted with 
diethyl ether (3 × 100 mL). The combined organic fractions were washed again with HCl (100 
mL), H2O (100 mL) and 10% NaOH (100 mL), dried over MgSO4 and the solvent removed under 
reduced pressure. Purification by chromatography using a silica-gel column (50 g; 
EtOAc/hexane, 1:9) afforded product 127 as a light-orange precipitate, (0.38 g, 84%). Mp. 112-
113 oC; νmax /cm-1 (CHCl3): 3495s + 3389s (NH, primary amine), 2961m + 2931m (CH, aliphatic), 
2209s (C-N, nitrile), 1633s (C=C, aromatic); ¹H NMR (CDCl3, 300 MHz) δH 0.98 (3H, t, J = 7.8 
Hz, H-10), 1.62 (2H, sext, J = 7.8 Hz, H-9), 2.13 (3H, s, H-7), 2.42 (2H, t, J = 7.8 Hz, H-8), 4.19 
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20.9 (C-9), 32.7 (C-8), 98.8 (C-4), 120.6 (C-11), 121.6 (C-2/C-6), 125.4 (C-2/C-6), 130.9 (C-3/C-
5), 131.6 (C-3/C-5), 146.8 (C-1); HRMS (EI): m/z 174.11577 [M+]. Calculated for C11H14N2, 
174.11570 [M+]; C, H, N Microanalysis found: C, 75.81; H, 8.95; N, 16.05%; C11H14N2 requires C, 






















A reaction vessel was charged with 4-amino-6-chloro-2-(methylthio)pyrimidine (0.20 g, 1.14 
mmol) and p-bromoaniline (0.39 g, 2.30 mmol) under a stream of argon gas. The two solids were 
heated to a melt at 160 oC without any use of solvent. TLC confirmed reaction completion after 2 
hrs. The reaction mixture was diluted with aq. NaHCO3 (50 mL) and extracted with EtOAc (3 × 
50 mL), the organic layer dried over MgSO4 and the solvent removed under reduced pressure. 
Purification by chromatography using a silica-gel column (20 g; EtOAc/hexane, 4:6) afforded 
product 131 as a white solid, (0.10 g, 28%). Mp. 125-126 oC; νmax /cm-1 (CHCl3): 3548s + 3439s 
(N-H, primary amine), 1639s (C=C, aromatic), 794m (C-Br, halogen); ¹H NMR (DMSO-D6, 400 
MHz) δH 2.39 (3H, s, SCH3), 5.50 (1H, s, H-5), 6.38 (2H, bs, NH2), 7.40 (2H, d, J = 8.8 Hz, H-2’, 
H-6’), 7.49 (2H, d, J = 8.8 Hz, H-3’, H-5’), 9.01 (1H, bs, NH); ¹³C NMR (DMSO-D6, 100 MHz) δC 
14.1 (SCH3), 82.1 (C-5), 113.2 (C-4’), 121.9 (C-3’, C-5’), 131.9 (C-2’, C-6’), 140.9 (C-1’), 160.8 
(C-6), 164.3 (C-4), 170.1 (C-2); HRMS (EI): m/z 309.98892 [M+]. Calculated for C11H11N4BrS, 
309.98878 [M+]; C, H, N Microanalysis found: C, 42.49; H, 3.66; N, 17.75; S, 10.27%; 






















A reaction vessel was charged with 4-amino-6-chloro-2-(methylthio)pyrimidine (0.40 g, 2.28 
mmol) and 4-aminobenzonitrile (0.64 g, 2.72 mmol) under a stream of argon gas. The two solids 
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after 1 hr. The reaction mixture was diluted with aq. NaHCO3 (50 mL) and extracted with EtOAc 
(3 × 50 mL), the organic layer dried over MgSO4 and the solvent removed under reduced 
pressure. Purification by chromatography using a silica-gel column (30 g; EtOAc/hexane, 4:6) 
afforded product 132 as a bright yellow solid, (0.20 g, 35%). Mp. 130-133 oC; νmax /cm-1 (CHCl3): 
3398s + 3439s (N-H, primary amine), 2223m (C-N, nitrile), 1633s (C=C, aromatic); ¹H NMR 
(DMSO-D6, 400 MHz) δH 2.41 (3H, s, SCH3), 5.60 (1H, s, H-5), 6.54 (2H, bs, NH2), 7.65 (2H, d, J 
= 8.8 Hz, H-2’, H-6’), 7.75 (2H, d, J = 8.8 Hz, H-3’, H-5’), 9.46 (1H, bs, NH); ¹³C NMR (DMSO-D6, 
100 MHz) δC 14.1 (SCH3), 83.2 (C-5), 102.5 (C-4’), 119.2 (C-3’, C-5’), 120.2 (CN), 133.7 (C-2’, 
C-6’), 146.1 (C-1’), 160.2 (C-6), 164.7 (C-4), 170.5 (C-2); HRMS (EI): m/z 257.07333 [M+]. 
Calculated for C12H11N5S, 257.07352 [M+]; C, H, N Microanalysis found: C, 55.93; H, 4.46; N, 





















A reaction vessel was charged with 4-amino-6-chloro-2-(methylthio)pyrimidine (0.10 g, 0.68 
mmol) and 4-cyano-2,6-dimethylaniline (0.12 g, 0.68 mmol) under a stream of argon gas. The 
two solids were heated to a melt at 200 oC without any use of solvent. TLC confirmed reaction 
completion after 3 hrs. The reaction mixture was diluted with NaHCO3 (50 mL) and extracted 
with EtOAc (3 × 50 mL), the organic layer dried over MgSO4 and the solvent removed under 
reduced pressure. Purification by chromatography using a silica-gel column (15 g; 
EtOAc/hexane, 2:8) afforded product 133 as a white solid, (0.07 g, 35%). Mp. 120-121 oC; νmax 
/cm-1 (CHCl3): 3411s (N-H, primary amine), 2251m (C-N, nitrile), 1633s (C=C, aromatic); ¹H 
NMR (DMSO-D6, 400 MHz) δH 2.07 (6H, s, ArCH3), 2.39 (3H, s, SCH3), 5.50 (2H, bs, NH2), 6.16 
(1H, s, H-5), 7.18 (2H, s, H-3’, H-5’), 7.22 (1H, bs, NH); ¹³C NMR (DMSO-D6, 100 MHz) δC 13.3 
(SCH3), 17.4 (ArCH3), 95.9 (C-4’), 98.5 (C-5), 120.9 (C-2’, C-6’), 129.2 (CN), 131.4 (C-3’, C-5’), 
149.8 (C-1’), 158.4 (C-6), 165.2 (C-4), 172.1 (C-2); C, H, N Microanalysis found: C, 60.09; H, 






































A reaction vessel was charged with 4-amino-6-chloro-2-(methylthio)pyrimidine (0.10 g, 0.57 
mmol) and 4-cyano-2-propyl-6-methylaniline (0.20 g, 1.14 mmol) under a stream of argon gas. 
The two solids were heated to a melt at 200 oC without any use of solvent. TLC confirmed 
reaction completion after 3 hrs. The reaction mixture was diluted with aq. NaHCO3 (50 mL) and 
extracted with EtOAc (3 × 50 mL), the organic layer dried over MgSO4 and the solvent removed 
under reduced pressure. Purification by chromatography using a silica-gel column (15 g; 
EtOAc/hexane, 2:8) afforded product 134 as a white solid, (0.10 g, 35%). Mp. 121-124 oC; νmax 
/cm-1 (CHCl3): 3411s (N-H, primary amine), 2251m (C-N, nitrile), 1633s (C=C, aromatic); ¹H 
NMR (DMSO-D6, 400 MHz) δH 0.96 (3H, t, J = 7.80 Hz, H-10’), 1.60 (2H, sext, J = 7.8 Hz, H-9’), 
2.11 (3H, s, H-7’), 2.38 (3H, s, SCH3), 2.45 (2H, t, J = 7.8 Hz, H-8’), 5.56 (2H, bs, NH2), 6.14 
(1H, s, H-5), 7.15 (2H, s, H-3’, H-5’), 7.25 (1H, bs, NH); ¹³C NMR (DMSO-D6, 100 MHz) δC 13.5 
(C-10’), 13.9 (SCH3), 17.4 (C-7’), 20.5 (C-9’), 32.6 (C-8’), 99.1 (C-4’), 99.6 (C-5), 120.6 (CN), 
121.4 (C-6’), 125.4 (C-2’), 130.3 (C-5’), 130.9 (C-3’), 151.7 (C-1’), 160.5 (C-6), 166.8 (C-4), 























To a solution of 4-amino-6-chloro-2-(methylthio)pyrimidine (0.10 g, 0.57 mmol) and 3-hydroxy-4-
chloroaniline (0.084 g, 0.57 mmol) dissolved in 1,4-dioxane (3 mL) was added anhydrous TsOH 
(98 mg, 0.57 mmol) at room temperature. The reaction mixture was heated to 100 oC and TLC 
confirmed reaction completion after 2 hrs. The reaction mixture was diluted with H2O (50 mL) 
and extracted with EtOAc (3 × 50 mL), the organic layer dried over MgSO4 and the solvent 
removed under reduced pressure. Purification by chromatography using a silica-gel column (20 
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νmax /cm-1 (CHCl3): 3434s (N-H, primary amine), 1657m (C=C, aromatic), 824m (C-Cl, halogen); 
¹H NMR (Acetone-D6, 300 MHz) δH 2.43 (3H, s, SCH3), 5.65 (1H, s, H-5), 5.76 (2H, bs, NH2), 
7.01 (1H, dd, J = 8.8, 3.0 Hz, H-6’), 7.18 (1H, d, J = 8.8 Hz, H-5’), 7.37 (1H, d, J = 3.0 Hz, H-2’), 
8.08 (1H, bs, NH), 8.58 (1H, bs, OH); ¹³C NMR (Acetone-D6, 75.5 MHz) δC 13.4 (SCH3), 81.3 (C-
5), 108.4 (C-2’), 112.1 (C-6’), 112.5 (C-4’), 129.6 (C-5’), 140.6 (C-1’), 153.0 (C-3’), 160.2 (C-6), 
163.8 (C-4), 169.7 (C-2); HRMS (ES): m/z 282.03339 [M+]. Calculated for C11H11N4OSCl, 
282.03336 [M+]; C, H, N Microanalysis found: C, 47.77; H, 4.14; N, 19.39; S, 9.86%; 



























To a solution of 128 (0.03 g, 0.10 mmol) dissolved in acetone (3 mL) was added anhydrous 
K2CO3 (17 mg, 0.12 mmol) at room temperature. Allyl bromide (0.01 mL, 0.13 mmol) was slowly 
added to this mixture followed by tert-butylammonium iodide (4 mg, cat.). The reaction mixture 
was left to react at room temperature and TLC confirmed reaction completion after 6 hrs. The 
reaction mixture was diluted with H2O (50 mL) and extracted with EtOAc (3 × 50 mL), the organic 
layer dried over MgSO4 and the solvent removed under reduced pressure. Purification by 
chromatography using a silica-gel column (5 g; EtOAc/hexane, 6:4) afforded product 129 as a 
brown viscous oil, (28 mg, 46%). Mp.151-153 oC; νmax /cm-1 (CHCl3): 3464s (N-H, primary 
amine), 1751s (C=C, alkene), 1657m (C=C, aromatic), 830m (C-Cl, halogen); ¹H NMR (Acetone-
D6, 300 MHz) δH 2.45 (3H, s, SCH3), 4.65 (2H, m, H-1’’), 5.28 (1H, d, Jcis = 10.7 Hz, H-3’’), 5.50 
(1H, d, Jtrans = 16.6 Hz, H-3’’), 5.67 (1H, s, H-5), 5.79 (2H, bs, NH2), 6.12 (1H, m, H-2’’), 7.06 (1H, 
dd, J = 8.8, 2.9 Hz, H-6’), 7.26 (1H, d, J = 8.8 Hz, H-5’), 7.55 (1H, d, J = 2.9 Hz, H-2’), 8.19 (1H, 
bs, NH); ¹³C NMR (Acetone-D6, 75.5 MHz) δC 13.1 (SCH3), 69.5 (C-1’’), 81.4 (C-5), 106.4 (C-2’), 
112.8 (C-6’), 115.0 (C-4’), 117.1 (C-3’’), 129.8 (C-5’), 133.4 (C-2’’), 141.1 (C-1’), 154.3 (C-3’), 
160.8 (C-6), 164.3 (C-4), 170.5 (C-2); HRMS (ES): m/z 323.0732 [M+H]+. Calculated for 






































To a solution of 4-amino-6-chloro-2-(methylthio)pyrimidine (0.12 g, 0.68 mmol) and 4-chloro-3-
prop-2-ynyloxyaniline (0.16 g, 0.68 mmol) dissolved in 1,4-dioxane (3 mL) was added anhydrous 
p-TsOH (0.12 mg, 0.68 mmol) at room temperature. The reaction mixture was heated to 100 oC 
and TLC confirmed reaction completion after 6 hrs. The reaction mixture was diluted with H2O 
(50 mL) and extracted with EtOAc (3 × 50 mL), the organic layer dried over MgSO4 and the 
solvent removed under reduced pressure. Purification by chromatography using a silica-gel 
column (15 g; EtOAc/hexane, 5:5) afforded product 130 as a brown precipitate, (105 mg, 49%). 
Mp.167-168,νmax /cm-1 (CHCl3): 3434s (N-H, primary amine), 2253s (C≡C, alkyne), 824m (C -Cl, 
halogen); ¹H NMR (Acetone-D6, 300 MHz) δH 2.46 (3H, s, SCH3), 2.46 (1H, t, J = 2.4 Hz, H-3’’), 
4.86 (2H, d, J = 2.4 Hz, H-1’’), 5.69 (1H, s, H-5), 5.80 (2H, bs, NH2), 7.18 (1H, dd, J = 8.8, 3.0 
Hz, H-6’), 7.29 (1H, d, J = 8.8 Hz, H-5’), 7.58 (1H, d, J = 3.0 Hz, H-2’), 8.21 (1H, bs, NH); ¹³C 
NMR (Acetone-D6, 75.5 MHz) δC 13.8 (SCH3), 56.9 (C-1’’), 76.4 (C-3’’), 77.9 (C-2’’), 80.4 (C-5), 
108.8 (C-2’), 112.7 (C-6’), 115.8 (C-4’), 130.6 (C-5’), 138.5 (C-1’), 153.5 (C-3’), 160.7 (C-6), 










































Alkyne 130 (80 mg, 0.22 mmol) was added together with 5-iodo-d4U 5’-benzoate (88 mg, 0.19 
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(v/v), 3 mL) was then added to the reaction vessel whilst the mixture stirred at room temperature 
under nitrogen. Subsequent addition of triethylamine (0.05 mL, 0.38 mmol) was followed by 
addition of copper(I) iodide (19 mg, 0.10 mmol) and tetrakis(triphenylphosphine)palladium (22 
mg, 0.02 mmol) respectively. The reaction was stirred continuously at room temperature and 
TLC confirmed completion of the reaction after 2 hrs. The reaction mixture was diluted with a 5% 
EDTA solution (30 mL) and extracted with chloroform (3 × 20 mL). The organic fractions were 
dried with MgSO4 and the solvent removed under reduced pressure. Purification by 
chromatography using a silica-gel column afforded product 135 as a colourless solid, (100 mg, 
83%). [α]D +12.2° (c = 1.03, acetone); νmax /cm-1 (Acetone): 2254s (C≡C), 1720s (C=O, ester), 
1693s (C=O, pyrimidine), 1599s (C-N stretching), 1514s + 1492s (C=C, aromatic); 1H NMR (300 
MHz, Acetone-D6): δH 2.45 (3H, s, SCH3), 4.56 (1H, dd, J = 12.4, 3.0 Hz, H-1), 4.57 (1H, dd, J = 
12.4, 4.4 Hz, H-1), 4.85 (2H, s, H-15), 5.25 (1H, m, H-2), 5.74 (1H, s, H-28), 5.82 (2H, bs, NH2), 
6.10 (1H, m, H-3), 6.58 (1H, dt, J = 6.0, 1.7 Hz, H-4), 6.81 (1H, m, H-5), 7.17 (1H, dd, J = 8.6, 
2.3 Hz, H-19), 7.26 (1H, d, J = 8.6 Hz, H-18), 7.45-7.60 (4H, m, H-21, OBz), 7.80 (1H, s, H-12), 
8.00 (2H, m, OBz), 8.20 (1H, bs, N-H), 10.40 (1H, bs, N-H); 13C NMR (75 MHz, Acetone-D6): δC 
13.2 (SCH3), 57.3 (C-15), 65.5 (C-1), 79.7 (C-11), 81.4 (C-28), 85.2 (C-2), 87.6 (C-13), 90.9 (C-
5), 98.8 (C-14), 106.9 (C-21), 113.9 (C-19), 115.3 (C-17), 126.9 (C-3), 128.9 (C-Bz), 129.7 (C-
18), 130.1 (C-Bz), 132.1 (C-Bz), 133.5 (C-Bz), 134.0 (C-4), 140.9 (C-20), 144.1 (C-12), 149.8 (C-
8), 153.5 (C-16), 160.8 (C-27), 161.1 (C-10), 164.3 (C-23), 166.0 (OCOC6H5), 170.8 (C-25); 







































Sodium methoxide in methanol (1.97 M, 1 drop, cat.) was added to methanol (3 mL) at 0oC. This 
was followed by addition of 135 (35 mg, 0.05 mmol) at 0oC and the reaction mixture was left to 
stir at room temperature. After 1 hr, the reaction mixture was diluted with dichloromethane (2mL) 
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[α]D +13.4° (c = 1.21, acetone); νmax /cm-1 (Acetone): 3592b (O-H), 2254 (C≡C), 1693 (C=O, 
pyrimidine), 1599 (C-N stretching), 1514 + 1492 (C=C, aromatic); 1H NMR (300 MHz, Acetone-
D6): δH 2.45 (3H, s, SCH3), 3.82 (2H, m, H-1), 4.29 (1H, bs, OH), 4.87 (1H, m, H-2), 5.00 (2H, s, 
H-15), 5.75 (1H, s, H-28), 5.81 (2H, bs, NH2),  5.95 (1H, m, H-3), 6.42, (1H, m, H-4), 6.92 (1H, 
m, H-5), 7.24 (1H, dd, J = 8.6, 2.3 Hz, H-19), 7.26 (1H, d, J = 8.6 Hz, H-18), 7.50 (1H, d, J = 2.3 
Hz, H-21), 8.19 (1H, bs, N-H), 8.28 (1H, s, H-12), 10.24 (1H, s, N-H); 13C NMR (75 MHz, 
Acetone-D6): δC  13.1 (SCH3), 57.3 (C-15), 62.7 (C-1), 80.3 (C-11), 81.3 (C-28), 87.0 (C-13), 
88.1 (C-2), 90.2 (C-5), 97.9 (C-14), 107.0 (C-21), 114.0 (C-19), 115.3 (C-17), 126.1 (C-3), 130.1 
(C-18), 135.6 (C-4), 140.9 (C-20), 146.1 (C-12), 149.9 (C-8), 153.5 (C-16), 160.8 (C-27), 161.5 
(C-10), 164.4 (C-23), 171.0 (C-25); HRMS (ES): m/z 529.1073 [M+H]+. Calculated for 




















To a solution of 2-chloro-4-methoxypyrimidine (440 mg, 3.00 mmol) dissolved in 1,4-dioxane (7 
mL) was added anhydrous p-TsOH (430 mg, 2.50 mmol) at room temperature. To this mixture 
was added 3-amino-6-chlorophenol 119b (364 mg, 2.50 mmol) and the reaction mixture was 
heated to 100 oC. TLC confirmed reaction completion after 12 hrs. The reaction mixture was 
diluted with aq. NaHCO3 (50 mL) and extracted with EtOAc (3 × 50 mL), the organic layer dried 
over MgSO4 and the solvent removed under reduced pressure. Purification by chromatography 
using a silica-gel column (40 g; EtOAc/hexane, 3:7) afforded product 136 as a white solid, (600 
mg, 95%). Mp. 154-155 oC; νmax /cm-1 (CHCl3): 3387s + 3321s (NH), 2978m + 2930m (CH, 
aromatic), 1638s (C=C, aromatic), 738s (C-Cl, halogen); ¹H NMR (Acetone-D6, 400 MHz) δH 
2.85 (1H, bs, OH), 3.93 (3H, s, OCH3), 6.23 (1H, d, J = 5.7 Hz, H-5), 7.21 (1H, d, J = 8.7 Hz, H-
5'), 7.27 (1H, dd, J = 8.7, 2.4 Hz, H-6'), 7.72 (1H, d, J = 2.4 Hz, H-2'), 8.16 (1H, d, J = 5.7 Hz, H-
6), 8.46 (1H, bs, NH); ¹³C NMR (Acetone-D6, 100 MHz) δC 53.3 (OCH3), 99.2 (C-5), 107.8 (C-2'), 
111.7 (C-6'), 113.0 (C-4'), 129.6 (C-5'), 141.0 (C-1'), 152.6 (C-3'), 158.3 (C-6), 160.0 (C-4), 170.2 
(C-2); HRMS (ES): m/z 252.0544 [M+H]+. Calculated for C11H11N3O2Cl, 252.0540 [M+H]+; C, H, 



































To a solution of 2-chloro-4-methoxypyrimidine (1.10 g, 7.60 mmol) dissolved in 1,4-dioxane (20 
mL) was added anhydrous p-TsOH (1.10 g, 6.30 mmol) at room temperature. To this mixture 
was added substituted aniline 120 (1.15 g, 6.30 mmol) and the reaction mixture was heated to 
100 oC. TLC confirmed reaction completion after 12 hrs. The reaction mixture was diluted with 
aq. NaHCO3 (50 mL) and extracted with EtOAc (3 × 50 mL), the organic layer dried over MgSO4 
and the solvent removed under reduced pressure. Purification by chromatography using a silica-
gel column (70 g; EtOAc/hexane, 2:8) afforded product 137 as a white solid, (1.32 g, 73%). Mp. 
123-124 oC; νmax /cm-1 (CHCl3): 3377s + 3339s (NH, amine), 2259s (C≡C), 1627s (C=C, 
aromatic), 725s (C-Cl, halogen); ¹H NMR (Acetone-D6, 400 MHz) δH 3.10  (1H, t, J = 2.40 Hz, H-
3''), 3.98 (3H, s, OCH3), 4.87 (1H, d, J = 2.4 Hz, H-1''), 6.26 (1H, d, J = 5.7 Hz, H-5), 7.30 (1H, d, 
J = 8.7 Hz, H-5'), 7.45 (1H, dd, J = 8.7, 2.4 Hz, H-6'), 7.96 (1H, d, J = 2.4 Hz, H-2'), 8.19 (1H, d, 
J = 5.7 Hz, H-6), 8.71 (1H, bs, NH); ¹³C NMR (Acetone-D6, 100 MHz) δC 53.6 (OCH3), 56.6 (C-
1''), 76.8 (C-3''), 78.7 (C-2''), 99.5 (C-5), 105.9 (C-2'), 112.8 (C-6'), 114.1 (C-4'), 129.9 (C-5'), 
140.8 (C-1'), 153.8 (C-3'), 158.4 (C-6), 160.0 (C-4), 170.4 (C-2); HRMS (ES): m/z 290.0703 
[M+H]+. Calculated for C14H13N3O2Cl, 290.0696 [M+H]+; C, H, N Microanalysis found: C, 58.00; 
H, 4.40; N, 14.64%; C14H12N3O2Cl requires C, 58.04; H, 4.17; N, 14.50%. 
 
5-{3-[5-(4-Methoxy-1,3-pyrimidin-2-yl)amino-2-chlorophenoxy]prop-1-ynyl}uridine-2’,3’-
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Alkyne 137 (140 mg, 0.48 mmol) was added together with 5-iodo-d4U 5’-benzoate (195 mg, 0.44 
mmol) and the mixture dried carefully on a vacuum pump. A mixture of degassed DMF:THF (1:2 
(v/v), 3 mL) was then added to the reaction vessel whilst the mixture stirred at room temperature 
under nitrogen. Subsequent addition of triethylamine (0.13 mL, 0.88 mmol) was followed by 
addition of copper(I) iodide (42 mg, 0.22 mmol) and tetrakis(triphenylphosphine)palladium (51 
mg, 0.04 mmol) respectively. The reaction was stirred continuously at room temperature and 
TLC confirmed completion of the reaction after 5 hrs. The reaction mixture was diluted with a 5% 
EDTA solution (30 mL) and extracted with chloroform (3 × 20 mL). The organic fractions were 
dried with MgSO4 and the solvent removed under reduced pressure. Purification by 
chromatography using a silica-gel column afforded product 138 as a colourless solid, (145 mg, 
55%). [α]D +10.9° (c = 1.01, acetone); νmax /cm-1 (Acetone): 2255s (C≡C), 1723s (C=O, ester), 
1688s (C=O, pyrimidine), 1598s (C-N stretching), 1516s + 1488s (C=C, aromatic), 726s (C-Cl, 
halogen); Mp. 99–102 oC; ¹H NMR (DMSO-D6, 300 MHz) δH 3.92 (3H, s, OCH3), 4.45 (2H, d, J = 
3.9 Hz, H-1), 4.85 (2H, s, H-15), 5.13 (1H, s, H-2), 6.05 (1H, m, H-3), 6.28 (1H, d, J = 5.7 Hz, H-
26), 6.46 (1H, dt, J = 6.0, 1.6 Hz, H-4), 6.72 (1H, m, H-5), 7.26 (1H, d, J = 8.7 Hz, H-18), 7.34 
(1H, dd, J = 8.7, 2.2 Hz, H-19), 7.46 (2H, t, J = 7.3 Hz, Bz-m), 7.58 (1H, t, J = 7.3 Hz, Bz-p), 7.65 
(1H, s, H-12), 7.85 (2H, d, J = 7.3 Hz, Bz-o), 7.89 (1H, d, J = 2.2 Hz, H-21), 8.19 (1H, d, J = 5.7 
Hz, H-27), 9.61 (1H, bs, NH), 11.67 (1H, bs, NH); ¹³C NMR (DMSO-D6, 75.5 MHz) δC 53.2 
(OCH3), 56.9 (C-15), 65.2 (C-1), 79.3 (C-11), 84.3 (C-13), 87.2 (C-2), 90.3 (C-5), 97.7 (C-14), 
98.8 (C-26), 105.0 (C-21), 112.4 (C-19), 113.3 (C-17), 126.3 (C-3), 128.7 (Bz-m), 129.0 (Bz-o), 
129.1 (Bz-p), 129.4 (C-18), 133.2 (Bz-i), 133.7 (C-4), 140.6 (C-20), 143.8 (C-12), 149.4 (C-8), 
152.4 (C-16), 158.2 (C-27), 159.4 (C-25), 161.2 (C-10), 165.4 (OCOC6H5), 169.4 (C-23); HRMS 
(ES): m/z 602.1449  [M+H]+. Calculated for C30H25N5O7Cl, 602.1443 [M+H]+; C, H, N 
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5-{3-[5-(4-Methoxy-1,3-pyrimidin-2-yl)amino-2-chlorophenoxy]prop-1-ynyl}-2’,3’-didehydro 



































Sodium methoxide (1.97 M) in methanol (0.05 mL, 0.08 mmol) was added to methanol (5 mL) at 
0oC. This was followed by addition of 138 (50 mg, 0.08 mmol) at 0oC and the reaction mixture 
was left to stir at room temperature. After 2 hr, the reaction mixture was diluted with 
dichloromethane (2mL) and flash chromatography performed directly affording product 115 as a 
white solid, (35 mg, 88%). Mp. 102-106oC; [α]D +11.9° (c = 1.02, acetone); νmax /cm-1 (Acetone): 
3590b (O-H), 2248 (C≡C), 1692 (C=O, pyrimidine), 1599 (C-N stretching), 1510 + 1472 (C=C, 
aromatic), 720s (C-Cl, halogen); ¹H NMR (DMSO-D6, 300 MHz) δH 3.64 (2H, m, H-1), 4.01 (3H, 
s, OCH3), 4.86 (1H, m, H-2), 5.04 (1H, bs, OH), 5.06 (2H, s, H-15), 5.96 (1H, m, H-3), 6.36 (1H, 
d, J = 5.7 Hz, H-26), 6.45 (1H, m, H-4), 6.83 (1H, m, H-5), 7.35 (1H, d, J = 8.7 Hz, H-18), 7.42 
(1H, dd, J = 8.7, 2.2 Hz, H-19), 7.93 (1H, d, J = 2.2 Hz, H-21), 8.17 (1H, s, H-12), 8.27 (1H, d, J 
= 5.7 Hz, H-27), 9.60 (1H, bs, NH), 11.65 (1H, bs, NH); ¹³C NMR (DMSO-D6, 75.5 MHz) δC 53.3 
(OCH3), 57.0 (C-15), 61.8 (C-1), 79.7 (C-11), 86.8 (C-13), 87.6 (C-2), 89.5 (C-5), 97.0 (C-14), 
98.8 (C-26), 105.1 (C-21), 112.5 (C-19), 113.3 (C-17), 125.4 (C-3), 129.4 (C-18), 135.4 (C-4), 
140.5 (C-20), 145.4 (C-12), 149.6 (C-8), 152.5 (C-16), 158.2 (C-27), 159.4 (C-25), 161.3 (C-10), 
169.4 (C-23); HRMS (ES): m/z 498.1184 [M+H]+. Calculated for C23H21N5O6Cl, 498.1180 [M+H]+; 
C, H, N Microanalysis found: C, 55.47; H, 3.56; N, 14.71%; C23H20N5O6Cl requires C, 55.48; H, 
4.05; N, 14.09%. 
 









Benzyl bromide (7.60 mL, 64.4 mmol) was added dropwise to a suspension of NaH (60%, 1.55 
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mixture was diluted with EtOAc (60 mL) and washed with aq. NH4Cl (40 mL) and H2O (2 × 40 
mL), the organic layer dried over MgSO4 and the solvent removed under reduced pressure. The 
crude product was purified by distillation [bp: 102 oC/0.7 mm Hg (lit. 90-95 oC/0.7 mm Hg)] to 
give product 140 as a colourless oil, (5.19 g, 53%). ¹H NMR (CDCl3, 300 MHz) δH 2.52 (1H, s, 
OH), 3.58 (2H, t, J = 4.6 Hz, H-1), 3.74 (2H, t, J = 4.6 Hz, H-2), 4.56 (2H, s, ArCH2O), 7.34 (5H, 
m, ArH); ¹³C NMR (CDCl3, 75.5 MHz) δC 61.8 (C-1), 71.5 (C-2), 73.3 (ArCH2O), 127.8, 128.4, 
128.7 (ArCH), 138.0 (C-1’). 
 









To a solution of the alcohol 140 (2.00 g, 13.1 mmol) and PPh3 (4.14 g, 15.8 mmol) in CH2Cl2 (20 
mL) was added CBr4 (5.23 g, 15.8 mmol) at 0 oC. The reaction mixture was stirred at 0 oC for 30 
min and the solvent removed under reduced pressure. Purification by chromatography afforded 
product 141 as a colourless oil, (2.68 g, 95%). ¹H NMR (CDCl3, 300 MHz) δH 3.50 (2H, t, J = 6.2 
Hz, H-1), 3.80 (2H, t, J = 6.2 Hz, H-2), 4.60 (2H, s, ArCH2O), 7.36 (5H, m, ArH); ¹³C NMR 
(CDCl3, 75.5 MHz) δC 30.4 (C-1), 70.0 (C-2), 73.1 (ArCH2O), 127.7, 127.8, 128.5 (ArCH), 137.8 
(C-1’). 
 
























To a solution of 136 (500 mg, 2.00 mmol) dissolved in acetone (20 mL) was added anhydrous 
K2CO3 (550 mg, 4.00 mmol) at room temperature. 1-(2-Bromoethoxy)benzyl ether 141 (1.30 g, 
6.00 mmol) was slowly added to this mixture followed by tetra-butylammonium iodide (50 mg, 
cat.). The reaction mixture was left to react at room temperature. After 16 hrs the mixture was 
diluted with H2O (100 mL) and extracted with EtOAc (3 × 100 mL), the organic layer dried over 
MgSO4 and the solvent removed under reduced pressure. Purification by chromatography 
afforded product 142 as a white solid, (791 mg, 100%). Mp. 121–122oC; νmax /cm-1 (Acetone): 
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halogen); ¹H NMR (Acetone-D6, 300 MHz) δH 3.90 (2H, t, J = 4.8 Hz, H-2''), 3.95 (3H, s, OCH3), 
4.29 (2H, t, J = 4.8 Hz, H-1''), 4.67 (2H, s, H-3''), 6.25 (1H, d, J = 5.7 Hz, H-5), 7.25-7.42 (7H, m, 
H-5', H-6', Ph ), 7.88 (1H, d, J = 2.2 Hz, H-2'), 8.18 (1H, d, J = 5.7 Hz, H-6), 8.61 (1H, bs, NH); 
¹³C NMR (Acetone-D6, 75.5 MHz) δC 53.2 (OCH3), 68.5 (C-2''), 68.9 (C-1''), 72.9 (C-3''), 99.4 (C-
5), 105.2 (C-2'), 112.1 (C-6'), 114.7 (C-4'), 127.5 (Bn-m), 127.6 (Bn-p), 128.4 (Bn-o), 129.7 (C-
5'), 139.1 (Bn-i), 140.9 (C-1'), 154.6 (C-3'), 158.4 (C-6), 160.1 (C-4), 170.3 (C-2); HRMS (ES): 
m/z 386.1261 [M+H]+. Calculated for C20H21N3O3Cl, 386.1271 [M+H]+; C, H, N Microanalysis 
























The benzyl ether 142 (750 mg, 1.94 mmol) was dissolved in absolute ethanol (10 mL) and 
stirred at room temperature. Subsequent addition of palladium-on-carbon (10%, 200 mg, 0.19 
mmol) was followed by careful placement of a hydrogen gas balloon over the reaction flask. The 
reaction never went to completion even after 2 days of stirring. The reaction mixture was filtered 
through a Celite-packed sintered funnel and washed with EtOAc (100 mL). Purification by 
chromatography using a silica-gel column (20 g; EtOAc/hexane, 5:5) afforded product 143 as a 
colourless oil, (401 mg, 70%). νmax /cm-1 (Acetone): 3594b (O-H), 3377s + 3339s (NH, amine), 
1514 + 1492 (C=C, aromatic), 723s (C-Cl, halogen); ¹H NMR (Acetone-D6, 400 MHz) δH 3.93 
(2H, t, J = 4.8 Hz, H-2''), 3.96 (3H, s, OCH3), 4.17 (2H, t, J = 4.8 Hz, H-1''), 6.26 (1H, d, J = 5.7 
Hz, H-5), 7.26 (1H, d, J = 8.7 Hz, H-5'), 7.39 (1H, dd, J = 8.7, 2.3 Hz, H-6'), 7.86 (1H, d, J = 2.3 
Hz, H-2'), 8.18 (1H, d, J = 5.7 Hz, H-6), 8.62 (1H, bs, NH); ¹³C NMR (Acetone-D6, 100 MHz) δC 
53.9 (OCH3), 60.8 (C-2''), 70.9 (C-1''), 99.4 (C-5), 104.7 (C-2'), 112.1 (C-6'), 114.7 (C-4'), 130.2 
(C-5'), 140.9 (C-1'), 154.7 (C-3'), 158.3 (C-6), 161.0 (C-4), 170.6 (C-2); HRMS (ES): m/z 














































Alcohol 143 (150 mg, 0.51 mmol) was dissolved in dichloromethane (5 mL). Triethylamine (0.10 
mL, 0.51 mmol) was added at 0oC followed by a catalytic amount of DMAP (0.60 mg, 0.005 
mmol) to the reaction mixture. p-Toluenesulfonyl chloride (145 mg, 0.76 mmol) in 
dichloromethane (2 mL) was then added dropwise and the solution left to stir at room 
temperature. TLC confirmed completion of the reaction after 4hrs. The reaction mixture was 
diluted with brine (50 mL) and extracted with dichloromethane (3 × 50 mL). The organic fractions 
were dried with MgSO4 and removed under reduced pressure. Purification by chromatography 
using a silica-gel column (10 g; EtOAc/hexane, 5:5) afforded product 144 as a white solid, (160 
mg, 70%). Mp. 118-122oC; νmax /cm-1 (Acetone): 3377s + 3339s (NH, amine), 1514 + 1492 (C=C, 
aromatic), 1369s + 1177s (-SO2-O-), 723s (C-Cl, halogen); ¹H NMR (Acetone-D6, 400 MHz) δH 
2.43 (3H, s, ArCH3), 3.94 (3H, s, OCH3), 4.34 (2H, t, J = 4.4 Hz, H-2''), 4.46 (2H, t, J = 4.4 Hz, H-
1''), 6.25 (1H, d, J = 5.7 Hz, H-5), 7.26 (1H, d, J = 8.7 Hz, H-5'), 7.38 (1H, dd, J = 8.7, 2.2 Hz, H-
6'), 7.45 (2H, d, J = 8.6 Hz, Ar-m), 7.79 (1H, d, J = 2.2 Hz, H-2'), 7.84 (2H, d, J = 8.6 Hz, Ar-o), 
8.18 (1H, d, J = 5.7 Hz, H-6), 8.61 (1H, bs, NH); ¹³C NMR (Acetone-D6, 100 MHz) δC 20.8 (Ar-
CH3), 53.3 (OCH3), 66.8 (C-2''), 68.7 (C-1''), 99.4 (C-5), 105.3 (C-2'), 112.6 (C-6'), 114.8 (C-4'), 
128.0 (Ar-o), 129.9 (C-5'), 130.1 (Ar-m), 133.6 (Ar-p), 140.9 (C-1'), 145.5 (Ar-i), 154.2 (C-3'), 
158.3 (C-6), 160.3 (C-4), 170.2 (C-2); HRMS (ES): m/z 450.0876 [M+H]+. Calculated for 
C20H21N3SO5Cl, 450.0890 [M+H]+; C, H, N Microanalysis found: C, 53.24; H, 4.73; N, 9.42; S, 


















































To a suspension of sodium hydride (60%, 50 mg, 1.24 mmol) suspension in THF (7 mL) at 0oC, 
was added propargyl alcohol (0.11 mL, 1.87 mmol) slowly whilst stirring. To this was added 
tosylate 144 (140 mg, 0.31 mmol) and the reaction mixture refluxed. TLC confirmed completion 
after a total of 20 hrs. The reaction mixture was diluted with aq. NH4Cl (50 mL) and extracted 
with EtOAc (3 × 50 mL). The organic fractions were dried with MgSO4 and removed under 
reduced pressure. Purification by chromatography using a silica-gel column (10 g; 
EtOAc/hexane, 4:6) afforded product 145 as a colourless oil, (822 mg, 98%). νmax /cm-1 
(Acetone): 3365s + 3340s (NH, amine), 2251 (C≡C), 1517 + 1450 (C=C, aromatic), 723s (C-Cl, 
halogen);  ¹H NMR (CDCl3, 300 MHz) δH 2.45 (1H, t, J = 2.4 Hz, H-5''), 3.95 (3H, s, OCH3), 3.96 
(2H, t, J = 4.9 Hz, H-2''), 4.23 (2H, t, J = 4.9 Hz, H-1''), 4.32 (2H, d, J = 2.4 Hz, H-3''), 6.22 (1H, 
d, J = 5.7 Hz, H-5), 7.01 (1H, dd, J = 8.6, 2.4 Hz, H-6'), 7.14 (1H, bs, NH), 7.26 (1H, d, J = 8.6 
Hz, H-5'), 7.58 (1H, d, J = 2.4 Hz, H-2'), 8.13 (1H, d, J = 5.7 Hz, H-6); ¹³C NMR (CDCl3, 100 
MHz) δC 53.7 (OCH3), 56.1 (C-3''), 61.1 (C-2’’), 70.8 (C-1’’), 76.8 (C-5''), 78.3 (C-4''), 99.4 (C-5), 
105.9 (C-2'), 112.2 (C-6'), 114.2 (C-4'), 129.8 (C-5'), 140.2 (C-1'), 153.8 (C-3'), 158.2 (C-6), 


































































Alkyne 145 (55 mg, 0.16 mmol) was added together with 5-iodo-d4U 5’-benzoate (66 mg, 0.15 
mmol) and the mixture dried carefully on a vacuum pump. A mixture of degassed DMF:THF (1:2 
(v/v), 3 mL) was then added to the reaction vessel whilst the mixture stirred at room temperature 
under nitrogen. Subsequent addition of triethylamine (0.04 mL, 0.30 mmol) was followed by 
addition of copper(I) iodide (14 mg, 0.08 mmol) and tetrakis(triphenylphosphine)palladium (17 
mg, 0.02 mmol) respectively. The reaction was stirred continuously at room temperature and 
TLC confirmed completion of the reaction after 4 hrs. The reaction mixture was diluted with a 5% 
EDTA solution (30 mL) and extracted with chloroform (3 × 20 mL). The organic fractions were 
dried with MgSO4 and the solvent removed under reduced pressure. Purification by 
chromatography using a silica-gel column afforded product 146 as a colourless oil, (68 mg, 
70%). [α]D +9.4° (c = 1.01, acetone); νmax /cm-1 (Acetone): 2254s (C≡C), 1720s (C=O, ester), 
1693s (C=O, pyrimidine), 1599s (C-N stretching), 1514s + 1492s (C=C, aromatic); ¹H NMR 
(DMSO-D6, 400 MHz) δH 3.77 (2H, t, J = 4.6 Hz, H-16), 3.91 (3H, s, OCH3), 4.14 (2H, t, J = 4.6 
Hz, H-17), 4.26 (2H, s, H-15), 4.49 (2H, s, H-1), 5.15 (1H, m, H-2), 6.09 (1H, m, H-3), 6.29 (1H, 
d, J = 5.7 Hz, H-28), 6.52 (1H, m, H-4), 6.76 (1H, m, H-5), 7.26 (1H, d, J = 8.7 Hz, H-20), 7.33 
(1H, dd, J = 8.7, 2.1 Hz, H-21), 7.54 (2H, t, J = 8.0 Hz, Bz-m), 7.62 (1H, t, J = 8.0 Hz, Bz-p), 7.66 
(1H, s, H-12), 7.75 (1H, d, J = 2.1 Hz, H-23), 7.93 (2H, d, J = 8.0 Hz, Bz-o), 8.21 (1H, d, J = 5.7 
Hz, H-29), 9.59 (1H, bs, NH), 11.70 (1H, bs, NH); ¹³C NMR (DMSO-D6, 100 MHz) δC 53.4 
(OCH3), 58.3 (C-15), 65.2 (C-1), 67.4 (C-16), 67.8 (C-17), 77.7 (C-11), 84.3 (C-13), 88.8 (C-2), 
90.1 (C-5), 98.1 (C-14), 98.7 (C-28), 104.6 (C-23), 111.8 (C-21), 113.2 (C-19), 126.2 (C-3), 
128.5 (Bz-m), 129.3 (Bz-p), 131.8 (Bz-o), 132.2 (Bz-i), 133.3 (C-20), 133.6 (C-4), 140.5 (C-22), 
143.0 (C-12), 149.5 (C-8), 153.4 (C-18), 156.2 (C-29), 159.3 (C-27), 161.3 (C-10), 165.6 
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5-{6-[5-(4-Methoxy-1,3-pyrimidin-2-yl)amino-2-chlorophenoxy]hexa-4-oxa-1-ynyl}-2’,3’-








































Sodium methoxide (1.97 M) in methanol (0.02 mL, 0.04 mmol) was added to methanol (3 mL) at 
0oC. This was followed by addition of 146 (25 mg, 0.04 mmol) at 0oC and the reaction mixture 
was left to stir at room temperature. After 2 hr, the reaction mixture was diluted with 
dichloromethane (2mL) and flash chromatography performed directly affording product 116 as a 
clear oil, (11 mg, 51%). [α]D +8.3° (c = 1.24, acetone); νmax /cm-1 (Acetone): 3590b (O-H), 2248 
(C≡C), 1692 (C=O, pyrimidine), 1599 (C-N stretching), 1510 + 1472 (C=C, aromatic), 720s (C-
Cl, halogen); ¹H NMR (DMSO-D6, 300 MHz) δH 3.61 (2H, m, H-1), 3.84 (2H, t, J = 4.5 Hz, H-16), 
3.93 (3H, s, OCH3), 4.17 (2H, t, J = 4.5 Hz, H-17), 4.42 (2H, s, H-15), 4.82 (1H, m, H-2), 4.97 
(1H, bs, OH), 5.94 (1H, m, H-3), 6.29 (1H, d, J = 5.7 Hz, H-28), 6.40 (1H, m, H-4), 6.79 (1H, m, 
H-5), 7.26 (1H, d, J = 8.7 Hz, H-20), 7.35 (1H, dd, J = 8.7, 2.2 Hz, H-21), 7.74 (1H, d, J = 2.2 Hz, 
H-23), 8.11 (1H, s, H-12), 8.22 (1H, d, J = 5.7 Hz, H-29), 9.52 (1H, bs, NH), 11.54 (1H, bs, NH); 
¹³C NMR (DMSO-D6, 75.5 MHz) δC 52.1 (OCH3), 57.9 (C-15), 64.8 (C-1), 66.5 (C-16), 66.7 (C-
17), 76.2 (C-11), 83.5 (C-13), 87.7 (C-2), 89.2 (C-5), 97.2 (C-14), 97.5 (C-28), 103.6 (C-23), 
110.9 (C-21), 112.5 (C-19), 125.1 (C-3), 132.4 (C-20), 132.2 (C-4), 139.7 (C-22), 142.1 (C-12), 
148.5 (C-8), 152.8 (C-18), 157.8 (C-29), 158.3 (C-27), 160.0 (C-10), 168.9 (C-25); HRMS (ES): 















To a solution of sodium hydroxide (16 g, 390 mmol) in water (140 mL) was added 2-thiouracil 
(25.63 g, 200 mmol). This was followed by methyl iodide (14 mL) and the reaction mixture stirred 
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the precipitate collected after being washed several times with cold water (3 × 50 mL). Drying 
over P2O5 afforded compound 161 as a white solid, (20.7 g, 73%). Mp. 185-188 oC (lit. = 188-
189 oC); νmax /cm-1 (Acetone): 1687 (C=O, pyrimidine), 1600 (C-N stretching), 1512 + 1493 (C=C, 
aromatic); ¹H NMR (DMSO-D6, 400 MHz) δH 2.43 (3H, s, SCH3), 6.05 (1H, d, J = 6.5 Hz, H-5), 
6.65 (1H, bs, NH), 7.82 (1H, d, J = 6.5 Hz, H-6); ¹³C NMR (DMSO-D6, 100 MHz) δC 12.8 (SCH3), 
109.1 (C-5), 153.5 (C-6), 164.0 (C-2), 164.1 (C-4); HRMS (ES): m/z 143.0276 [M+H]+. 





















2-(Methylthio)pyrimidin-4(3H)-one 161 (5.00 g, 35.2 mmol) was dissolved in diglyme (25 mL) and 
to this was added 4-aminobenzonitrile (5.00 g, 42.0 mmol). The mixture was refluxed for 18 hrs 
according to the known procedure, where after cooling, diethyl ether (20 mL) was added and the 
desired compound precipitated. The precipitate was filtered and after recrystallization from 
boiling methanol (10 mL) afforded product 162 as a yellow solid, (2.65 g, 36%). Mp. 260-261 oC 
(lit. = 259-260 oC); νmax /cm-1 (Acetone): 2210s (C-N, nitrile), 1687 (C=O, pyrimidine), 1600 (C-N 
stretching), 1512 + 1493 (C=C, aromatic); ¹H NMR (DMSO-D6, 400 MHz) δH 6.00 (1H, d, J = 6.3 
Hz, H-5), 6.08 (1H, bs, NH), 6.60 (1H, s, NH), 7.36 (1H, d, J = 6.3 Hz, H-6), 7.71 (2H, d, J = 8.7 
Hz, H-3'), 7.81 (2H, d, J = 8.7 Hz, H-2'); ¹³C NMR (DMSO-D6, 100 MHz) δC 101.7 (C-4'), 108.9 
(C-5), 118.7 (C-3'/C-5’), 118.9 (C≡N), 132.7 (C-2'/C-6’), 145.9 (C-1'), 153.3 (C-6), 160.0 (C-2), 
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2-[(4-Cyanophenyl)amino]pyrimidin-4(3H)-one 162 (500 mg, 2.30 mmol) was dissolved in neat 
phosphorus oxychloride (5 mL, excess) and the reaction mixture heated to 100 oC. TLC 
confirmed reaction completion after 5 hrs. The mixture was cooled to 0 oC and diluted with H2O 
(10 mL), aq. NaHCO3 (50 mL) and extracted with EtOAc (3 × 50 mL), the organic layer dried 
over MgSO4 and the solvent removed under reduced pressure. Purification by chromatography 
afforded product 154 as a yellow solid, (480 mg, 90%). Mp. 161-162 oC; νmax /cm-1 (Acetone): 
2209s (C-N, nitrile), 1517 + 1481 (C=C, aromatic), 720s (C-Cl, halogen); ¹H NMR (Acetone-D6, 
300 MHz) δH 7.03 (1H, d, J = 5.3 Hz, H-5), 7.73 (2H, d, J = 9.0 Hz, H-3'), 8.06 (2H, d, J = 9.0 Hz, 
H-2'), 8.49 (1H, d, J = 5.3 Hz, H-6), 9.39 (1H, bs, NH); ¹³C NMR (Acetone-D6, 75.5 MHz) δC 
102.1 (C-4'), 113.7 (C-5), 118.7 (C-3'/C-5’), 119.0 (C≡N), 129.7 (C-4), 133.3 (C-2'/C-6’), 142.6 
(C-1'), 158.9 (C-6), 159.1 (C-2); HRMS (ES): m/z 231.0433 [M+H]+. Calculated for C11H8N4Cl, 
231.0437 [M+H]+; C, H, N Microanalysis found: C, 57.12; H, 3.09; N, 24.29; C11H7N4Cl requires 
























To a solution of 2-[(4-cyanophenyl)amino]-4-chloro-1,3-pyrimidine 154 (120 mg, 0.51 mmol) 
dissolved in 1,4-dioxane (10 mL) was added anhydrous p-TsOH (18 mg, 0.10 mmol) at room 
temperature. To this mixture was added substituted aniline 119b (54 mg, 0.36 mmol) and the 
reaction mixture was heated to 100 oC. TLC confirmed reaction completion after 12 hrs. The 
reaction mixture was diluted with aq. NaHCO3 (50 mL) and extracted with EtOAc (3 × 50 mL), 
the organic layer dried over MgSO4 and the solvent removed under reduced pressure. 
Purification by chromatography using a silica-gel column (10 g; EtOAc neat) afforded product 
168 as a clear oil, (174 mg, 100%). νmax /cm-1 (CHCl3): 3574b (O-H), 3381s + 3333s (NH, 
amine), 2209s (C-N, nitrile), 1521 + 1492 (C=C, aromatic), 726s (C-Cl, halogen); ¹H NMR 
(DMSO-D6, 300 MHz) δH 6.32 (1H, d, J = 5.8 Hz, H-5), 7.11 (1H, d, J = 2.1 Hz, H-2''), 7.25 (1H, 
d, J = 8.6 Hz, H-5''), 7.30 (1H, dd, J = 8.6, 2.10 Hz, H-6''), 7.65 (2H, d, J = 9.0 Hz, H-3'), 7.94 
(2H, d, J = 9.0 Hz, H-2'), 8.08 (1H, d, J = 5.8 Hz, H-4), 9.43 (1H, s, NH), 9.66 (1H, s, OH), 10.02 
(1H, s, NH); ¹³C NMR (DMSO-D6, 75.5 MHz) δC 99.9 (C-5), 101.7 (C-4'), 108.7 (C-2''), 112.5 (C-
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145.1 (C-1'), 152.9 (C-3''), 155.9 (C-4), 158.7 (C-6), 160.4 (C-2); HRMS (ES): m/z 337.0738 [M+]. 




















Benzyl bromide (3.06 mL, 25.7 mmol) was added dropwise to a suspension of NaH (60%, 1.03 
g, 25.7 mmol) and tetraethylene glycol (4.44 mL, 25.7 mmol) in THF (50 mL). After 20 hrs the 
mixture was diluted with EtOAc (3 × 50 mL) and washed with aq. NH4Cl (50 mL) and H2O (2 × 
50 mL), the organic layer dried over MgSO4 and the solvent removed under reduced pressure. 
Purification by chromatography afforded product 166 as a colourless oil, (2.88 g, 39%). ¹H NMR 
(CDCl3, 300 MHz) δH 2.80 (1H, brs, OH), 3.58 (2H, t, J = 4.8 Hz, H-1), 3.66 (14H, m, 7 × CH2O), 
4.56 (2H, s, ArCH2O), 7.34 (5H, m, ArH); ¹³C NMR (CDCl3, 75.5 MHz) δC 61.6 (C-1), 69.3 
(CH2O), 70.2 (CH2O), 70.5 (2 × CH2O), 70.6 (2 × CH2O), 72.4 (CH2O), 73.1 (ArCH2O), 127.4 (C-




















To a solution of the alcohol 166 (2.50 g, 8.79 mmol) and PPh3 (2.77 g, 10.5 mmol) in CH2Cl2 (20 
mL) was added CBr4 (3.50 g, 10.5 mmol) at 0 oC. The reaction mixture was stirred at 0 oC for 30 
min and the solvent removed under reduced pressure. Purification by chromatography afforded 
product 167 as a colourless oil, (2.69 g, 88%). ¹H NMR (CDCl3, 300 MHz) δH  3.45 (2H, t, J = 6.3 
Hz, H-1), 3.67 (12H, m, 6 × CH2O), 3.80 (2H, t, J = 6.3 Hz, CH2O), 4.57 (2H, s, ArCH2O), 7.28 
(1H, m, ArH), 7.35 (4H, m, ArH); ¹³C NMR (CDCl3, 75.5 MHz) δC 30.2 (C-1), 69.4 (CH2O), 70.4 
(CH2O), 70.5 (2 × CH2O), 70.6 (2 × CH2O), 71.1 (CH2O), 73.1 (ArCH2O), 127.5 (C-4””), 127.6 (C-














CHAPTER 6: ___________________________________________EXPERIMENTAL SECTION  
 204 
4-[3-(2-Benzyloxyethoxy)-2-ethoxy)-2-ethoxy)-2-ethoxy)-4-chlorophenylamino]-2-[(4-cyano 






























To a solution of DAPY 168 (120 mg, 0.36 mmol) dissolved in acetonitrile (10 mL) was added 
anhydrous K2CO3 (75 mg, 0.54 mmol) at room temperature. Tether 167 (135 mg, 0.40 mmol) 
was slowly added to this mixture and the reaction mixture heated to 50 oC. After 12 hrs the 
mixture was diluted with H2O (100 mL) and extracted with EtOAc (3 × 100 mL), the organic layer 
dried over MgSO4 and the solvent removed under reduced pressure. Purification by 
chromatography afforded product 169 as a white solid, (218mg, 100%). Mp. 183-185 oC; νmax 
/cm-1 (Acetone): 3381s + 3333s (NH, amine), 2209s (C-N, nitrile), 1521 + 1492 (C=C, aromatic), 
726s (C-Cl, halogen); ¹H NMR (DMSO-D6, 400 MHz) δH 3.40-3.60 (12H, m, H-3''' - H-8'''), 3.75 
(2H, t, J = 4.6 Hz, H-2'''), 4.10 (2H, t, J = 4.6 Hz, H-1'''), 4.45 (2H, s, H-9'''), 6.33 (1H, d, J = 5.8 
Hz, H-5), 7.26-7.35 (8H, m, H-2'' + H-5'' + H-6'' + Ph), 7.65 (2H, d, J = 8.9 Hz, H-3'), 7.93 (2H, d, 
J = 8.9 Hz, H-2'), 8.10 (1H, d, J = 5.8 Hz, H-6), 9.55 (1H, bs, NH), 9.70 (1H, bs, NH); ¹³C NMR 
(DMSO-D6, 100 MHz) δC 59.6 (OCH2), 60.1 (OCH2), 68.3 (OCH2), 68.6 (OCH2), 69.0 (OCH2), 
69.7 x 2 (OCH2), 70.0 (OCH2), 71.9 (C-9’’’), 100.1 (C-5), 101.8 (C-4'), 106.2 (C-2''), 113.2 (C-6''), 
114.6 (C-4''), 118.3 (C-2'/C-6’), 119.5 (C≡N), 127.2 (Bn-p), 127.4 (Bn-m), 128.0 (Bn-o), 129.5 (C-
5''), 132.7 (C-3'/C-5’), 138.3 (Bn-i ), 139.7 (C-1''), 145.1 (C-1'), 153.7 (C-3''), 156.0 (C-6), 158.7 
(C-4), 160.3 (C-2); HRMS (ES): m/z 604.2344 [M+H]+. Calculated for C32H35N5O5Cl, 604.2327 
[M+H]+; C, H, N Microanalysis found: C, 63.65; H, 5.98; N, 11.58; C32H34N5O5Cl requires C, 
































The benzyl ether 169 (250 mg, 0.40 mmol) was dissolved in absolute ethanol/THF (1:1) (4mL) 
and stirred at room temperature. Subsequent addition of palladium-on-carbon (10%, 220 mg, 
0.20 mmol) was followed by careful placement of a hydrogen gas balloon over the reaction flask. 
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filtered through a Celite-packed sintered funnel and washed EtOAc (100 mL). Purification by 
chromatography using a silica-gel column (20 g; EtOAc neat) afforded product 170 as a 
colourless oil, (60 mg, 30%). νmax /cm-1 (Acetone): 3577b (O-H), 3363s + 3336s (NH, amine), 
2213s (C-N, nitrile), 1541 + 1422 (C=C, aromatic), 722s (C-Cl, halogen); ¹H NMR (Acetone-D6, 
300 MHz) δH 3.04 (1H, bs, OH), 3.49-3.70 (12H, m, H-3''' + H-8'''), 3.85 (2H, t, J = 4.76 Hz, H-
2'''), 4.17 (2H, t, J = 4.7 Hz, H-1'''), 6.40 (1H, d, J = 5.8 Hz, H-5), 7.29 (2H, m, H-5'' + H-6''), 7.46 
(1H, m, H-2''), 7.63 (2H, d, J = 9.0 Hz, H-3'), 8.00 (2H, d, J = 9.0 Hz, H-2'), 8.09 (1H, d, J = 5.8 
Hz, H-6), 8.80 (1H, bs, NH), 8.89 (1H, bs, NH); ¹³C NMR (Acetone-D6, 75.5 MHz) δC 61.3 
(OCH2), 69.1 (OCH2), 69.5 (OCH2), 70.4 (OCH2), 70.5 x 2 (OCH2), 70.9 (OCH2), 72.8 (OCH2), 
100.3 (C-5), 103.4 (C-4'), 107.3 (C-2''), 114.1 (C-6''), 116.3 (C-4''), 118.8 (C-2'/C-6’), 119.4 
(C≡N), 129.9 (C-5''), 132.9 (C-3'/C-5’), 139.9 (C-1''), 145.4 (C-1'), 154.7 (C-3''), 156.5 (C-6), 












To 2,6-dimethylphenol 163 (2.50 g, 20.4 mmol), in diethyl ether (100 mL) was added morpholine 
(7.20 mL, 81.6 mmol), followed by iodine (5.20 g, 20.4 mmol) in diethyl ether (50 mL) with rapid 
stirring at room temperature. TLC confirmed reaction completion after 1½ hrs. The reaction 
precipitate was filtered off and the filtrate extracted into diethyl ether (3 × 100 mL) following 
addition of 1M HCl (100 mL). The combined organic extracts were dried over MgSO4 and the 
solvent removed under reduced pressure. Purification by chromatography using a silica-gel 
column afforded product 153 as a light yellow solid, (4.60 g, 90%). Mp. 93-95 oC (Mp. Lit. 94-95 
oC); νmax /cm-1 (Acetone): 3573b (O-H), 1514s + 1492s (C=C, aromatic), 721s (C-I, halogen); ¹H 
NMR (CDCl3, 300 MHz) δH 2.19 (6H, s, ArCH3), 4.62 (1H, bs, OH), 7.31 (2H, s, H-3, H-5); ¹³C 
NMR (CDCl3, 75.5 MHz) δC 15.4 (ArCH3), 82.3 (C-4), 125.7 (C-2), 137.0 (C-3), 152.1 (C-1); 
HRMS (ES): m/z 246.9635 [M-H]+. Calculated for C8H9OI, 246.9620 [M-H]+; C, H, N 
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Sodium hydride (60%, 1.10 g, 25.7 mmol) was suspended in dry THF (50 mL) at 0oC (ice slurry), 
and to the solution was added tetraethylene glycol (4.40 mL, 25.7 mmol) portionwise. Once gas 
evolution had subsided, propargyl bromide (2.50 mL, 28.3 mmol) was added slowly. The ice 
bath was then removed and the mixture stirred at room temperature. TLC confirmed completion 
of the reaction after 6 hrs. The reaction mixture was diluted with water (100 mL) and extracted 
with EtOAc (3 × 100 mL), the organic layer dried over MgSO4 and the solvent removed under 
reduced pressure. Purification by chromatography using a silica-gel column (80 g, MeOH/EtOAc, 
0.5:9.5) afforded product 151 as a clear oil, (2.50 g, 42%). νmax /cm-1 (Acetone): 2940s + 2872s 
(C-H, aliphatic), 2251s (C≡C); ¹H NMR (CDCl3, 400 MHz) δH 2.42 (1H, t, J = 2.4 Hz, H-11), 2.79 
(1H, bs, OH), 3.57-3.63 (16H, m, H-1 - H8), 4.17 (2H, d, J = 2.4 Hz, H-9); ¹³C NMR (CDCl3, 100 
MHz) δC 58.0 (C-9), 61.2 (OCH2), 68.7 (OCH2), 69.7 (OCH2), 69.9 (OCH2), 70.1 (OCH2), 70.2 
(OCH2), 70.3 (OCH2), 72.2 (OCH2), 74.4 (C-11), 79.3 (C-10); HRMS (ES): m/z 233.1385 [M+H]+. 
Calculated for C11H21O5, 233.1389 [M+H]+. 
 



















Sodium hydride (60%, 284 mg, 7.08 mmol) was suspended in dry THF (50 mL) at 0oC (ice 
slurry), and to the solution was added hexaethylene glycol (2.00 g, 7.08 mmol) portionwise. 
Once gas evolution had subsided, propargyl bromide (0.70 mL, 7.80 mmol) was added slowly. 
The ice bath was then removed and the mixture stirred at room temperature. TLC confirmed 
completion of the reaction after 5 hrs. The reaction mixture was diluted with water (100 mL) and 
extracted with EtOAc (3 × 100 mL), the organic layer dried over MgSO4 and the solvent removed 
under reduced pressure. Purification by chromatography using a silica-gel column (30 g; 
MeOH/EtOAc, 2:8) afforded product 183 as a clear oil, (1.20 g, 53%). νmax /cm-1 (Acetone): 
2940s + 2872s (C-H, aliphatic), 2251s (C≡C); ¹H NMR (CDCl3, 300 MHz) δH 2.43 (1H, t, J = 2.4 
Hz, H-15), 2.78 (1H, bs, OH), 3.61-3.65 (24H, m, H-1 - H-12), 4.15 (2H, d, J = 2.4 Hz, H-13); ¹³C 
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(OCH2), 72.6 (OCH2), 74.4 (C-15), 79.5 (C-14); HRMS (ES): m/z 321.1927 [M+H]+. Calculated 




















To a solution of cesium carbonate (840 mg, 2.60 mmol) and 4-iodo-2,6-dimethylphenol 153 (470 
mg, 1.90 mmol) in DMF (8 mL), was added 2-[(4-Cyanophenyl)amino]-4-chloro-1,3-pyrimidine 
154 (400 mg, 1.72 mmol) and the mixture heated to 90 oC. TLC confirmed reaction completion 
after 1 hr. The reaction mixture was diluted with brine (100 mL) and extracted with EtOAc (3 × 
100 mL), the organic layer dried over MgSO4 and the solvent removed under reduced pressure. 
Purification by chromatography using a silica-gel column (35 g; EtOAc/hexane, 5:5) afforded 
product 152 as a yellow solid, (758 mg, 99%). Mp. 218-220 oC; νmax /cm-1 (Acetone): 3381s + 
3333s (NH, amine), 2211s (C-N, nitrile), 1516s + 1489s (C=C, aromatic), 723s (C-I, halogen);  
¹H NMR (DMSO-D6, 300 MHz) δH 2.02 (6H, s, ArCH3), 6.61 (1H, d, J = 5.6 Hz, H-5), 7.46 (2H, d, 
J = 8.9 Hz, H-3'), 7.56 (2H, d, J = 8.9 Hz, H-2'), 7.58 (2H, s, H-3'', H-5’’), 8.43 (1H, d, J = 5.6 Hz, 
H-6), 9.99 (1H, bs, NH); ¹³C NMR (DMSO-D6, 75.5 MHz) δC 15.4 (ArCH3), 90.4 (C-4''), 99.0 (C-
5), 102.4 (C-4'), 118.2 (C-2'/C-6’), 119.3 (C≡N), 132.4 (C-3'/C-5’), 133.2 (C-2''/C-6’’), 137.0 (C-
3''/C-5’’), 144.4 (C-1'), 149.5 (C-1'' ), 159.0 (C-2), 160.3 (C-6), 168.0 (C-4); HRMS (ES): m/z 
443.0348 [M+H]+. Calculated for C19H16N4OI, 443.0369 [M+H]+; C, H, N Microanalysis found: C, 

































Alkyne 151 (231 mg, 1.00 mmol) was added together with DAPY 152 (485 mg, 1.10 mmol) and 
the mixture dried carefully on a vacuum pump. A mixture of degassed DMF:THF (1:2 (v/v), 6 mL) 
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nitrogen. Subsequent addition of triethylamine (0.30 mL, 2.20 mmol) was followed by addition of 
copper(I) iodide (104 mg, 0.55 mmol) and tetrakis(triphenylphosphine)palladium (127 mg, 0.11 
mmol) respectively. The reaction was stirred continuously at room temperature and TLC 
confirmed completion of the reaction after 30 min. The reaction mixture was diluted with a 5% 
EDTA solution (50 mL) and extracted with chloroform (3 × 100 mL). The organic fractions were 
dried with MgSO4 and the solvent removed under reduced pressure. Purification by 
chromatography using a silica-gel column afforded product 150 as a clear oil, (450 mg, 75%). 
νmax /cm-1 (Acetone): 3577b (O-H), 3353s + 3340s (NH, amine), 2253s (C≡C),  2208s (C-N, 
nitrile), 1541 + 1428 (C=C, aromatic); ¹H NMR (Acetone-D6, 300 MHz) δH 2.11 (6H, s, ArCH3), 
2.81 (1H, s, OH), 3.52-3.62 (12H, m, H-9'' - H-14''), 3.69 (2H, m, H-15''), 3.76 (2H, m, H-8'' ), 
4.45 (2H, s, H-7''), 6.64 (1H, d, J = 5.6 Hz, H-5), 7.32 (2H, s, H-3''/H-5’’), 7.48 (2H, d, J = 8.8 Hz, 
H-3'/H-5’), 7.71 (2H, d, J = 8.8 Hz, H-2'/H-6’), 8.45 (1H, d, J = 5.6 Hz, H-6), 9.13 (1H, bs, NH); 
¹³C NMR (Acetone-D6, 75.5 MHz) δC 15.7 (ArCH3), 58.6 (C-7'' ), 61.3 (OCH2), 69.2 (OCH2), 70.4 
x 2 (OCH2), 70.6 x 3 (OCH2), 72.9 (OCH2), 85.4 (C-6''), 85.7 (C-5''), 99.4 (C-5), 104.0 (C-4'), 
118.6 (C-2'/C-6’), 119.2 (C≡N), 120.4 (C -4''), 131.7 (C-2''/C-6’’)), 132.1 (C-3'/C-5’), 132.8 (C-
3''/C-5’’), 144.8 (C-1'), 150.5 (C-1'' ), 159.8 (C-2), 160.4 (C-6), 169.1 (C-4); HRMS (ES): m/z 








































DAPY alcohol 150 (390 mg, 0.71 mmol) was dissolved in THF (10 mL). Triethylamine (0.14 mL, 
1.00 mmol) was added at 0oC followed by a catalytic amount of DMAP (18.0 mg, 0.14 mmol) to 
the reaction mixture. p-Toluenesulfonyl chloride (210 mg, 1.00 mmol) dissolved in THF (2 mL) 
was then added dropwise and the solution left to stir at room temperature. TLC confirmed 
completion of the reaction after 10 hrs. The reaction mixture was diluted with brine (50 mL) and 
extracted with EtOAc (3 × 50 mL). The organic fractions were dried with MgSO4 and the solvent 
removed under reduced pressure. Purification by chromatography using a silica-gel column (30 
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3353s + 3340s (NH, amine), 2253s (C≡C),  2208s (C-N, nitrile), 1541 + 1428 (C=C, aromatic), 
1372s + 1180s (-SO2-O-); ¹H NMR (Acetone-D6, 400 MHz) δH 2.08 (3H, s, H-5'''), 2.09 (6H, s, 
ArCH3), 3.61 (12H, m, H-9'' - H-14''), 3.73 (2H, m, H-8''), 3.79 (2H, m, H-15''), 4.43 (2H, s, H-7''), 
6.61 (1H, d, J = 5.6 Hz, H-5), 7.32  (2H, s, H-3''/H-5’’), 7.45 (2H, d, J = 8.6 Hz, H-3'''/H-5’’’), 7.48 
(2H, d, J = 8.8 Hz, H-3'/H-5’), 7.62 (2H, d, J = 8.6 Hz, H-2'''/H-6’’’), 7.69 (2H, d, J = 8.8 Hz, H-
2'/H-6’), 8.44 (1H, d, J = 5.6 Hz, H-6), 9.11 (1H, bs, NH); ¹³C NMR (Acetone-D6, 100 MHz) δC 
15.6 (ArCH3), 20.7 (C-5'''), 58.6 (C-7'' ), 64.1 (OCH2), 68.6 (OCH2), 69.3 (OCH2), 69.8 (OCH2), 
70.0 (OCH2), 70.5 (OCH2), 70.6 x 2  (OCH2), 85.3 (C-6'' ), 85.7 (C-5''), 99.3 (C-5), 104.0 (C-4'), 
118.6 (C-2'/C-6’), 119.2 (C≡N), 120.5  (C-4''), 125.4 (C-4'''), 128.0 (C-2'''/C-6’’’), 129.8 (C-3'''/C-
5’’’), 130.1 (C-1'''), 131.7 (C-2''/C-6’’), 132.1 (C-3'/C-5’), 132.8 (C-3''/C-5’’), 144.8 (C-1'), 150.5 
(C-1'' ), 159.7 (C-2), 160.4 (C-6), 169.0 (C-4); HRMS (ES): m/z 701.2693 [M+H]+. Calculated for 
































To a suspension of sodium hydride (60%, 100 mg, 2.50 mmol) suspension in THF (20 mL) at 
0oC, was added propargyl alcohol (0.21 mL, 3.60 mmol) slowly whilst stirring. To this was added 
DAPY tosylate 165 (420 mg, 0.60 mmol) and the reaction mixture refluxed. TLC confirmed 
completion after a total of 20 hrs. The reaction mixture was diluted with aq. NH4Cl (100 mL) and 
extracted with EtOAc (3 × 100 mL). The organic fractions were dried with MgSO4 and removed 
under reduced pressure. Purification by chromatography using a silica-gel column (50 g; 
EtOAc/hexane, 9:1) afforded product 149 as a colourless oil, (301 mg, 86%). νmax /cm-1 
(Acetone): 3353s + 3340s (NH, amine), 2253s (C≡C), 2208s (C-N, nitrile), 1541 + 1428 (C=C, 
aromatic); ¹H NMR (CDCl3, 400 MHz) δH 2.10 (6H, s, ArCH3), 2.42 (1H, t, J = 2.4 Hz, H-18''), 
3.67 (12H, m, H-9'' - H-14''), 3.75 (2H, m, H-15'' ), 3.80 (2H, m, H-8'' ), 4.20 (2H, d, J = 2.4 Hz, H-
16''), 4.46 (2H, s, H-7''), 6.49 (1H, d, J = 5.7 Hz, H-5), 7.26 (2H, d, J = 8.8 Hz, H-3'’/H-5’’), 7.41 
(4H, m, H-2'/H-6’ + H-3’/H-5’), 8.34 (1H, d, J = 5.7 Hz, H-6); ¹³C NMR (CDCl3, 100 MHz) δC 16.1 
(ArCH3), 58.2 (C-7''), 59.2 (C-16''), 69.2 (OCH2), 70.6 x 7 (OCH2), 74.4 (C-18'' ), 79.7 (C-17''), 
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131.2 (C-2''/C-6’), 132.1 (C-3'/C-5’), 133.0 (C-3''/C-5’’), 143.3 (C-1'), 150.0 (C-1''), 159.1 (C-2), 
















































A mixture of (tetrakis)triphenylphosphinepalladium (0) (30.0 mg, 0.026 mmol) and copper (I) 
iodide (30.0 mg, 0.16 mmol) was added rapidly to a solution of 5-iodo-5´-benzoyl-d4U 60 (110 
mg, 0.25 mmol) and alkyne 149 (99.0 mg, 0.17 mmol) in a degassed mixture of THF and DMF (6 
ml, 2:1) at room temperature under nitrogen.  TLC indicated reaction to a more polar product to 
be complete after 3 hours with complete consumption of alkyne.  Work-up involved adding EDTA 
solution (20 ml, 5%) and extracting the product into EtOAc (3 x 50 ml).  Drying (Na2SO4) and 
evaporation of solvent followed by column chromatography of the residue on silica-gel using 
EtOAc / hexane mixtures as eluent furnished the bifunctional compound 171 (91.0 mg, 59%). 1H-
NMR (CDCl3, 500 MHz) δH 2.06 (6H, s, ArCH3), 3.58-3.80 (16H, m, H-16 - H-23), 4.20 (2H, s, H-
15), 4.43 (2H, s, H-24), 4.49 (1H, dd, J = 3.0, 10.0 Hz, H-1), 4.67 (1H, dd, J = 4.5, 10.0 Hz, H-1), 
5.19 (1H, m, H-2), 5.96 (1H, m, H-3), 6.39 (1H, m, H-4), 6.47 (1H, d, J = 5.7 Hz, H-36), 6.94 (1H, 
m, H-5), 7.22 (2H, s, H-28), 7.32 (4H, m, H-38, H-39), 7.43 (2H, m, Bz-m), 7.56 (1H, m, Bz-p), 
7.67 (1H, s, H-12), 7.99 (2H, m, Bz-o), 8.42 (1H, d, J = 5.7 Hz, H-35), 8.95 (1H, s, NH), 11.82 
(1H, s, NH); 13C-NMR (CDCl3, 500 MHz) δC 16.2 (ArCH3), 59.0 (C-24), 59.2 (C-15), 65.0 (C-1), 
69.2 x 2 (OCH2), 70.3 (OCH2), 70.4 (OCH2), 70.5 x 2 (OCH2), 70.6 (OCH2), 77.0 (OCH2), 85.1 
(C-14), 85.2 (C-25), 85.6 (C-2), 90.1 (C-5), 90.6 (C-26), 99.0 (C-13), 100.2 (C-36), 104.2 (C-40), 
118.2 (C-11), 119.5 (C-38/C-42), 120.2 (CN), 120.8 (C-27), 126.8 (C-3), 128.7 (Bz-m), 129.1 










CHAPTER 6: ___________________________________________EXPERIMENTAL SECTION  
 211 
142.5 (C-12), 143.6 (C-37), 150.1 (C-8), 150.3 (C-35), 158.9 (C-30), 159.0 (C-33), 162.2 (C-10), 
















































To a solution of benzoate 171 (38.0 mg, 0.042 mmol) dissolved in methanol (3 mL) at 0°C was 
added a solution of sodium methoxide in methanol (0.5 M, 0.1 mL).  After 2 h, the solution was 
allowed to warm to rt.  Once TLC indicated the complete consumption of starting material, acetic 
acid was added (3.0 mg, 0.05 mmol) and the methanol removed on the rotoevaporator.  The 
residue was immediately chromatographed on silica-gel using EtOAc/ MeOH mixtures to obtain 
nucleoside 147 (31.5 mg, 94%) as a colourless oil. 1H-NMR (CDCl3, 500 MHz) δH 2.06 (6H, s, 
ArCH3), 3.48 (1H, brs, OH), 3.60-3.80 (16H, m, H-16 - H-23), 3.84 (1H, dd, J = 2.0, 11.2 Hz, H-
1), 3.94 (1H, dd, J = 3.0, 11.2 Hz, H-1), 4.32 (2H, s, H-15), 4.44 (2H, s, H-24), 4.94 (1H, m, H-2), 
5.82 (1H, d, J = 5.8 Hz, H-3), 6.34 (1H, d, J = 5.8 Hz, H-4), 6.47 (1H, d, J = 5.2 Hz, H-36), 6.98 
(1H, m, H-5), 7.22 (2H, s, H-28), 7.33 (4H, m, H-38, H-39), 8.34 (1H, s, H-12), 8.38 (1H, d, J = 
5.2 Hz, H-35), 8.88 (1H, bs, NH), 11.54 (1H, bs, NH); 13C-NMR (CDCl3, 500 MHz) δC 16.3 
(ArCH3), 59.2 (C-24), 59.2 (C-15), 62.7 (C-1), 69.0 (OCH2), 69.2 (OCH2), 70.3 (OCH2), 70.4 
(OCH2), 70.4 (OCH2), 70.5 x 3 (OCH2), 77.9 (C-14), 85.0 (C-25), 85.7 (C-2), 89.1 (C-5), 90.1 (C-
26), 99.0 (C-13), 99.4 (C-36), 104.2 (C-40), 118.3 (C-11), 119.5 (C-38/C-42), 120.1 (CN), 120.8 
(C-27), 126.0 (C-3), 131.3 (C-29), 132.1 (C-39/C-41), 132.8 (C-28), 135.0 (C-4), 143.6 (C-12), 
145.2 (C-37), 150.2 (C-8), 150.5 (C-35), 158.9 (C-30), 159.1 (C-33), 162.4 (C-10), 169.2 (C-31); 





































































The bifunctional nucleoside 147 (95.0 mg, 0.120 mmol) was dissolved in a 1:1 mixture of 
DMF/Pyridine (1.0 ml) and the flask cooled to -20°C. 2-Chloro-1,3,2-benzodioxaphosphorin-4-
one (30.0 mg, 0.148 mmol) dissolved in THF (0.5 mL) was added slowly and the reaction left to 
warm to rt.  After 60 mins, bis(tributylammonium) pyrophosphate (92.0 mg, 0.168 mmol) in DMF 
(0.5 ml) was added followed by triethylamine (0.5 ml) and the solution left stirring for 1 h.  I2 (43.0 
mg, 0.170 mmol) dissolved in pyridine/water (2 ml, 98:2) was then added, and the solution left 
stirring for 15 min before being quenched by aq. Na2S2O3 (0.5 M, 0.5 ml).  TEAB (1 M, 3.0 ml) 
was immediately added and the solution left stirring for 2h at rt.  The solution was then 
evaporated to dryness before being chromatographed on a Sephadex ion-exchange (DEAE) 
column (3.0 g) using aq. TEAB as the mobile phase.  The bifunctional triphosphate eluted at 
around 0.6 M.  Fractions identified from TLC (amine-impregnated silica-gel plates using 
TEAB/MeOH = 3.5/6.5) were combined and the solvent evaporated.  Following several additions 
of methanol with pumping, the tris(tiethylammonium) triphosphate 148 (60.0 mg, 0.045 mmol, 37 
%) was obtained as a colourless oil. 1H-NMR (CD3OD, 500 MHz) δH 1.25 (27H, bs, NCH2CH3), 
2.04 (6H, s, ArCH3), 3.13 (18H, bs, NCH2CH3), 3.54 – 3.74 (16H, m, H-16 - H-23), 4.12 (2H, m, 
H-1), 4.32 (2H, s, H-15), 4.42 (2H, s, H-24), 5.02 (1H, m, H-2), 5.88 (1H, m, H-3), 6.55 (2H, m, 
H-36, H-4), 6.85 (1H, m, H-5), 7.23 (2H, s, H-28), 7.33 (2H, m, H-38), 7.43 (2H, m, H-39), 7.78 
(1H, s, H-12), 8.32 (1H, m, H-35); 13C-NMR (CD3OD, 75 MHz) δC 9.1 (NCH2CH3), 16.4 (ArCH3), 
47.2 (NCH2CH3), 59.7 (C-24), 59.8 (C-15), 68.4 (C-1), 70.2 x 2 (OCH2), 71.4 (OCH2), 71.5 x 5 
(OCH2), 86.0 (C-14), 86.6 (C-25), 87.5 (C-2), 90.9 (C-5), 91.8 (C-26), 100.1 (C-13), 100.5 (C-
36), 104.6 (C-40), 119.6 (C-11), 120.4 (CN), 121.5 (C-38/C-42), 120.8 (C-27), 126.5 (C-3), 132.8 
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151.8 (C-35), 160.8 (C-30), 161.2 (C-33), 164.1 (C-10), 170.4 (C-31); 31P-NMR (CD3OD, 202.4 
MHz) δP -8.9 (d, J = 20.2 Hz), -9.8 (d, J = 20.2 Hz), -22.1 (t, J = 20.2 Hz); HRMS (EI): m/z 



















































DAPY alkyne 149 (140 mg, 0.24 mmol) was added together with acyclic phosphonate 175b (100 
mg, 0.22 mmol) and the mixture dried carefully on a vacuum pump. A mixture of degassed 
DMF:THF (1:2 (v/v), 3 mL) was then added to the reaction vessel whilst the mixture stirred at 
room temperature under nitrogen. Subsequent addition of triethylamine (0.07 mL, 0.48 mmol) 
was followed by addition of copper(I) iodide (23 mg, 0.12 mmol) and 
tetrakis(triphenylphosphine)palladium (28 mg, 0.02 mmol) respectively. The reaction was stirred 
continuously at room temperature and TLC confirmed completion of the reaction after 1½ hrs. 
The reaction mixture was diluted with a 5% EDTA solution (50 mL) and extracted with chloroform 
(3 × 50 mL). The organic fractions were dried with MgSO4 and the solvent removed under 
reduced pressure. Purification by chromatography using a silica-gel column afforded product 
172 as a yellow solid, (121 mg, 60%). Mp.113-115 oC; [α]D +15.7° (c = 1.31, acetone); νmax /cm-1 
(Acetone): 3353s + 3340s (NH, amine), 2253s (C≡C), 2208s (C-N, nitrile), 1725s (C=O, ester), 
1691s (C=O, pyrimidine), 1538 + 1430 (C=C, aromatic); ¹H NMR (Acetone-D6, 300 MHz) δH 1.29 
(12H, m, H-1), 2.14 (6H, s, ArCH3), 3.59-3.80 (18H, m, H-16 - H-21, H-3 -H-5), 3.85 (2H, t, J = 
4.9 Hz, H-15), 4.01 (2H, t, J = 4.92 Hz, H-22), 4.33 (2H, s, H-14), 4.46 (2H, s, H-23), 4.68 (2H, 
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41), 7.61 (2H, m, H-38, H-40), 7.87 (1H, s, H-11), 8.54 (1H, d, J = 5.65 Hz, H-34), 10.28 (1H, bs, 
NH); ¹³C NMR (Acetone-D6, 75.5 MHz) δC 16.1 (ArCH3), 23.9 (C-1), 48.3 (C-5), 58.9 (C-23), 59.1 
(C-14), 66.1 (d, JC-P = 148.3 Hz, C-3), 66.8 (C-4), 69.2 (OCH2), 69.4 (C-2), 70.6 x 7 (OCH2), 78.7 
(C-13), 85.3 (C-24), 86.0 (C-25), 89.1 (C-12), 99.5 (C-35), 104.7 (C-39), 111.1 (C-10), 119.0 (C-
37/C-41), 119.1 (C≡N), 120.8 (C-26), 131.9 (C-28), 132.2 (C-38/C-40), 132.8 (C-27), 137.8 (C-
11), 143.8 (C-36), 149.5 (C-34), 150.4 x 2 (C-7 + C-29), 157.5 (C-32), 162.1 (C-9), 170.0 (C-30); 
31P NMR (Acetone-D6, 121.5 MHz) δP 23.2; HRMS (ES): m/z 917.3848 [M+H]+. Calculated for 




































Alkyne 183 (197 mg, 0.62 mmol) was added together with DAPY 152 (300 mg, 0.67 mmol) and 
the mixture dried carefully on a vacuum pump. A mixture of degassed DMF:THF (1:2 (v/v), 3 mL) 
was then added to the reaction vessel whilst the mixture stirred at room temperature under 
nitrogen. Subsequent addition of triethylamine (0.20mL, 1.34 mmol) was followed by addition of 
copper(I) iodide (64 mg, 0.34 mmol) and tetrakis(triphenylphosphine)palladium (77 mg, 0.07 
mmol) respectively. The reaction was stirred continuously at room temperature and TLC 
confirmed completion of the reaction after 3 hrs. The reaction mixture was diluted with a 5% 
EDTA solution (50 mL) and extracted with chloroform (3 × 100 mL). The organic fractions were 
dried with MgSO4 and the solvent removed under reduced pressure. Purification by 
chromatography using a silica-gel column afforded product 184 as a clear oil, (180 mg, 46%). 
νmax /cm-1 (Acetone): 3577b (O-H), 3353s + 3340s (NH, amine), 2253s (C≡C),  2208s (C-N, 
nitrile), 1541 + 1428 (C=C, aromatic); ¹H NMR (Acetone-D6, 300 MHz) δH 2.11 (6H, s, ArCH3), 
3.53-3.63 (20H, m, H-9'' - H-18''), 3.70 (2H, m, H-19'' ), 3.77 (2H, m, H-8''), 4.46 (2H, s, H-7'' ), 
6.63 (1H, d, J = 5.6 Hz, H-5), 7.32 (2H, s, H-3''/H-5’’), 7.46 (2H, d, J = 8.8 Hz, H-3'/H-5’), 7.68 
(2H, d, J = 8.8 Hz, H-2'/H-6’), 8.44 (1H, d, J = 5.6 Hz, H-6), 9.12 (1H, bs, NH); ¹³C NMR 
(Acetone-D6, 75.5 MHz) δC 15.6 (ArCH3), 58.6 (C-7''), 61.2 (OCH2), 69.1 (OCH2), 70.4 x 4 
(OCH2), 70.5 x 5 (OCH2), 72.7 (OCH2), 85.3 (C-6''), 85.7 (C-5''), 99.3 (C-5), 104.1 (C-4'), 118.6 
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144.9 (C-1'), 150.7 (C-1''), 159.8 (C-2), 160.4 (C-6), 169.3 (C-4); HRMS (ES): m/z 635.3089 












































DAPY alcohol 184 (290 mg, 0.47 mmol) was dissolved in THF (10 mL). Triethylamine (0.08 mL, 
0.56 mmol) was added at 0oC followed by a catalytic amount of DMAP (12.0 mg, 0.09 mmol) to 
the reaction mixture. p-Toluenesulfonyl chloride (131 mg, 0.70 mmol) in THF (2 mL) was then 
added dropwise and the solution left to stir at room temperature. TLC confirmed completion of 
the reaction after 12 hrs. The reaction mixture was diluted with brine (100 mL) and extracted with 
EtOAc (3 × 100 mL). The organic fractions were dried with MgSO4 and the solvent removed 
under reduced pressure. Purification by chromatography using a silica-gel column (30 g; 
MeOH/EtOAc, 0.5:9.5) afforded product 185 as a clear oil, (210 mg, 57%). νmax /cm-1 (Acetone): 
3353s + 3340s (NH, amine), 2253s (C≡C),  2208s (C-N, nitrile), 1541 + 1428 (C=C, aromatic), 
1372s + 1180s (-SO2-O-); ¹H NMR (Acetone-D6, 400 MHz) δH 2.11 (6H, s, ArCH3), 2.45 (3H, s, 
H-5'''), 3.57-3.67 (20H, m, H-9'' - H-18''), 3.75 (2H, m, H-8''), 4.16 (2H, m, H-19''), 4.45 (2H, s, H-
7''), 6.63 (1H, d, J = 5.6 Hz, H-5), 7.31 (2H, s, H-3''/H-5’’), 7.45 (2H, d, J = 8.8 Hz, H-3'/H-5’), 
7.46 (2H, d, J = 8.4 Hz, H-3'''/H-5’’’), 7.69 (2H, d, J = 8.8 Hz, H-2'/H-6’), 7.81 (2H, d, J = 8.4 Hz, 
H-2'''/H-6’’’), 8.44 (1H, d, J = 5.6 Hz, H-6), 9.09 (1H, bs, NH); ¹³C NMR (Acetone-D6, 100 MHz) 
δC 15.7 (ArCH3), 20.9 (C-5'''), 58.6 (C-7''), 68.6 (OCH2), 69.3 (OCH2), 70.0 (OCH2), 70.4 x 3 
(OCH2), 70.5 x 3 (OCH2), 70.6 x 3 (OCH2), 85.3 (C-6''), 85.7 (C-5''), 99.3 (C-5), 104.0 (C-4'), 
118.6 (C-2'/C-6’), 119.2 (C≡N), 120.4 (C-4''), 125.6 (C-4'''), 128.1 (C-2'''/C-6’’’), 130.2 (C-3'''/C-
5’’’), 131.7 (C-1’’’), 131.7 x 2 (C-2''/C-6’’), 132.1 (C-3'/C-5’), 132.8 (C-3''/C-5’’), 144.8 (C-1'), 
150.2 (C-1''), 159.8 (C-2), 160.4 (C-6), 169.1 (C-4); HRMS (ES): m/z 789.3163 [M+H]+. 






















































To a suspension of sodium hydride (60%, 32 mg, 0.80 mmol) suspension in THF (8 mL) at 0oC, 
was added propargyl alcohol (0.07 mL, 1.20 mmol) slowly whilst stirring. To this was added 
DAPY tosylate 185 (160 mg, 0.20 mmol) and the reaction mixture refluxed. TLC confirmed 
completion after a total of 20 hrs. The reaction mixture was diluted with water (50 mL) and 
extracted with EtOAc (3 × 50 mL). The organic fractions were dried with MgSO4 and the solvent 
removed under reduced pressure. Purification by chromatography using a silica-gel column (40 
g; MeOH/EtOAc, 0.5:9.5) afforded product 174 as a colourless oil, (120 mg, 89%). νmax /cm-1 
(Acetone): 3353s + 3340s (NH, amine), 2253s (C≡C), 2208s (C-N, nitrile), 1541 + 1428 (C=C, 
aromatic); ¹H NMR (Acetone-D6, 400 MHz) δH 2.11 (6H, s, ArCH3), 2.89 (1H, t, J = 2.4 Hz, H-
22''), 3.57-3.60 (20H, m, H-9'' - H-18''), 3.68 (2H, m, H-19''), 3.75 (2H, m, H-8''), 4.17 (2H, d, J = 
2.4 Hz, H-20''), 4.45 (2H, s, H-7''), 6.63 (1H, d, J = 5.6 Hz, H-5), 7.31 (2H, s, H-3''/H-5’’), 7.48 
(2H, d, J = 8.8 Hz, H-3'/H-5’), 7.71 (2H, d, J = 8.8 Hz, H-2'/H-6’), 8.44 (1H, d, J = 5.6 Hz, H-6), 
9.09 (1H, bs, NH); ¹³C NMR (Acetone-D6, 100 MHz) δC 15.6 (ArCH3), 57.9 (C-7''), 58.6 (C-20''), 
69.2 (OCH2), 70.6 x 11 (OCH2), 75.1 (C-22’’), 80.2 (C-21''), 85.3 (C-6''), 85.9 (C-5''), 99.3 (C-5), 
104.0 (C-4'), 118.5 (C-2'/C-6’), 119.3 (C≡N), 120.6 (C -4''), 131.6 (C-2''/C-6’’), 132.1 (C-3'/C-5’), 
132.7 (C-3''/C-5’’), 144.7 (C-1'), 150.7 (C-1''), 159.8 (C-2), 160.3 (C-6), 169.1 (C-4); HRMS (ES): 













































































DAPY alkyne 174 (65 mg, 0.10 mmol) was added together with acyclic phosphonate 175b (41 
mg, 0.09 mmol) and the mixture dried carefully on a vacuum pump. A mixture of degassed 
DMF:THF (1:2 (v/v), 3 mL) was then added to the reaction vessel whilst the mixture stirred at 
room temperature under nitrogen. Subsequent addition of triethylamine (0.03 mL, 0.20 mmol) 
was followed by addition of copper(I) iodide (10 mg, 0.05 mmol) and 
tetrakis(triphenylphosphine)palladium (12 mg, 0.01 mmol) respectively. The reaction was stirred 
continuously at room temperature and TLC confirmed completion of the reaction after 3 hrs. The 
reaction mixture was diluted with a 5% EDTA solution (50 mL) and extracted with chloroform (3 
× 50 mL). The organic fractions were dried with MgSO4 and the solvent removed under reduced 
pressure. Purification by chromatography using a silica-gel column afforded product 173 as a 
yellow oil, (70 mg, 70%). [α]D +14.7° (c = 1.04, acetone); νmax /cm-1 (Acetone): 3353s + 3340s 
(NH, amine), 2253s (C≡C),  2208s (C-N, nitrile), 1725s (C=O, ester), 1691s (C=O, pyrimidine), 
1538 + 1430 (C=C, aromatic); ¹H NMR (Acetone-D6, 300 MHz) δH 1.28 (12H, m, H-1), 2.11 (6H, 
s, ArCH3), 3.57-3.80 (26H, m, H-16 - H25 + H-3 - H-5), 3.85 (2H, t, J = 4.9 Hz, H-15), 4.01 (2H, t, 
J = 4.9 Hz, H-26), 4.34 (2H, s, H-14), 4.46 (2H, s, H-27), 4.67 (2H, sept, J = 6.2 Hz, H-2), 6.63 
(1H, d, J = 5.7 Hz, H-39), 7.32 (2H, s, H-31), 7.47 (2H, d, J = 8.9 Hz, H-42), 7.68 (2H, d, J = 8.9 
Hz, H-41), 7.87 (1H, s, H-11), 8.43 (1H, d, J = 5.7 Hz, H-38), 9.17 (1H, bs, NH); ¹³C NMR 
(Acetone-D6, 75.5 MHz) δC 15.6 (ArCH3), 23.6 (C-1), 48.3 (C-5), 58.6 (C-27), 61.6 (C-14), 64.7 
(d, JC-P = 150.1 Hz, C-3), 66.9 (C-4), 66.1 (OCH2), 69.2 (OCH2), 69.5 (OCH2), 69.7 (OCH2), 70.0 
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85.7 (C-29), 88.9 (C-12), 99.3 (C-39), 104.0 (C-43), 111.0 (C-10), 118.6 (C-41), 119.2 (C≡N), 
120.4 (C-30), 131.7 (C-32), 132.1 (C-42), 132.8 (C-31), 144.8 (C-40), 149.6 (C-11), 150.4 (C-7), 
150.5 (C-33), 159.8 (C-36), 160.3 (C-38), 162.1 (C-9), 169.1 (C-34); 31P NMR (Acetone-D6, 
121.5 MHz) δP 23.3; HRMS (ES): m/z 1005.4344 [M+H]+. Calculated for C50H66N6O14P, 
1005.4375 [M+H]+. 
 





Isopropanol (5.24 g, 68.82 mmol) was added dropwise to a suspension of NaH (60% in mineral 
oil, 1.84 g, 45.88 mmol) in THF (60 mL) and the mixture was stirred for 15 min at 0 oC. 
Phosphorus trichloride (2.00 mL, 22.94 mmol) was added dropwise and then the mixture was 
warmed to rt with stirring for 1h. The reaction was quenched using aqueous NH4Cl (10 mL). The 
mixture was diluted with EtOAc (80 mL), washed with aq NH4Cl (50 mL), water (2 × 40 mL), 
dried over MgSO4 and the solvent was evaporated under reduced pressure to give the product 
177 without purification as a colourless oil (11.20 g, 98%). 1H NMR (300 MHz, CDCl3) δH 1.28 
and 130 (2 × 6H, 2 × d, CH(CH3)2), 4.67 (2H, m, CH(CH3)2), 6.77 (1H, d, JHP = 687.0 Hz, H-
P=O); 31P NMR (CDCl3) δP 4.6. 
 






To a solution of diisopropyl hydrogen phosphonate 177 (5.00 g, 30.10 mmol), paraformaldehyde 
(1.05 g, 36.12 mmol) in isopropanol (20 mL) was added anhydrous potassium carbonate (0.21 g, 
1.51 mmol). The mixture was stirred vigorously for 1h at 60 oC, filtered through Celite and the 
solvent was evaporated in vacuum to give the product 178 as a colourless oil (5.81 g, 98%) pure 
enough for the next step. 1H NMR (300 MHz, CDCl3) δH 1.32 (12H, d, J = 6.3 Hz, CH(CH3)2), 
2.15 (1H, brs, OH), 3.82 (2H, d, JHP  = 6.6 Hz, CH2P), 4.73 (2H, m, CH(CH3)2); 31P NMR (CDCl3) 
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To a solution of diisopropyl hydroxymethyl phosphonate 178 (5.00 g, 25.49 mmol) in dry CH2Cl2 
(30 mL), were added triethylamine (4.26 mL, 30.59 mmol) and p-toluenesulfonyl chloride (5.81 g, 
30.59 mmol) followed by DMAP (0.02 g). The reaction mixture was stirred at rt for 16h. The 
mixture was diluted with CH2Cl2 (120 mL), washed with aq NH4Cl (60 mL), water (70 mL), dried 
over MgSO4 and solvent was removed under reduced pressure. Purification by column 
chromatography using EtOAc / pet ether (6 / 4) gave a colourless oil 176 (8.20 g, 92%). νmax /cm-
1 (Chloroform): 2986 (C-H), 1252 (P=O), 1176 (O-SO2-), 1003 (P-O) cm-1; 1H NMR (400 MHz, 
CDCl3) δH 1.29 and 1.33 (2 × 6H, 2 × d, J = 6.2 Hz, CH(CH3)2), 2.46 (3H, s, ArCH3), 4.12 (2H, d, 
JHP  = 10.0 Hz, CH2P), 4.73 (2H, m, CH(CH3)2), 7.36 (2H, d, J = 8.0 Hz, H-3, H-5), 7.80 (2H, d, J 
= 8.0 Hz, H-2, H-6); 13C NMR (100 MHz, CDCl3) δC 23.7 (d, JCP = 4.6 Hz, CH(CH3)2), 23.9 (d, JCP 
= 3.8 Hz, CH(CH3)2), 61.9 (d, JCP = 169.1 Hz, CH2P), 72.3 (d, JCP = 6.1 Hz, CH(CH3)2), 128.1 (C-
2, C-6), 129.9 (C-3, C-5), 131.8 (C-4), 145.3 (C-1); 31P NMR (CDCl3) δP 13.3; HRMS (ES): m/z 
351.1044 [M+H]+. Calculated for C14H24O6SP, 351.1031 [M+H]+. 
 






2-Benzyloxyethanol 140 (2.09 g, 13.70 mmol) was added dropwise to a suspension of NaH 
(60% mineral oil, 0.69 g, 17.13 mmol) in THF (60 mL) at 0 oC. The mixture was stirred for 30 min 
and the tosylate 176 (4.00 g, 11.42 mmol) was added. The mixture was heated at reflux for 3 h. 
The crude mixture was added to EtOAc (80 mL), which washed with aqueous NH4Cl (50 mL), 
water (2 × 40 mL), dried over MgSO4 and the solvent was evaporated under reduced pressure. 
The crude product was purified by column chromatography employing EtOAc / pet ether (7 / 3) 
to give  compound 179 as a colourless oil (2.70 g, 72%). νmax /cm-1 (Chloroform): 2986, 2935 (C-
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6.3 Hz, CH(CH3)2), 3.66 (2H, t, J = 4.7 Hz, H-1), 3.79 (2H, t, J = 4.7 Hz, H-2), 3.82 (2H, d, JHP = 
8.4 Hz, H-4), 4.54 (2H, s, ArCH2O), 4.76 (2H, m, CH(CH3)2), 7.29 (1H, m, H-4’), 7.31 (4H, m, 
ArH); 13C NMR (100 MHz, CDCl3) δC 24.0 (m, CH(CH3)2), 66.1 (d, JCP = 165.9 Hz, C-4), 69.4 (C-
1), 71.0 (d, JCP = 6.6 Hz, CH(CH3)2), 72.5 (d, JCP = 10.5 Hz, C-2), 73.2 (ArCH2O), 127.5 (C-4’), 
127.6 (C-3’, C-5’), 128.3 (C-2’, C-6’), 138.2 (C-1’); 31P NMR (CDCl3) δP 19.7; HRMS (ES): m/z 
331.1668 [M+H]+. Calculated for C16H28O5P, 331.1674 [M+H]+. 
 






Hydrogen gas was introduced at atmospheric pressure to compound 179 (2.00 g, 6.05 mmol) 
and a suspension of 10% palladium-on-carbon (0.65 g, 0.61 mmol) in MeOH:THF (1:1) (15 mL). 
The mixture was stirred at room temperature for 6h. The catalyst was filtered through a pad of 
Celite, washed with MeOH (2 × 15 mL) and the filtrate evaporated in vacuo to give the product 
180 as a colourless oil pure enough for the next step (1.12 g, 77%). νmax /cm-1 (Chloroform): 
3200 (OH), 2986 (C-H), 1234 (P=O), 996 (P-O) cm-1: 1H NMR (300 MHz, CDCl3) δH 1.33 (12H, d, 
J = 6.2 Hz, CH(CH3)2), 2.52 (1H, brs, OH), 3.72 (4H, m, H-1, H-2), 3.79 (2H, d,  JHP = 7.8 Hz, H-
4), 4.75 (2H, m, CH(CH3)2); 13C NMR (75 MHz, CDCl3) δC 23.9 (m, CH(CH3)2), 61.5 (C-1), 66.0 
(d, JHP = 167.3 Hz, C-4), 71.2 (d, JCP = 6.6 Hz, CH(CH3)2), 75.0 (d, JCP = 9.5 Hz, C-2); 31P NMR 
(CDCl3) δP 20.2.   
 




   
 
p-Toluenesulfonyl chloride (1.05 g, 5.50 mmol) was added to a stirring solution of the alcohol 
180 (1.10 g, 4.58 mmol) containing triethylamine (0.77 mL, 5.50 mmol), and a catalytic a mount 
of DMAP in dry CH2Cl2 (20 mL) at 0 oC. The reaction mixture was stirred at rt for 16 h. The 
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over MgSO4 and the solvent removed under reduced pressure. Purification by column 
chromatography using EtOAc / pet ether (9 / 1) gave a colourless oil 181 (1.63 g, 90%). νmax /cm-
1 (Chloroform): 2986 (C-H), 1234 (P=O), 1176 (O-SO2), 999 (P-O) cm-1: 1H NMR (300 MHz, 
CDCl3) δH 1.28 and 1.31 (2 × 6H, 2 × d, J = 6.0 Hz, CH(CH3)2);  2.43 (3H, s, ArCH3), 3.69 (2H, 
JHP = 8.4 Hz, H-4), 3.77 (2H, t, J = 4.8 Hz, H-2), 4.14 (2H, t, J = 4.8 Hz, H-1), 4.71 (2H, m, 
CH(CH3)2), 7.33 (2H, d, J = 8.3 Hz, H-3’, H-5’), 7.78 (2H, d, J = 8.3 Hz, H-2’, H-6’); 13C NMR (75 
MHz, CDCl3) δC 21.5 (d, JCP = 3.7 Hz, ArCH3), 24.0 (m, CH(CH3)2), 66.1 (d, JCP = 166.5 Hz, C-4), 
68.7 (C-1), 70.4 (d, JCP = 11.0 Hz, C-2), 71.2 (d, JCP = 6.6 Hz, CH(CH3)2), 127.9 (C-2’, C-6’), 
129.8 (C-3’, C-5’), 132.9 (C-4’), 144.8 (C-1’); 31P NMR (CDCl3) δP 18.6; HRMS (ES): m/z 
395.1297 [M+H]+. Calculated for C16H28O7PS, 395.1293 [M+H]+. 
 






















To a solution of cesium carbonate (815 mg, 2.50 mmol) and uracil (572 mg, 5.00 mmol) in DMF 
(10 mL), was added tosylate 181 (1.00 g, 2.50 mmol) and the mixture heated to 100 oC. TLC 
confirmed reaction completion after 6 hr. The reaction mixture was diluted with brine (100 mL) 
and extracted with EtOAc (3 × 100 mL), the organic layer dried over MgSO4 and the solvent 
removed under reduced pressure. Purification by chromatography using a silica-gel column (70 
g; MeOH/EtOAc, 1:9) afforded product 175a as a clear oil, (471 mg, 56%). νmax /cm-1 (Acetone): 
1720s (C=O, ester), 1693s (C=O, pyrimidine), 721 (C-I, halogen); ¹H NMR (CDCl3, 400 MHz) δH 
1.32 (12H, m, H-5'), 3.71 (2H, d, JH-P = 8.4 Hz, H-3'), 3.80 (2H, t, J = 4.6 Hz, H-2'), 3.93 (2H, t, J 
= 4.6 Hz, H-1'), 4.71 (2H, sept, J = 6.2 Hz, H-4'), 5.62 (1H, d, J = 7.9 Hz, H-5), 7.34 (1H, d, J = 
7.9 Hz, H-6), 9.06 (1H, bs, NH); ¹³C NMR (CDCl3, 100 MHz) δC 23.9 (C-5'), 48.3 (C-1'), 66.1 (d, 
JC-P = 168.4 Hz, C-3'), 71.1 (d, JC-P = 11.0 Hz, C-2'), 71.2 (d, JC-P = 6.3 Hz, C-4'), 101.5 (C-5), 
145.8 (C-6), 150.8 (C-2), 163.6 (C-4); 31P NMR (Acetone-D6, 121.5 MHz) δP 19.8; HRMS (ES): 






































Cerium ammonium nitrate (IV) (492 mg, 0.90 mmol) and iodine (274 mg, 1.10 mmol) were added 
to a solution of phosphonate 175a (600 mg, 1.80 mmol) in CH3CN (20 mL). The reaction mixture 
was cooled to room temperature and diluted with sodium thiosulphate (50 mL) and extracted 
with EtOAc (3 × 50 mL), the organic layer dried over MgSO4 and the solvent removed under 
reduced pressure. Purification by chromatography using a silica-gel column (50 g; EtOAc neat) 
afforded product 175b as a yellow solid, (520 mg, 63%). Mp. 91-92 oC; νmax /cm-1 (Acetone): 
1720s (C=O, ester), 1693s (C=O, pyrimidine), 1599s (C-N stretching); ¹H NMR (DMSO-D6, 400 
MHz) δH 1.21 (12H, m, H-5'), 3.70 (2H, t, JH-P = 8.4 Hz, H-3'), 3.75 (2H, d, J = 5.0 Hz, H-2'), 3.87 
(2H, t, J = 5.0 Hz, H-1'), 4.57 (2H, sept, J = 6.2 Hz, H-4'), 8.04 (1H, s, H-6), 11.50 (1H, bs, NH); 
¹³C NMR (DMSO-D6, 75.5 MHz) δC 23.5 x 4 (C-5'), 47.1 (C-1'), 64.8 (d, JC-P = 163.9 Hz, C-3'), 
67.3 (C-5), 69.6 (d, JC-P = 11.3 Hz, C-2'), 70.0 (d, JC-P = 6.4 Hz, C-4'), 150.1 (C-6), 150.4 (C-2), 
160.7 (C-4); 31P NMR (Acetone-D6, 121.5 MHz) δP 20.1; HRMS (ES): m/z 461.0333 [M+H]+. 
Calculated for C13H23N2O6PI, 461.0339 [M+H]+; C, H, N Microanalysis found: C, 33.71; H, 4.88; 
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The Tetrazolium-based colorimetric (MTT) assay 
Since its first description 20 years ago, the tetrazolium-based colorimetric (MTT) assay using 
MT-2 or MT-4 cells for the detection of anti-HIV compounds has been widely used. The 
replication is normally monitored over 5 days after infection; therefore this protocol can be 
divided into three steps: the infection (at day 0), an incubation period (5 days) and the evaluation 
(at day 5). Exact details are summarized below. 
 
1 × 105 MT-2 cells per millilitre were infected with HIV-1 IIIB at 0.1 multiplicity of infection (MOI). 
100 μL of this solution was mixed with each serial dilution of inhibitor in triplicate on a 96-well 
plate. Mock infected cells were also mixed with inhibitor in a similar manner. After 5 days of 
incubation, a cell-permeable tetrazolium dye (MTT) was added. The MTT reaction was stopped 
after 5 hrs by adding acidified isopropanol. The plates were gently shaken overnight, quantified 
on a plate reader and the absorbance measured at 595 nm. The absorbance values were then 
plotted versus inhibitor concentration to generate EC50 and CC50 values. The 50% effective 
concentration (EC50) and 50% cytotoxic concentration (CC50) of the test compounds were 
defined as the compound concentrations required to inhibit cell viability (MT-2) by 50% the 
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                         PhD Corrections
PhD candidate: Ebrahim Mohamed Supervisor: Professor Roger Hunter
Student number: MHMEBR008 Department: Chemistry (UCT)
Title of Thesis: Probing the HIV reverse transcriptase enzyme with novel bifunctional HIV-1 RT
                      i nhibitors of the general formula NRTI-spacer-NNRTI.
Chapter 1 Examiner Recommendation Action
1 CM1 P2 - spelling 'everyday' corrected to 'every day'
P5 - typo '400' corrected to '400/'
P6 - citation required for Fig. 1.5 corrected and cited reference 18
P8 - mention fuzeon, raltegravir, maraviroc corrected and included on P8
P8 - 'nucleotides' to 'ANP' corrected to acyclic nucleoside phosphonate
P9 - mention RT in list corrected and RT listed
P10 - show stereochemistry of 3TC ignored - stereochemistry correctly shown (Fig. 1.8)
P10 - PI's worse for lipid disfunction corrected - D4T changed to PI's and rephrased
P11 - add 'viral replication' at end corrected - viral replication added
P11 - for AZT 2nd step rate limiting corrected - 1st to 2nd step and rephrased
P11 - esterase should read phosphatase corrected - reads phosphatase
P14 - preface by 'in most cases' corrected - preface added
P14 - Cyclo SAL mis-drawn corrected - change one benzyl to phenyl phosphate
P16 - phosphorylases to phosphatases corrected - reads phosphatases
P16 - carboxyesterase to enzymatic corrected - reads enzymatic
P17 - carboxylate to carboxyl corrected - reads carboxyl
P18 - 'OH-' is oddly drawn corrected - redrawn and adjusted Fig. 1.15
P19 - replace arrows (Fig. 1.16a) corrected - solid arrows replaced by dotted arrows 
P21 - english unclear corrected - rephrased english
P23 - TSAO derivative oddly named corrected - renamed to TSAO-N3Me
P24 - use different arrow ignored - is non-synthetic arrow
P25 - change 'fold resistance' in header corrected -  header changed in Table 1.2
P30 - say 'further studies', not toxicology corrected - changed 'toxicology studies' to further...
P32 - enormously crucial an overstatement corrected - rephrased to just crucial 
P38 - add 'phosphorylated' after 'released' corrected - phosphorylated added
P39 - check stereochemistries checked and correct
P40 - add number of approved drugs/step ignored - mentioned in other parts of this thesis
P41 - rephrase 'considerable boost' corrected - changed to simply 'boost'
P41 - rephrase 'remarkable' to significant corrected - changed to significant
P48 - Isnt simultaneous binding the goal? ignored - wording is OK as it corcerns a hypothesis
P49 - give AZT data corrected and data included (AZT = 6 nM)
DC P53 - paragraph needs reference corrected - reference 132 cited










Chapter 1 Examiner Recommendation Action
2 CM1 P60 - 'lead pass' unclear corrected - lead past
P61 - BVDU of 'limited' clinical use corrected - added 'limited' to sentence
P67 - spelling 'aas' corrected - 'aas' to 'as'
P76 - explain 'crystal argon' corrected - high purity argon gas (> 99%)
P77 - show thio attempts ignored - mentioned in text
P79 - 'is' to 'maybe' ; 'also' to 'may' corrected as recommended
P79 - comment on 100x reduction of 100 ignored - rationale requires a more in depth study
with modelling. Sentence rephrased.
DC P77 - check if compound 102 correct checked and correct
P78 - correct last sentence ignored - no errors found
P83 - compound 104 missing ignored - cmpd 104 is pentanediol on P81 (Sch 2.12)
P91 - activity of 113 written somewhere? corrected - noted 'no activity' on P92
P92 - is compound 112 correct? checked and correct as is
3 CM1 P96 - insert 'protected' before '5'-iodo corrected - changed to 'protected 5'-iodo…'
P100 - level of spectroscopic detail? ignored - details required for proof of success
P117 - elaborate on phosphorylation? corrected and elaborated on P117
4 CM1/CM2 P146 - explain choice of isopropyl phosph- corrected - prototype explained on P140
           ate protection?
CM1/CM2 P151 - proof of synergy? corrected and worded accordingly on P151-152
Examiner legend: Prof Chris McGuigan (CM1); Prof Chris Meier (CM2); Prof David Chu (DC) 
Note: Professor Chris Meier's comments were noted and are highly appreciated. The comments were taken into account and were 
in sync with comments and corrections made for Professor Chris McGuigan. All comments were useful and will contribute to future 
publications.
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